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A. Synthetic Receptors for the Differentiation 
of Phosphorylated Peptides 
1. Introduction 
1.1. Protein Phosphorylation 
Since the first isolation of phosphoserine (first described as serine phosphoric acid) in 
1932 by Levene and Lipmann, protein phosphorylation has turned out to be one of the 
most biologically relevant and ubiquitous posttranslational modifications of proteins. 
Phosphorylation is a reversible modification affecting the folding and function of proteins, 
regulating nearly every basic cellular process, including metabolism, growth, division, 
differentiation, motility, organelle trafficking, membrane transport, muscle contraction, 
immunity, learning and memory.1, 2 Protein kinases catalyze the transfer of the 
γ-phosphate from ATP to specific amino acids in proteins. In eukaryotes, these are usually 
the side chains of Ser, Thr and Tyr. 
 
Figure 1: The basic catalytic cycle for substrate phosphorylation by a kinase (adapted 
from literature3). 
Section A 1. Introduction 
 2 
According to comprehensive databases, the estimated number of phosphorylation sites in 
the mammalian proteome could be as high as 105. 30-50 % of the entire proteome are 
estimated to be phosphorylated on at least one point.4, 5 If it is assumed that there are 
about 10,000 different proteins in a typical eukaryotic cell, with an average length of about 
400 amino acids (of which 8.5 % are Ser, 5.7 % Thr and 3.0 % Tyr residues6), then there 
are approx. 700,000 potential phosphorylation sites for any given kinase. It is estimated 
that about 2 - 3 % of the eukaryotic genome is involved in phosphorylation processes, this 
fact additionally underlines the importance of protein phosphorylation.7, 8 For example, 
about 2 % of the human and also of the mouse genomes encode protein kinases with 518 
and 540 distinct protein kinases found in human1 and mouse,8 respectively. The analysis 
of the genome of Saccharomyces cerevisiae (baker’s yeast) has revealed the presence of 
123 protein kinases and 40 protein phosphatases, constituting approximately 2 % of the 
expressed yeast proteins.9 The interplay of kinases and phosphatases precisely regulates 
protein phosphorylation and dephosphorylation. 
Among the amino acids which can be phosphorylated, serine, threonine and tyrosine are 
by far the most important. The occurrence of phosphorylation on Ser and Thr residues is 
more frequent than on Tyr residues, with the ratio pSer/pThr/pTyr in the order of 
1800:200:1.10 The phosphoamidates of arginine, histidine and lysine also occur in nature, 
although they are less abundant.11 
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1.2. Analysis of Protein Phosphorylation 
Due to the biological importance, the analysis of protein phosphorylation is of paramount 
importance.12 A variety of analytical tools are available for scientists to investigate, monitor 
or specifically inhibit the phosphorylation of proteins. These methods include radioisotope 
labeling, phosphoamino acid selective antibodies,13 chromatographic, staining or surface 
device techniques (see Chapter 1.2.1). Several biosensors for protein kinase activity 
based on GFP-FRET probes (see Chapter 1.2.2) or synthetic fluorescent probes14 which 
typically signal their own phosphorylation or dephosphorylation have also been reported. 
Recently, the group of Hamachi et al. reported a fluorescent dinuclear zinc complex for 
the detection of peptide phosphorylation and extended the concept to a hybrid receptor 
(see Chapter 1.2.3).15 
In the following some of the above mentioned analytical methods will be discussed briefly. 
1.2.1. Chromatographic and Surface Device Techniques 
1.2.1.1. Immobilized Metal-Ion Affinity Chromatography (IMAC) 
IMAC is the most frequently used technique for the separation and purification of 
phosphopeptides and phosphoproteins. It is based on interactions between metal ions 
immobilized on a solid support and biopolymers in solution. It was originally introduced for 
the purification of His-tagged proteins.16 Phosphorylated peptides or proteins are bound to 
an IMAC stationary phase by electrostatic interactions of the negatively charged 
phosphate group with positively charged metal cations bound to the resin beads via 
chelating groups like nitrilotriacetic acid (NTA), iminodiacetic acid (IDA) and 
tris(carboxymethyl)ethylenediamine (TED).17 Immobilized Fe(III), Ca(II) and Al(III) have 
been demonstrated to show high binding affinities towards phosphopeptides.18 Recently, 
immobilized Zr(IV) has been reported to bind phosphopeptides with high specificity.19 One 
of the major drawbacks of IMAC-based strategies is the nonspecific binding of peptides 
containing the acidic amino acids Glu and Asp, and the overly strong binding of multiply 
phosphorylated peptides. Nonspecific binding of acidic peptides can be reduced by 
esterification of carboxylic acids to methyl esters using HCl-saturated dried methanol, 
however this is obviously a denaturating step which is often undesired.20 
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Figure 2: Schematic principle of the IMAC technique, adapted from literature.21 
IMAC procedures have become very popular rapidly due to their good compatibility with 
other separation and detection techniques such as LC-ESI-MS/MS and MALDI-MS.22 
1.2.1.2. Electrophoresis 
Kinoshita and coworkers developed a dinuclear metal complex (i.e. 1,3-bis[bis(pyridine-2-
ylmethyl)amino]propan-2-olatodizinc(II) complex) which acts as a phosphate-binding tag 
(called Phos-tag) in an aqueous solution and is commercially available. The Phos-tag has 
vacancies on two metal ions that are suitable for binding of phosphatemonoester dianions 
as bridging ligands. Its high selectivity for phosphatemonoester dianions lead to the 
development of procedures for MALDI-TOF-MS,23 IMAC24 and surface plasmon 
resonance (SPR).25 
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metal ions 
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desorption 
Solid support 
Spacer 
 
Chelating group 
 
Metal ion 
Protein 
 
Displacer 
Section A 1. Introduction 
 5
O-
NN
NN
N N
Mn2+ Mn2+
O
H
N
N
H
O
+
-O
P
O O
O-
R
O-
NN
NN
N N
Mn2+ Mn2+
O
H
N
N
H
O
O-
P
O O
O-
R
1 2
3
 
Figure 3: Structure of the Mn(II) Phos-tag complex 1 and scheme of the reversible 
capturing of a phosphatemonoester dianion 2. 
Recently, another application using complex 1 was reported by the same group. They 
were able to separate a phosphorylated protein from the corresponding 
nonphosphorylated one using a novel phosphate affinity sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) technique. The dinuclear Mn(II) complex 
1 was used as a gel additive to enhance the phosphate affinity of the SDS-PAGE. The 
principle of this method is as follows: phosphorylated proteins coordinate to the Mn(II)-
Phos-tag ligand copolymerized into the gel and move therefore slower in the SDS-PAGE 
than the corresponding nonphosphorylated forms. This novel technique was successfully 
used to detect different proteins containing phosphorylated Ser, Thr and Tyr residues.26 In 
addition, it was possible to perform an in vitro kinase activity profiling for the analysis of 
phosphoprotein isotypes derived from various kinases as well as an in vivo kinase activity 
profiling for the analysis of extracellular signal-dependent protein phosphorylation.27 
A similar metal complex based on a tyrosine was developed by König et al. The 
advantage of compound 4 is the in comparison to the previously synthesized Phos-tags 
more facile synthesis. They successfully used the Mn(II) complex as gel additive to 
separate phosphorylated proteins from unphosphorylated ones.28 
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Figure 4: Structure of the acrylamide-pendant Mn(II) complex 4. 
In general, the Mn(II)-Phos-tag SDS-PAGE technique offers the significant advantages: (i) 
No radioactive or chemical labels are needed. (ii) The amino acid sequence plays no role 
for the phosphate binding specificity. (iii) A downstream procedure, such as Western 
blotting analysis, is possible. (iv) The procedure is almost identical to that of the general 
SDS-PAGE.29 
1.2.1.3. Microarray Technology 
A method available for profiling the proteome without the use of separation techniques 
such as liquid chromatography, two-dimensional gel electrophoresis, or mass 
spectrometry is the use of microarray technology.30 This new method offers the possibility 
to investigate the biochemical activities of proteins in a high-throughput and systematic 
manner.31 However, one limitation of antibody-based arrays is the difficulty to recognize 
isoforms of particular proteins that result from prost-translational modifications, such as 
phosphorylation.32 
The feasibility of a microfluidic chip-based assay for measurements of cAMP-dependent 
protein kinase activity has been reported.33 The lab-on-a-chip system is based on the 
phosphorylation of a fluorescein-labeled peptide. The additional negative charges from the 
phosphate group allow the separation of the phosphorylated from unphosphorylated 
peptides by capillary electrophoresis. The system could be used in the screening of 
protein kinase activators and inhibitors. Proof-of-concept studies for the detection of the 
phosphorylation of substrates by protein kinases on glass slides have been demonstrated 
using cAMP-dependent protein kinase, casein kinase II and p42 mitogen-activated protein 
(MAP) kinase.34 Immobilized peptide chips for the quantitative analysis of protein kinase 
activity have recently been reported as well.35 Additionally, the study demonstrated the 
feasibility of detecting protein kinase activity on these chips using an antibody raised 
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against phosphotyrosine in combination with surface plasmon resonance (SPR) or 
fluorescence microscopy.36 
1.2.2. GFP-FRET 
Another technique to monitor protein phosphorylation in living cells is the use of 
fluorescent indicators. This method was developed to visualize second messengers such 
as Ca(II),37 diacylglycerol,38 cAMP39 and cGDP.40 The measurements based on these 
fluorescent indicators have been found to provide high spatial and temporal resolution 
sufficient for dissecting the single-cell events of the second messengers.41 
In the last years, this method was also adopted for the study of kinase and phosphatase 
functions. 
The principle of this method is shown schematically in Figure 5. A target substrate domain 
for a kinase of interest is connected with a phosphorylation recognition domain via a 
flexible linker sequence. The resulting substrate/linker/recognition unit is sandwiched 
between two differently-colored fluorescent proteins, cyan fluorescent protein (CFP) and 
yellow fluorescent protein (YFP). They are mutants of the green fluorescent protein (GFP) 
and serve as the donor and the acceptor fluorophores for fluorescence resonance energy 
transfer (FRET).42  
Phosphorylation of the substrate domain and subsequent binding of the phosphorylated 
substrate domain with the adjacent phosphorylation recognition domain induces FRET 
between the two fluorescent units and this in turn brings about the phosphorylation-
dependent changes in fluorescence emission ratios of the donor and acceptor 
fluorophores. Upon activation of phosphatases, the phosphorylated substrate domain is 
dephosphorylated and the FRET signal is decreased. 
This method has been used for the investigation of the phosphorylation kinetics in living 
cells by the use of a genetically encoded A-kinase activity reporter.43 Another example is 
the use of the GFP-FRET technique for the in vivo analysis of CrkII phosphorylation by 
employing the property that CrkII changes its conformation upon intramolecular binding of 
the Src homology (SH) 2 domain to phosphorylated Tyr221. Using this probe allowed the 
visualization of the rapid and transient phosphorylation of CrkII in living cells.44 
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Figure 5: Fluorescent indicator for protein phosphorylation in living cells. Upon 
phosphorylation of the substrate domain by a kinase, the phosphorylation recognition 
domain binds to the phosphorylated substrate domain, which results in a change in the 
FRET intensity. (adapted from literature45) 
1.2.3. Synthetic Metal Containing Receptors 
In 2002 Hamachi et al. introduced the Zn(II)-dipicolylamine (DPA) conjugated anthracene 
fluorophores 5 and 6 which can be applied to probing phosphorylated tyrosine and also 
phosphorylated peptides in aqueous media with association constants logK in the range of 
4.1 - 7.3. The probes are based on suppression of the photoinduced electron transfer 
(PET) process. The fluorescence of 5 and 6 is increased four to five fold after recognition 
of a tyrosine-phosphorylated peptide having an overall negative charge. This, in turn, was 
not the case for the corresponding non-phosphorylated peptide.46 
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Figure 6: Fluorescent receptors 5 and 6 for the recognition of mono-phosphorylated 
peptides. 
In an expansion of their previous work, Hamachi et al. developed the receptor 7 based on 
the Zn(II)-DPA recognition unit for the detection of a multiple-phosphorylated peptide in 
aqueous solution. In contrast to the above shown receptors 5 and 6, the receptor 7 shows 
a decrease in fluorescence intensity after addition of the bis-phosphorylated target 
peptide. This is also the case when adding a mono-phosphorylated peptide but to a much 
lesser extent. An unphosphorylated peptide causes no change in fluorescence at all.47 
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Figure 7: Fluorescent receptor 7 for the recognition of multiply-phosphorylated peptides. 
Another probe, 8, based on the Zn(II)-DPA motif was subsequently developed. It was 
employed to investigate the selectivity of the so-called Pin1 protein to the 
multiphosphorylated C-terminal domain (CTD) repeat sequence of RNA polymerase II via 
the phosphoprotein binding domain (WW domain). It was shown by X-ray crystallographic 
analysis that the Pin1 WW domain only interacts with one (pSer5) of two phosphate 
groups on a serine phosphorylated CTD peptide. 
N
NN
N
O
O
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Figure 8: Artificial Zn(II)-DPA chemosensor. 
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It was intended to improve the binding affinity of the Pin1 WW domain for the CTD peptide 
by the introduction of the artificial probe 8. The maleimide group of compound 8 was used 
to link it to a cystein residue which was introduced by mutation into the protein sequence 
of the WW domain. After addition of the bisphosphorylated CTD peptide the fluorescence 
intensity increased by about 60 %. The developed receptor was also used to establish 
real-time fluorescence monitoring of CDK9-catalyzed phosphorylation.15, 48 
P
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Figure 9: Construction of the hybrid biosensor with 8 and fluorescence sensing of a 
doubly phosphorylated peptide. (adapted from literature15a) 
Another interesting approach towards the use of Zn(II) complexes for molecular 
recognition of phosphorylated compounds was presented by the groups of Kimura and 
König (see Chapter 2.2.1). 
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2. Receptor Development 
The above shown examples are interesting and versatile, but the number of artificial 
systems for the specific recognition of phosphorylated peptides is still limited. Especially 
interesting is the work of Hamachi et al. with their ditopic receptor showing micromolar 
affinity and selectivity towards diphosphorylated peptides derived from sequences of the 
C-terminal domain of RNA polymerase II. This approach is appealing, but has the 
limitation of being only applicable for peptide sequences which show two phosphorylated 
amino acid side chains in close proximity to each other. We now seeked to expand this 
concept towards the synthesis of synthetic ditopic receptors which are able to bind 
phosphorylated peptide sequences, which in addition to the phosphate have a second 
amino acid residue present in the peptide that can also be bound by the ditopic receptor. 
Besides the phosphorylated amino acid, glutamic and aspartic acids as well as histidine 
were chosen as secondary recognition motif.  
 
Figure 10: Exemplary binding event of the artificial ditopic receptors to their target 
peptides. The affinity can be determined for example by an enhanced fluorescence of the 
labeled peptide as shown in the cartoon. For further information about the selected 
binding sites of the receptors see Chapter 2.2. 
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2.1. Potential Targets 
We chose peptide sequences resembling the C-terminal domain of RNA polymerase II 
and the signal transducers and activators of transcription for our ditopic receptors because 
of their great biological relevance. 
2.1.1. The C-Terminal Domain of RNA Polymerase II 
The synthesis of mRNA by the RNA polymerase II (Pol II) requires precise regulation of 
the different transcription steps as there are the initiation, elongation and termination 
processes. The transcription elongation process is affected in part by the binding of 
regulatory factors to the phosphorylated C-terminal domain (CTD) of the Pol II.49 The 
binding of these factors depends on a specific CTD phosphorylation pattern, which 
changes during the transcription cycle, due to the action of CTD-modifying enzymes and 
coordinates events of nuclear mRNA biogenesis.50 
The CTD is linked to the Pol II via a flexible linker and forms an extension from the Pol II. 
Due to the high mobility of the linker and the CTD, they are not visible in the crystal 
structures of yeast Pol II.51 The CTD sequence consists of heptapeptide repeats of the 
sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. The number of repeats depends on the species 
and is 26 in yeast and 52 in human. At least eight repeats are required for yeast viability. 
52, 53 
 
Figure 11: Pol II crystal structure and CTD β-spiral model. (adapted from literature54) 
Section A 2. Receptor Development 
 13
The CTD can be modified at five of the seven side chains of one consensus repeat. 
However, CTD phosphorylation occurs mainly at Ser2 and Ser5 and these two 
phosphorylations are not equivalent in function.55, 56 
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Figure 12: Structure of the diphosphorylated heptapeptide in complex.  
Phosphorylation at Ser2 and Ser5 results in four different phosphorylation states of one 
CTD repeat. The phosphorylated form of Pol II carries, on average, one phosphate per 
repeat.57 The exact phosphorylation state results from the balanced action of CTD kinases 
on the one side and phosphatases on the other side. During the transcription cycle the 
phosphorylation pattern changes, resulting in activation of specific RNA-processing 
factors. For example the CTD becomes phosphorylated at Ser5 during transcription 
initiation, while the adjacent transcription elongation is triggered by CTD phosphorylation 
at Ser2 residues.58 Thus, it seems that the different CTD phosphorylation patterns 
connect distinct stages of the transcription cycle to the associated RNA-processing 
events.59 During or after transcription termination, the CTD is dephosphorylated, resulting 
in Pol II recycling. 
2.1.2. The Signal Transducers and Activators of Transcription 
Other targets of interest were the signal transducers and activators of transcription 
(STATs). This family of transcription factors transduce signals from the surface of a cell to 
the nucleus.60 Up to now, seven members of the STAT family were identified. STATs bind 
to activated cytokine receptors or to growth factor receptors via their Src homology 2 
(SH2) domain. Upon ligand-induced receptor dimerisation, receptor-associated Janus 
kinases (JAKs) phosphorylate the cytokine receptors to create binding sites for the 
STATs. The STATs are phosphorylated after binding by JAKs or other cytoplasmic 
tyrosine kinases. This phosphorylation of STATs induces dimerisation by reciprocal 
phosphotyrosine-SH2 domain interactions. The so formed STAT dimers are then able to 
translocate to the nucleus, where they play an important role in the regulation of gene 
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expression.61 Due to the fact that the intracellular location of STATs depends on their 
activation state, they are often referred to as “latent cytoplasmic” transcription factors (see 
Figure 13).62 
 
Figure 13: Simplified model of signal transduction via STATs. (adapted from literature63) 
One member of the STAT family, STAT3, has proven to be overactive in numerous of 
primary human tumors and also in tumor-derived cell lines.64 Inhibition of constitutively 
active STAT3 results in growth inhibition and apoptosis of the tumor cell lines.65 In 
common with other STAT proteins, also the STAT3 binds to phosphotyrosines at two 
stages in the activation of STAT3: firstly prior to the phosphorylation the binding of the 
activated kinase occurs and secondly the dimerisation of the phosphorylated STAT3 
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proteins takes place (see Figure 13). Therefore, small molecules like the complexes 
shown in this work could potentially be used as inhibitors for the STAT activation. 
2.1.3. Target Peptide Sequences 
After the STAT and the CTD proteins were chosen as the potential targets for the ditopic 
receptors, in the next step some target peptide sequences were chosen as starting point 
for the receptor development. 
In the following some short peptide sequences derived from the CTD and STAT proteins 
are presented which were selected as potential targets for the receptors. All of the 
peptides have at least two amino acids with functional groups which could serve as 
binding partners for the different receptor moieties presented in the following Chapter 2.2. 
All peptides have a phosphorylated tyrosine, threonine or serine and in addition a second 
function like a glutamic acid, aspartic acid, histidine or a second phosphorylated amino 
acid. They were derived either from the active centers of kinases known to be involved in 
the STAT phosphorylation process (P1 – P5) or from the CTD sequence (P6). 
a) Carboxyfluorescein–Gly-pTyr-Asp-Lys-Pro-His-Val-Leu-OH (P1) 
b) 5-Carboxyfluorescein–Gly-Phe-Asp-pThr-Tyr-Leu-Ile-Arg-Arg-OH 5- (P2) 
c) 5-Carboxyfluorescein–Gly-pTyr-Glu-Glu-Ile-Pro-OH (P3) 
d) 5-Carboxyfluorescein–Gly-pTyr-Leu-Val-Leu-Asp-Lys-Trp-OH (P4) 
e) 5-Carboxyfluorescein–Gly-pTyr-Leu-Pro-Gln-Thr-Val-NH2 (P5) 
f) H-Tyr-pSer-Pro-Thr-pSer-Pro-Ser-OH (P6) 
The red marked phosphorylated tyrosine, threonine or serine residues can be bound by 
the bis(Zn(II)-cyclen) complex. As a secondary binding site, histidine (marked in green) in 
the sequence of P1 could be coordinated by the bis(Zn(II)-cyclen) complex or the blue 
marked glutamic or aspartic acids (sequences P1 - P5 which might be bound by a 
guanidinium moiety or a Zn(II)-NTA complex are possible targets. 
In addition, peptides P1 - P5 are labeled with the fluorescent dye 5-carboxyfluorescein, 
thus making it possible to use fluorescence intensity or fluorescence polarization 
spectroscopy as method for the determination of the binding affinities. 
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2.2. Binding Sites 
After the target peptides were selected and with that also the side chains which could be 
bound by our ditopic receptors (pSer, pTyr, pThr, His, Asp and Glu), the receptor binding 
sites for those amino acids were chosen. 
The bis(Zn(II)-cyclen) triazine complex 16 was selected as the binding site for the 
phospho amino acids and the histidine side chain. The Zn(II)-NTA complex 17 and a 
guanidinium moiety 20 were chosen to bind the side chains of the glutamic and aspartic 
acids. 
2.2.1. The Bis(Zn(II)-Cyclen) Triazine Complex 16 
1,4,7,10-Tetraaza-cyclododecane (also [12]aneN4 or cyclen) is able to incorporate a metal 
ion into its center. The metal cation is bound by the free electron pairs of the four ring 
nitrogen atoms. Such complexes are known of a variety of metals like Zn(II), Ni(II), Cu(II), 
Cd(II), Co(III) but also Rh(III) and Ru(II).66 Of special interest is here Zn(II) because 
complexes of this ion with cyclen have proven their ability to bind phosphate monoesters 
in several tests. Ni(II), Cu(II) and Cd(II) in the contrary show no affinity towards phosphate 
monoesters.66, 67  
It was also already shown that phosphate esters can coordinate up to three Zn(II) cyclen 
complexes at the same time.68 This offers the possibility to create a receptor by linking two 
or even three cyclen complexes with each other. Such a molecule should have an 
increased selectivity and also a higher binding constant. Kimura et al. were able to show 
that the affinity constant of a Zn(II)-cyclen complex containing receptor towards 
4-nitrophenyl phosphate (NPP2-) and also phenyl phosphate (PP2-) increases by 
incorporating more complexes into the receptor.69 
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Figure 14: Mono-, bi- and tridentate complexes of Zn(II)-cyclen used by Kimura et al. 
Counter ions were omitted for clarity. 
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The affinity constants (logK) for the Zn(II)-cyclen 9 towards NPP2- and PP2- are 3.1 for the 
former and 3.5 for the latter. Those determined for the bis-Zn(II)-cyclen 10 are 4.0 and 
4.6, respectively. For the tris-Zn(II)-cyclen 11 the binding constants are even higher with 
5.8 for the coordination of NPP2- and 6.6 for the binding to PP2-.70 
In addition to the affinity of bis-Zn(II)-cyclen complexes towards phosphate-monoesters, 
these complexes also have proven to be able to bind nitrogen containing compounds like 
barbital,71 thymidine 3’-monophosphate72 and imidazole.73, 74 
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Figure 15: Binding of barbital and thymidine 3’-monophosphate to bis(Zn(II)-cyclen) (left 
and center); drawing of a complex of two Zn(II)-cyclens coordinated to one imidazole 
(right). Counter ions were omitted for clarity. 
The binding constants of the bis(Zn(II)-cyclen) complex 10 towards their targets are in a 
range of logK = 5.5 - 6.4 as determined by potentiometric titrations which is nearly two 
orders of magnitude higher than the affinity of the mono(Zn(II)-cyclen) 9.75 
As binding moiety, we selected the bis-cyclen compound 15 developed by our group105 
because it is rigid and the triazine has an additional site available for further 
functionalization. 
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Figure 16: Protected ligand 15 developed by our group (left) and the resulting bis(Zn(II)-
cyclen) triazine complex 16 (right) after deprotection and complexation of two Zn(II) ions. 
Counter ions were omitted for clarity. 
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The bis(Zn(II)-complex) 16 was previously used in a rational approach to control 
molecular recognition of phosphate, nucleobases, and nucleotides on 2-D templates 
presenting amphiphilic bis(Zn(II)-cyclen) assembled at the air/water and water/solid 
interfaces. In these systems, the metal-complexes act as highly specific divalent hosts for 
phosphate and imide groups.76 
 
Figure 17: Schematically drawn structure of a SAM-supported monolayer of bis(Zn(II)–
cyclen) on a gold-coated surface.76 
The amphiphilic bis(Zn(II)–cyclen) derivatives are ordered into a planar matrix through 
Langmuir-Blodgett (LB) transfer of bis(Zn(II)–cyclen) monolayers from an aqueous 
subphase onto a gold-coated surface covered with a loosely packed self-assembled 
monolayer (SAM) of octanethiol (see Figure 17). This combination of SAM and LB 
techniques preserves the uniform order of the precursor monolayer and gives a stable, 
interdigitated bilayer with macrocyclic fragments exposed to the solution. The bis(Zn(II)–
cyclen) immobilized in such a film is capable of binding nucleotide constituents modeled 
with uracil and an inorganic phosphate dianion while no binding to adenine or 
monoanionic phosphates was observed.77 
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Figure 18: Schematic illustration of the divalent binding mode for 5’-UMP attached to the 
SAM/bis(Zn(II)-cyclen) surface.77 
2.2.2. The Zn(II)-NTA Complex 17 
Nitrilotriacetic acid (NTA) has been widely used as a chelate for more than 60 metal 
ions.78 Most common are NTA complexes of Al(III),79 Cu(II),80 Ni(II),81 Zn(II),82 Cr(II and 
III)83 and Fe (II and III).84 
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Figure 19: Zn(II) complex 17 of the lysine NTA derivative used in this work with the two 
free valences (left), Zn(II)-EDTA complex 18 (center) and the expected Zn(II)-NTA 
complex 19 coordinated to a carboxylate (right). 
As metal ion, Zn(II) was chosen because unlike Cu(II)- and Ni(II)-NTA complexes which 
bind imidazole and are widely used for the purification of His-tagged proteins by 
immobilized metal affinity chromatography (IMAC),85, 86 the binding affinity of Zn(II)-NTA 
complexes for imidazole is significantly reduced.87 However, the NTA ligand also 
represents a truncated EDTA motif which itself is known to bind Zn(II) with an affinity of 
logK = 16.5.88 Accordingly, it can be expected that a carboxylate can coordinate to the two 
unoccupied coordination sites in the Zn(II)-NTA complex intramolecularly, thus completing 
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a mimic of an EDTA coordination sphere.89 Intermolecularly, this interaction has already 
been described.90 
As shown in Figure 19, the NTA ligand forms an octahedral complex with the Zn(II) as 
central ion, in which the nitrilotriacetic acid’s three carboxylic acid groups and the tertiary 
amine form a tetradentate chelation around the metal cation. This leads to the formation of 
three five-membered rings.91 The two free valences which are left after the coordination of 
the NTA to the metal ion are occupied in the free complex by non-chelating oxygen atoms 
from other [Zn(NTA)]- ions and can be used for the binding to the carboxylic side chain of 
amino acids like glutamic or aspartic acid.92 
2.2.3. The Guanidinium Moiety 20 
The guanidinium moiety is a common motif in biology and is widely used as mediator of 
specific non-covalent binding93 of different enzyme substrates (e.g. like lactate by the 
enzyme lactate dehydrogenase) or the base pairing in nucleic acids (guanine is an 
acylated guanidine). 
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Figure 20: Diagram of a protonated planar guanidinium group, showing 2 hydrogen bonds 
to a carboxylic acid. 
Based on its important role in nature, the guanidinium group has attracted much attention 
especially from the supramolecular community.94 However, most investigations were 
limited to organic solvents of low polarity, due to the fact that the ion pairs between 
guanidinium cations and oxoanions are normally stable only in this kind of media. In 
aqueous solutions, the competing solvation of both donor and acceptor sites significantly 
reduces the ion pair stability.95 Of course, this is no problem for nature because of the 
rather hydrophobic interior of proteins where such ion pairing normally occurs.96 However, 
for synthetic receptors the weak binding of ion pairs in polar solvents represents a severe 
limitation. This is especially the case for any application of such supramolecular systems. 
Nevertheless, in the recent years different guanidinium based compounds were 
synthesized which show high affinities to oxoanions even in water.97, 98 
Section A 2. Receptor Development 
 21
One example of oxoanion binding guanidinium cations and additional binding sites in 
water is shown in Figure 21. Schmuck et al. used a focused combinatorial library to find a 
hit for their target tetrapeptide, Ac-Val-Val-Ile-Ala-OH 22.99 This short peptide represents 
the C-terminal sequence of the amyloid-β-peptide (Aβ) which is responsible for the 
formation of protein plaques within the brain of patients suffering from Alzheimer’s 
disease.100 An artificial receptor such as 21 could be useful to derive more information 
about the molecular basis of the self-aggregation of the amyloid-peptide.101 To identify 
which amino acid side chain in the receptor is most important, a library of 512 different but 
structurally related receptors 21 was synthesized and screened.102, 103 The binding affinity 
of the best hits from the screening was afterwards determined in buffered water. The data 
showed that exceptionally strong binding occurred with association constants of up to 
104 M-1 for the best receptors.99a 
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Figure 21: A tripeptide based library of cationic guanidinocarbonyl pyrrole receptors 21 
(blue) designed for the binding of Dansyl-Val-Val-Ile-Ala-OH 22, a tetrapeptide model 
representing the C-terminus of Aβ (black). 
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2.3. Receptor Design 
As previously shown, three different types of receptor moieties, the bis(Zn(II)-cyclen) 
triazine complex 16, the Zn(II)-NTA complex 17 and the guanidinium moiety 20 have been 
combined in different ways to form ditopic receptors with an increased affinity and 
selectivity in comparison to the single receptors. As all potential target peptides possess a 
phosphorylated amino acid either a tyrosine, a serine or a threonine, every receptor has 
as one recognition functionality a bis(Zn(II)-cyclen) triazine complex 16. As additional 
binding unit, a second bis(Zn(II)-cyclen) triazine complex 16, a Zn(II)-NTA complex 17 or a 
guanidinium moiety 20 were chosen. This lead to three groups of receptors which were 
expected to be able to selectively recognize different patterns in phosphorylated peptide 
sequences. 
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Figure 22: The three different groups of receptors, all of which contain a bis(Zn(II)-cyclen) 
triazine complex 16 and as second binding site a second bis(Zn(II)-cyclen) triazine 
complex 16, a Zn(II)-NTA complex 17 or a guanidinium moiety 20. 
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The receptor group I was expected to selectively bind to peptides containing either two 
phosphorylated amino acids in the side chain or a combination of one phosphate mono 
ester and an imidazole group. The second group II in which a guanidine is incorporated 
instead of the second bis(Zn(II)-cyclen) triazine complex 16 should have a high affinity to 
peptides containing one phosphorylated amino acid and in addition a glutamic or aspartic 
acid as binding partner for the guanidinium group 20. The third and last group III where a 
bis(Zn(II)-cyclen) triazine complex 16 and a Zn(II)-NTA 17 complex form the receptor 
should bind to phosphorylated peptides containing a glutamic or aspartic acid as a second 
group. The synthesis of this last group will not be presented here as these compounds 
were already prepared in the scope of my diploma thesis.104 
2.3.1. Receptors With Two Bis(Zn(II)-Cyclen) Triazine Complexes 
For the receptor group I a spacer molecule containing two amine functionalities which 
would offer the possibility to introduce both protected bis-cyclen triazines 15 in one step 
was synthesized. A variety of spacers with different lengths and functionalities, for 
example fluorescent groups is possible. 
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Figure 23: Synthesis of group I receptors. 
As spacers between the two binding sites several diamines were chosen. The shortest 
spacer was the commercially available butane-1,4-diamine 23. For the longer linkers 24 
and 25 ethylenediamine in combination with glycine or glycylglycine were used. Due to the 
amide bonds introduced into the chain these spacers are more rigid than the alkyl 
diamines of the same length. Additionally this modular synthesis of the linkers offered the 
possibility to introduce other amino acids instead of the glycine. One example is the 
diamine 26. Here glycine was replaced by a lysine which makes it possible to add a 
further functionality to the receptor. The introduction of a fluorescent group like the dansyl 
unit would allow the use of fluorescence spectroscopy for the determination of the binding 
abilities of the several receptors. 
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Figure 24: Spacer molecules. 
In addition to above shown flexible linkers also two spacer molecules were chosen which 
are very rigid, resulting in receptors with defined distance of the two recognition moieties. 
These spacers are fluorescent due to their large conjugated ring system, offering the 
possibility to study also peptide sequences like P6 which are not labeled with a dye. Two 
fluorescent aromatic dianhydrides, the naphthalene-1,4,5,8-tetracarboxylic dianhydride 27 
and the perylene-3,4,9,10-tetracarboxylic dianhydride 28 were chosen. With these 
dianhydrides the synthesis had to be changed as the two spacer molecules do not bear 
any amine functions necessary for the substitution reaction shown in Figure 23. Therefore 
it was decided to functionalize the protected bis-cyclen triazine 15 with ethylene diamine 
before using it in the reaction with the dianhydrides 27 and 28. 
O
O
O O
O
OO
O
O O
O
O
27 28  
Figure 25: Rigid, fluorescent spacer molecules. 
2.3.2. Receptors With One Bis(Zn(II)-Cyclen) Triazine Complex and 
One Guanidine Moiety 
For the receptors containing a protected bis-cyclen triazine 15 and a guanidine moiety, 
similar spacer molecules were chosen. But as two different binding sites needed to be 
coupled to the linker this could not be performed in one single step. Therefore it was 
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necessary to first introduce the guanidine and then afterwards couple it with the protected 
bis-cyclen triazines 15. 
N
H
H
N
H
N
O
O
NH2
29
H2N N
H
O
NH2 N
H
H
NH2N
O
O
NH2
24 25
O
H2N
 
Figure 26: Spacer molecules. 
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3. Receptor Synthesis 
The protected bis-cyclen triazine 15 can be easily synthesized in two steps starting from 
commercially available cyclen which is first threefold protected by the use of di-tert-butyl 
dicarbonate and afterwards is coupled to 2,4,6-trichloro-1,3,5-triazine with an over all yield 
of 80 %.105 
3.1. Synthesis of the Tetra(Zn(II)-Cyclen) Receptors 
The reaction leading to the smallest receptor containing two bis(Zn(II)-cyclen) triazine 
moieties started with a substitution reaction in which two equivalents of the precursor 15 
were brought to reaction with butane-1,4-diamine 23. The reaction mixture was refluxed 
for three days and gave the product 30 in 67 % yield. In the following step the Boc-
protecting groups were cleaved quantitatively with ice-cold HCl saturated diethyl ether. 
The resulting hydrochloride salt of the product was deprotonated over a strongly basic ion 
exchanger column. The obtained ligand was complexated using Zn(ClO4)2 · 6 H2O, giving 
the product 31 after recrystallization from a water/methanol mixture in 17 % yield. 
Scheme 1: Synthesis of complex 31 containing two bis(Zn(II)-cyclen) triazine moieties. 
H2N
NH2
N
N
N
N N
NN
BocBoc
Boc
N N
NN
Boc
Boc
Boc
30
K2CO3, dioxane
67 %
N
N
N
Cl
N N
NN
BocBoc
Boc
N N
NN
Boc
Boc
Boc
+
15 23
N
N
N
NN
N N
Boc Boc
Boc
NN
N N
Boc
Boc
Boc
N
H
H
N
2
 
 
Section A 3. Receptor Synthesis 
 27
N
N
N
N N
NN
HH
H
N N
NN
H
H
H
31
N
N
N
NN
N N
H H
H
NN
N N
H
H
H
N
H
H
N
1) HCl sat. diethyl ether
2) strongly basic ion exchanger
3) Zn(ClO4)2x6H2O, H2O/EtOH
14 % overall
30
Zn2+
Zn2+
Zn2+
Zn2+
-HO OH
-
6+
6 ClO4-
 
 
For the longer homologue of 31, a spacer molecule was prepared from Boc-protected 
glycine 32 and mono Boc-protected ethylene diamine 33. As coupling reagents for the 
peptide coupling reaction EDC and HOBt were used. The protected diamine was 
deprotected with ice-cold HCl saturated diethyl ether to give the hydrochloride salt 34 in 
57 % yield over two steps. The salt 34 was used for the substitution reaction without 
further purification. Compound 35 was formed after three days of refluxing in dioxane in a 
yield of 67 %. After the protecting groups of compound 35 were cleaved, again by the use 
of ice-cold HCl saturated diethyl ether, the resulting hydrochloride salt was purified over a 
strongly basic ion exchange column. The resulting free amine was used in the 
complexation reaction together with Zn(ClO4)2 · 6 H2O to form the complex 36 in a yield of 
14 % over three steps. 
Scheme 2: Synthesis of the diamine 34 used as linker in the receptor 36. 
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Scheme 3: Synthesis of complex 36 containing two bis(Zn(II)-cyclen) triazine moieties 
and the diamine 24 as linker. 
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For the third and longest receptor with two bis(Zn(II)-cyclen) triazine moieties, the linker 
was prepared starting from Boc-protected glycine 32 which was coupled to glycine methyl 
ester hydrochloride 37 by the use of EDC and HOBt as coupling reagents. After the ester 
saponification using a 1M aqueous NaOH solution in combination with methanol as 
solvent, the resulting free acid 38 was used in a second peptide coupling reaction with 
Boc-protected ethylene diamine 33. The resulting precursor was deprotected using ice-
cold HCl saturated diethyl ether to give the hydrochloride salt 39. This was then used 
directly without further purification for the formation of the fully protected receptor 40. After 
cleavage of the protecting groups with HCl saturated diethyl ether and purification over a 
strongly basic ion exchange column the complexation was performed using Zn(ClO4)2 · 
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6 H2O. After recrystallization from a water/methanol mixture the pure complex 41 was 
obtained in 63 % yield over three steps. 
Scheme 4: Synthesis of complex 41 containing two bis(Zn(II)-cyclen) triazine moieties 
and the diamine 25 as linker. 
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The synthesis of the fluorescently labeled receptor precursor 46 followed a similar 
pathway. The linker was prepared by a peptide coupling reaction of N-terminally Boc- and 
side chain Cbz-protected lysine 42 with Boc-protected diethyl amine 33 using EDC and 
Scheme 5: Synthesis pathway leading to a dansyl labeled receptor precursor 46. 
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HOBt as reagents to activate the carboxylic acid 42. The product was deprotected after 
purification using palladium on activated charcoal under an atmosphere of hydrogen. This 
gave compound 43 in a good yield of 79 % over two steps. The dansyl moiety was 
introduced in a substitution reaction by the use of dansyl chloride 44 and NEt3 as organic 
base. The resulting yellow compound was Boc-deprotected, giving the linker 45 in 86 % 
yield and ready for the last substitution reaction. The following reaction, which should 
have provided the fully protected fluorescent precursor 46 of the desired complex 
unfortunately did not yield product in sufficient amounts. The reaction was tested in 
dioxane under reflux and also in DMF under reflux. In dioxane, traces of the desired 
product were formed but the main product was the mono substitution product. The same 
reaction in DMF showed only decomposition products. 
One reason causing the reaction to fail could have been a change in reactivity of the 
diamine 45 caused by the dansyl unit, therefore the reaction was tried again with the still 
Cbz-protected diamine 48. Unfortunately, this reaction also gave a mixture of different 
compounds with only traces of product 49. This indicates that it is not the dansyl unit 
causing the substitution reaction to fail. However, the presence of the lysine side chain 
seems to change the reactivity of the linker in a way that the twofold substitution can not 
take place anymore. 
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Scheme 6: Alternative synthesis pathway leading to the dansyl labeled receptor precursor 
49. 
H2N N
H
O
NH2
HN
HCl in diethyl ether
quant.
48
H
N
N
H
O H
N
HN
47
BocBoc
Cbz Cbz
* 2 HCl
N
N
N
N N
NN
BocBoc
Boc
N N
NN
Boc
Boc
Boc
49
K2CO3, dioxaneN
N
N
Cl
N N
NN
BocBoc
Boc
N N
NN
Boc
Boc
Boc
+
15 48
N
N
N
NN
N N
Boc Boc
Boc
NN
N N
Boc
Boc
Boc
2 H2N N
H
O
NH2 * 3 HCl
H
N
N
H
O H
N
HN
HN
Cbz
Cbz
 
 
Due to the fact that the synthesis of the dansyl labeled lysine containing receptors proved 
to be difficult and also because of the poor fluorescence properties of the dansyl motif, 
namely the low quantum yield and also the short excitation wavelength λex of about 337 
nm. Therefore, it was decided to discontinue the synthesis of this kind of receptor. Further 
reasons were that with the compounds 55 and 56 presented in Chapter 3.2 fluorescently 
labeled receptors were available. 
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3.2. Synthesis of the Fluorescent Tetra(Zn(II)-Cyclen) Receptors 
The precursor necessary for the formation of the diimides 53 and 54 was synthesized by a 
substitution reaction between the protected bis-cyclen triazine 15 and the previously 
prepared Cbz-protected diethyl amine 50. The reaction carried out in dioxane under reflux 
gave the product after three days in 84 % yield. 
Scheme 7: Synthesis of the precursor 52. 
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The cleavage of the Cbz group did not work under the normally applied conditions of 
palladium on activated charcoal as catalyst and stirring the mixture over night under 10 
bar of hydrogen. The Cbz protecting group of this compound is more stable and can only 
be cleaved by 30 bar of hydrogen atmosphere and a reaction time of three days. Although 
this led to a partial decomposition, it still gave the product 52 in a good yield of 79 %. 
To form the complex precursor 53, one equivalent of naphthalene-1,4,5,8-tetracarboxylic 
dianhydride 27 was stirred together with 2.2 equivalents of 52 and DIPEA as base for 24 
hours at 100 °C in toluene.106 The product was formed in a yield of 94 % after column 
chromatography. The reaction giving the larger compound 54 proved to be more 
challenging than the one leading to compound 53. The major difficulty was the extremely 
low solubility of the perylene-3,4,9,10-tetracarboxylic dianhydride 28 in nearly every 
solvent. A variety of organic solvents (methanol, DMSO, MeCN, toluene, dioxane) was 
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tested, but in all of them the dianhydride was not soluble enough to perform the reaction. 
In the end, a very unusual solution for the problem was found in literature.107, 108 It is 
possible to perform diimide formation reactions in an imidazole melt. To do so, the starting 
materials, in this case compound 52 and naphthalene-1,4,5,8-tetracarboxylic dianhydride 
28, were mixed with solid imidazole in a Schlenk tube. The mixture was then heated with 
a heat gun until the imidazole had completely melted and put into a hot oil bath preheated 
to 120 °C. The mixture was stirred with a conventional stirring bar for 24 hours. The 
addition of a base was not necessary due to the basicity of the imidazole. After the 
reaction was completed, the hot mixture was poured into water and extracted with ethyl 
acetate. Using this method, the imidazole remained in the aqueous phase and only the 
product 54 and some starting materials were extracted with the organic phase. This 
procedure gave the product 54 in 68 % yield.  
Scheme 8: Synthesis of the protected receptor precursor 53. 
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Scheme 9: Synthesis of the protected receptor precursor 54. 
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Both receptor precursors 53 and 54 were analyzed for their UV and fluorescence 
properties. Both molecules show characteristic UV patterns with three maxima. For the 
smaller fluorophore the maxima occur at 338 nm, 356 nm and 376 nm. For the larger 
aromatic system, the maxima are red-shifted and appear at 456 nm, 484 nm and 521 nm. 
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Figure 27: UV spectra of compounds 53 and 54 at a concentration of 1·10-5 M in MeCN. 
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Additionally, the fluorescence properties of both compounds 53 and 54 were investigated, 
where it was found that only compound 54 is fluorescent. The smaller precursor 53 did not 
show any fluorescence. The reason could be some kind of intramolecular quenching due 
to a photoelectron transfer. Despite this, the synthesis of the complex 55 was performed 
in the hope that structural and electronical chages upon complexation might lead to a 
reappearance of the fluorescence. 
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Figure 28: UV and fluorescence spectra of the protected receptor 54 at a concentration of 
1·10-5 M in MeCN. 
The fluorescence of compound 54 was measured at two different excitation wavelengths 
of 486 nm and 520 nm. The emission maxima are at 532 and 570 nm. For measurements, 
the excitation at 486 nm is better suited than the one at 520 nm due to the higher 
emission intensity and because of the fact that the entire emission peak at 532 nm can be 
recorded. When excitating at the higher wavelength, the Stokes shift is so small that the 
first emission maximum can not be recorded entirely. Additionally, the quantum yield is 
lower for an excitation at 520 nm compared to an excitation at 486 nm resulting in a 
comparable lower fluorescence output of the system. 
Perylene bisimide dyes and their derivatives are known to form stackings through their 
planar π–systems. This effect is well documented in crystal structures.109, 110 Only recently 
has the aggregation of these dyes also been studied in solution.111 These π-π-aggregates 
could possibly create some artifacts in the binding assays of receptor 56 and the model 
peptides. It is possible to analyze the aggregation process by UV/Vis-spectroscopy. 
Therefore, concentration-dependent spectra of compound 54 were recorded in toluene in 
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a concentration range of 10-6 – 10-4 M. Indication for aggregation would be the 
appearance of red-shifted peaks in the UV/Vis-spectra with increasing concentration. The 
recorded spectra (see Figure 29) show no shift of the peaks at all, indicating that in the 
measured concentration range and below only the monomeric species of compound 54 
exists. Above a concentration of 10-4 M, the absorption is so high that UV/Vis-
spectroscopy cannot be used for a proper characterization of the aggregation 
properties.112 
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Figure 29: Concentration-dependent UV spectra of 54 in toluene recorded in a 
concentration range between 1·10-4 and 1·10-6 M. 
However when different solutions in a concentration range of 10-7 – 10-2 M were excited 
on a UV-table at 316 nm, a marked shift in emission was observed (see Figure 30). With 
increasing concentration, the luminescence changes from green for the de-aggregated 
species to yellow, orange and even to red for the aggregated dyes. 
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Figure 30: Concentration-dependent luminescence of 54 in toluene irradiated at 316 nm. 
The concentrations from left to right are: 10-7, 10-6, 10-5, 10-4, 10-3, 10-2 M. 
After the analysis of the spectral properties of compounds 53 and 54, both were used for 
the synthesis of the metal complexes 55 and 56. Accordingly, the protecting groups were 
cleaved with ice-cold HCl saturated diethyl ether the resulting HCl salts were purified over 
a strongly basic ion exchanger column followed by the complexation using Zn(ClO4)2 · 
6 H2O. After recrystallization from a water/methanol mixture the pure complex 55 was 
obtained in 64 % yield over three steps and complex 56 was obtained in 60 % yield. 
Scheme 10: Synthesis of the two Zn(II) complexes 55 and 56. 
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Figure 31: UV spectra of the metal complexes 55 and 56 at a concentration of 1·10-5 M in 
HEPES buffered aqueous solution at pH 7.4. 
The fluorescence spectra of the water-soluble perylene complex 56 was measured in 
HEPES pH 7.4 and displays qualitatively the same features as those found for the 
corresponding protected precursor 54. The only differences are drastically decreased 
emission intensity and a red-shift of the whole spectrum showing now two peaks, at 550 
nm and 594 nm. The fluorescence of compound 56 was measured at two different 
excitation wavelengths of 497 nm and 520 nm. Again, for measurements, the excitation at 
497 nm is better suited than the one at 520 nm due to the higher emission and because of 
the fact that the whole emission spectra can be recorded. 
Obviously, the metal complex 56 can also potentially aggregate at higher concentrations, 
which might lead to artifacts in the fluorescence titrations as explained before. But due to 
the previous results showing that there is no aggregation at concentrations below 1·10-5 
and 1·10-6 M this is no problem for the binding assays because those titrations are carried 
out in a concentration range which is at least two orders of magnitude below the 
concentration necessary for an aggregation. 
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Figure 32: UV (blue) and fluorescence spectra (green) of the metal complex 56 at a 
concentration of 1·10-5 M in HEPES buffered aqueous solution at pH 7.4. 
Again, the smaller compound 55 did not show any fluorescence at a concentration of 
1·10-5 M or lower in water, thus making it unsuitable for binding studies with un-labeled 
peptides but still this rigid molecule could be used for the analysis of fluorescent peptides. 
However, the fact that compound 55 shows no fluorescence at all was very surprising, as 
similar complexes containing the naphthalene diimide were previously used as 
chemoselective sensors for phosphate esters.113 
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3.3. Synthesis of the Bis(Zn(II)-Cyclen)-Guanidine-Receptors 
For the synthesis of compound 60, tbutyl 2-aminoethylcarbamate 33 was used in a 
substitution reaction together with the commercially available Cbz-protected guanidine 
precursors 57. After the coupling reaction, the Boc-group was removed by the use of ice-
cold HCl saturated diethyl ether giving the salt 58 in a very good yield of 91 % over the 
two steps. In the following, a peptide coupling reaction using EDC and HOBt as coupling 
reagents was performed to link the amine 58 with Boc-Gly-OH 32. Again, the Boc-group 
was cleaved and the salt 59 was obtained in very good yield (83 % over two steps). The 
amine 59 was now ready for the substitution reaction which should result in the Boc and 
Cbz protected precursor 60. Unfortunately only decomposition products emerged from the 
reaction and the desired product was not obtained. 
Scheme 11: Attempted synthesis of the protected precursor 60. 
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These results made a complete change in the reaction pathway necessary. As it was 
possible to obtain the ethylene diamine functionalized bis-cyclen triazine 52 in very good 
yields, it was decided to change the last step of the formation of the protected receptor 
precursor 60 from a substitution reaction to a peptide coupling reaction. This meant that 
the guanidine functionalized free acid 64 had to be synthesized which would then be 
coupled in the last step to the amine 52. Because no Boc protecting groups would be 
needed during the synthesis of the guanidine acid 64, the Cbz groups protecting the 
guanidine 57 were replaced by Boc groups to reduce the final deprotecting steps from two 
to one. 
In the first step, S-methylisothiourea sulfate 61 was two-fold protected to give 1,3-
bis(Boc)-2-methyl-2-thiopseudourea 63 in a yield of 98 % after column chromatography. 
The substitution reaction was performed with H-Gly-OMe 37 and after saponification of 
the methyl ester the acid 64 was obtained in good yield. The peptide coupling reaction 
gave the receptor precursor 65 in a yield of 25 % by the use of EDC and HOBt as 
coupling reagents. The precursor 65 was then Boc-deprotected with ice-cold HCl 
saturated diethyl ether, deprotonated over a strongly basic ion exchange column and 
afterwards used in the complexation reaction with Zn(ClO4)2 · 6 H2O to give complex 66 in 
an overall yield of 63 %. 
Scheme 12: Synthesis of the precursor 64. 
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Scheme 13: Synthesis of complex 66. 
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The receptor precursor 69 with the spacer 25 was synthesized in a similar way as 
compound 65 shown above. Glycylglycine methylester hydrochloride 67 was used for the 
substitution reaction at the compound 63. After saponification of the resulting ester, the 
free acid 68 was obtained in 67 % yield over two steps. The following peptide coupling 
reaction gave the protected receptor precursor 69 in 23 % yield by the use of EDC and 
HOBt as coupling reagents. The precursor 69 was then Boc-deprotected with ice-cold HCl 
saturated diethyl ether, deprotonated over a strongly basic ion exchange column and 
afterwards used in the complexation reaction with Zn(ClO4)2 · 6 H2O to give the complex 
70 in an overall yield of 63 %. 
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Scheme 14: Synthesis of complex 70. 
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The receptor 74 containing a bis(Zn(II)-cyclen) triazine and a guanidine moiety was 
synthesized like the receptors shown before. The glycine tripeptide methylester precursor 
69 was coupled in a substitution reaction with compound 64 to give the free acid 72 after 
saponification of the methyl ester in 24 % yield over the two steps. The following peptide 
coupling reaction gave the protected receptor precursor 73 in 50 % yield by the use of 
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EDC and HOBt as coupling reagents. The precursor 73 was then Boc-deprotected with 
ice-cold HCl saturated diethyl ether, deprotonated over a strongly basic ion exchange 
column and afterwards used in the complexation reaction with Zn(ClO4)2 · 6 H2O to give 
the complex 74 in a overall yield of 26 %. 
Scheme 15: Synthesis of complex 74. 
1) NEt3, CHCl3/methanol
2) LiOH, THF/water
24 % overall
N
H
H
N
H
N
Boc
N
H
H
N+
N
N
N
N N
NN
BocBoc
Boc
N N
NN
Boc
Boc
Boc
73
60 %
N
N
N
NH
N N
NN
BocBoc
Boc
N N
NN
Boc
Boc
Boc
+
52 72
63 71
72
SN
H
N
Boc
Boc
N
Boc
H
N
N
H
N
H
Boc
N
Boc
N
H
H
N
N
H
H
N
N
H
O
*HCl
O
O
H2N
O
H
N
NH2
O
O
O
O
O
N
H
N
N
N
N N
NN
HH
H
N N
NN
H
H
H
74
1) HCl sat. diethyl ether
2) strongly basic ion exchanger
3) Zn(ClO4)2x6H2O, H2O/EtOH
26 %
73
Zn2+
Zn2+
-HO
3+
3 ClO4-N
H
H
N
H
N
O
O
N
HO
O
O
EDC, HOBt
   DIPEA, DMF
O
HO
N
N
H
Boc
Boc
N
H
NH2
NH
OH
O
 
Section A 4. Binding Studies 
 46 
4. Binding Studies 
In addition to the receptors 31, 36, 41, 55, 66, 70 and 74, the previously synthesized104 
receptors 75 – 78 were also used in different assays. Beside the bidentate receptors the 
complexes 80 and 81 which represent receptor substructures were also measured to 
derive information about the contribution of the second binding site to the affinity of the 
receptors. 
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Figure 33: Bis(Zn(II)-cyclen) triazine Zn(II)-NTA complexes 75 – 78 and complexes 80 
and 81 representing receptor substructures. 
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4.1. Binding Affinities Towards Different STAT Proteins 
4.1.1. Binding Assay 
The group of T. Berg has developed a high-throughput fluorescence polarization assay 
which allows the screening of small molecules that can bind to the STAT SH2 domain and 
thereby inhibit its activity. This assay is based on the binding of small fluorescein-labeled 
phosphotyrosine-peptides to unphosphorylated STAT. In nature, the unphosphorylated 
STAT binds to kinases and is then phosphorylated by them. This tyrosine phosphorylation 
of STATs induces dimerisation and with that activates the STAT. If the binding of STAT to 
the kinase is inhibited, the activity of the STAT is blocked. 
The developed polarization assay is based on this interaction. At first, an 
unphosphorylated STAT is incubated with a short fluorescein-labeled phospho-peptide 
(such as peptides P1 – P5) with a sequence derived from the active site of kinases known 
to interact with the STAT. A small molecule inhibitor can displace the peptide bound to 
STAT protein. The bound peptide exhibits a decrease in fluorescence polarization due to 
its significantly reduced molecular mass.114 
4.1.2. Binding Results and Discussion 
The binding affinities of receptors 66, 70, 74 and 77 – 79 towards the different peptides 
P1, P2 and P3 were investigated.1 
a) 5-Carboxyfluorescein–Gly-pTyr-Asp-Lys-Pro-His-Val-Leu-OH (P1) 
b) 5-Carboxyfluorescein–Gly-Phe-Asp-pThr-Tyr-Leu-Ile-Arg-Arg-OH (P2) 
c) 5-Carboxyfluorescein–Gly-pTyr-Glu-Glu-Ile-Pro-OH (P3) 
The complexes 66, 70, 74 and 77 – 79 are potential receptors for the peptides because all 
have a phosphorylated amino acid side chain (pTyr or pThr) and an aspartic or glutamic 
acid as a second binding motif in their sequence. 
                                                
1 Peptides were synthesized by Dr. F. Freudenmann. Binding investigations were performed by 
Bianca Sperl under the supervision of Dr. Thorsten Berg (Max Planck Institute of Biochemistry, 
Martinsried). 
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4.1.2.1. Inhibitory Effect Against the P1-STAT1-Complex 
The influence of the metal complexes 66, 70, 77 – 79 on the binding between P1 and 
STAT1 was investigated by the detection of the fluorescence polarization change of the 
system upon addition of the receptors. The diagram in Figure 34 shows the dependence 
of the peptide – protein binding on the concentration of added receptor. (The y-axis shows 
the ratio of P1-STAT1-complex in %, the x-axis the receptor concentration in μM) As a 
reference, the receptor substructure complex 80 was used for all measurements. The 
influence of this receptor (80) should appear at higher concentrations when compared to 
the other receptors as it consists of only one binding site and should therefore have a 
lower affinity. All measurements were conducted in duplicates under the same conditions  
 
Figure 34: Titration curves of receptors 66, 70, 77 – 79 and the reference compound 80 in 
the fluorescence polarization assay with the P1-STAT1-complex. 
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The measurements revealed that receptors 66, 77 and 78 have an influence on the P1-
STAT1 binding at a concentration of about 300 μM while slightly higher concentrations of 
receptors 70 and 79 are needed to show the same effect (400 μM and 500 μM, 
respectively). The reference compound 80 inhibits the complex formation at a 
concentration of nearly 1 mM. These results indicate that the structure of the complexes 
has little influence on their inhibitory effect. Only the two largest compounds 70 and 79 of 
each group are slightly less active than their smaller homologues.  
The results show that all bidentate receptors have an increased inhibitory effect when 
compared to the monodentate substructure 80. The complexes 66, 77 and 78 show the 
same effect at a threefold lower concentration while the complexes 70 and 79 do so at 
half the inhibitory concentration of 80. This shows that the synthetic receptors with two 
binding sites have a higher affinity to the target peptide in the competitive binding than the 
one with only one binding site. However, the kind of the second binding site is not 
decisive, as comparable results were obtained regardless of whether the second binding 
site is a guanidine moiety (receptors 66 and 70) or a Zn(II)-NTA complex (receptors 77 – 
79). 
4.1.2.2. Inhibitory Effect Against the P2-STAT3-Complex 
Additionally, titration experiments with the peptide-protein complex P2-STAT3 were 
performed. Nearly the same results as for the P1-STAT1 inhibition were obtained in these 
experiments. The bidentate receptors showed an influence on the P2-STAT3 binding at 
an inhibitor concentration of 300 - 400 μM while a slightly higher concentration of receptor 
80 was needed to result in the same effect (600 μM). 
As before, the length and also the kind of the second binding site of the receptors did not 
play an important role for the activity of the receptors. The bidentate receptors have an 
increased inhibitory effect being active at half of the inhibitory concentration when 
compared to the monodentate substructure 80. Interestingly, when comparing peptide P1 
to peptide P2, the inhibitor concentration necessary for an influence on the P2-STAT3 
binding when using receptors 66, 70, and 77 – 79 is nearly the same while for the 
complex 80 the concentration is reduced from about 1000 μM for the P1-STAT1-complex 
to 600 μM for the P2-STAT3-complex. 
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Figure 35: Titration curves of receptors 66, 70, 77 – 79 and the reference compound 80 in 
the fluorescence polarization assay with the P2-STAT3-complex. 
4.1.2.3. Inhibitory Effect Against the P3-Gst-Lck-Complex 
The titration experiments with the bidentate ligands 66, 70, 74 and the reference complex 
80 with the P3-GST-Lck-complex were performed in analogy to the systems shown 
before. In contrast to peptides P1 and P2, P3 bears two carboxyl side chain functionalities 
in close proximity to the phosphorylated amino acid. Therefore it was expected to be a 
good binding partner for the receptors containing the bis(Zn(II)-cyclen) triazine complex 
and the guanidinium moiety. However, the measurements revealed almost no difference 
between the bidentate inhibitors 66, 70 and 74 and the reference complex 80. The 
concentrations of all complexes at 50 % of the P3-GST-Lck-complex were found to be in 
the range of 500 – 600 μM. This indicates that only one binding moiety of the bidentate 
receptors 66, 70 and 74 can interact with the P3-GST-Lck-complex. Therefore they show 
the same inhibitory effect as the reference compound 80. 
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Figure 36: Titration curves of receptors 66, 70, 74 and the reference compound 80 in the 
fluorescence polarization assay with the P3-GST-Lck-complex. 
4.1.2.4. Summary 
In conclusion the results of the titration experiments showed that the bidentate receptors 
66, 70 and 77 – 79 show an insignificantly higher inhibitory effect than the reference 
compound 80, at least for the peptide protein complexes P1-STAT1 and P2-STAT3. For 
the P3-GST-Lck-complex this is not the case. Further, no relationship between the 
structure of the receptor and the binding affinity could be determined. 
Because these indirect measurements based on the influence of the metal complexes on 
the inhibition of the interaction between the short fluorescein-labeled peptides P1 - P3 with 
their natural partners (STAT1, STAT3 and GST-Lck) were not entirely successful, it was 
decided to determine the affinity of the metal complexes towards different peptides directly 
through fluorescence measurements. 
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4.2. Binding Affinities Towards the Peptides P7 and P8 
Because the ditopic receptors used in the STAT assay did not show a significantly 
increased activity when compared to the receptor substructure complex 80 and also 
because the results from the inhibitor assay showed a high deviation and a bad 
reproducibility, it was decided to determine the binding of complexes 31, 36, 41, 55, 66, 
70 and 74 – 79 towards peptides with two side chain functionalities. As target peptides, 
the molecules P7 and P8 were selected in analogy to sequences of the human STAT 
proteins and prepared by standard solid-phase peptide synthesis. The peptides were 
N-terminally labeled with 5/6-carboxyfluorescein to allow the measurement of the binding 
constants by fluorescence emission and fluorescence polarization spectroscopy.2 
a) 5/6-Carboxyfluorescein–Gly–pSer–Ala–Ala–His–Val–NH2 (P7) 
b) 5/6-Carboxyfluorescein–Gly–pSer–Ala–Ala–Glu–Val–NH2 (P8) 
The two potential binding sites of peptide P7 are a phosphorylated serine and a histidine. 
Therefore the receptors 31, 36, 41 and 55 comprising of two bis(Zn(II)-cyclen) triazine 
complexes should show a higher affinity towards P7 than towards P8 which, with its pSer, 
presents only one possible binding site for the receptors 31, 36, 41 and 55. In contrast the 
receptors 66, 70 and 74 consisting of one bis(Zn(II)-cyclen) and a guanidinium moiety 
should show a higher affinity towards peptide P8 with its two possible binding sites, 
namely the pSer and the glutamic acid. Like receptors 66, 70 and 74 also receptors 75 – 
79 bearing one bis(Zn(II)-cyclen) triazine and one Zn(II)-NTA complex should bind peptide 
P8 with a higher binding constant than peptide P7.  
4.2.1. Binding Assay 
All binding studies were conducted in buffered aqueous solution (50 mM HEPES buffer, 
pH 7.5, 154 mM NaCl) with an excitation wavelength of λex = 494 nm at a constant 
temperature of 298 K. A Varian Cary Eclipse fluorometer was used for the emission 
titrations. The cuvette with peptide P7 or P8 in HEPES buffer was titrated stepwise with 
small amounts (beginning with 0.13 eq) of the receptor solution. After each addition the 
solution was allowed to equilibrate for 2 min before the fluorescence intensity and the UV 
                                                
2 The synthesis of peptides P7 and P8 and the binding investigations were performed by Alexander 
Riechers under the supervision of Prof. Dr. Burkhard König (Institute of Organic Chemistry, 
University of Regensburg, Regensburg). 
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spectrum (where permitted by the concentration range) were recorded. The 
stoichiometries were determined by Job’s plots calculated from the titration data. To 
determine the binding constants, the obtained fluorescence intensities at 520 nm were 
volume corrected, plotted against the concentration of receptor and evaluated by 
nonlinear fitting. 
Fluorescence polarization titrations were conducted under identical conditions using an 
ISS K2 Multifrequency Phase Fluorometer. 
4.2.2. Binding Results 
Fluorescence titration results of the receptors 31, 36, 41, 55, 66, 70, 74 – 79 and the 
receptor substructures 80 and 81 against the test peptides P7 (shown on the left) and P8 
(shown on the right) are printed below in Figure 37 - Figure 50. The blue and red dashed 
lines represent the measured data while the solid black lines represent the non linear 
fitting of the data. 
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Figure 37: Emission titrations of receptor 31 against peptides P7 (left) and P8 (right). 
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Figure 38: Emission titrations of receptor 36 against peptides P7 (left) and P8 (right). 
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Figure 39: Emission titrations of receptor 41 against peptides P7 (left) and P8 (right). 
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Figure 40: Emission titrations of receptor 55 against peptides P7 (left) and P8 (right). 
 
 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2
concentration 66 [10-4 M]
Δ
 in
te
ns
ity
 [a
.u
.]
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2
concentration 66 [10-8 M]
Δ
 in
te
ns
ity
 [a
.u
.]
 
Figure 41: Emission titrations of receptor 66 against peptides P7 (left) and P8 (right). 
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Figure 42: Emission titrations of receptor 70 against peptides P7 (left) and P8 (right). 
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Figure 43: Emission titrations of receptor 74 against peptides P7 (left) and P8 (right). 
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Figure 44: Emission titrations of receptor 75 against peptides P7 (left) and P8 (right). 
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Figure 45: Emission titrations of receptor 76 against peptides P7 (left) and P8 (right). 
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Figure 46: Emission titrations of receptor 77 against peptides P7 (left) and P8 (right). 
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Figure 47: Emission titrations of receptor 78 against peptides P7 (left) and P8 (right). 
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Figure 48: Emission titrations of receptor 79 against peptides P7 (left) and P8 (right). 
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Figure 49: Emission titration of complex 80 representing a receptor substructure against 
peptide P7. 
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Figure 50: Emission titration of complex 81 representing a receptor substructure against 
peptide P7. 
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4.2.3. Discussion of the Binding Results 
Binding constants of receptors 31, 36, 41, 55, 66, 70, 74 – 79 to peptides P7 and P8 were 
determined by fluorescence emission titrations and non-linear fitting of the data. Job’s 
plots were used to determine the binding stoichiometry, which was found to be 1:1 for all 
experiments. For comparison, the affinity of complexes 80 and 81, representing the 
separate binding sites, to peptides P7 and P8 were measured. Table 1 summarizes the 
results. 
Table 1: Binding affinities of complexes 31, 36, 41, 55, 66, 70, 74 and 75 – 81 to peptides 
P7 and P8. 
binding affinity [logK] 
entry receptor 
peptide P7 peptide P8 
1 31 6.5 5.0 
2 36 7.5 5.0 
3 41 6.5 4.9 
4 55 6.5 4.9 
5 66 4.8 8.0/8.0a 
6 70 4.6 7.9 
7 74 4.8 7.8 
8 75 5.1 8.3 
9 76 4.8 8.2 
10 77 5.0 8.4 
11 78 5.0 7.8 
12 79 5.2 7.5 
13 80 4.8 4.8 
14 81 < 3 n.d. 
a Reference value from fluorescence polarization titrations. 
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The tetra(Zn(II)-cyclen) receptors 31, 36, 41 and 55 show affinities for the histidine 
containing peptide 5/6-carboxyfluorescein–Gly–pSer–Ala–Ala–His–Val–NH2 (P7) of logK 
= 6.5 – 7.5, while the binding to peptide P8 is one to two orders of magnitude weaker 
(logK = 4.9 - 5.0). The interaction of the second bis(Zn(II)-cyclen) triazine with the 
imidazole side chain contributes to the aggregate’s stability. Additional entropic 
stabilization comes from the bivalent structure of 31, 36, 41 and 55 with two identical 
binding sites, in our eyes an example of positive cooperativity in enthalpy.115 The reverse 
binding selectivity is observed for the receptors 66, 70 and 74: The glutamic acid 
containing peptide P8 is bound three orders of magnitude stronger (logK = 8.0, 7.9 and 
7.8, respectively) than peptide P7 (logK = 4.8, 4.6 and 4.8, respectively). This is in 
accordance with our expectations, as the interaction of the guanidine binding site with the 
glutamate carboxylate of peptide P7 is significantly stronger than with the imidazole side 
chain of peptide P8 due to electrostatic attraction. The selectivity of complexes 66, 70 and 
74 is even more pronounced than in the case of the receptors 31, 36, 41 and 55 
containing two bis(Zn(II)-cyclen) triazine complexes. The bis(Zn(II)-cyclen) triazine Zn(II)-
NTA complexes 75 – 79 again show a pronounced selectivity towards peptide P8 with 
logK = 7.5 – 8.3. The binding to peptide P7 is about one thousand fold weaker (logK = 4.8 
– 5.2) and we attribute the selectivity to the interaction of the Zn(II)-NTA with the 
glutamate carboxylate. 
Generally, strong cooperativity of binding in the “matched” cases was found, a behavior 
which has been described before for artificial receptors.116 
A comparison of the peptide binding affinities of bis(Zn(II)-cyclen) triazine complex 80 to 
receptors 31, 36, 41, 55, 66, 70, 74 and 75 – 79 reveals the contribution of the second 
binding site to the overall affinity. Complex 80 binds to both peptides with identical 
strength (logK = 4.8), which shows that the interaction of the phosphate ester with the 
bis(Zn(II)-cyclen) binding site is not affected by the peptide sequence. The binding 
affinities of receptors 31, 36, 41 and 55 to peptide P8 are similar to this value. This leads 
to the conclusion that only one bis(Zn(II)-cyclen) complex is involved in the binding of 
peptide P8 while both are involved in the binding of peptide P7, leading to remarkably 
higher affinity compared to peptide P8. A similar result can be found for the receptors 66, 
70 and 74 which show a similar affinity to P7 as the receptor substructure 80 does, 
leading to the conclusion that the interactions of the guanidinium moiety to peptide P7 are 
negligible. The same applies to the interaction of receptors 75 - 79 with peptide P7: The 
Zn(II)-NTA – imidazole interaction does not contribute to the receptor affinity as the Zn(II)-
NTA – carboxylate binding does. This is confirmed by the binding data of Zn(II)-NTA 
complex 81 to peptides P7 and P8. A weak, but significant interaction was observed with 
peptide P8, while no interaction was found with peptide P7. 
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The influence of the length and type of the linkers was also analyzed. The smallest and 
the largest tetra(Zn(II)-cyclen) complexes with a diamine linker 31 and 41 show exactly 
the same binding affinities to peptide P7 (logK = 6.5). The naphthalene containing 
tetra(Zn(II)-cyclen) complex 55 also has the same binding affinity of logK = 6.5 towards 
P7. Only the medium sized complex 41 has a 10-fold higher affinity with logK = 7.5. 
Reason for this could be that the recognition moieties of receptor 41 have the right 
distance to match the pSer and the i+3 glutamic acid side chains of peptide P7. Although 
the receptors 66, 70 and 74 have different lengths, the spacer of 66 contains one glycine 
while 70 has two and 74 three glycines in the linker, this has nearly no influence on the 
binding constants (logK = 8.0, 7.9 and 7.8, respectively). Similarly, for the Zn(II)-NTA 
containing receptors 75 - 79 only a very slight difference of the binding constants towards 
peptide P8 was observed. The three receptors 75 – 77 which have nearly the same length 
have also nearly the same binding affinities (logK = 8.3, 8.2 and 8.4, respectively). For the 
longer receptor 78 the affinity decreases to logK = 7.8, again it seems that the receptor 
becomes too large for an optimal fit to the peptide binding sites. The affinity of receptor 79 
is even more reduced because this receptor is even larger than complex 78 and in 
addition has an aromatic ring in the linker reducing the flexibility of the spacer and with 
that the affinity towards peptide P8. In summary, it was found that the length or type of the 
linkers connecting the two receptor binding sites has little or no influence on the binding 
affinity. This is not surprising as the short peptides display no stable secondary structure 
in solution and the receptors’ linkers are highly flexible. This means the binding selectivity 
and affinity of the receptor molecules rely on the presence of complementary functional 
groups for non-covalent interaction in reach and not on their exact spatial position. 
To verify the results from the emission titrations by an independent method, fluorescence 
polarization titrations were conducted under identical conditions as the emission titrations. 
The value determined for receptor 66 (see Table 1) is in good agreement with the result 
from the emission titration. Fluorescent labels may falsify binding results by contributing to 
the peptide affinity. To exclude interactions of the label with the receptors, fluorescein 
sodium was titrated with a receptor of each binding motif showing no emission changes 
even at large receptor excess. 
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5. Conclusion 
The combination of bis(Zn(II)-cyclen) triazine metal complex binding sites with 
guanidinium moieties or Zn(II)-NTA complexes leads to artificial receptors for the 
differentiation of phosphorylated peptides which contain either a histidine side chain or a 
glutamic acid side chain as a second binding site. 
General methods for the synthesis of such bidentate receptors consisting either of two 
bis(Zn(II)-cyclen) triazine complexes (31, 36, 41, 55) or of one bis(Zn(II)-cyclen) triazine 
complex and a guanidinium moiety (66, 70, 74) were developed and several receptors 
varying in length were synthesized. 
These complexes in combination with previously prepared complexes consisting of a 
bis(Zn(II)-cyclen) triazine complex in combination with a Zn(II)-NTA complex (75 – 79) 
were tested in a fluorescence polarization assay against the peptide-protein interaction of 
different peptides P1 – P3 and their corresponding proteins STAT1, STAT3 and GST-Lck. 
All receptors were found to be active showing an influence on the peptide-protein binding 
at receptor concentrations of 200 – 600 μM. Unfortunately, it was also found that the 
incorporation of a second binding site into the receptors did not alter the activity of the 
compounds significantly. 
In addition, the synthesized complexes were used to determine their binding affinities 
towards the fluorescently labeled peptides 5/6-Carboxyfluorescein–Gly–pSer–Ala–Ala–
His–Val–NH2 (P7) and 5/6-Carboxyfluorescein–Gly–pSer–Ala–Ala–Glu–Val–NH2 (P8). 
The right combination of binding moieties leads to nanomolar peptide binding affinities in 
aqueous media at physiological pH. To the best of our knowledge these are the highest 
affinities of phosphopeptide binding by artificial receptors reported so far. Depending on 
the second functional group (His or Glu/Asp) beside the phosphate ester, selectivities of 
up to three orders of magnitude of the binding constant are observed. 
Although the bidentate receptors did not show the supposed increased activity in the 
STAT assay, their remarkably high binding affinities and also selectivities to certain 
peptide sequences could make them a versatile tool for the inhibition of peptide-protein 
interactions. Therefore further effort should be undertaken to test the receptors in other 
biologically relevant systems. 
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6. Experimental Part 
General 
All reactions were performed under an inert atmosphere of N2 using standard Schlenk 
techniques if not otherwise stated. A Varian Cary BIO 50 UV/VIS/NIR Spectrometer was 
used. A 1 cm quartz cell was purchased from Hellma and Uvasol solvents from Merck or 
Baker. IR spectra were recorded on a Bio-Rad FT-IR FTS 155 and a Bio-Rad FTS 2000 
MX FT-IR using a Specac Golden Gate Mk II ATR accessory where stated. NMR 
spectrometers used were: Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 
K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K) and Bruker Avance 
300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ 
[ppm] relative to external standards (solvent residual peak). The spectra were analyzed by 
first order, the coupling constants are given in Hertz [Hz]. Characterization of the signals: 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, psq = 
pseudo quintet, dd = double doublet, dt = double triplet, ddd = double double doublet. 
Integration is determined as the relative number of atoms. Assignment of signals in 13C-
spectra was determined with DEPT-technique (pulse angle: 135°) and given as (+) for 
CH3 or CH, (-) for CH2 and (Cquat) for quaternary C. Error of reported values: chemical 
shift: 0.01 ppm for 1H-NMR, 0.1 ppm for 13C-NMR and 0.1 Hz for coupling constants. The 
solvent used is reported for each spectrum. Mass spectra were recorded on Varian CH-5 
(EI), Finnigan MAT 95 (CI; FAB and FD) and Finnigan MAT TSQ 7000 (ESI). Xenon 
served as the ionization gas for FAB. Melting Points were determined on a Büchi SMP-20 
melting point apparatus and are uncorrected. TLC analyses were performed on silica gel 
60 F-254 with a 0.2 mm layer thickness. Detection was via UV light at 254 nm / 366 nm or 
by staining with ninhydrin in EtOH. For preparative column-chromatography, Merck 
Geduran SI 60 silica gel was used. Commercially available solvents of standard quality 
were used. If otherwise stated, purification and drying was done according to accepted 
general procedures.117 
The following compounds were synthesized according to literature known procedures: 
complex 10,118 bis-cyclen triazine 14,105 benzyl 2-aminoethylcarbamate 35,119 tert-butyl 2-
aminoethylcarbamate 45,120 complexes 74 – 78,104 bis(Zn(II)-cyclen) triazine complex 
79118 and Zn(II)-NTA 80.74 
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N1,N2-Bis(4,6-bis-(tri-Boc-cyc)-1,3,5-triazin-2-yl)butane-1,2-diamine (30): 
1,4-Diaminobutane 23 (125 mg, 1.42 mmol) was suspended in dioxane and potassium 
carbonate (785 mg, 5.68 mmol) was added. To the mixture compound 15 (3.00 g, 2.84 
mmol) was added and the solution was refluxed for three days under vigorous stirring. 
The potassium carbonate was filtered off and the solution was evaporated to dryness. The 
crude product was purified by chromatography on silica gel with EtOAc (Rf = 0.76) as 
eluent to give the product as colorless solid (2.01 g, 0.95 mmol, 67 %). 
MP 139-141 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.43 (s, 108 H, Boc-CH3), 1.56 (s, 4 H, 
NH-CH2-CH2), 2.93-3.92 (m, 68 H, Cyclen-CH2 + NH-CH2), 4.73 (bs, 2 H, NH). – 13C-NMR 
(75 MHz, CDCl3): δ = 27.5 (-, 2 C, NH-CH2-CH2), 28.5 (+, 36 C, Boc-CH3), 40.4 (-, 2 C, 
NH-CH2), 50.3 (-, 32 C, Cyclen-CH2), 79.7 (Cquat, 12 C, OC(CH3)3), 156.4 (Cquat, 12 C, 
Boc-CO), 165.8 (Cquat, 6 C, Ar-C). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) 
= 1065.0 (100) [M + 2 H+], 2129.1 (9) [MH+]. – Elemental analysis calcd. (%) for 
C102H182N24O24 (2128.68) + H2O: C 57.07, H 8.64, N 15.66; found: C 57.04, H 8.76, N 
15.44. – IR (neat) [cm-1]: ν~  = 2980, 2932, 2909, 2863, 1689, 1538, 1466, 1408, 1364, 
1245, 1157, 1103, 970, 775. – MF C102H182N24O24. – MW 2128.68. 
N
N
N
N N
NN
BocBoc
Boc
N N
NN
Boc
Boc
Boc
N
H
H
N
N
N
N
NN
N N
Boc Boc
Boc
NN
N N
Boc
Boc
Boc
Section A 6. Experimental Part 
 64 
Complex 31: 
Compound 30 (1.80 mg, 0.85 mmol) was dissolved in methanol and cooled to 0 °C in an 
ice bath. To the solution HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added. 
The mixture was allowed to warm to room temperature and was stirred over night. The 
solvent was evaporated and the crude product was dissolved in water and purified over an 
ion exchanger column using a strongly basic ion exchanger to give a colorless solid after 
freeze drying. Two solutions, one containing the obtained colorless solid from the column 
in water and a second containing Zn(ClO4)2 · 6 H2O (655 mg, 1.76 mmol) in absolute 
ethanol were prepared. These two solutions were simultaneously added to 80 °C hot 
water. The resulting mixture was stirred at 90 °C over night. The solution was freeze dried 
and the product was recrystallized from a water methanol mixture to give the complex 31 
as colorless solid in 17% yield. (250 mg, 0.14 mmol) 
MP > 250 °C. – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc) (K8+ = C42H88N24Zn4) : m/z (%) 
= 257.7 (72) [K8+ + 3 Cl-], 282.7 (62) [K8+ + Cl- + 2 ClO4-], 446.1 (100) [K8+ + 2 OH- +2 Cl- + 
CH3COO-], 477.4 (81) [K8+ + 2 OH- + CH3COO- + ClO4-], 1393.9 (2) [K8+ + 2 OH- + 3 OH- + 
Cl- + ClO4-]. – IR (neat) [cm-1]: ν~  = 3277, 2943, 2843, 2366, 2335, 1550, 1420, 1343, 
1066, 1055, 962, 809, 621. – MF [C42H86N24Zn4]8+(ClO4)6(OH-)2. – MW 1819.54. 
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2-(Boc-amino)-N-(2-(Boc-amino)ethyl)acetamide (82): 
Boc-Gly-OH (32) (1.0 g, 5.7 mmol), HOBt (0.85 g, 6.3 mmol) and DIPEA (1.9 ml, 11 
mmol) were dissolved in DCM (15 ml). To the solution tert-butyl 2-aminoethylcarbamate 
(33) (1.1 g, 6.9 mmol) was added and the mixture was cooled to 0 °C in an ice bath. Then 
EDC (1.1 ml, 6.3 mmol) was added. The reaction was monitored by TLC (EtOAc). After 
24 h the solution was added to water and extracted with DCM. The combined organic 
layers were washed twice with an aqueous citric acid solution (10 %) and twice with brine, 
the solution was dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by column chromatography on silica gel (EtOAc, Rf = 0.28) to give 
the product as a colorless solid (1.0 g, 3.3 mmol, 57 %). 
MP 110-111 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.44 (s, 18 H, 1 + 15), 3.24 (s,2 H, 10), 
3.32-3.41 (m, 2 H, 9), 3.78 (s, 2 H, 6), 5.15 (s, 1 H, 11), 5.34 (s, 1 H, 5), 6.91 (s, 1 H, 8). – 
13C-NMR (75 MHz, CDCl3): δ = 28.3 (+, 3 C, 1/15), 28.4 (+, 3 C, 1/15), 40.4 (-, 2 C, 9 + 
10), 44.3 (-, 1 C, 6), 79.7 (Cquat, 1 C, 2/14), 80.3 (Cquat, 1 C, 2/14), 156.1 (Cquat, 1 C, 4/12) , 
156.7 (Cquat, 1 C, 4/12), 170.3 (Cquat, 1 C, 7). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 318.1 (100) [MH+], 635.5 (16) [2 M + H+]. – IR (neat) [cm-1]: ν~  = 
3334, 2980, 2936, 2360, 1685, 1650, 1521, 1365, 1281, 1244, 1167, 1066, 864. – 
MF C14H27N3O5. – MW 317.38. 
2-Amino-N-(2-aminoethyl)acetamide·2 HCl (34): 
Compound 82 (1.0 g, 3.2 mmol) was dissolved in methanol and cooled to 0 °C in an ice 
bath. To this mixture 10 ml of HCl saturated diethyl ether were added. The mixture was 
allowed to warm to room temperature and stirred over night. The reaction progress was 
monitored by 1H-NMR. The mixture was concentrated under reduced pressure and dried 
at high vacuum to obtain the product as a colorless solid in quantitative yield (0.60 g, 
3.2 mmol). 
MP > 180 °C. – 1H-NMR (300 MHz, D2O): δ = 3.10 (t, 3JH,H = 5.9, 2 H, 6), 3.51 (t, 3JH,H = 
6.0, 2 H, 5), 3.78 (s, 2 H, 2). – 13C-NMR (75 MHz, D2O): δ = 36.9 (-, 1 C, CH2), 39.1 (-, 1 
C, CH2), 40.6 (-, 1 C, CH2),168.1 (Cquat, 1 C, CO). – MS (CI, NH3): m/z (%) = 118.1 (100) 
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[MH+]. – IR (neat) [cm-1]: ν~  = 3166, 2913, 2757, 2360, 2061, 1673, 1567, 1494, 1391, 
1274, 1176, 1070, 901, 757. – MF C4H11N3O x 2 HCl. – MW 254.07. 
Hexa-tert-butyl 10,10'-(6-(2-(2-(4,6-bis(4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetraaza-
cyclodo-decan-1-yl)-1,3,5-triazin-2-ylamino)acetamido)ethylamino)-1,3,5-triazine-2,4-diyl) 
bis(1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate) (35): 
Compound 34 (0.20 g, 1.1 mmol) was suspended in dioxane and potassium carbonate 
(5.8 g, 42 mmol) was added. The mixture was stirred for 30 min then compound 15 (2.2 g, 
2.1 mmol) was added and the solution was refluxed for three days under vigorous stirring. 
The potassium carbonate was filtered off, the solution was evaporated to dryness and the 
crude product was purified by chromatography on silica gel with EtOAc (Rf = 0.76) as 
eluent to give the product 35 as colorless solid (1.5 g, 0.71 mmol, 68 %). 
MP 179-180 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.43 (s, 108 H, Boc-CH3), 2.85-3.93 
(m, 70 H, Cyclen-CH2 + NH-CH2), 5.27 (bs, 2 H, NH), 7.34 (s, 1 H, NH). – 13C-NMR (75 
MHz, CDCl3): δ = 28.5 (+, 36 C, Boc-CH3), 40.6 (-, 1 C, NH-CH2), 42.3 (-, 1 C, NH-CH2-
CH2), 46.4 (-, 1 C, CH2-CO), 50.3 (-, 32 C, Cyclen-CH2), 79.9 (Cquat, 12 C, OC(CH3)3), 
156.3 (Cquat, 12 C, Boc-CO), 165.8 (Cquat, 6 C, Ar-C), 169.5 (Cquat, 1 C, CH2-CO). – MS 
(ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 1079.5 (100) [M + 2 H+], 2158.2 (13) 
[MH+]. – IR (neat) [cm-1]: ν~  = 2974, 2932, 2359, 1686, 1539, 1466, 1408, 1364, 1246, 
1158, 1105, 971, 776. – MF C102H181N25O25. – MW 2157.68. 
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Complex 36: 
Compound 35 (0.94 g, 0.44 mmol) was dissolved in methanol and cooled to 0 °C in an ice 
bath. To the solution HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added. The 
mixture was allowed to warm to room temperature, stirred over night, the solvent was 
evaporated, the crude product was dissolved in water and purified over an ion exchanger 
column using a strongly basic ion exchanger to give the product as a colorless solid after 
lyophilization. Two solutions were prepared: one containing the obtained colorless solid 
from the column in water and a second containing Zn(ClO4)2 · 6 H2O (0.66 g, 1.8 mmol) in 
absolute ethanol. The two solutions were simultaneously added to hot water (80 °C). The 
resulting mixture was stirred at 90 °C over night. The solution was lyophilized and the 
product was recrystallized from a water/methanol mixture to give the complex 36 as 
colorless solid in 84% yield. (0.69 g, 0.37 mmol) 
MP > 250 °C. – MS (ES, H2O/MeOH + 10 mmol/l NH4OAc) (K6+ = C48H93N19O3ClZn4) : m/z 
(%) = 252.0 (50) [K6+ + OH-], 368.9 (41) [K6+ + Cl- + ClO4- + HClO4], 484.1 (93) [K6+ + OH- 
+ 2 ClO4-], 517.7 (100) [K6+ + OH- + 2 ClO4- + HClO4], 826.0 (29) [K6+ + OH- + 3 ClO4- + 
HClO4]. – IR (neat) [cm-1]: ν~  = 3567, 3527, 3284, 2942, 2890, 2357, 1549, 1480, 1423, 
1343, 1067, 812. – MF [C42H85N25OZn4]8+(ClO4)6(OH-)2. – MW 1848.54. 
N
N
N
N
N
H
NN
NN
H
H
N N
N
H
H H
H
N
N
N
N
N
H
N N
N N
H
H
NN
N
H
HH
H
Zn2+
Zn2+ Zn2+
Zn2+
OH--HO
6+
6 ClO4-
H
N
O
Section A 6. Experimental Part 
 68 
Methyl 2-(2-(tert-butoxycarbonylamino)acetamido)acetate (83): 
Boc-Gly-OH (32) (1.2 g, 6.7 mmol), HOBt (1.1 g, 8.0 mmol) and DIPEA (1.9 ml, 11 mmol) 
were dissolved in DCM (20 ml). The solution was cooled to 0 °C in an ice bath and then 
EDC (1.4 ml, 8.0 mmol) was added. After several minutes H-Gly-OMe·HCl (37) was 
added in portions. The solution was allowed to warm to room temperature and was stirred 
over night. The reaction was monitored by TLC (EtOAc). After 24 h the solution was 
added to water, extracted with DCM, the combined organic layers were washed twice with 
an aqueous citric acid solution (10 %) and twice with brine. The organic layer was dried 
over MgSO4, concentrated at reduced pressure and the crude product was purified by 
column chromatography on silica gel (EtOAc, Rf = 0.34) to give the product as a colorless 
oil (0.93 g, 3.8 mmol, 57 %). 
1H-NMR (300 MHz, CDCl3): δ = 1.45 (s, 9 H, 1), 3.75 (s, 3 H, 12), 3.85 (s, 2 H, 6), 4.06 (d, 
3JH,H = 5.5, 2 H, 9), 5.23 (s, 1 H, 5), 6.73 (s, 1 H, 8). – 13C-NMR (75 MHz, CDCl3): δ = 28.3 
(+, 3 C, 1), 41.1 (-, 1 C, 9), 44.2 (-, 1 C, ), 52.5 (+, 1 C, 12), 80.5 (Cquat, 1 C, 2), 156.1 
(Cquat, 1 C, 4), 169.8 (Cquat, 1 C, 4/7), 171.8 (Cquat, 1 C, 4/7). – MS (CI, NH3): m/z (%) = 
147.1 (49) [MH+ - Boc], 164.1 (51) [MNH4+ - Boc], 191.1 (16) [MH+ - C4H8], 208.1 (63) 
[MNH4+ - C4H8], 247.1 (58) [MH+], 264.1 (100) [MNH4+]. – IR (neat) [cm-1]: ν~  = 3281, 
2979, 2359, 2338, 1660, 1525, 1366, 1250, 1161, 1030, 953. – MF C10H18N2O5. – MW 
246.26. 
2-(2-(tert-Butoxycarbonylamino)acetamido)acetic acid (38): 
Boc-Gly-Gly-OMe (83) (0.50 g, 2.0 mmol) was dissolved in 10 ml of methanol and 4 ml of 
an 1 M aqueous sodium hydroxide solution was added. The solution was stirred over night 
and the methanol was evaporated under reduced pressure. The residue was acidified with 
aqueous KHSO4 solution (5 %), the mixture was extracted three times with EtOAc, the 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure to give the product as a colorless solid. (0.42 g, 1.8 mmol, 88 %). 
MP 115-116 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.28 (s, 9 H, 1), 3.63 (s, 2 H, 6), 3.81 
(s, 2 H, 9). – 13C-NMR (75 MHz, CDCl3): δ = 23.5 (+, 3 C, 1), 40.7 (+, 1 C, 6/9), 43.4 (+, 1 
C, 6/9), 80.1 (Cquat, 1 C, 2), 156.5 (Cquat, 1 C, 4), 170.7 (Cquat, 1 C, 7/10), 171.4 (Cquat, 1 C, 
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7/10). – MS (CI, NH3): m/z (%) = 231.0 (100) [M - H+], 267.0 (20) [MCl-], 462.8 (22) [2 M – 
H+]. – IR (neat) [cm-1]: ν~  = 3357, 2986, 2933, 2359, 1735, 1686, 1620, 1523, 1439, 1221, 
1156, 1056, 946, 857. – MF C9H16N2O5. – MW 232.23. 
tert-Butyl 2-(2-(2-(Boc-amino)acetamido)acetamido)ethylcarbamat (84): 
Boc-Gly-Gly-OH (38) (1.2 g, 5.2 mmol), HOBt (0.91 g, 6.7 mmol) and DIPEA (2.7 ml, 15 
mmol) were dissolved in DCM (15 ml). To the solution tert-butyl 2-aminoethylcarbamate 
(33) (1.2 g, 7.8 mmol) was added and the mixture was cooled to 0 °C in an ice bath. Then 
EDC (1.1 ml, 6.7 mmol) was added and the reaction was monitored by TLC (EtOAc). After 
24 h the solution was added to water and extracted with DCM. The combined organic 
layers were washed twice with an aqueous citric acid solution (10 %), twice with brine, the 
organic layer was dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by column chromatography on silica gel (EtOAc:EtOH 80:20, Rf = 
0.09) to give the product as a colorless oil (0.81 g, 2.2 mmol, 42 %). 
MP 116-117 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.43 (s, 9 H, 1/18), 1.45 (s, 9 H, 1/18), 
3.19-3.30 (s, 2 H, 13), 3.32-3.43 (m, 2 H, 12), 3.85 (s, 2 H, 6), 3.97 (d, 3JH,H = 5.5, 2 H, 9), 
5.31 (bs, 1 H, 14), 5.56 (bs, 1 H, 5), 7.19 (bs, 2 H, 8 + 11). – 13C-NMR (75 MHz, CDCl3): δ 
= 28.3 (+, 3 C, 1/18), 28.4 (+, 3 C, 1/18), 40.4 (-, 2 C, 9 + 10), 42.9 (-, 1 C, 9), 44.4 (-, 1 C, 
6), 79.8 (Cquat, 1 C, 2/117), 80.5 (Cquat, 1 C, 2/17), 156.4 (Cquat, 1 C, 4/15) , 156.8 (Cquat, 1 
C, 4/15), 169.4 (Cquat, 1 C, 10), 170.4 (Cquat, 1 C, 7). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 319.1 (36) [MH+ - C4H8], 375.2 (100) [MH+], 392.2 (32) [MNH4+]. – IR 
(neat) [cm-1]: ν~  = 3280, 3184, 2983, 2360, 1677, 1660, 1569, 1464, 1262, 1178, 1108, 
954, 878. – MF C16H30N4O6. – MW 374.43. 
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2-Amino-N-(2-(2-aminoethylamino)-2-oxoethyl)acetamide · 2 HCl (39): 
Compound 84 (0.81 g, 2.2 mmol) was dissolved in methanol and cooled to 0 °C in an ice 
bath. To this mixture 12 ml of HCl saturated diethyl ether were added. The mixture was 
allowed to warm to room temperature and stirred over night. The reaction progress was 
monitored by 1H-NMR. The mixture was concentrated under reduced pressure and dried 
under high vacuum to obtain the product as a colorless solid in 90% yield (0.48 g, 
1.9 mmol). 
MP > 250 °C. – 1H-NMR (300 MHz, D2O): δ = 3.07 (t, 3JH,H = 5.8, 2 H, 9), 3.45 (t, 3JH,H = 
5.9, 2 H, 8), 3.82 (s, 2 H, 2), 3.92 (s, 2 H, 5). – 13C-NMR (75 MHz, D2O): δ = 36.9 (-, 1 C, 
9), 39.2 (-, 1 C, 8), 40.5 (-, 1 C, 2), 42.5 (-, 1 C, 5), 168.0 (Cquat, 1 C, CO), 172.2 (Cquat, 1 
C, CO). – MS (CI, NH3): m/z (%) = 175.1 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3280, 2990, 
2879, 2359, 2016, 1677, 1660, 1570, 1465, 1264, 1178, 1108, 1009, 906, 788. – 
MF C6H14N4O2 x 2 HCl. – MW 247.12. 
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Hexa-tert-butyl 10,10'-(6-(2-(2-(2-(4,6-bis(4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetra-
azacyclododecan-1-yl)-1,3,5-triazin-2-ylamino)acetamido)acetamido)ethylamino)-1,3,5-
triazine-2,4-diyl)bis(1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate) (40): 
Compound 39 (0.35 g, 1.4 mmol) was suspended in dioxane and potassium carbonate 
(7.9 g, 57 mmol) was added. The mixture was stirred for 30 min, then compound 15 
(3.0 g, 2.8 mmol) was added and the solution was refluxed for three days under 
vigorous stirring. The potassium carbonate was filtered off. The solution was evaporated 
to dryness and the crude product was purified by chromatography on silica gel with EtOAc 
(Rf = 0.30) as eluent to give the product 40 as a colorless solid (1.9 g, 0.62 mmol, 44 %). 
MP 162-163 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.43 (s, 108 H, Boc-CH3), 2.85-4.08 
(m, 72 H, Cyclen-CH2 + NH-CH2), 5.05 (bs, 2 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 
28.5 (+, 36 C, Boc-CH3), 39.9 (-, 1 C, NH-CH2), 42.8 (-, 1 C, NH-CH2-CH2), 44.8 (-, 1 C, 
CH2-CO), 47.4 (-, 1 C, CH2-CO), 50.3 (-, 32 C, Cyclen-CH2), 79.8 (Cquat, 12 C, OC(CH3)3), 
156.8 (Cquat, 12 C, Boc-CO), 165.8 (Cquat, 6 C, Ar-C), 169.5 (Cquat, 1 C, CH2-CO). – MS 
(ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 1108.5 (100) [M + 2 H+], 2115.3 (8) 
[MH+]. – IR (neat) [cm-1]: ν~  = 2974, 2933, 2360, 2344, 1686, 1539, 1466, 1409, 1364, 
1246, 1158, 971, 858. – MF C102H184N26O26. – MW 2214.73. 
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Complex 41: 
The Boc protected compound 40 (1.4 g, 0.62 mmol) was dissolved in methanol and 
cooled to 0 °C in an ice bath. To this solution HCl saturated diethyl ether (0.7 ml/mmol 
Boc-group) was added. The mixture was allowed to warm to room temperature and was 
stirred over night. The solvent was evaporated, the crude product was dissolved in water 
and purified over an ion exchanger column using a strongly basic ion exchanger 
(OH--form, loading 0.9 mmol/ml, 4 eq. per protonated nitrogen) to give a colorless solid 
after lyophilization. Then two solutions were prepared: one containing the obtained 
colorless solid from the column in water and a second one containing Zn(ClO4)2 · 6 H2O 
(0.90 g, 2.4 mmol, 4.4 eq. per deprotected receptor) in absolute ethanol. These two 
solutions were simultaneously added drop wise to water at 80 °C under vigorous stirring. 
The resulting mixture was stirred at 90 °C over night, and then lyophilized. The product 
was recrystallized from a water methanol mixture to give the complex as a colorless solid 
in 63 % yield. (0.75 g, 0.39 mmol). 
MP > 250 °C. – MS (ES, H2O/AcN/MeOH + 10 mmol/l NH4OAc) (K8+ = C44H88N26O2Zn4) : 
m/z (%) = 377.7 (82) [K8+ + 4 CH3COO-], 503.4 (52) [K8+ + OH- + Cl- + 3 CH3COO-], 536.8 
(100) [K8+ + 4 CH3COO- + ClO4-], 854.5 (15) [K8+ + OH- + 2 CH3COO- + 3 ClO4-], 875.4 
(14) [K8+ + OH- + CH3COO- + 4 ClO4-], 896.0 (16) [K8+ + OH- + 5 ClO4-]. – IR (neat) [cm-1]: 
ν~  = 3585, 3387, 3296, 2943, 2894, 2360, 1652, 1548, 1480, 1424, 1343, 1286, 1232, 
1067, 962, 808. – MF [C44H90N26O2Zn4]8+(ClO4)6(OH)2. – MW 1905.59. 
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Boc-Lys(Cbz)-ED-Boc (47): 
Boc-Lys(Cbz)-OH 42 (2.00 g, 5.26 mmol), HOBt (781 mg, 5.78 mmol) and DIPEA (1.80 
ml, 10.5 mmol) were dissolved in DCM (15 ml). To the solution tert-butyl 
2-aminoethylcarbamate 33 (1.01 g, 6.31 mmol) was added and the mixture was cooled to 
0 °C in an ice bath. Then EDC (1.02 ml, 5.78 mmol) was added. The reaction was 
monitored by TLC (EtOAc). After 24 hours the solution was uptaken in water and 
extracted with DCM. The combined organic layers were then washed twice with an 
aqueous citric acid solution (10 %) and twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel (EtOAc, Rf = 0.45) to give the product as colorless 
solid (2.31 g, 4.42 mmol, 84 %). 
MP 101-102 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.29-91 (m, 24 H, 1 + 15 +16 + 17 
+18), 3.12-3.29 (m, 4 H, 10 + 19), 3.31-3.42 (m, 2 H, 9), 4.01 (m, 1 H, 6), 4.95-5.18 (m, 4 
H, 11 + 20 + 23), 5.26 (s, 1 H, 5), 6.74 (s, 1 H, 8), 7.28-7.40 (m, 5 H, 25 + 26 + 27). – 13C-
NMR (75 MHz, CDCl3): δ = 22.5 (-, 1 C, 17), 28.3 (+, 3 C, 1/15), 28.4 (+, 3 C, 1/15), 29.4 
(-, 1 C, 18), 32.0 (-, 1 C, 16), 40.4 (-, 3 C, 9 + 10 + 19), 54.5 (-, 1 C, 6), 66.7 (-, 1 C, 23), 
79.7 (Cquat, 1 C, 2/14), 80.1 (Cquat, 1 C, 2/14), 128.1 (+, 3 C, 25 + 27), 128.5 (+, 2 C, 26), 
136.6 (Cquat, 1 C, 24), 155.9 (Cquat, 1 C, 4/12/22), 156.6 (Cquat, 1 C, 4/12/22), 156.7 (Cquat, 1 
C, 4/12/21), 172.7 (Cquat, 1 C, 7). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 
423.3 (15) [MH+ - Boc], 523.4 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3336, 2985, 2941, 1683, 
1656, 1521, 1367, 1242, 1163, 1055, 981, 694. – MF C26H42N4O7. – MW 522.63. 
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Boc-Lys-ED-Boc (43): 
Compound 47 (1.00 g, 1.91 mmol) was dissolved in methanol. To this mixture one spatula 
of Pd on activated charcoal (10 % Pd) was added. The mixture was stirred under 10 bar of 
H2 over night. The Pd was filtered off and the mixture was concentrated under reduced 
pressure and dried under high vacuum to obtain the product as colorless oil in 94 % yield 
(700 mg, 1.80 mmol). No further purification was necessary. 
MP 44-45 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.35-86 (m, 24 H, 1 + 15 + 16 + 17 + 18), 
2.45 (s, 2 H, 20), 2.72 (t, 3JH,H = 6.3, 2 H, 19), 3.15-3.29 (m, 2 H, 10), 3.30-3.41 (m, 2 H, 
9), 4.04 (s, 1 H, 6), 5.23 (s, 2 H, 5 + 11), 7.03 (s, 1 H, 8). – 13C-NMR (75 MHz, CDCl3): δ = 
22.6 (-, 1 C, 17), 28.4 (+, 6 C, 1 + 15), 32.2 (-, 1 C, 16/18), 32.4 (-, 1 C, 16/18), 40.2 (-, 2 
C, 9 + 10), 41.3 (-, 1 C, 19), 54.5 (+, 1 C, 6), 79.5 (Cquat, 1 C, 2/14), 80.0 (Cquat, 1 C, 2/14), 
155.8 (Cquat, 1 C, 4/12) , 156.6 (Cquat, 1 C, 4/12), 172.7 (Cquat, 1 C, 7). – MS (ES, 
DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 389.1 (100) [MH+], 777.6 (31) [2M + H+]. – 
IR (neat) [cm-1]: ν~  = 2976, 2931, 2866, 1689, 1658, 1516, 1365, 1247, 1167, 1045, 1015. 
– MF C18H36N4O5. – MW 388.50. 
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Boc-Lys(Ds)-ED-Boc (85): 
Compound 43 (700 mg, 1.80 mmol) was dissolved in 10 ml of DCM and was cooled to 
0 °C in an ice bath. To the solution NEt3 (749 μl, 5.41 mmol) was added drop by drop. 
Then the dansyl chloride 44 (729 mg, 2.70 mmol) was added in portions. The solution was 
allowed to warm to room temperature and was stirred over night. The solution was 
uptaken in water and was extracted with DCM three times. The combined organic layers 
were washed twice with brine. Afterwards the solution was dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography on silica gel (EtOAc, Rf = 0.51) to give the product as yellow solid 
(1.04 g, 1.67 mmol, 93 %). 
MP 88-89 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.24-1,78 (m, 24 H, 1 + 15+ 16 + 17 + 
18), 2.83-2.95 (m, 8 H, 19 + 33), 3.19-3.41 (m, 4 H, 9 + 10), 4.00 (s, 1 H, 6), 5.16-5.32 (m, 
2 H, 5 + 11), 5.46 (s, 1 H, 20), 6.80 (s, 1 H, 8), 7.19 (d, 3JH,H = 7.4, 1 H, H-Ar), 7.48-7.59 
(m, 2 H, H-Ar), 8.23 (dd, 3JH,H = 7.4, 3JH,H = 1.1, 1 H, H-Ar), 8.32 (d, 3JH,H = 8.5, 1 H, H-Ar), 
8.55 (d, 3JH,H = 8.5, 1 H, H-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 22.3 (-, 1 C, 17), 28.4 (+, 
6 C, 1/15), 29.0 (-, 1 C, 18), 32.0 (-, 1 C, 16), 40.3 (-, 2 C, 9 + 10), 42.8 (-, 1 C, 19), 45.5 
(+, 2 C, 33), 54.3 (+, 1 C, 6), 79.6 (Cquat, 1 C, 2/14), 80.1 (Cquat, 1 C, 2/14), 115.4 (+, 1 C, 
28), 123.4 (+, 1 C, 30), 128.3 (+, 1 C, 23), 129.6 (+, 2 C, 24 + 29), 129.6 (Cquat, 1 C, 26), 
129.7 (Cquat, 1 C, 31), 130.2 (+, 1 C, 25), 134.9 (Cquat, 1 C, 22), 155.8 (Cquat, 1 C, 4/12), 
155.9 (Cquat, 1 C, 27), 156.7 (Cquat, 1 C, 4/12), 172.6 (Cquat, 1 C, 7). – MS (ES, DCM/MeOH 
+ 10 mmol/l NH4OAc): m/z (%) = 566.3 (34) [MH+ - C4H8], 622.4 (100) [MH+]. – IR (neat) 
[cm-1]: ν~  = 2978, 2940, 2870, 2833, 1688, 1660, 1506, 1365, 1246, 1159, 1140, 1094, 
1046, 862, 790. – MF C30H47N5O7S. – MW 622.79. 
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2-Amino-N-(2-aminoethyl)-6-(5-(dimethylamino)naphthalene-1-sulfonamido)hexanamide · 
3 HCl (45): 
Compound 85 (1.00 g, 1.61 mmol) was dissolved in methanol and cooled to 0 °C in an ice 
bath. To the solution HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added. The 
mixture was allowed to warm to room temperature and stirred over night. The reaction 
progress was monitored by 1H-NMR. The mixture was concentrated under reduced 
pressure and dried under high vacuum to obtain the product as colorless solid in 92 % 
yield (760 mg, 1.47 mmol). 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 1.35-1.58 (m, 4 H, 9 + 10), 1.73-1.92 
(m, 2 H, 8), 2.89 (t, 3JH,H = 6.6 ,2 H, 11), 3.04-3.21 (m, 2 H, 6), 3.38-3.49 (m, 1 H, 5), 3.53 
(s, 6 H, 24), 3.57-3.69 (m, 1 H, 5), 3.88 (t, 3JH,H = 6.6, 2 H, 2), 7.86-7.97 (m, 2 H, H-Ar), 
8.18 (d, 3JH,H = 7.4, 1 H, H-Ar), 8.39 (dd, 3JH,H = 0.4, 3JH,H = 7.0, 1 H, H-Ar), 8.65 (d, 3JH,H = 
8.8, 1 H, H-Ar), 8.97 (d, 3JH,H = 8.8, 1 H, H-Ar). – 13C-NMR (75 MHz, MeOH-d4): δ = 22.6 (-
, 1 C, CH2), 29.1 (-, 1 C, 10), 34.0 (-, 1 C, 8), 36.6 (-, 1 C, 5/6), 39.2 (-, 1 C, 5/6), 42.7 (-, 1 
C, 11), 45.4 (+, 2 C, 25), 54.8 (+, 1 C, 2), 115.2 (+, 1 C, Ar-CH), 119.0 (+, 1 C, Ar-CH), 
123.2 (+, 1 C, Ar-CH), 128.2 (+, 1 C, Ar-CH), 129.1 (+, 1 C, Ar-CH), 129.6 (Cquat, 1 C, Ar-
C), 129.8 (Cquat, 1 C, Ar-C), 130.2 (+, 1 C, Ar-CH), 135.1 (Cquat, 1 C, Ar-C), 151.1 (Cquat, 1 
C, 19), 174.0 (Cquat, 1 C, 3). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 
231.9 (100) [M + 2H+], 422.0 (24) [MH+]. – IR (neat) [cm-1]: ν~  = 2943, 2864, 2832, 2793, 
1655, 1574, 1307, 1139, 1092, 1075, 911, 789, 725. – MF C20H31N5O3S · 3 HCl. – MW 
530.94. 
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Benzyl 5-amino-6-(2-aminoethylamino)-6-oxohexylcarbamate · 2 HCl (48): 
Compound 85 (500 mg, 0.96 mmol) was dissolved in methanol and cooled to 0 °C in an 
ice bath. To the solution HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added. 
The mixture was allowed to warm to room temperature and stir over night. The reaction 
progress was controlled by 1H-NMR. The mixture was concentrated under reduced 
pressure and dried under high vacuum to obtain the product as colorless solid in 
quantitative yield (379 mg, 0.96 mmol). 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 1.45-1.61 (m, 2 H, 10), 1.67-1.81 (m, 2 
H, 9), 1.84-2.03 (m, 2 H, 8), 2.98 (t, 3JH,H = 7.6 ,2 H, 11), 3.05-3.24 (m, 2 H, 6), 3.44 (dt, 
2JH,H = 15.0, 1 H, 3JH,H = 6.2, 1 H, 1 H, 5), 3.69 (ddd, 2JH,H = 5.3, 3JH,H = 7.2, 2JH,H = 14.5, 1 
H, 5), 3.97 (t, 3JH,H = 6.7, 2 H, 2), 5.49 (s, 2 H, 15), 7.26-7.43 (m, 5 H, H-Ar). – 13C-NMR 
(75 MHz, MeOH-d4): δ = 23.2 (-, 1 C, 9), 28.0 (-, 1 C, 10), 31.8 (-, 1 C, 8), 38.3 (-, 1 C, 
5/6), 40.4 (-, 1 C, 5/6), 40.6 (-, 1 C, 11), 54.5 (+, 1 C, 2), 67.0 (-, 1 C, 15), 129.4-129.8 (+, 
5 C, 17-19), 139.4 (Cquat, 1 C, 16), 163.8 (Cquat, 1 C, 13), 171.3 (Cquat, 1 C, 3). – MS (ES, 
MeCN + 0.059 % TFA): m/z (%) = 182.7 (38) [M + MeCN + 2H+], 203.0 (31) [M + 2 MeCN 
+ 2 H+], 323.1 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 2940, 2862, 2829, 2796, 1652, 1574, 
1304, 1140, 1092, 1075, 909, 789. – MF C16H26N4O3 · 2 HCl. – MW 395.33. 
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Hexa-tert-butyl 10,10'-(6-(2-(benzyloxycarbonylamino)ethylamino)-1,3,5-triazine-2,4-diyl) 
bis(1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate) (51): 
Benzyl 2-aminoethylcarbamate 50 (1.47 g, 7.6 mmol) was suspended in dioxane and 
potassium carbonate (42 g, 0.30 mol) was added. The mixture was stirred for half an hour, 
then compound 15 (5.0 g, 4.7 mmol) was added and the solution was refluxed for three 
days under vigorous stirring. The potassium carbonate was filtered off and the solution 
was evaporated to dryness. The crude product was purified by chromatography on silica 
gel with PE:EtOAc 80:20 (Rf (PE:EtOAc 1:1) = 0.47) as eluent to give the product as a 
colorless solid (4.8 g, 4.0 mmol, 84 %). 
MP 134-135 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.22-1.56 (m, 54 H, Boc-CH3), 2.81-
3.88 (m, 36 H, Cyclen-CH2 + NH-CH2-CH2), 4.88 (s, 1 H, NH), 5.05 (s, 2 H, CH2-Cbz), 
6.67 (s, 1 H, NH), 7.27-7.37 (m, 5 H, CH-Cbz). – 13C-NMR (75 MHz, CDCl3): δ = 28.5 (+, 
18 C, Boc-CH3), 40.2 (-, 1 C, NH-CH2), 41.0 (-, 1 C, NH-CH2), 49.5-51.1 (-, 16 C, Cyclen-
CH2), 66.4 (-, 1 C, CH2-Cbz), 79.8 (Cquat, 6 C, OC(CH3)3), 127.9 (+, 1 C, CH-Cbz), 128.2 
(+, 1 C, CH-Cbz), 128.3 (+, 1 C, CH-Cbz), 136.9 (Cquat, 1 C, C-Ar-Cbz), 155.9-157.4 (Cquat, 
7 C, Boc-CO + Cbz-CO), 166.0 (Cquat, 3 C, Ar-C). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 1214.9 (100) [MH+]. – Elemental Analysis calcd. (%) for 
C49H99N13O14 (1214.50): C 58.35, H 8.22, N 14.99. - found: C 58.33, H 8.19, N 14.79. – IR 
(neat) [cm-1]: ν~  = 3350, 2974, 2932, 1685, 1538, 1409, 1364, 1246, 1158, 1105, 972, 
776. – MF C49H99N13O14. – MW 1214.50. 
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Hexa-tert-butyl 10,10'-(6-(2-aminoethylamino)-1,3,5-triazine-2,4-diyl)bis(1,4,7,10-tetraaza-
cyclododecane-1,4,7-tricarboxylate) (52): 
Compound 51 (4.8 g, 4.0 mmol) was dissolved in methanol. To this mixture a spatula of 
palladium on activated charcoal was added (10 % Pd). The mixture was stirred at 30 bars 
of H2 pressure for three days. The charcoal was filtered off. The mixture was concentrated 
under reduced pressure and dried under high vacuum to obtain the product as a colorless 
solid in 79 % yield (3.4 g, 3.1 mmol). No further purification was necessary. 
MP 126-127 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.29-1.58 (m, 54 H, Boc-CH3), 2.85-
2.96 (m, 2 H, CH2-NH2), 3.13-3.86 (m, 34 H, Cyclen-CH2 + CH2-CH2-NH2). –13C-NMR (75 
MHz, CDCl3): δ = 28.5 (+, 18 C, Boc-CH3), 41.7 (-, 1 C, CH2), 43.0 (-, 1 C, CH2), 50.3 (-, 
16, Cyclen-CH2), 79.9 (Cquat, 6 C, Boc- Cquat), 156.5 (Cquat, 6 C, Boc-CO), 166.1 (Cquat, 3 C, 
C-Ar). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 1081.1 (100) [MH+]. – IR 
(neat) [cm-1]: ν~  = 2973, 2930, 1686, 1539, 1466, 1408, 1364, 1247, 1159, 1105, 971, 
776. – MF C51H93N13O12. – MW 1080.36. 
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Compound 53: 
Compound 27 (975 mg, 0.90 mmol) was suspended in 20 ml of toluene and 
diisopropylethyl amine (170 µl, 0.99 mmol) was added. The mixture was stirred for half an 
hour then compound 52 (110 mg, 0.41 mmol) was added and the solution was stirred for 
one day at 100 °C. After filtration of the mixture, the solution was concentrated under 
reduced pressure and the crude product was purified via flash-chromatography on silica 
gel with EtOAc (Rf = 0.69) as eluent to give the product as pale yellow solid (940 mg, 
0.39 mmol, 94 %). 
MP 178-180 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.29-1.60 (m, 108 H, Boc-CH3), 3.12-
4.02 (m, 68 H, Cyclen-CH2 + 2), 4.41 (s, 4 H, 3), 4.93-5.22 (m, 2 H, 1), 8.74 (s, 4 H, 7). – 
13C-NMR (75 MHz, CDCl3): δ = 28.5 (+, 36 C, Boc-CH3), 40.4 (-, 2 C, 2), 50.3 (-, 32 C, 
Cyclen-CH2), 51.0 (-, 2 C, 3), 79.7 (Cquat, 12 C, OC(CH3)3), 126.6 (Cquat, 4 C, 6) , 126.8 
(Cquat, 2 C, 8), 131.1 , 126.6 (+, 4 C, 7), 155.7-157.0 (Cquat, 12 C, Boc-CO), 162.9 (Cquat, 4 
C, 5), 165.9 (Cquat, 6 C, triacene-C). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z 
(%) = 1197.6 (100) [M + 2 H+], 2394.3 (7) [MH+]. – Elemental analysis calcd. (%) for 
C116H186N26O28 (2392.88) + EtOAc: C 58.09, H 7.88, N 14.68; found: C 58.08, H 7.96, N 
14.26. – IR (neat) [cm-1]: ν~  = 2977, 2928, 1688, 1667, 1536, 1495, 1466, 1408, 1364, 
1244, 1157, 1105, 972, 771. – UV/VIS (MeCN): λ (lg ε) = 338 nm (4.066), 356 nm (4.272), 
376 nm (4.311). – MF C116H186N26O28. – MW 2392.88. 
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Complex 55: 
Compound 53 (144 mg, 0.06 mmol) was dissolved in methanol and cooled to 0 °C in an 
ice bath. To the solution HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added. 
The mixture was allowed to warm to room temperature and was stirred over night. The 
solvent was evaporated and the crude product was dissolved in water and purified over an 
ion exchanger column using a strongly basic ion exchange resin (OH- -form, loading 0.9 
mmol/ml, 4 eq. per protonated nitrogen) to give a colorless solid after freeze drying. Two 
solutions one containing the obtained colorless solid from the column in water and a 
second containing Zn(ClO4)2 · 6 H2O (96 mg, 0.26 mmol, 4.4 eq. per deprotected receptor) 
in absolute ethanol were prepared. These two solutions were then simultaneously added 
drop wise to 80 °C hot water under vigorous stirring. The resulting mixture was stirred at 
90 °C over night. The solution was freeze dried and the product was recrystallized from a 
water methanol mixture to give the complex as ocher solid in 64 % yield. (85 mg, 
0.04 mmol). 
MP > 180 °C. – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc) (K8+ = C56H90N26O4Zn4) : m/z 
(%) = 420.8 (100) [K8+ + 4 CH3COO-], 541.3 (44) [K8+ - 2 H- + 3 CH3COO-], 560.7 (100) 
[K8+ - H- + 4 CH3COO-], 566.7 (49) [K8+ + OH-, 4 CH3COO-], 580.7 (73) [K8+ + 5 CH3COO-], 
594.0 (40) [K8+ + 4 CH3COO- + ClO4-]. – IR (neat) [cm-1]: ν~  = 3374, 3289, 3268, 2941, 
2896, 1698, 1659, 1539, 1424, 1343, 1070, 965, 807, 769, 621. – UV/VIS (HEPES pH 
7.4): λ (lg ε) = 362 nm (4.178), 383 nm (4.176). – MF [C56H90N26O4Zn4]8+(ClO4)6(OH)2. – 
MW 2083.74. 
6+
6 ClO4-
O
N
O
O
N
O
H
N
N
H
NN
N
N
N
N
N
H
H
H
N
N
N
N
H
H
H
N N
N
N
N
N
N
H
H
H
N
N
N
N
H
H
H
Zn2+
Zn2+
Zn2+
Zn2+
OH-
OH-
Section A 6. Experimental Part 
 82 
Compound 54: 
Compounds 52 (991 mg, 0.92 mmol) and 28 (150 mg, 0.38 mmol) were mixed with 4 g of 
imidazole and filled into a Schlenk tube. Under an atmosphere of nitrogen the mixture was 
melted with a heat gun and then put into an oil bath where it was stirred at 120 °C for one 
day. The hot melt was poured into 20 ml of water and the product was extracted three 
times with 15 ml EtOAc. The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash-
chromatography on silica gel with DCM:MeOH 97:3 (Rf(DCM:MeOH 97:3) = 0,28) as eluent to 
give the product as dark red solid (1.53 g, 0.71 mmol, 68 %). 
MP 175-176 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.23-1.53 (m, 108 H, Boc-CH3), 2.66-
3.92 (m, 68 H, Cyclen-CH2 + CH2), 4.39 (bs, 4 H, CH2), 5.30 (bs, 2 H, NH), 8.30 (d, 3JH,H = 
7.41, 4 H, 2), 8.43 (d, 3JH,H = 7.68, 4 H, 3). – 13C-NMR (75 MHz, CDCl3): δ = 28.5 (+, 36 C, 
Boc-CH3), 39.5 (-, 2 C, CH2), 40.1 (-, 2 C, CH2), 49.5-51.5 (-, 32 C, Cyclen-CH2), 79.7 
(Cquat, 12 C, OC(CH3)3), 122.9 (Cquat, 2 C, 6), 123.2 (+, 4 C, 3), 125.9 (Cquat, 2 C, 5), 129.0 
(Cquat, 4 C, 1), 131.2 (+, 4 C, 2), 134.2 (Cquat, 4 C, 4), 155.5-157.4 (Cquat, 12 C, Boc-CO), 
163.3 (Cquat, 4 C, 5), 166.0 (Cquat, 6 C, Triacene-C). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 1259.6 (100) [M + 2 H+]. – Elemental analysis calcd. (%) for 
C126H190N26O28 (2517.01) + 2 H2O: C 59.28, H 7.66, N 14.26; found: C 59.32, H 7.67, N 
14.01. – IR (neat) [cm-1]: ν~  = 3297, 2986, 2942, 2928, 2898, 2366, 2336, 1697, 1655, 
1542, 1476, 1419, 1349, 1061, 1049, 965, 811, 738, 620. – UV/VIS (MeCN): λ (lg ε) = 456 
nm (3.873), 484 nm (4.355), 521 nm (4.497). – MF C126H190N26O28 – MW 2517.01. 
N
O
N
O
H
N
N
H
NN
N
N
N
N
N
Boc
Boc
Boc
N
N
N
N
Boc
Boc
Boc
N N
N
N
N
N
N
Boc
Boc
Boc
N
N
N
N
Boc
Boc
Boc
O
O
1
6
4
5
3
2
Section A 6. Experimental Part 
 83
Complex 56: 
Compound 54 (230 mg, 0.09 mmol) was dissolved in methanol and cooled to 0 °C in an 
ice bath. To the solution HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added. 
The mixture was allowed to warm to room temperature and was stirred over night. The 
solvent was evaporated and the crude product was dissolved in water and purified over an 
ion exchanger column using a strongly basic ion exchange resin (OH--form, loading 
0.9 mmol/ml, 4 eq. per protonated nitrogen) to give a colorless solid after freeze drying. 
Two solutions one containing the obtained colorless solid from the column in water and a 
second containing Zn(ClO4)2 · 6 H2O (125 mg, 0.33 mmol, 4.4 eq. per deprotected 
receptor) in absolute ethanol were prepared. These two solutions were simultaneously 
added drop wise to 80 °C hot water under vigorous stirring. The resulting mixture was 
stirred at 90 °C over night. The solution was freeze dried and the product was 
recrystallized from a water methanol mixture to give the complex as violet red solid in 
60 % yield. (118 mg, 0.05 mmol) 
MP > 180 °C. – MS (ES, H2O/MeOH + 10 mmol/l NH4OAc) (K8+ = C66H92N26O4Zn4) : m/z 
(%) = 436.3 (35) [K8+ - H+ + 3 CH3COO-], 451.8 (100) [K8+ + 4 CH3COO-], 602 (48) [K8+ - 
H+ + 4 CH3COO-], 608.0 (32) [K8+ + OH- + 4 CH3COO-], 621.5 (36) [K8+ + 5 CH3COO-]. – 
IR (neat) [cm-1]: ν~  = 3276, 2926, 1692, 1654, 1558, 1438, 1361, 1347, 1089, 964, 810, 
746. – UV/VIS (HEPES pH 7.4): λ (lg ε) = 500 nm (3.733), 538 nm (3.844). – 
MF [C66H94N26O4Zn4]8+(ClO4)6(OH)2. – MW 2207.88. 
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tert-Butyl 2-(2,3-bis(Cbz)guanidino) ethylcarbamate (86): 
Tert-butyl 2-aminoethylcarbamate 33 (335 mg, 2.09 mmol) was dissolved in dioxane and 
triethylamine (0.58 ml, 4.19 mmol) was added. The mixture was stirred for 10 minutes. 
Then 1,3-bis(Cbz)-2-methyl-2-thiopseudourea 57 (500 mg, 1.40 mmol) was added and the 
mixture was stirred for 100 min at room temperature. The reaction process was controlled 
by TLC. The reaction mixture was uptaken in water and extracted three times with DCM. 
Afterwards the solution was dried over MgSO4 and concentrated under reduced pressure. 
The crude product was purified by column chromatography on silica gel (EtOAc:PE 1:1, 
Rf = 0,56). The pure product was obtained as colorless solid in 91 % yield. (600 mg, 1.28 
mmol) 
MP 80-83 °C. – 1H-NMR (300 MHz, CDCl3): δ = 3.25-3.39 (m, 2 H, 6), 3.50-3.61 (m, 2 H, 
7), 5.06 (s, 1 H, 5), 5.13 (s, 2 H, 13/21), 5.17 (s, 2 H, 13/21), 7.27-7.44 (m, 10 H, 15-17 + 
23-25), 8.54 (s, 1 H, 8), 11.77 (s, 1 H, 10). – 13C-NMR (75 MHz, CDCl3): δ = 28.3 (+, 3 C, 
1), 40.2 (-, 1 C, 6), 41.3 (-, 1 C, 7), 67.3 (-, 1 C, 10/18), 68.3 (-, 1 C, 10/18), 79.5 (Cquat., 1 
C, 2), 128.0-128.9 (+, 10 C, 15-17 + 23-25), 134.6 (Cquat., 1 C, 14/22), 136.6 (Cquat., 1 C, 
14/22), 153.6 (Cquat., 1 C, 11/19), 156.1 (Cquat., 1 C, 9), 156.3 (Cquat., 1 C, 4), 163.3 (Cquat., 1 
C, 11/19). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 471 (100) [MH+]. – IR 
(neat) [cm-1]: ν~  = 3133, 2964, 1762, 1736, 1668, 1592, 1496, 1264, 1241, 1206, 1155, 
1061, 981, 915, 790, 772, 735, 693. – MF C24H30N4O6. – MW 470.52. 
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1-(2-Aminoethyl)-2,3-di(Boc)guanidine·HCl (58):  
Tert-butyl 2-(2,3-bis(Cbz)guanidino) ethylcarbamate 86 (600 mg, 1.28 mmol) was 
dissolved in DCM and cooled to 0 °C in an ice bath. To this solution 6 ml of HCl saturated 
diethyl ether were added. The mixture was allowed to warm to room temperature and 
stirred over night. The reaction progress was monitored by 1H-NMR. The solvent was 
evaporated under reduced pressure to obtain the hydrochloride salt of the product as 
colorless solid in quantitative yield (521 mg, 1.28 mmol). 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 3.25 (t, 3JH,H = 6.0, 2 H, 2), 3.85 (t, 
3JH,H = 5.9, 2 H, 3), 5.31 (s, 2 H, 9/17), 5.34 (s, 2 H, 9/17), 7.29-7.53 (m, 10 H, 11-13 + 19-
21). – 13C-NMR (75 MHz, MeOH-d4): δ = 39.5 (-, 1 C, 2), 41.6 (-, 1 C, 3), 67.3 (-, 1 C, 
9/17), 70.7 (-, 1 C, 9/17), 128.8-130.1 (+, 10 C, 11-13 + 19-21), 136.1 (Cquat., 1 C, 10/18), 
138.4 (Cquat., 1 C, 10/18), 153.7 (Cquat., 1 C, 7/15), 155.6 (Cquat., 1 C, 7/15), 156.3 (Cquat., 1 
C, 5). – MS (ESI, MeCN/Water + 0.0059 % TFA): m/z (%) = 371.0 (100) [MH+], 741.4 (17) 
[M + 2 H+]. – IR (neat) [cm-1]: ν~  = 3137, 2961, 1763, 1737, 1669, 1592, 1497, 1457, 1408, 
1338, 1274, 1241, 1217, 1156, 1062, 982, 916, 792, 736, 694. – MF C19H22N4O4 · HCl. – 
MW 406.87. 
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Compound 87: 
Boc-Gly-OH 32 (744 mg, 4.25 mmol), HOBt (867 mg, 6.37 mmol) and DIPEA (2.18 ml, 
12.7 mmol) were dissolved in DMF (20 ml). The mixture was cooled to 0 °C in an ice bath 
and EDC (1.13 ml, 6.37 mmol) was added. Then compound 58 (1.50 g, 3.54 mmol) was 
added slowly in portions. The reaction was monitored by TLC (EtOAc). After 24 hours the 
solution was uptaken in water and extracted with DCM. The combined organic layers were 
washed twice with an aqueous citric acid solution (10 %) and twice with brine. Afterwards 
the solution was dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by column chromatography on silica gel (EtOAc, Rf = 0.41) to give 
the product as colorless solid (1.55 g, 2.94 mmol, 83 %). 
MP 122 - 124 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.44 (s, 9 H, 1), 1.78 (s, 1 H, NH), 
3.40-3.50 (m, 2 H, CH2), 3.51-3.62 (m, 2 H, CH2), 3.69-3.78 (m, 2 H, CH2), 5.12 (s, 2 H, 
CH2-Bzl), 5.19 (s, 2 H, CH2-Bzl), 7.21 (s, 1 H, NH), 7.40-7.52 (m, 10 H, CH-Ar), 8.59 (s, 1 
H, NH), 11.67 (s, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 28.3 (+, 3 C, 1), 39.8 (-, 1 C, 
10), 40.7 (-, 1 C, 9), 44.1 (-, 1 C, 6), 67.3 (-, 1 C, 16), 68.4 (-, 1 C, 24), 80.0 (Cquat, 1 C, 2), 
127.8-128.9 (+, 10 C, CH-Ar), 134.5 (Cquat, 1 C, 17/25), 136.5 (Cquat, 1 C, 17/25), 153.6 
(Cquat, 1 C, 4/14/22), 156.0 (Cquat, 1 C, 4/14/22), 156.9 (Cquat, 1 C, 4/14/22), 163.3 (Cquat, 1 
C, 12), 170.2 (Cquat, 1 C, 7). – MS (ESI, MeCN/Water + 0.0059 % TFA): m/z (%) = 528.1 
(100) [MH+], 1055.7 (10) [M + 2 H+]. – IR (neat) [cm-1]: ν~  = 3340, 3298, 1726, 1639, 1586, 
1534, 1380, 1317, 1269, 1217, 1150, 1128, 1055, 916, 811, 769, 745, 695, 658. – 
MF C26H33N5O7. – MW 527.57. 
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Compound 59: 
Compound 87 (775 mg, 1.47 mmol) was dissolved in DCM and cooled to 0 °C in an ice 
bath. To this solution 8.5 ml of HCl saturated diethyl ether were added. The mixture was 
allowed to warm to room temperature and stirred over night. The reaction progress was 
monitored by 1H-NMR. The solvent was evaporated under reduced pressure to give the 
hydrochloride salt of the product as colorless solid in quantitative yield (681 mg, 
1.47 mmol). 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 3.51 (bs, 2 H, CH2), 3.77 (bs, 2 H, 
CH2), 4.59 (s, 2 H, CH2), 5.26 (s, 2 H, Bzl-CH2), 5.33 (s, 2 H, Bzl-CH2), 7.22-7.52 (m, 10 
H, Ar-CH). – 13C-NMR (75 MHz, MeOH-d4): δ = 41.8 (-, 1 C, CH2), 42.4 (-, 1 C, CH2), 48.3 
(-, 1 C, CH2), 70.0 (-, 1 C, Bzl-CH2), 70.9 (-, 1 C, Bzl-CH2), 128.8-130.2 (+, 10 C, Ar-CH), 
135.9 (Cquat., 1 C, Ar-C), 139.9 (Cquat., 1 C, Ar-C), 153.6 (Cquat., 1 C, CNH), 154.3 (Cquat., 1 
C, Cbz-CO), 154.5 (Cquat., 1 C, Cbz-CO), 168.4 (Cquat., 1 C, CONH). – MS (ESI, 
MeCN/Water + 0.0059 % TFA): m/z (%) = 255.4 (34) [M + 2 H+ + 2 MeCN], 428.0 (100) 
[MH+], 855.5 (11) [M + 2 H+]. – IR (neat) [cm-1]: ν~  = 2959, 1762, 1736, 1670, 1592, 1495, 
1457, 1408, 1337, 1276, 1242, 1213, 1061, 985, 917, 789, 733, 692. – MF C21H25N5O5 · 
HCl. – MW 463.92. 
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1,3-Bis(Boc)-2-methyl-2-thiopseudourea (63): 
Literature known compound but improved synthesis.121 
S-Methylisothiourea sulfate 61 (2.50 g, 18.0 mmol) and di-tert-butyl dicarbonate 62 
(9.41 g, 43.1 mmol) were dissolved in 40 ml of a 1:1 mixture of DCM and saturated 
NaHCO3 solution. The mixture was vigorously stirred at room temperature for three days. 
The organic layer was separated off and the aqueous solution was extracted two times 
with DCM. The combined organic layers were dried over MgSO4 and the solvent was 
evaporated under reduced pressure. The crude product was purified by column 
chromatography on silica gel using (EE:PE 10:90, Rf = 0.46) to give the product as 
colorless solid (5.11 g, 17.6 mmol, 98 %). 
MP 112-114 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.51 (s, 18 H, 1 + 11), 2.40 (s, 3 H, 13), 
11,06 (bs, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 14.4 (+, 1 C, 13), 28.3 (+, 6 C, 1 + 
11), 81.1 (Cquat, 1 C, 2), 83.2 (Cquat, 1 C, 10), 150.7 (Cquat, 1 C, 4), 160.9 (Cquat, 1 C, 8), 
171.5 (Cquat, 1 C, 6). – MS (CI, NH3): m/z (%) = 191 (22) [MH+ - C4H8 – CO2], 291 (100) 
[MH+]. – MF C12H22N2O4S. – MW 290.38. 
Compound 88: 
H-Gly-OMe · HCl (37) (1.5 g, 12.1 mmol) was dissolved in dioxane and triethylamine 
(3.3 ml, 24 mmol) was added. The mixture was stirred for 10 min. Then 1,3-bis(Boc)-2-
methyl-2-thiopseudourea (63) (2.5 g, 8.6 mmol) was added and the mixture was stirred for 
30 h at room temperature. The reaction progress was monitored by TLC. The reaction 
mixture was dissolved in water and extracted three times with DCM. Afterwards the 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel using 
PE:EtOAc 2:1 (Rf(PE: EtOAc 1:1) = 0,78) as eluent. The pure product was obtained as a 
colorless solid in 67 % yield. (1.9 g, 5.8 mmol) 
MP 132-133 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.49 (s, 9 H, 1/15), 1.50 (s, 9 H, 1/15), 
3.77 (s, 3 H, 11), 4.23 (s, 3JH,H = 4.9, 2 H, 8), 8.86 (s, 1 H, NH), 11.43 (s, 1 H, NH). – 
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13C-NMR (75 MHz, CDCl3): δ = 28.2 (+, 6 C, 1 + 16), 42.7 (-, 1 C, 8), 52.5 (+, 1 C, 11), 
79.6 (Cquat, 1 C, 2), 83.4 (Cquat, 1 C, 15), 152.9 (Cquat, 1 C, 4), 156.0 (Cquat, 1 C, 13), 163.2 
(Cquat, 1 C, 6), 169.9 (Cquat, 1 C, 9). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) 
= 332.2 (100) [MH+], 663.5 (42) [2 M + H+]. – IR (neat) [cm-1]: ν~  = 3318, 2982, 2952, 
2362, 1757, 1725, 1614, 1292, 1138, 1094, 1060, 975, 811, 761. – MF C14H25N3O6. – MW 
331.36. 
Compound 64: 
Compound 88 (1.6 g, 4.7 mmol) was dissolved in a mixture of water and acetone 1:4. 
LiOH (0.17 g, 7.1 mmol) was added and the mixture was stirred at room temperature over 
night. The solution was acidified with saturated NH4Cl solution and extracted with DCM. 
The combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure to give the product as a colorless salt in quantitative yield. (1.5 g, 4.7 mmol) 
MP 104-105 °C. – 1H-NMR (300 MHz, DMSO-d6): δ = 1.39 (s, 9 H, Boc-CH3), 1.49 (s, 9 H, 
Boc-CH3), 3.98 (d, 3JH,H = 5.4, 2 H, CH2), 8.62 (s, 1 H, NH), 11.47 (s, 1 H, NH. – 13C-NMR 
(75 MHz, DMSO-d6): δ = 27.5 (+, 3 C, Boc-CH3), 27.8 (+, 3 C, Boc-CH3), 42.2 (-, 1 C, 
CH2), 78.3 (Cquat, 1 C, C(CH3)3), 83.0 (Cquat, 1 C, C(CH3)3), 151.7 (Cquat, 1 C, Boc-CO), 
155.2 (Cquat, 1 C, Boc-CO), 162.7 (Cquat, 1 C, C-NH), 170.4 (Cquat, 1 C, COO). – MS (ES, 
DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 206.1 (60) [MH+ - 2 C4H8], 262.2 (32) [MH+ - 
C4H8], 318.2 (100) [MH+], 635.5 (40) [2 M + H+]. – IR (neat) [cm-1]: ν~  = 3329, 2978, 2932, 
2362, 1795, 1726, 1633, 1398, 1319, 1229, 1144, 1102, 1060, 987, 883, 763. – 
MF C13H23N3O6. – MW 317.34. 
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Compound 65: 
The acid 64 (0.46 g, 1.4 mmol), HOBt (0.28 g, 2.1 mmol) and DIPEA (0.71 ml, 4.2 mmol) 
were dissolved under nitrogen atmosphere in dry DMF (10 ml). The mixture was cooled to 
0 °C in an ice bath and EDC (0.37 ml, 2.1 mmol) was added. Then the amine 52 (1.0 g, 
0.93 mmol) was added slowly in portions. The reaction progress was monitored by TLC 
(EtOAc). After 24 h water was added and extracted with DCM. The combined organic 
layers were washed three times with an aqueous citric acid solution (10 %) and twice with 
brine. Afterwards the solution was dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel 
(PE:EtOAc 1:1, Rf = 0.43) to give the product as a colorless solid (0.33 g, 0.24 mmol, 
25 %). 
MP 158-159 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.25-1.61 (m, 72 H, 1 + 22 + cyclen 
Boc-CH3), 2.74-3.91 (m, 38 H, 8 + 11 + 12 + cyclen-CH2), 4.92 (s, 1 H, NH), 7.53 (bs, 1 H, 
NH), 8.92 (s, 1 H, NH), 11.21 (s, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 28.1-29.4 (+, 
34 C, 1 + 22 + cyclen Boc-CH3), 44.4 (-, 2 C, 8 + 11), 50.3 (-, 16 C, cyclen-CH2), 54.9.2 (-, 
2 C, 12), 79.9 (Cquat, 7 C, 2 + cyclen Boc-Cquat), 83.1 (Cquat, 1 C, 21), 152.7 (Cquat, 1 C, 4), 
154.6-145.7 (Cquat, 7 C, 19 + cyclen Boc-CO), 163.2 (Cquat, 1 C, 6), 165.9 (Cquat, 3 C, 14 + 
16), 168.4 (Cquat, 1 C, 9). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 690.7 
(76) [M + 2 H+], 1380.2 (100) [MH+]. – Elemental Analysis calcd. (%) for C64H114N16O17 
(1379.69) + 2 H2O: C 54.30, H 8.40, N 15.83. - found: C 54.27, H 8.47, N 15.01. – IR 
(neat) [cm-1]: ν~  = 3318, 2981, 2942, 2362, 1757, 1726, 1638, 1615, 1367, 1292, 1249, 
1141, 1095, 1059, 975, 812, 774. – MF C64H114N16O17. – MW 1379.69. 
1
N
N
N
NN
N N
Boc Boc
Boc
NN
N N
Boc
Boc
Boc
N
H
H
N
O
N
H
HN
N
O
O O
O
2
3
4
5
6
7 8 9
10 11
12
13
14
15
16
17
18
1921
22
20
Section A 6. Experimental Part 
 91
Complex 66: 
Compound 65 (0.25 g, 0.18 mmol) was dissolved in methanol, cooled to 0 °C in an ice 
bath and HCl-saturated diethyl ether (0.7 ml/mmol Boc-group) was added. The mixture 
was allowed to warm to room temperature and was stirred over night. The solvent was 
evaporated. The crude product was dissolved in water and purified over an ion exchanger 
column using a strongly basic ion exchange resin (OH--form, loading 0.9 mmol/ml, 4 eq. 
per protonated nitrogen) to give a colorless solid after freeze drying. Two aqueous 
solutions, one containing the obtained colorless solid from the column and a second 
containing Zn(ClO4)2 · 6 H2O (0.15 g, 0.40 mmol) were prepared. These two solutions 
were simultaneously added to water at 80 °C. The resulting mixture was stirred at 90 °C 
over night. The solution was lyophilized and the product was recrystallized from a water 
methanol mixture to give the complex as a colorless solid in 83 % yield. (0.16 g, 
0.15 mmol) 
MP > 250 °C. – MS (ES, H2O/MeOH + 10 mmol/l NH4OAc) (K3+ = C24H51N16O2ClZn2) : m/z 
(%) = 353.3 (62) [K3+ - H+ - H2O], 363.8 (100) [K3+ - H+], 385.3 (71) [K3+ + OH- + MeOH], 
822.9 (19) [K3+ - H+ + ClO4-]. – IR (neat) [cm-1]: ν~  = 3568, 3527, 3370, 2942, 1625, 1548, 
1480, 1421, 1342, 1285, 1063, 963, 814, 744. – MF [C24H50N16OZn2]4+(ClO4)3(OH). – MW 
1024.89. 
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Compound 89: 
Peptide H-Gly-Gly-OMe · HCl (67) (1.1 g, 6.2 mmol) was dissolved in CHCl3 :methanol 5:1 
and triethylamine (1.7 ml, 12 mmol) was added. The mixture was stirred for 10 minutes. 
Then 1,3-bis(Boc)-2-methyl-2-thiopseudourea (62) (2.0 g, 6.9 mmol) was added and the 
mixture was stirred for 6 h at room temperature. The reaction progress was monitored by 
TLC. The reaction mixture was added to water and extracted three times with DCM. 
Afterwards the combined organic layers were dried over MgSO4 and concentrated under 
reduced pressure. The crude product was purified by column chromatography on silica gel 
using PE:EtOAc 1:1 (Rf = 0,35) as eluent. The pure product was obtained as a colorless 
solid in 46 % yield. (1.1 g, 2.8 mmol) 
MP 149-150 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.42 (s, 9 H, 1/19), 1.43 (s, 9 H, 1/19), 
3.69 (s, 3 H, 14), 4.00 (d, 3JH,H = 5.2, 2 H, 9), 4.10 (d, 3JH,H = 4.9, 2 H, 11), 6.98 (d, 3JH,H = 
4.9, 1 H, NH), 8.88 (t, 3JH,H = 4.8, 1 H, NH), 11.32 (s, 1 H, NH). – 13C-NMR (75 MHz, 
CDCl3): δ = 28.2 (+, 6 C, 1 + 19), 41.3 (-, 1 C, 11), 44.4 (-, 1 C, 8), 52.4 (+, 1 C, 14), 79.6 
(Cquat, 1 C, 2), 83.5 (Cquat, 1 C, 18), 152.8 (Cquat, 1 C, 4), 156.2 (Cquat, 1 C, 16), 163.0 (Cquat, 
1 C, 6), 168.6 (Cquat, 1 C, 12), 170.0 (Cquat, 1 C, 9). – MS (CI, NH3): m/z (%) = 389.0 (100) 
[MH+]. – IR (neat) [cm-1]: ν~  = 3347, 3305, 2977, 2936, 2363, 1723, 1678, 1641, 1525, 
1430, 1395, 1349, 1303, 1220, 1148, 1123, 1091, 1055, 971, 811. – MF C16H28N4O7. – 
MW 388.42. 
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Compound 68: 
Compound 89 (1.0 g, 2.6 mmol) was dissolved in a mixture of water and THF 1:4. LiOH 
(74 mg, 3.1 mmol) was added and the mixture was stirred at room temperature over night. 
The solution was acidified with 5 % aqueous KHSO4 solution and extracted with DCM. 
The combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure to give the product as a colorless salt in 68 % yield. (0.64 g, 1.7 mmol) 
MP 111-112 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 1.46 (s, 9 H, Boc-CH3), 1.53 (s, 9 H, 
Boc-CH3), 3.78 (s, 2 H, CH2), 4.09 (s, 2 H, CH2). – 13C-NMR (75 MHz, MeOH-d4): δ = 28.6 
(+, 3 C, Boc-CH3), 29.0 (+, 3 C, Boc-CH3), 44.6 (-, 1 C, CH2), 45.0 (-, 1 C, CH2), 78.9 
(Cquat, 1 C, C(CH3)3), 82.8 (Cquat, 1 C, C(CH3)3), 162.7 (Cquat, 1 C, Boc-CO), 164.2 (Cquat, 1 
C, Boc-CO), 171.8 (Cquat, 1 C, C-NH), 176.1 (Cquat, 1 C, COO). – MS (ES, DCM/MeOH + 
10 mmol/l NH4OAc): m/z (%) = 275.2 (32) [MH+ - Boc], 319.2 (18) [MH+ - C4H8], 375.2 
(100) [MH+]. – IR (neat) [cm-1]: ν~  = 2975, 2935, 1559, 1541, 1499, 1408, 1366, 1303, 
1249, 1148, 1056, 973, 864. – MF C15H26N4O7. – MW 374.39. 
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Compound 69: 
The acid 68 (0.26 g, 0.69 mmol), HOBt (0.14 g, 1.0 mmol) and DIPEA (0.36 ml, 2.0 mmol) 
were dissolved under nitrogen atmosphere in dry DMF (10 ml). The mixture was cooled to 
0 °C in an ice bath and EDC (0.18 ml, 1.0 mmol) was added. Then the amine 52 (0.50 g, 
0.46 mmol) was added slowly in portions. The reaction progress was monitored by TLC 
(EtOAc). After 24 h the solution was added to water and extracted with DCM. The 
combined organic layers were then washed three times with an aqueous citric acid 
solution (10 %) and twice with brine. Afterwards the solution was dried over MgSO4 and 
concentrated under reduced pressure. The crude product was then purified by flash 
chromatography on silica gel (EtOAc, Rf = 0.26) to give the product as a colorless solid 
(0.15 g, 0.11 mmol, 23 %). 
MP 162-163 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.24-1.57 (m, 72 H, 1 + 25 + Cyclen 
Boc-CH3), 3.02-3.73 (m, 36 H, 14 + 15 + Cyclen-CH2), 3.89 (d, 3JH,H = 4.7, 2 H, 8), 4.10 (d, 
3JH,H = 4.9, 2 H, 11), 5.00 (s, 1 H, NH), 6.91 (s, 1 H, NH), 7.49 (s, 1 H, NH), 8.87 (s, 1 H, 
NH), 11.34 (s, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 28.0-28.5 (+, 34 C, 1 + 25 + 
Cyclen Boc-CH3), 40.5 (-, 1 C, 14), 42.8 (-, 1 C, 15), 44.2 (-, 2 C, 8 + 11), 50.3 (-, 16 C, 
Cyclen-CH2), 79.4 (Cquat, 1 C, 2), 79.9 (Cquat, 6 C, Cyclen Boc-Cquat), 83.2 (Cquat, 1 C, 24), 
152.8 (Cquat, 1 C, 4), 155.9 (Cquat, 6 C, Cyclen Boc-CO), 156.4 (Cquat, 1 C, 22), 163.2 (Cquat, 
1 C, 6), 168.1-168.5 (Cquat, 3 C, 17 + 18), 171.1 (Cquat, 2 C, 9 + 12). – MS (ES, 
DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 619.2 (67) [M + 2 H+ - 2 Boc], 719.3 (26) [M 
+ 2H+], 1437.3 (100) [MH+]. – Elemental Analysis. (%) for C66H117N17O18 (1436.74) + 2 
H2O: C 53.82, H 8.28, N 16.17. - found: C 53.69, H 8.31, N 15.61. – IR (neat) [cm-1]: ν~  = 
3318, 3109, 2982, 2952, 1757, 1725, 1637, 1614, 1292, 1138, 1094, 1060, 975, 874, 811. 
– MF C66H117N17O18. – MW 1436.74. 
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Complex 70: 
Compound 69 (0.15 g, 0.11 mmol) was dissolved in methanol and cooled to 0 °C in an ice 
bath. HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added to the solution. The 
mixture was allowed to warm to room temperature and was stirred over night. The solvent 
was evaporated and the crude product was dissolved in water and purified over an ion 
exchanger column using a strongly basic ion exchange resin (OH--form, loading 0.9 
mmol/ml, 4 eq. per protonated nitrogen) to give a colorless solid after lyophilization. Two 
aqueous solutions, one containing the obtained colorless solid from the column and a 
second containing Zn(ClO4)2 · 6 H2O (90 mg, 0.24 mmol, 2.2 eq. per deprotected receptor) 
were prepared. These two solutions were then simultaneously added drop wise to water 
at 80 °C under vigorous stirring. The resulting mixture was stirred at 90 °C over night. The 
solution was freeze dried and the product was recrystallized from a water methanol 
mixture to give the complex as colorless solid in 63 % yield. (75 mg, 0.07 mmol). 
MP > 250 °C. – MS (ES, H2O/MeOH + 10 mmol/l NH4OAc) (K4+ = C26H53N17O2Zn2) : m/z 
(%) = 353.9 (29) [K4+ + ClO4- + 2 HClO4], 392.3 (100) [K4+ + OH- - H+], 413.8 (41) [K4+ + 
CH3COO- - H+], 909.3 (8) [K4+ + OH- + 2 Cl- + CH3COOH]. – IR (neat) [cm-1]: ν~  = 3282, 
2950, 2896, 2364, 2343, 1652, 1558, 1429, 1347, 1285, 1084, 970, 815, 777. – 
MF [C26H53N17O2Zn2]4+(ClO4)3(OH). – MW 1081.94. 
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Compund 90: 
H-Gly-Gly-Gly-OMe · HCl 71 (500 mg, 2.09 mmol) was dissolved in CHCl3:methanol 5:1 
and triethylamine (578 µl, 4.17 mmol) was added. The mixture was stirred for 10 minutes. 
Then 1,3-bis(Boc)-2-methyl-2-thiopseudourea 63 (727 mg, 2.50 mmol) was added and the 
mixture was stirred for 24 hours at room temperature. The reaction progress was 
monitored by TLC. The reaction mixture was uptaken in water and extracted three times 
with DCM. Afterwards the combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash-
chromatography on silica gel using EtOAc (Rf = 0.20) as eluent. The pure product was 
obtained as colorless solid in 49 % yield. (460 mg, 1.03 mmol) 
MP 117-118 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.46 (s, 9 H, 1/22), 1.49 (s, 9 H, 1/22), 
3.72 (s, 3 H, 17), 3.97-4.06 (m, 4 H, 8 + 11), 4.15-4.24 (m, 2 H, 14), 7.21 (t, 3JH,H = 5.2, 1 
H, 10/13), 7.41 (t, 3JH,H = 5.1, 1 H, 10/13), 9.00 (s, 1 H, 5/7), 11.38 (s, 1 H, 5/7). – 13C-
NMR (75 MHz, CDCl3): δ = 28.0 (+, 3 C, 1/22), 28.2 (+, 3 C, 1/22), 41.2 (-, 1 C, 8/11/14), 
43.1 (-, 1 C, 8/11/14), 44.5 (-, 1 C, 8/11/14), 52.4 (-, 1 C, 17), 80.1 (Cquat, 1 C, 2), 83.8 
(Cquat, 1 C, 21), 156.2 (Cquat, 1 C, 4), 156.2 (Cquat, 1 C, 19), 162.5 (Cquat, 1 C, 6), 169.0 
(Cquat, 1 C, 9/12), 169.2 (Cquat, 1 C, 9/12), 170.2 (Cquat, 1 C, 15). – MS (ES, DCM/MeOH + 
10 mmol/l NH4OAc): m/z (%) = 390.1 (13) [MH+ - C4H8], 446.2 (100) [MH+]. – IR (neat) 
[cm-1]: ν~  = 3334, 3298, 3276, 2978, 2938, 1731, 1641, 1612, 1547, 1368, 1304, 1224, 
1144, 1107, 1058, 1032, 977. – MF C18H31N5O8. – MW 445.47. 
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Compund 72: 
Compound 90 (460 mg, 1.03 mmol) was dissolved in a mixture of water and THF 1:4. 
LiOH (30 mg, 1.24 mmol) was added and the mixture was stirred at room temperature 
over night. The solution was acidified with 5 % aqueous KHSO4 solution and was 
extracted with DCM. The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure to give the product as colorless solid in 79 % yield. 
(350 mg, 0.81 mmol) 
MP 87-88 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.44 (s, 9 H, Boc-CH3), 1.48 (s, 9 H, Boc-
CH3), 3.92 (d, 3JH,H = 4.9, 2 H, CH2), 4.05 (d, 3JH,H = 4.7, 2 H, CH2), 4.18 (s, 2 H, CH2), 
7.67 (t, 3JH,H = 5.0, 1 H, NH), 8.02 (t, 3JH,H = 5.2, 1 H, NH), 9.28 (bs, 1 H, NH), 11.39 (bs, 1 
H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 28.0 (+, 6 C, Boc-CH3), 42.0 (-, 1 C, CH2), 42.8 
(-, 1 C, CH2), 44.0 (-, 1 C, CH2), 80.6 (Cquat, 1 C, OC(CH3)3), 83.9 (Cquat, 1 C, OC(CH3)3), 
152.6 (Cquat, 1 C, Boc-CO), 155.7 (Cquat, 1 C, Boc-CO), 161.7 (Cquat, 1 C, Guanidine), 
168.8 (Cquat, 1 C, CONH), 170.5 (Cquat, 1 C, CONH), 172.5 (Cquat, 1 C, COOH). – MS (ES, 
DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 432.1 (100) [MH+], 863.6 (9) [2 M + H+]. – 
IR (neat) [cm-1]: ν~  = 3135, 2962, 1759, 1671, 1593, 1498, 1454, 1411, 1339, 1272, 1244, 
1216, 1157, 1062, 981, 915, 795, 732, 697. – MF C17H29N5O8. – MW 431.44. 
N
H
H
N
O
N
H
N
Boc
Boc
N
H
O
OH
O
Section A 6. Experimental Part 
 98 
Compound 73: 
The acid 72 (350 mg, 0.81 mmol), HOBt (219 mg, 1.62 mmol) and DIPEA (417 μl, 
2.43 mmol) were dissolved under nitrogen atmosphere in dry DMF (14 ml). The mixture 
was cooled to 0 °C in an ice bath and EDC (287 μl, 1.62 mmol) was added. Then the 
amine 52 (1.05 g, 0.97 mmol) was added slowly in portions. The reaction progress was 
monitored by TLC (EtOAc). After 24 h the solution was added to water and extracted with 
DCM. The combined organic layers were then washed three times with an aqueous citric 
acid solution (10 %) and twice with brine. Afterwards the solution was dried over MgSO4 
and concentrated under reduced pressure. The crude product was purified by flash-
chromatography on silica gel (EtOAc, Rf = 0.26) to give the product as a colorless solid 
(730 mg, 0.49 mmol, 60 %). 
MP 174 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.22-1.53 (m, 72 H, Boc-CH3), 3.04-3.75 
(m, 36 H, CH2 + Cyclen-CH2), 3.84-3.93 (m, 4 H, CH2), 4.11 (d, 3JH,H = 5.1, 2 H, CH2), 8.92 
(s, 1H, NH), 11.32 (s, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 28.0-28.5 (+, 34 C, Boc-
CH3), 40.3 (-, 1 C, CH2), 42.9 (-, 1 C, CH2), 44.4 (-, 2 C, CH2), 50.3 (-, 16 C, Cyclen-CH2), 
79.7 (Cquat, 1 C, Boc-Cquat), 79.9 ((Cquat, 6 C, Cyclen Boc-Cquat), 83.4 (Cquat, 1 C, Boc-Cquat), 
152.7 (Cquat, 1 C, Boc-CO), 156.3 (Cquat, 6 C, Cyclen Boc-CO), 156.4 (Cquat, 1 C, Boc-CO), 
162.6 (Cquat, 3 C), 163.0 (Cquat, 1 C), 165.9 (Cquat, 2 C, CO), 168.9 (Cquat, 1 C, CO). – MS 
(ESI, MeCN/water + 0.0059% TFA): m/z (%) = 747.7 (100) [M + 2 H+], 1494.5 (100) [MH+]. 
– IR (neat) [cm-1]: ν~  = 2974, 2927, 2869, 1686, 1536, 1504, 1408, 1364, 1307, 1246, 
1152, 1105, 1058, 1029, 812, 777. – MF C68H120N18O19. – MW 1493.79. 
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Complex 74: 
Compound 73 (634 mg, 0.49 mmol) was dissolved in methanol and cooled to 0 °C in an 
ice bath. To the solution HCl saturated diethyl ether (0.7 ml/mmol Boc-group) was added. 
The mixture was allowed to warm to room temperature and stirred over night. The solvent 
was evaporated and the crude product was dissolved in water and purified over an ion 
exchanger column using a strongly basic ion exchange resin (OH--form, loading 
0.9 mmol/ml, 4 eq. per protonated nitrogen) to give a colorless solid after freeze drying. 
Two aqueous solutions one containing the obtained colorless solid from the column and a 
second containing Zn(ClO4)2 · 6 H2O (90 mg, 0.24 mmol, 2.2 eq. per deprotected receptor) 
were prepared. These two solutions were then simultaneously added drop wise to 80 °C 
hot water under vigorous stirring. The resulting mixture was stirred at 90 °C over night. 
The solution was freeze dried and the product was recrystallized from a water methanol 
mixture to give the complex as colorless solid in 20 % yield. (109 mg, 0.10 mmol). 
MP > 180 °C. – MS (ES, H2O/MeOH + 10 mmol/l NH4OAc) (K4+ = C28H57N18O3Zn2) : m/z 
(%) = 419.8 (100) [K4+ + OH- - H+]. – IR (neat) [cm-1]: ν~  = 2973, 2929, 2870, 1684, 1535, 
1501, 14011, 1364, 1308, 1247, 1153, 1104, 1061, 1030, 812, 776. MF 
[C28H57N18O3Zn2]4+(ClO4)3(OH). – MW 1140.00. 
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B. Synthesis and Use of Tetrahydrofuran 
Amino Acids 
1. Introduction 
1.1. Proteins 
Proteins are omnipresent in the living world. The structure, function and metabolism of all 
cells and tissues rely on the presence of specific proteins. They are in some way the carr-
ier of the live functions and can be found likewise in animal, plants and micro organism, 
 
Figure 51: Organization of the protein structures in different levels. (adapted from 
literature123) 
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for example in muscles (actin, myoglobin), in the blood (hemoglobin), in connective 
tissues, sinews and ligaments (collagen, elastin) to mention only a very few. But not only 
is their occurrence manifold, their functions are also very diverse for example in the 
immune response, as hormone- or neurotransmitter-receptors but also as enzymes and 
regulators. These functions of proteins are particularly dependent on the 3D-structure of 
the amino acid backbone. The construction of such complex protein folds relies on the 
precise conversion of one ore more linear polypeptide chains into a 3D-structure.122 
Until now it is not completely understood how the amino acid sequence (primary structure) 
is linked to the tertiary or quaternary structure of proteins. When having a closer look into 
these higher folds a limited number of secondary structural elements can be found as 
there are helices, turns and strands which are connected via loosely structured turns (see 
Figure 51).123 The folding of proteins consisting of different secondary structures arises 
from tertiary interactions between residues which are distant in the sequence. Main forces 
for the stabilization of the overall protein structure are hydrophobic interactions. The 
protein folds in such a way that the hydrophobic side chains of amino acids like valine or 
isoleucine can aggregate in the center of the protein while polar side chains point towards 
the surrounding water. Other important forces are electrostatic interactions like van-der-
Waals-forces, H-bonds or salt bridges. In addition, the protein structure can be stabilized 
by covalent disulfidbridges formed between two cystein residues or by metal-ions like 
Zn(II) which can also serve as a bridging element in the interior of proteins.124 In the last 
years increasing effort was put into the development of a deeper understanding of the 
protein structure itself but also into the relationship of amino acid sequence, 3D-structure 
and function of proteins.125 
1.1.1. Protein-Protein Interactions 
One way how nature controls protein function within living cells is by regulating protein-
protein interactions. These interactions exist at nearly every level of cellular function which 
means they are of key importance for virtually every process in a living organism. To 
mention only a few, there are the signal transduction pathway important for the 
transportation of information through the organism and from the exterior of cells to the 
inside, the transport machinery across the biological membranes, the regulation of gene 
expression or the muscle contraction. Protein-protein interactions play a decisive role in 
biological processes and their disregulation leads to diseases like Creutzfeld-Jacob, 
Alzheimer, cancer or HIV.126 
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1.1.2. Protein Design 
In the same way that the structure analysis and the development of a deeper 
understanding of protein-protein interactions are fields of active research, the de novo 
design of natural occurring or novel peptides is also being investigated. Synthesis 
methods like the solid phase peptide synthesis (SPPS) developed by Bruce Merrifield 
made it possible to synthesize polypeptides with almost fifty amino acids in length in 
quantities making them suitable for pharmacological and clinical assays as well as for use 
as drugs or in diagnostics.127 As a result, different new peptide-based drugs are nowadays 
available for the treatment of prostate and breast cancer, as HIV protease inhibitors or as 
ACE inhibitors to treat hypertension and congestive heart failures, to mention only a 
few.128 
Despite the fact that such polypeptides based on natural amino acids are widely used as 
therapeutic agents, there are also problems connected with the use of natural peptides as 
drugs. The problems arise mainly from the low stability against proteolysis resulting in a 
short duration of activity in vivo and a low bioavailability, thus limiting the use of peptides 
as drugs. They also often show a decreased activity in comparison to the protein from 
which they are derived. A major difficulty in these studies is the conformational flexibility of 
most peptides and the high dependence of their conformations on the surrounding 
environment which often leads to a conformational equilibrium.129 
 
Figure 52: The torsional degrees of freedom in a peptide bond. (adapted from 
literature125b) 
The high flexibility of natural polypeptides originates from the multiple conformations 
which are energetically possible at each residue of the incorporated amino acids. Every 
amino acid has two degrees of conformational freedom, N-Cα (Φ) and Cα-CO (Ψ) resulting 
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in approximately 9 (32) stable local conformations. For a small peptide with only 40 amino 
acids in length the number of possible conformations which need to be considered 
escalates to nearly 1040. Pioneering work by Ramachandran et al. resulted in the so called 
Ramachandran plots which restrict the allowed values for the torsion angles Φ and Ψ and 
with that the conformational space accessible to the amino acids to about one-third of the 
total structural space. Nevertheless the remaining degrees of freedom still make a 
prediction of the structure extremely difficult. This extraordinary high flexibility of natural 
amino acids leads to the fact that short polypeptides consisting of the 20 proteinogenic 
amino acids rarely form any stable 3D-structures in solution.130 
 
Figure 53: Peptides can exist in different conformations. By introducing conformational 
constraints into the peptide backbone (blue dashed line) the equilibrium can be shifted 
towards the conformation which leads to the desired biological effect. In addition, it might 
be possible to suppress undesired side effects or proteolysis. (adapted from literature131) 
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There are only few examples reported in literature where short to medium sized peptides 
(< 30-50 amino acids) were able to form stable structures. In most cases they exist 
unordered in aqueous solution in numerous of conformations which are in a dynamic 
equilibrium with each other. Additionally, the number of structures which are accessible is 
very limited because of the need to use amino acids which have a strong structure 
inducing effect like for example helix-inducing amino acids like leucine, glutamic acid or 
lysine. In addition, it is questionable whether the solid state conformations determined by 
X-ray analysis are identical to those occurring in solution or during the interactions of 
proteins with each other.132 
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1.2. Peptidomimetics 
One way to overcome these disadvantages of natural short polypeptides is the use of so 
called peptidomimetics. These are small protein-like molecules designed to mimic natural 
peptides or proteins. These mimetics should have the ability to bind to their natural targets 
in the same way as the natural peptide sequences do from which their structure was 
derived. They should produce the same biological effects. It is possible to design these 
molecules in such a way that they show the same biological effects as their peptide role 
models but with enhanced properties like a higher proteolytic stability, higher 
bioavailability and also often with improved selectivity or potency. This makes them 
interesting targets for the discovery of new drug candidates.133,134,135,136 
For the development of potent peptidomimetics it is necessary to understand the forces 
that lead to protein-protein interactions with nanomolar or often even higher affinities. 
These strong interactions between peptides and their corresponding proteins are mainly 
based on side chain interactions indicating that the peptide backbone itself is not an 
absolute requirement for high affinities. This allows chemists to design peptidomimetics 
basically from any scaffold known in chemistry by replacing the amide backbone partially 
or completely by other structures. Most important is that the backbone is able to place the 
amino acid side chains in a defined 3D-position to allow interactions with the target 
protein. Therefore it is necessary to develop an idea of the required structure of the 
peptidomimetic to show a high activity against its biological target. This can be achieved 
by conducting structure-activity relationship (SAR) investigations. By this method, the 
shortest active sequence in the natural protein-protein interaction can be identified. To do 
so, shorter analogues of the natural sequence are synthesized and tested against the 
target protein to identify the minimum sequence necessary for biological activity. The most 
significant parameters such as stereochemistry, charge and hydrophobicity can be 
examined by systematic exchange of single amino acids. As a result, the key residues 
which are essential for the biological activity can be identified. As next step the 3D 
arrangement of these key residues needs to be analyzed by the use of compounds with 
rigid conformations to identify the most active structure.132, 137 When a clear model of the 
moieties necessary for the interaction and their location in the 3D space has been 
gathered, these elements can then be reassembled by the use of peptidic or non-peptidic 
structures to form a peptidomimetic with the same biological activity as the natural role 
model which it should replace.138 This is a rather expensive and time-consuming method 
but the use of new techniques that allow the fast synthesis and analysis of receptor 
binding of a great variety of peptides allows the whole process to become more 
efficient.139, 140 
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All in all, the development of peptidomimetics is based mainly on the knowledge of the 
electronic, conformational and topochemical properties of the native peptide its target. 
Two structural factors are especially important for the synthesis peptidomimetics with high 
biological activity. Firstly the mimetic has to have a convenient fit to the binding site and 
secondly the functional groups, polar and hydrophobic regions of the mimetic need to be 
placed in defined positions to allow the useful interactions to take place.141 
As previously mentioned the major problem in this area of research is the conformational 
flexibility of most natural peptides and the high dependence of their conformation on the 
environment. One very successful approach to overcome these drawbacks is the 
introduction of conformational constraints into the peptide sequence. This can be done for 
example by cyclisation (main chain to main chain; side chain to main chain or side chain 
to side chain) or by the incorporation of amino acids which can only adopt a very limited 
number of different conformations.142 
In the following, a summary of approaches leading to peptidomimetics is given. Different 
approaches to the design of peptidomimetics will be presented together with a few select 
examples. However, due to the large number of different unnatural amino acids and 
peptidomimetics the overview can not be comprehensive. Therefore the following 
selection should be seen as an overview illustrating the importance and diversity of the 
design and synthesis of peptidomimetics. 
1.2.1. Amino Acid Modifications 
One way which leads to conformationally restricted and metabolically stable 
peptidomimetics is the use of unnatural amino acids. In principal, two different starting 
points exist for the modification of peptides at the amino acid level. One is the amino acid 
side chain which can be rigidified for example by the use of sterically demanding groups, 
the other is the backbone of the peptide. 
1.2.1.1. Side Chain Modification 
Side chains of natural amino acids are of great importance for the activity of proteins due 
to their various functional groups which allow them to interact with other peptides or 
proteins. The problem hereby is their quite high conformational flexibility with energy 
barriers of rotation around their torsion angles χ1 (Cα–Cβ bond), χ2 (Cβ–Cγ bond), etc. of 
normally less than 8 kcal/mol. Therefore they can rotate freely at physiological 
temperatures, with the exception the proline which is restricted due to the five-membered 
ring system.143 In order to derive more information about the interactions of peptides with 
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proteins, nucleic acids, other peptides, lipids and sugars in biological systems, side chain 
conformational restriction can provide a versatile tool for design of peptidomimetics.144  
β-Substitution 
β-Substituted analogues of the naturally occurring amino acids are one example for 
rigidification in the side chain. Three of the natural 20 amino acids also show 
β-disubstitutions. These are valine 91 which has a two β-methyl substituents, isoleucine 
92 which has a β-methyl and a β-ethyl substitution and threonine 93 which has a β-methyl 
and a β-hydroxy substitution. Both the isoleucine 92 and the threonine 93 have a β-chiral 
center. Various analogues of natural amino acids alkylated at the β-carbon can be found 
in literature. For example, the introduction of three methylgroups at the 2’-, 6’- and β-
position of natural tyrosine hinders the free rotation around the Cβ-Cγ bond and by that 
might sometimes favor the formation of biologically active conformations (94).145 
Introduction of a methyl group into the side chains of phenylalanine or tryptophan leads to 
the compounds β-MePhe 95 and β-MeTrp 96. Replacement of the natural amino acids 
Phe or Trp by their rigidified analogues 95 in the former and 96 in the latter case often 
results in a in comparison higher activity and an increased biological stability of the 
modified peptides.146 For example, the activity of short peptides which are active at the 
δ-opioid receptor was successfully altered by exchanging phenylalanine by its 
β-methylated analogue 95.147 
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Figure 54: The three β-methylated natural amino acids valine 91, isoleucine 92 and 
threonine 93 and some selected examples of unnatural β-methylated amino acids 94-97. 
Another interesting example is the 2-(carboxycyclopropyl)-glycine (CCG) 97. A library 
containing all possible diastereomers of compound 97 was used to investigate 
neuroreceptors activated by L-glutamic acid. Several types of such receptors are known 
until now and it has been suggested that L-glutamic acid interacts with different receptors 
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adopting different conformations. This hypothesis was strongly supported by the findings 
resulting from the use of the CCG diastereomers.148 
Besides β-disubstituted amino acids numerous other side chain modified amino acids 
were developed, for example the 2-naphthylalanine 98.149 Gonadotropin-releasing 
hormone (GnRH) antagonists containing this compound in addition to other unnatural 
amino acids, show high affinity to the receptor.150 
H2N COOH
98  
Figure 55: 2-Naphthylalanine 98, a building block for novel GnRH antagonists. 
Proline Analogues 
A further, thoroughly investigated group of side chain modified amino acids are analogues 
of the natural proline. Proline has a special place among the proteinogenic amino acids 
because of its secondary structure inducing and stabilizing properties and hence its 
influence on the biological behavior of peptides.151 This is due to the cyclic structure of 
proline which restricts the conformational space of the peptide chain drastically.152  
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Figure 56: L-Proline 99 and some natural derivatives 100-102. 
Besides proline itself, numerous derivatives were found in proteins as results of 
posttranslational modifications. cis-4-Methyl-L-proline 100 was discovered in hydrolysates 
of different leucinostatine.153 These are peptide antibiotics which were isolated from 
several Paecilomyces strains. These leucinostatines have antitumor activity as well as a 
wide antimicrobial spectrum against fungi, yeast and Grampositive bacteria.154 Trans-4-
hydroxy-L-proline 101 was first isolated from hydrolysates of Mediterranean sponge and 
later found in several other organisms.155 The free amino acid 101 can also be found in 
human urine as a result of collagen metabolism. Also amino side chain modified proline 
derivatives like the cis-3-amino-L-proline 102 can be found in nature.156 Additionally to the 
naturally occurring proline analogues countless proline derivatives were synthesized by 
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the introduction of alkyl chains or aromatic groups in the 3-, 4- and 5- position of the ring. 
Derivatives with additional heteroatoms and halogenated prolines were also synthesized 
and extensively studied.157 
1.2.1.2. Backbone Modification 
Apart from the side chains, the backbone of a peptide can also be modified in various 
ways by isosteric or isoelectronic exchange of units in the peptide or by the introduction of 
additional fragments.158 Figure 57 summarizes the most important ways to modify the 
backbone of peptides at different positions. 
 
Figure 57: Some of the more common modifications to the peptide backbone. (adapted 
from literature159) 
Three main groups of modifications are known, with the first being the exchange of 
individual groups like, the replacement of the α-CH group by nitrogen to form azapeptides, 
the change from amide to ester bond to get depsipeptides and exchange of the carbonyl 
function by a CH2-group. The second possibility is the extension of the backbone for 
example by one or two CH2-groups resulting in polypeptides built from β-amino acids in 
the former and γ-amino acids in the latter case. A third widely used technique is the amide 
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bond inversion, yielding a retro-inverso peptidomimetic. Carba-, alkene- or 
hydroxyethylene- groups are also used in exchange for the amide bond. Most of these 
modifications do not lead to a higher restriction of the global conformations, but they have 
influence on the secondary structure due to the altered intramolecular interactions like 
different hydrogen bonding. Additionally, the length of the backbone can be different and a 
higher proteolytic stability occurs in most cases. 
Azapeptides 
Interesting and synthetically easy to approach are the so called azapeptides in which the 
α-CH group of the backbone was replaced isoelectronically by a nitrogen atom while the 
side chains remain untouched. The synthesis of azapeptides from substituted hydrazines 
or hydrazides can be carried out very easily.160 When incorporating azaamino acid esters 
like compound 103 into a peptide chain azapeptides are formed which can be 
therapeutically relevant inhibitors of serine and cystein proteases.161 The same is true for 
the aza analogue 104 including an amino acid chloromethyl ketone. Both compounds 103 
and 104 can be easily prepared by the acylation of hydrazines.162 
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Figure 58: Peptides containing aza amino acids. R = peptide chain; R1 = H, alkyl, benzyl; 
R2 = alkyl, aryl. 
Retro-inverso Peptides 
Another approach to peptidomimetics are retro-inverso modifications.163 These 
peptidomimetics can be synthesized in the same way as normal peptides just by 
exchanging the natural L-amino acids by D-amino acids and simultaneously reversing the 
sequence from N- to C-terminus. As shown in Figure 59 the side chain topologies of the 
natural peptide and the peptidomimetic are the same. Of course, the retro-inverso 
modification does not lead to a more highly constrained polypeptide. The major advantage 
over their natural models lies in the higher in vivo stability as they are no substrates for 
proteases any more. One disadvantage of these peptidomimetics is that with the inversion 
of their sequence the termini are also exchanged. This means that the positive charge 
located at the N-terminus of the natural sequence is replaced by a negative one in the 
peptidomimetic. The same is true for the C-terminus where the negative charge is 
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replaced by a positive one. To avoid this, one can introduce modified termini or the retro-
inverso structures can be incorporated into larger peptides. 
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Figure 59: A natural peptide sequence 105 (top) and the retro-inverso analogue 106 
(bottom). 
The nonapeptide 105 is an active agonist for bombesin while in contrast the retro-inverso 
analogue 106 shows no activity at all.164 Unfortunately only a limited number of retro-
inverso derivatives show a to their native sequences comparable activity which strongly 
indicates that the backbone although not always directly involved often has a large impact 
on the protein-protein binding.165 
N-Alkylated Peptides 
N-alkylation is an important modification of the peptide bond. The N-methylation is widely 
used by scientists but also occurs in the sequences of natural peptides from different 
sources. Some of these compounds show high biological activity as antibiotics (e.g. 
monamycins,166 echinomycin167), insecticides,168 antitumor agents (e.g. bouvardin169) and 
antiinflammatory peptides (e. g. cyclomarins170).171 Numerous peptides which show 
biological activity were modified by the use of N-methyl amino acids (NMAs), resulting in 
analogues with improved pharmacological properties such as metabolic stability, 
selectivity, enhanced potency and bioavailability.172, 173 
The structural effects of N-alkylation have been intensively examined in N-methylated 
analogues of biologically relevant peptides. They normally show an increased proteolytic 
stability, increased membrane permeability (lipophilicity) and altered conformational 
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preferences of the amide bond properties.174 These effects result from the different 
property changes in the peptide going along with the introduction of N-methylation. Firstly, 
there are steric constraints introduced by the N-alkyl group,175 which have an effect not 
only on the conformational freedom of the peptide backbone but also on the side chain of 
the neighboring amino acid.176 Secondly, the number of inter- and intramolecular 
hydrogen bonds decreases due to the removal of the backbone NH-groups. And thirdly, 
they show an increased basicity and decreased polarity of the attached carbonyl group. 
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Figure 60: Structures of Cyclosporin A and O; N-methylation is indicated in blue. 
In natural proteins only the N-methylation and N-benzylation were observed until now. 
One of the most outstanding examples of a N-methylated peptide is the cyclic 
undecapeptide cyclosporine A (Figure 60) with seven N-methylated amino acids. It was 
first isolated from Trichoderma polysporum and is a member of the cyclic peptide 
immunosuppressants which in addition shows improved pharmacological properties and a 
low toxicity. These properties make it one of the most successful drugs (Sandimmun) 
used after organ transplantations.177 Although the total synthesis of cyclosporine A was 
already accomplished by Wenger et al. in 1984,178 the interest in this group of 
immunosuppressants has not decreased as the example of cyclosporine O shows which 
was synthesized on solid support by Thern et al. in 2002.179 
N-Alkylation is also a powerful and often used tool for the study of structure-activity 
relationships. Biologically active peptides, often have insufficient pharmacological 
properties due to the low in vivo stability and their high flexibility. These properties disfavor 
their use as pharmacophores and in clinical studies. N-alkylated amino acids which are 
introduced into peptide chains can help to overcome the shortfalls of their natural models 
due to the above mentioned effects. 
Another important advantage of NMAs is that many of them are commercially available in 
protected form allowing the direct use of these building blocks in solid phase peptide 
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synthesis while several others can be easily synthesized.180 By this method, libraries of 
natural product analogues can be produced in a very short amount of time. By 
successively alkylating each backbone NH and evaluating the biological activity of the 
produced compounds, the most active peptide can be found and with that the residues 
important for the interaction can be identified. The method is known as N-alkyl-scan. This 
concept was invented by Sugano et al. who synthesized a series of analogues of the 
peptide H-Lys-Phe-Ile-Gly-Leu-Met-NH2 in which each peptide bond was N-methylated 
one after the other. Screening of this series of five peptides on the depressor activity of 
rabbit blood revealed that the modification of Ile and Met lead to inactive compounds while 
the exchange of Phe and Leu showed no effect. Using this information the peptidomimetic 
H-Lys-(Me)Phe-Ile-Gly-(Me)Leu-Met-NH2 was prepared. This compound showed full 
depressor activity while having a higher resistance against digestion.181 
Peptoids 
One very interesting subgroup of the N-alkylated amino acids are the so called peptoids 
which contain N-alkylated glycines linked in a peptide-like manner. The α-CH groups have 
been replaced by nitrogens (like in aza peptides) and conversely, the NH-groups by CH2-
groups (similar to carba peptides). As a result, the side chains and the carbonyl groups 
remain at their places, while the backbone CH- and NH-groups change their places. 
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Figure 61: Comparison of a natural peptide sequence 108 with a topologically similar 
peptoid sequence 109. 
Figure 61 illustrates that the sequence of peptoids are opposite to the ones of native 
peptides, which is similar to the retro-inverso peptidomimetics. Another difference to 
natural sequences is the loss of stereoinformation as the chiral α-carbon of natural amino 
acids is replaced by a CH2-group and the side chains are now attached to nitrogen atoms. 
Peptoid analogues of most natural amino acids have been prepared and they can also be 
used in solid phase synthesis.182 Analysis of peptoids has shown that they are stable to 
proteolytic enzymes and that they have an even higher conformational flexibility compared 
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to natural peptides. Further studies have shown that peptoids like Ac-Nhtrp-Narg-Nhtyr-
NH2183 can be as active as their natural models (Ac-Trp-Arg-Tyr-OMe), in this case as an 
α-amylase inhibitor. An interesting aspect of this system is that the inverse peptoid 
sequence Ac-Nhtyr-Narg-Nhtrp-NH2 shows an even higher activity than the nature like 
forward sequence.159 
Cα-Tetrasubstituted α-Amino Acids 
Other backbone modifications which have been extensively investigated in the last years 
are the so called Cα-tetrasubstituted α-amino acids (or Cα,α-disubstituted glycines). This 
kind of amino acid also occurs in natural sequences, for example in proteins in fungi. 50 
years ago the first α-aminobutyric acid (Aib, 110) containing peptide sequence from a 
fungal source was found.184 Because of their unique bioactivities and conformations, a 
fast growing group of peptide antibiotics, the so-called peptaibiotics, has regained 
particular interest.185 As the majority of Aib- or isovaline- (Iva, 111) containing peptides 
carry a C-terminal residue representing a 2-amino alcohol, they are referred to as 
peptaibols.186 
H2N COOH H2N COOH
110 111  
Figure 62: Cα-tetrasubstituted α-amino acids: α-aminobutyric acid (Aib, 110) and isovaline 
(Iva, 111) are found in natural products. 
One interesting peptaibol example is the Alamethicin. It is an antimicrobial membrane-
active peptide which is proposed as an alternative for the treatment of infections since the 
resistance to normal antibiotics becomes an increasing medical problem.187  
Besides the natural occurring peptidomimetics based on Cα-tetrasubstituted α-amino 
acids, a rapidly increasing number of unnatural amino acids are developed by scientists 
and used for the synthesis of peptidomimetics.188 Exchanging one glycine in the Leu-Enk 
sequence 112, which is an enkephalin (enkephalin is a pentapeptide involved in regulating 
pain and nociception in the body) by Cα-tetrasubstituted α-amino acids leads to the 
peptides 113-115. All of these analogues possess a β-turn like structure in solution 
induced by the unnatural amino acid and show high activity with IC50-values between 0.01 
nM and 0.4 nM.189 
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Figure 63: Structures of the enkephalin 112 and three potent analogues 113-115. 
1.2.2. Introduction of Global Restrictions 
Besides amino acid modifications several other methods for the preparation of highly 
active peptidomimetics exist. One example is the introduction of global restrictions into the 
peptide via cyclisation of the peptide strand. This typically results in a higher in vivo 
stability of the cyclic peptidomimetics compared to their linear analogues. Because of their 
reduced conformational flexibility they can be used to present divers functionalities in a 
defined and predictable manner. A variety of different techniques were developed for the 
synthesis of cyclic peptidomimetics. In principal three ways exist for the formation of cyclic 
analogues of natural peptides. The first is the connection of the N- with the C-terminus 
(head-to-tail), the second is to couple either the C- or the N-terminus with one of the side 
chains (backbone/side chain) and the third is to connect two side chains that are not 
involved in the interaction with other proteins with each other (side chain/side chain).190 
Head-to-Tail Cyclisation 
Although new ways were developed for the head-to-tail cyclisation of peptides, most of 
them are still formed by the cyclisation of activated precursors in solution phase, which 
means in most cases the use of standard peptide coupling conditions using HOBt/HBTU 
or HOAt/HATU as activating reagents. One example for the head-to-tail cyclisation of 
natural products is the previously shown cyclosporine O 107 (see Figure 60).191 This 
methodology was further used for the preparation of numerous cyclic RGD 
peptidomimetics, in which the RGD (Arg-Gly-Asp) is flanked by other amino acids to form 
a ring system. These compounds offer the possibility to present the side chains of the 
RGD sequence in a specific conformation. Amongst others these cyclopeptides have 
Leu-Enk 
[(R)-α-MeSer]-Enk [(R)-α-Ahp]-Enk [(R)]-α-Ahh]-Enk 
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been developed as fibrinogen receptor antagonists or as selective αVβ3 integrin 
antagonists for treatment of human tumor metastasis and tumor induced angiogenesis, 
bone remodeling and osteoporosis.192 
Besides the standard methods using peptide coupling reactions, other methodologies 
have also been developed. One example is the ruthenium catalyzed intramolecular 
nucleophilic aromatic substitution (SNAr) to form cyclic biphenyl ethers. In Figure 64, two 
natural products together with some analogues are shown. K-13 (116) is a natural 
noncompetitive inhibitor of angiotensin converting enzyme (ACE),193 while OF4949-III 
(119) is a competitive inhibitor for aminopeptidase B. The compound family 117-120 
exhibits immunopotentiating activity and were confirmed to have antitumor activity, but 
they lack classical toxicity.194 
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Figure 64: Structures of the naturally occurring protease inhibitor K13 (116) and OF4949-
III (119) together with some analogues 117, 118 and 120. 
Side chain-to-Side chain Cyclisation 
The most common methods to lock peptide chains into defined structures like α-helices by 
the formation of cyclic analogues are the disulfide linkage via the oxidation of two Cys 
residues and the formation of amide bonds between the side chain residues of the amino 
acids Lys and Asp/Glu. Disulfide bridging was used for example in the development and 
synthesis of the cyclic enkephalin analogue 121 which is active at the δ-opiate receptor. In 
this example the ring system was formed by linking two penicillamine residues via a 
disulfide bridge with each other. 
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Figure 65: The enkephalin analogue 121 is active at the δ-opiate receptor. 
The limitation of these methods is that the use of a single covalent bridge constrains only 
a limited section of the polypeptide. To overcome this problem several covalent bridges 
need to be incorporated into one sequence. One example showing the effectiveness of 
this method is the modification of the 31 N-terminal residues of the human parathyroid 
hormone (hPTH) to deliver the therapeutic osteogenic agent 122. The introduction of three 
lactam bridges between the i and i+4 amino acids results in a highly constrained peptide 
in which the residues 13-30 are forced into a helical structure. This makes the analogue a 
much more active compound than the natural sequence.195 
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Figure 66: The peptidomimetic 122 consisting of 31 residues of the human parathyroid 
hormone is stabilized by three lactam bridges. 
While disulfide and also lactam bridges effectively stabilize 3D structures, such structural 
elements are not always stable in vivo as they also occur in natural sequences and are 
susceptible to degradation. To overcome this limitation, cross-links consisting only of 
hydrocarbons were investigated as replacement for the above shown linking methods. 
The ring-closing step for example can be performed by a metathesis reaction using a 
Grubbs catalyst.196 An interesting approach was the synthesis of Fmoc-protected 
Cα-tetrasubstituted α-amino acids which are α-methylated and in addition bear a second 
alkene side chain. They can be used in solid phase peptide synthesis and if two of them 
are incorporated into one chain they can be cyclized by the use of metal catalysis.197 One 
example of this hydrocarbon cyclisation methodology is shown in Figure 67. The mimic of 
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the minimal death domain BH3 of the pro-apoptotic sub-family of proteins can be forced 
into a helical conformation through a metathesis reaction. This resulted in a significantly 
enhanced stability and an altered in vitro and in vivo activity appeared.198, 199 
Figure 67: α-Methyl Fmoc-protected unnatural amino acids 123 and 124 (top); scheme of 
a helix introduction into a peptide sequence via a ring-closing metathesis reaction with 
Grubbs’ catalyst (bottom). (adapted from literature198) 
Backbone-to-Side Chain Cyclisation 
A further way to introduce global constraints into peptides is the formation of backbone to 
side chain cyclisations. One example for such a molecule is the cyclic derivative 125 (Tyr-
c[-D-Orn-2-Nal-D-Pro-NMe-Ala]) of the natural occurring β-casomorphin-5. β-Caso-
morphins are short acyclic peptides derived from the milk protein β-casein and show a 
high selectivity for the μ-opioid receptor.200 The derivative 125 proved to be a potent and 
selective μ-opioid receptor agonist with an IC50 of 35 nM.201 
Another example for a backbone-side chain cyclisation is the cyclic peptidomimetic 
inhibitor of HIV-1 protease 126. In the mimetic 126 the tripeptide sequence Phe-Ile-Val 
from the natural peptide Ac-Leu-Val-Phe-CHOHCH2-{Phe-Ile-Val}-NH2 was replaced by a 
cyclic motif consisting of a tyrosine, a leucine and an alkyl amine. In an inhibition assay 
such peptides showed IC50-values of up to 2 nM.202 Inhibitors for HIV 1 protease are of 
great interest as this enzyme is essential for the assembly of the viral proteins. A 
successful inhibition would thus lead to noninfective virions.203, 204 
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Figure 68: The cyclic β-casomorphin-5 derivative Tyr-c[-D-Orn-2-Nal-D-Pro-NMe-Ala] 125 
(left) and a macrocyclic HIV protease inhibitor 126 (right). 
1.2.3. Synthetic Backbone Scaffolds 
All of the previously shown peptidomimetics still show a more or less peptide like scaffold, 
however, entirely non-peptidic mimetics have also been developed. The first example of 
this class of compounds which allows a synthesis in a modular fashion was reported by 
Hamilton et al. in 2002.205 These compounds present their residues with similar distances 
and angular relationships to those found in the side chains of α-helices. Subsequently, 
modifications to the initial terphenyl scaffold design were made to improve synthetic 
accessibility, solubility and flexibility.206 Inhibitors based on the terphenyl scaffold 128 
were developed for example to inhibit the interaction of Calmodulin (CaM) with smooth 
muscle myosin light chain kinase (smMLCK). CaM has a variety of functions in the cell 
cycle and interacts with a number of proteins including smMLCK which is supposed to 
play a significant role in the signaling cascade leading to muscle contraction, but it is also 
supposed to play a role in cancer.207 The designed derivative showed an IC50 of 800 nM 
and with that is one of the most potent CaM antagonists known until now.208  
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Figure 69: α-Helix mimics developed by Hamilton et al. 127-129 and by König et al. 130. 
The residues R1-R3 are mimics of i, i+3, i+4 and i+7 residues of the helix. 
Another interesting approach was the synthesis of 1,4-dipiperazino benzene 130, using a 
stepwise transition metal-catalyzed N-arylation of chiral piperazines to a benzene core. 
The structure determined by X-ray crystallography revealed a geometric arrangement of 
the side chains resembling the orientation of α-helical i, i+3 and i+7 residues.209 
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2. Synthesis of Novel Cα-tetrasubstituted α-Amino Acids 
2.1. Introduction 
As mentioned previously (see Chapter 1.2.1.2) Cα-tetrasubstituted α-amino acids are an 
important route to active peptidomimetics. The following factors can be seen as the main 
motivations for the synthesis and use of these building blocks: (i) The occurrence of 
Cα-tetrasubstituted α-amino acids in peptaibols.210 (ii) The usefulness of these residues in 
the synthesis of conformationally constrained and enzyme-resistant analogues of 
biologically active peptides.211 (iii) The severe restriction of the conformational freedom of 
peptides containing these residues212 which, allows the use of such compounds as 
precise molecular rulers,213 building blocks in the de novo design of peptide and protein 
mimetics214 or suitable models for spectroscopic studies. 215 
Cα-tetrasubstituted α-amino acids are commonly used to introduce constrains into a 
peptide backbone through the stable quaternary α-carbon and the attached substituents. 
One way to add even larger constraints is to covalently link the substituents at the 
α-carbon with each other leading to cyclic Cα-tetrasubstituted α-amino acids. This leads to 
a change in the chemical reactivity of the surrounding functional groups, like a reduced 
hydrolysis rate of an amide bond or ester group.216, 217 
H2N COOH
X n
X = CH2, NH, O, S
n = 1-5
131
 
Figure 70: General representation of cyclic Cα-tetrasubstituted α-amino acids. 
One representative of the group of cyclic unnatural amino acids are the 
Cα-tetrasubstituted tetrahydrofuran amino acids (TAAs) which were developed by our 
group.218 Attractive features of these amino acids are the easy accessibility in a four step 
synthesis starting from commercially available starting materials. In addition the amino 
acids do not only show a stable quaternary stereocenter at the α-carbon of the amino acid 
but also a second one at the β-carbon. An additional benefit is the variety of aromatic 
aldehydes which can be brought to reaction with the sulfonium salt 133, leading to 
numerous different amino acids with functional groups at the aromatic system. 
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Scheme 16: Exemplary synthesis pathway leading to the unnatural amino acid rac-135 as 
racemic mixture. 
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Scheme 16 shows the synthesis of a TAA, starting from methionine 132, which is two-fold 
protected and then converted to the sulfonium salt 133. To form the tetrahydrofuran ring 
the sulfonium salt 133 is first treated with KOH to abstract the acidic proton of the 
α-carbon of the amino acid. During this deprotonation, the stereoinformation is lost. The 
resulting ester enolate can then attack the carbonyl group of the aromatic aldehyde 134. 
The intermediate alkoxide substitutes the dimethylsulfide intramolecularly, giving the 
tetrahydrofuran amino acids rac-135. During this last step two new stereocenters are 
formed which can lead to four different stereoisomers. Fortunately the reaction shows a 
high diastereoselectivity for the formation of the trans-product. 
However, the TAA synthesis do suffer from some difficulties and limitations: Firstly, the 
protecting groups used until now are not entirely orthogonal, meaning that the conditions 
necessary for the saponification of the tbutyl-ester group also lead to a cleavage of the 
Boc-group. Another drawback is the fact that the reaction is not enantioselective, giving 
always a racemic mixture of the synthesized TAA. Additionally, the strongly basic reaction 
conditions needed for the abstraction of the α-proton of the methionine are a shortcoming 
of the synthesis as only aldehydes which lack protons in the α-position like benzaldehyde 
derivatives are unable to undergo undesired aldol-type side reactions. 
In the following some approaches to overcome these limitations will be presented. 
 
Section B 2. Synthesis of Novel Cα-tetrasubstituted α-Amino Acids 
 123
S O
NHBoc
O OtBu
H
ArI
OH
S O
NHBoc
+K-O OtBu
ArI
O NHBoc
O OtBu
Ar
Me2S
KI
S O
NHBoc
O OtBu
ArI
S O
NHBoc
ArI
O
OtBu
K+
K+
O
NHBoc
O OtBu
Ar
I
K+
S
O
Ar
I
K+
S
NHBoc
O
OtBu
O
NHBoc
Ar
O
OtBU
Me2S
KI  
Figure 71: Reaction mechanism for the formation of Cα-tetrasubstituted tetrahydrofuran 
amino acids as proposed by König et al.218 
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2.2. Orthogonal Protecting Groups for the THF Amino Acid 
Until now a drawback of the TAA synthesis was that the protecting groups used were not 
entirely orthogonal. Deprotecting the Boc-group in presence of the tbutyl-ester with HCl 
saturated diethyl ether is possible but the ester group cannot be saponified without 
eliminating the Boc-group. The only possibility to afford the N-terminally protected amino 
acid rac-138 was to first cleave both groups and then reprotect the amine. This procedure 
only gave a maximum yield of 50 % which could not be further optimized. 
Scheme 17: Deprotection conditions applied to the protected TAA rac-135. 
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Therefore we decided to synthesize a tetrahydrofuran amino acid with orthogonal 
protecting groups. We chose the Cbz-group for amine protection and the tbutyl-group for 
the protection of the carboxylic acid because both are stable to the strongly basic 
conditions which are used during the cyclisation reaction. 
The synthesis was performed similar to the one of the Boc-TAA-OtBu rac-135, starting 
from methionine 132 which was first protected at the N-terminus with benzyl 
carbonochloridate. In a second step the tbutyl-ester was introduced using a Steglich-type 
esterification reaction. After methylation resulting in the sulfonium salt 139, the cyclisation 
reaction was performed using para-bromobenzaldehyde 134. As with Boc-TAA-OtBu rac-
135 the new Cbz-TAA-OtBu rac-140 was also formed in a highly diastereoselective 
manner as a racemic mixture in a moderate yield of 48 %. 
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Scheme 18: Synthesis pathway leading to the Cbz-TAA-OtBu rac-140. 
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2.3. Enantioselective Ring Formation 
One of the major shortfalls of the synthesis of unnatural tetrahydrofuran amino acids is the 
formation of a racemic product. This racemisation occurred because of the mechanism of 
the reaction which starts with the deprotonation of the α-carbon destroying the 
stereochemical information in this position. We therefore attempted to induce 
stereoselectivity in the reaction by the use of an asymmetric auxiliary. We decided to use 
an optically pure alcohol to replace the tbutanol used until now. The alcohol should be 
easily coupled by a Steglich-type reaction and should also be easy to cleave afterwards to 
provide the free acid. In addition, the ester function should be stable under the cyclisation 
conditions. For these reasons, we chose (-)menthol which is inexpensive, commercially 
available and can easily be attached to the amino acid as well as cleaved again. 
The synthesis followed a similar route as for the Cbz-protected unnatural amino acid rac-
140. It started from methionine 132 which was first protected on the amine function and 
then coupled in good yields with (-)menthol. 
After the formation of the sulfonium salt 142 the cyclisation reaction was performed using 
again para-bromobenzaldehyde 134 as this afforded high yields and also a high 
diastereoselectivity so far. The reaction gave selectively the trans-product in 69 % yield. 
Unfortunately no enantioselectivity of the cyclisation reaction was observed and the 
product TAA (143 and 144) was formed again as a mixture but in this case not of two 
enantiomers but of two diastereomers which allowed us to separate them by flash-
chromatography. 
The deprotection reactions showed that the Boc-group could be easily cleaved using HCl-
saturated diethyl ether but also that the cleavage of the (-)menthol was a more 
challenging task. Under basic conditions using KOH in an ethanol/water mixture no 
saponification occurred even after refluxing for several hours. 6M aqueous HCl which was 
used for the total deprotection of Boc-TAA-OtBu rac-135 gave no deprotected product 
either. Better results were obtained with KOH in a mixture of methanol and water and 
performing the reaction not under conventional heating in an oil bath but under microwave 
irradiation. This procedure gave the free acid 146 in reasonable 55 % yield. The free 
amine 145 and acid 146 were further used in peptide coupling reactions to form dipeptides 
of tetrahydrofuran amino acids (see Chapter 3.2). 
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Scheme 19: Synthesis pathway leading to the two Boc-TAA-Omenthol 143 and 144 with 
exemplary deprotection reactions. 
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2.4. Aliphatic THF Amino Acids 
As shown before (Chapter 2.1) the key step of the TAA synthesis is the ring formation 
which is an aldol type reaction between the sulfonium salt 133 and an aldehyde: Applying 
strongly basic conditions leads to the abstraction of the α-proton of the methionine, the 
aldehyde is nucleophilic attacked by the ester enolate and the displacement of the 
sulfonium salt substituent by the alkoxy group gives the target TAA. To avoid undesired 
side reactions under the basic reaction conditions only aldehydes which lack protons in 
the α-position like benzaldehyde derivatives were used in the TAA-synthesis until now 
(see Scheme 20). 
In the following the synthesis and structural characterization of cyclic tetrahydrofuran 
Cα-tetrasubstituted amino acids which were prepared from aliphatic aldehydes will be 
shown. 
The major difference between the previously used aromatic aldehydes and their aliphatic 
counterparts is their ability to undergo an aldol reaction under the strongly basic 
conditions necessary for the formation of the tetrahydrofuran ring system. 
Scheme 20: Cyclisation reaction forming the tetrahydrofuran amino acid (TAA). 
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Therefore different bases namely KOH, KOtBu and CsOH and also different equivalents of 
sulfonium salt 133, aldehyde and base were screened to find the optimal conditions for 
the TAA synthesis. In all cases, dry acetonitrile was used as solvent, and the temperature 
was kept at -6 °C to improve the diastereoselectivity of the ring formation. n-Butyral-
dehyde (147) was chosen for the first set of reactions to optimize the reaction conditions. 
Table 2 summarizes the results. In total eight different reaction conditions were tried and 
the conversion was determined by 1H-NMR analysis after aqueous workup. Entries 1-3 
clearly indicate that cesium hydroxide is the base of choice for the conversion of aliphatic 
aldehydes which is in contrast to the reactions carried out with aromatic aldehydes where 
KOH gave the best results.218 In the next three experiments (entries 4 – 6), the amount of 
sulfonium salt 133 was increased with respect to the aldehyde and the optimal amount of 
base was investigated. The highest yield of TAA were obtained with identical amounts of 
base and sulfonium salt. To optimize the ratio of aldehyde to sulfonium salt 133, reactions 
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with ratios of 1:1.5, 2:1 and 8:1 aldehyde to sulfonium salt 133 were performed (entries 6 
– 8). Best results were obtained with a slight excess of the sulfonium salt. 
Table 2: Results of the reaction condition optimization of the reaction between the 
sulfonium salt 133 and the n-butyraldehyde 147. 
eq. basea 
entry 
eq. 
sulfonium 
salt 133a 
KOH KOtBu CsOH
yieldb 
1 1.1 1.1     16%c 
2 1.1   1.1   25%c 
3 1.1     1.1 32%c 
4 1.5     1.0 21%c 
5 1.5     1.25 15%c 
6 1.5     1.5 47%c 
7 0.5     0.5 24%d 
8 0.125     0.125 13%d 
All reactions were performed following GP1. 
a Equivalents are with respect to the n-butyraldehyde 147. b Yields were deter-
mined by 1H-NMR and have an error of ± 5% as estimated from repeating the 
reaction of entry 6. 
c Yields are based on the aldehyde as limiting compound. 
d Yields are based on the sulfonium salt as limiting compound. 
 
To explore the scope of the reaction a series of aliphatic aldehydes were converted using 
the optimized reaction conditions. The results are summarized in Table 3 and show that 
sterically demanding aliphatic aldehydes like pivalaldehyde (148) which has a tertiary 
α-carbon do not undergo the ring closing reaction. Aldehydes with a secondary α-carbon 
like 2-phenylpropanal (149) or isobutyraldehyde (150, entries 2 and 3) fail or form the 
product only in traces. 3-Methylbutanal (151, entry 4), which bears a secondary carbon 
atom in the β-position, gives increased product yields. The best results were obtained for 
the unbranched n-butyraldehyde (147) and acetaldehyde (152) with yields of 36 % and 
28 %, respectively, (entries 5 and 6). 
Methacrylaldehyde (153, entry 7) was reacted with the sulfonium salt 133 as an example 
of an unsaturated aldehyde. The corresponding TAA was obtained in 18% yield. To 
investigate the reactivity of ketones, acetone (154) was tested but no TAA product was 
formed. 
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Table 3: Scope of the reaction of sulfonium salt 133 with different aldehydes 
entry aldehyde product 
isolated 
yield (%)
trans/cis- 
ratioa 
1 
  
- - 
2 
  
- - 
3 
  
2 9/1 
4 
  
17 5/1 
5 
  
36 3/1 
6 
  
28 2/1 
7 
  
18 > 95/5 
8 
  
- - 
a The trans/cis-ratio was determined by NMR spectroscopy. 
 
The diastereoselectivity of the reaction was also examined. The previously reported ring 
formation reactions with aromatic aldehydes all showed a trans-selectivity,218 therefore it 
was assumed that this is here also the case. To proof this assumption 2-dimensional NMR 
spectroscopy was performed. The crystal structure obtained from compound 160 shows 
the trans-diastereomer (see Figure 73). In the trans-product the proton of the amine and 
the proton of the THF-CH group are located on the same side of the ring and are therefore 
in close proximity with a distance determined from the crystal structure of 2.18 Å. This 
close distance results in a strong NOE cross peak, while for the cis-product in which the 
two protons point to opposite sides of the ring no NOE cross peak occurs (see Figure 72). 
Section B 2. Synthesis of Novel Cα-tetrasubstituted α-Amino Acids 
 131
By this method the assumption that the trans-product is the main diastereomer could be 
proofed. 
 
Figure 72: Exemplary NOESY spectra (600 MHz, CDCl3) of compound 158. 
The diastereoselectivity of the reaction varies: For acetaldehyde (152) a ratio of to 2/1 in 
favor for the trans-product was found. This ratio increases to 3/1 (trans/cis) for the larger 
n-butyraldehyde (147). With increased steric demand of the aldehydes the ratio shifts in 
favor of to the trans-product as for the 3-methylbutanal (151, trans/cis = 5/1) and for 
isobutyraldehyde (150, trans/cis = 9:1). The highest trans-selectivity was found for 
methacrylaldehyde (153) where no cis-product could be detected by NMR. 
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Figure 73: X-Ray structure of compound 160. 
The results gathered, indicate that Cα-tetrasubstituted tetrahydrofuran α-amino acids can 
be obtained from aliphatic aldehydes in low to moderate yields. The diastereoselectivity of 
the reaction depends on the steric demand of the aldehyde and varies from trans/cis-
ratios of 2/1 up to 95/5. Although the scope of the reported reaction is certainly limited, the 
study shows that from selected aliphatic aldehydes Cα-tetrasubstituted tetrahydrofuran 
α-amino acids are accessible in synthetically useful yields and selectivities. 
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2.5. Experimental Part 
All reagents and solvents used were of analytical grade purchased from commercial 
sources and were used without further purification if not stated otherwise. All reactions 
were carried out under an atmosphere of nitrogen. Acetonitrile was dried previous to use. 
All aldehydes were distilled shortly before use. Silica gel 60 (230–400 mesh) was used for 
column chromatography. TLC was carried out with silica gel 60 F254 plates. Visualization 
was accomplished by UV light and Ninhydrin staining. All NMR spectra were recorded on 
a Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K) and a Bruker Avance 
600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K) instrument with external standard. 
The compounds Boc-Met-OH 141 and the sulfonium salt 133 were synthesized according 
to a literature know procedure.218 
General Procedure for the tetrahydrofuran amino acid synthesis (GP 1) 
In an oven dried Schlenk flask under nitrogen atmosphere the sulfonium salt (0.125 – 1.5 
eq. with respect to the aldehyde) was dissolved in dry acetonitrile (5 ml per 1 mmol 
sulfonium salt). The colorless solution was cooled to -6 °C and the base (0.125 – 1.5 eq. 
with respect to the aldehyde) followed by the freshly distilled aldehyde were added. The 
mixture was stirred at -6 °C for 4-7 hours. After complete consumption of starting material 
the reaction mixture was quenched with water (4 ml per mmol sulfonium salt) and was 
extracted with diethyl ether (1 x 4 ml/mmol, 2 x 5 ml/mmol sulfonium salt). The combined 
organic layers were washed with brine solution and dried over MgSO4. After removal of 
the solvent under reduced pressure the crude product was purified by flash 
chromatography using mixtures of diethyl ether and petrol ether (10:90 ? 20:80) as 
eluent. 
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(S)-2-(Benzyloxcarbonylamino)-4-(methylthio)butanoic acid (163): 
L-Methionine 132 (2.00 g, 13.4 mmol) was dissolved in 15 ml 1M aqueous sodium 
hydroxide solution and cooled to 0 °C in an ice bath. Under vigorous stirring benzyl 
carbonochloridate (1.79 ml, 12.7 mmol) was added drop by drop. After 45 minutes 50 ml 
of water were added and the mixture was extracted three times with 50 ml of EtOAc each. 
Afterwards the solution was dried over MgSO4 and concentrated under reduced pressure 
to give the product as colorless oil (3.07 g, 10.8 mmol, 85 %). 
MP 59 °C. - 1H-NMR (300 MHz, CDCl3): δ = 1.91-2.29 (m, 5 H, 12 + 15), 2.57 (t, 3JH,H = 
7.4, 2 H, 13), 4.45-4.61 (m, 1 H, 9), 5.13 (s, 2 H, 5), 5.44 (d, 3JH,H = 7.9, 1 H, 8), 7.28-7.44 
(m, 5 H, H-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 15.4 (+, 1 C, 15), 29.9 (-, 1 C, 13), 31.6 
(+, 1 C, 12), 53.0 (+, 1 C, 9), 67.3 (+, 1 C, 5), 128.2 (+, 2 C, 3), 128.3 (+, 1 C, 1) , 128.6 
(+, 2 C, 2), 136.0 (Cquat, 1 C, 4), 156.1 (Cquat, 1 C, 7), 176.6 (Cquat, 1 C, 10). - MS (CI, NH3): 
m/z (%) = 301.1 (100) [MNH+), 284.1 (14) [MH+]. – IR (NEAT) [cm-1]: ν~  = 3304, 2969, 
2917, 1739, 1682, 1647, 1539, 1400, 1293, 1269, 1203, 1061, 1027, 961, 910, 810, 744. - 
MF C13H17NO4S. - MW 283,34. 
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(S)-tert-Butyl 2-(benzyloxycarbonylamino)-4-(methylthio)butanoate (164): 
2-(Benzyloxycarbonylamino)-4-(methylthio)butanoic acid 163 (3.00 g, 10.6 mmol) was 
dissolved under a nitrogen atmosphere in 50 ml of dry DCM and cooled to 0 °C in an ice 
bath. To this solution DMAP (108 mg, 0.88 mmol) and tbutanol (1.21 ml, 12.7 mmol) were 
added. Under vigorous stirring dicyclohexyl carbonate (2.84 g, 13.8 mmol) was slowly 
added in portions. The mixture was stirred at 0 °C for 2 hours and was then allowed to 
warm to room temperature and was stirred for additional 12 hours. The urea was filtered 
off and washed twice with 25 ml of DCM. The solvent was evaporated under reduced 
pressure. The crude product was then purified by column chromatography on silica gel 
(EtOAc:PE 30 :70, Rf = 0.48) to give the product as colorless oil (1.84 g, 6.02 mmol, 
57 %). 
1H-NMR (300 MHz, CDCl3): δ = 1.46 (s, 9 H, 13), 1.82-2.20 (m, 5 H, 14 + 17), 2.41-2.61 
(m , 2 H, 15), 4.25-4.44 (m, 1 H, 9), 5.11 (s, 2 H, 5), 5.39 (d, 3JH,H = 7.4, 1 H, 8), 7.28-7.43 
(m, 5 H, H-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 15.5 (+, 1 C, 17), 28.0 (+, 3 C, 13), 29.9 
(-, 1 C, 15), 32.5 (+, 1 C, 14), 53.8 (+, 1 C, 9), 67.0 (+, 1 C, 5), 82.4 (Cquat, 1 C, 12), 128.1 
(+, 2 C, 3), 128.2 (+, 1 C, 1) , 128.5 (+, 2 C, 2), 136.3 (Cquat, 1 C, 4), 155.9 (Cquat, 1 C, 7), 
171.0 (Cquat, 1 C, 10). – MS (CI, NH3): m/z (%) = 284.0 (7) [MH+ - C4H8], 301.1 (52) 
[MNH4+ - C4H8], 340.1 (15) [MH+], 357.1 (100) [MNH4+]. – IR (NEAT) [cm-1]: ν~  = 2979, 
2917, 1708, 1523, 1455, 1368, 1224, 1149, 1046, 965, 845, 738, 696. – MF C17H25NO4S. 
– MW 339.45. 
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(S)-(3-(Benzyloxycarbonylamino)-4-tert-butoxy-4-oxobutyl)dimethylsulfonium iodide (139): 
tert-Butyl 2-(benzyloxycarbonylamino)-4-(methylthio)butanoate 164 (3.00 g, 10.6 mmol) 
was dissolved in 32 ml methyl iodine (3 ml/mmol) and stirred for three days at room 
temperature in the dark. The solution was cooled to 0 °C in an ice bath and 32 ml of 
heptane (3 ml/mmol) were added to precipitate the product. The mixture was kept at 0 °C 
in the dark for four hours to complete the precipitation. The hygroscopic and light sensitive 
product was obtained after filtration and washing with ice-cold heptane as a colorless solid 
(1.39 g, 2.89 mmol, 98%) in analytically pure form. 
MP 35-37 °C. - 1H-NMR (300 MHz, CDCl3): δ = 1.46 (s, 9 H, 13), 2.20-2.49 (m, 2 H, 14), 
3.19 (s, 3 H, 17), 3.23 (s, 3 H, 17), 3.59-3.81 (m, 1 H, 15), 3.85-4.02 (m, 1 H, 15), 4.21-
4.38 (m, 1 H, 9), 5.10 (s, 2 H, 5), 6.09 (d, 3JH,H = 7.1, 1 H, 8), 7.28-7.47 (m, 5 H, 1 -3). – 
13C-NMR (75 MHz, CDCl3): δ = 25.7 (+, 1 C, 17), 26.0 (+, 1 C, 17), 28.0 (+, 3 C, 13), 31.9 
(-, 1 C, 14), 40.5 (+, 1 C, 15), 53.2 (+, 1 C, 9), 67.2 (+, 1 C, 5), 83.5 (Cquat, 1 C, 12), 128.2 
(+, 2 C, 3), 128.3 (+, 1 C, 1) , 128.6 (+, 2 C, 2), 136.3 (Cquat, 1 C, 4), 156.5 (Cquat, 1 C, 7), 
169.9 (Cquat, 1 C, 10). - MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 354.1 (100) 
[M+]. – IR (NEAT) [cm-1]: ν~  = 2980, 2928, 1707, 1518, 1238, 1151, 1047, 740, 698. – MF 
C18H28NO4SI. – MW 481.39. 
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rac-tert-butyl 3-(benzyloxycarbonylamino)-2-(4-bromophenyl)-tetrahydrofuran-3-carboxy-
late (rac-140): 
Synthesis followed GP 1 using (3-(benzyloxycarbonylamino)-4-tert-butoxy-4-oxobutyl)-
dimethylsulfonium iodide 139 (4.68 g, 9.73 mmol, 1.2 eq.), potassium hydroxide (546 mg, 
9.73, 1.2 eq.) and para-bromobenzaldehyde 133 (1.50 g, 8.11 mmol, 1 eq.). The product 
was purified with a 80:20 mixture of PE:diethyl ether (Rf = 0.15) to give a white crystalline 
solid in 48 % yield (1.85 g, 3.90 mmol). 
MP 133-135 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.11(s, 9 H, tBu), 2.54-2.81 (m, 2 H, 
CH2), 4.22-4.37 (m, 2 H, S-CH2), 5.08-5.21 (m, 3 H, CH2–Cbz + CH), 6.00 (bs, 1 H, NH), 
7.20 (d, 3JH,H = 7.9, 2 H, CH-Ar), 7.28-7.45 (m, 7 H, CH-Cbz, CH-Ar). – 13C-NMR (75 MHz, 
CDCl3): δ = 27.4 (+, 3 C, CH3-tBu), 35.8 (-, 1 C, CH2), 66.8 (-, 1 C, O-CH2), 67.9 (-, 1 C, 
CH2-Bzl), 69.5 (Cquat, 1 C, C-NH), 83.0 (Cquat, 1 C, C-tBu), 83.8 (+, 1 C, CH) , 121.7 (Cquat, 
1 C, C-Br), 127.7 (+, 2 C, CH-Bzl), 128.2 (+, 2 C, CH-Bzl), 128.3 (+, 1 C, CH-Bzl), 128.6 
(+, 2 C, CH-Ar), 131.0 (+, 2 C, CH-Ar), 136.2 (Cquat, 1 C, C-Ar), 136.5 (Cquat, 1 C, C-Ar), 
154.6 (Cquat, 1 C, CO-Bzl), 169.9 (Cquat, 1 C, COOtBu). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 476.2 (7) [MH+], 495.2 (100) [MNH4+], 476.1 (100) [M – H+], 536.2 
(10) [M + CH3COO-]. – Elemental analysis calcd. (%) for C23H26BrNO5 (524.49): C 57.99, 
H 5.50, N 2.94; found: C 58.04, H 5.55, N 2.82. – IR (NEAT) [cm-1]: ν~  = 3334, 2977, 
2947, 2860, 1702, 1593, 1524, 1491, 1361, 1247, 1154, 1073, 1011, 986, 827, 790, 750, 
697. – MF C23H26BrNO5. – MW 476,36. 
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X-Ray structure and crystal data of rac-140: 
Orthorhombic; space group: P 21 21 21; cell dimensions: a = 5.70000 Å, α = 90°, b = 
16.24330(10) Å, β = 90°, c = 23.2665(2) Å, γ = 90°; V = 2154.17(2) Å3; Z = 4, Dx = 1.469 
Mg/m3; µ = 2.893 mm-1; F(000) = 984. Data collection: T = 123 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.440 x 0.080 x 0.060 
mm was used to measure 45343 reflections (3404 unique reflections, Rint = 0.1645) from 
3.32° to 62.28° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan 
method. Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit 0f 1.038 for all reflections and 275 parameters. 
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(S)-(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-(tert-butoxycarbonylamino)-4-(methyl-
thio) butanoate (165): 
Boc-Met-OH 141 (10.0 g, 40.1 mmol) was dissolved under a nitrogen atmosphere in 
200 ml of dry DCM and cooled to 0 °C in an ice bath. To this solution DMAP (408 mg, 
3.34 mmol) and (-)menthol (7.52 ml, 48.1 mmol) were added. Under vigorous stirring 
dicyclohexyl carbonate (10.8 g, 52.1 mmol) was slowly added in portions. The mixture 
was stirred at 0 °C for 2 hours and was then was allowed to warm to room temperature 
and was stirred for additional 12 hours. The urea was filtered off and washed twice with 
50 ml of DCM. The solvent was evaporated under reduced pressure. The crude product 
was then purified by column chromatography on silica gel (PE:diethyl ether 80:20, Rf = 
0.20) to give the product as colorless solid (13.3 g, 34.3 mmol, 86 %). 
MP 59-60 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.74 (d, 3JH,H = 6.9, 3 H, 19), 0.88 (d, 3JH,H 
= 4.4, 3 H, 21), 0.90 (d, 3JH,H = 4.1, 3 H, 21), 0.92-1.26 (m, 3 H), 1.32-1.65 (m, 11 H), 1.63-
1.75 (m, 2 H), 1.79 (2.04 (m, 3 H), 2.07-2.18 (m, 4 H), 2.45-2.61 (m, 2 H, 16), 4.36 (dd, 
3JH,H = 7.0, 3JH,H = 12.5, 1 H, 6), 4.73 (dt, 3JH,H = 4.4, 3JH,H = 11.0, 1 H, 9), 4.36 (d, 3JH,H = 
5.1, 1 H, 5). – 13C-NMR (75 MHz, CDCl3): δ = 15.5 (+, 1 C, 21), 16.2 (+, 1 C, 21), 20.8 (+, 
1 C, 18), 22.0 (+, 1 C, 19), 23.3 (-, 1 C, 13), 26.1 (+, 1 C, 20), 28.3 (+, 3 C, 1), 29.9 ( -, 1 
C, 16), 31.4 (+, 1 C, 11), 32.6 (-, 1 C, 15), 34.1 (-, 1 C, 12), 40.7 (-, 1 C, 10), 46.9 (+, 1 C, 
14), 53.0 (+, 1 C, 6), 75.6 (+, 1 C, 9), 79.9 (Cquat, 1 C, 2), 155.3 (Cquat, 1 C,4), 171.8 (Cquat, 
1 C, 7). - 30.1 (-, 1 C, 9), 53.8 (+, 1 C, 6), 70.0 (-, 1 C, 17), 80.1 (Cquat, 1 C, 2), 114.9 (+, 1 
C, 14), 128.8 (+, 2 C, 19/20) , 128.9 (+, 2 C, 19/20), 129.2 (Cquat, 1 C, 21), 133.9 (Cquat, 1 
C, 10), 136.8 (+, 1 C, 12), 139.6 (Cquat, 1 C, 18), 148.4 (Cquat, 1 C, 15), 173.9 (Cquat, 1 C, 
7). – MS (CI, NH3): m/z (%) = 405.2 (100) [MNH4+], 388.2 (54) [MH+], 349.1 (45) [MNH4+ - 
C4H8], 288.2 (16) [MH+ - Boc]. – Elemental analysis calcd. (%) for C20H37NO4S (387.58): 
C 61.98, H 9.62, N 3.61; found: C 61.81, H 9.33, N 3.47. – IR (NEAT) [cm-1]: ν~  = 3345, 
2927, 2970, 2121, 1703, 1508, 1458, 1365, 1310, 1275, 1247, 1227, 1152, 1055, 1001, 
960, 866, 789. – MF C20H37NO4S. – MW 387.58. 
4
2
3
5
6
7
8
9
10
11
12
13
14
15
16
1718
19
20 21
N
H
O
O
S
O
O1
Section B 2. Synthesis of Novel Cα-tetrasubstituted α-Amino Acids 
 140 
(S)-(3-(tert-Butoxycarbonylamino)-4-((1S,2S,5R)-2-isopropyl-5-methylcyclohexyloxy)-4-
oxobutyl) di-methylsulfonium iodide (142): 
(S)-(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-(tert-butoxycarbonylamino)-4-(methyl-
thio) butanoate 165 (5.00 g, 12.9 mmol) was dissolved in 39 ml methyl iodine (3 ml/mmol) 
and stirred for three days at room temperature in the dark. The solution was cooled to 0 
°C in an ice bath and 39 ml of heptane (3 ml/mmol) were added and the methyl iodine was 
evaporated under reduced pressure until the product started to precipitate. The mixture 
was kept at 0 °C in the dark for four hours to complete precipitation. The hygroscopic and 
light sensitive product was obtained after filtration and washing with ice-cold heptane as a 
colorless solid (10.8 g, 5.71 mmol, 84%) in analytically pure form. 
MP 42 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.68 (d, 3JH,H = 6.9, 3 H, 19), 0.81-0.88 (m, 7 
H, 2 CH3 + CH), 0.92-1.16 (m, 2 H, CH2), 1.14-1.23 (m, 2 H, CH2), 1.38 (s, 9 H, CH3), 
1.56-1.69 (m, 2H, CH2), 1.71-1.84 (m, 1 H, CH), 1.85-1,95 (m, 1 H, CH), 2.13-2.41 (m, 2 
H, CH2), 3.61-3.79 (m, 1 H, CH2), 3.88-4.03 (m, 1 H, CH2), 4.11-4.36 (m, 1 H, CH), 4.69 
(dt, 3JH,H = 4.5, 3JH,H = 10.8, 1 H, CH), 5.62 (d, 3JH,H = 5.8, 1 H, NH). – 13C-NMR (75 MHz, 
CDCl3): δ = 14.1 (+, 1 C, CH3), 16.2 (+, 1 C, CH), 20.8 (+, 1 C, CH3), 22.0 (+, 1 C, CH3), 
22.7 (-, 1 C, CH2), 23.1 (-, 1 C, CH2), 25.9 (+, 1 C, CH3), 26.1 (+, 1 C, CH3), 28.3 (+, 3 C, 
CH3), 31.4 (+, 1 C, CH), 31.9 (- 1 C, CH2), 34.0 (-, 1 C, CH2), 40.7 (-, 1 C, CH2), 46.7 (+, 1 
C, CH), 52.1 (+, 1 C, CH), 76.6 (-, 1 C, CH), 80.8 (Cquat, 1 C, C(CH3)3), 155.9 (Cquat, 1 C, 
CO), 170.1 (Cquat, 1 C, CO). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 
2402.3 (100) [M+], 931.6 (100) [2M+ + I-]. – IR (NEAT) [cm-1]: ν~  = 2957, 2925, 2870, 2361, 
1704, 1508, 1456, 1366, 1310, 1274, 1246, 1161, 1048, 982, 784. – MF C21H40NO4SI . – 
MW 529.52. 
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(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl 2-(4-bromophenyl)-3-(tert-butoxycarbonyl-
amino)-tetra-hydrofuran-3-carboxylate (143/144): 
Synthesis followed GP 1 using the sulfonium salt 142 (601 mg, 1.14 mmol, 1.4 eq.), 
potassium hydroxide (64 mg, 1.14, 1.4 eq.) and para-bromobenzaldehyde 133 (150 mg, 
0.81 mmol, 1 eq.). The product was purified with a 90:10 mixture of PE:diethyl ether (Rf = 
0.10, 0.17) to give a 1:1 mixture of diastereomers as white crystalline solid in 69 % yield 
(293 mg, 0.56 mmol). 
143: 
MP 52-53 °C. – 1H-NMR (600 MHz, COSY, CDCl3): δ = 0.44 (q, 3JH,H = 11.5, 1 H, 14), 
0.61 (d, 3JH,H = 6.6, 3 H, 23), 0.69-0.78 (m, 1 H, 16), 0.80 (d, 3JH,H = 6.6, 3 H, 25), 0.82 (d, 
3JH,H = 7.0, 3 H, 25), 0.86-0.94 (m, 1 H, 17), 1.15-1.22 (m, 1 H, 14), 1.24-1.30 (m, 2 H, 15 
+ 18), 1.48 (s, 9 H, 1), 1.52-1.62 (m, 3 H,16 + 17 + 24), 2.60-2.67 (m, 1 H, 7), 2.68-2.76 
(m, 1 H, 7), 4.25-4.33 (m, 2 H, 8), 4.41 (dt, 3JH,H = 4.4, 3JH,H = 10.9, 1 H, 13), 5.12 (s, 1 H, 
10), 5.71 (s, 1 H, 5), 7.20 (d, 3JH,H = 8.3, 2 H, 20), 7.40 (d, 3JH,H = 8.6, 2 H, 21). – 13C-NMR 
(150 MHz, HSQC, HMBC, CDCl3): 15.7 (+, 1 C, 23), 20.9 (+, 1 C, 25), 21.9 (+, 1 C, 25), 
22.8 (-, 1 C, 17), 25.8 (+, 1 C, 24), 28.4 (+, 3 C, 1), 31.1 (+, 1 C, 15), 33.9 (-, 1 C, 16), 35.6 
(-, 1 C, 7), 39.8 (-, 1 C, 14), 46.7 (+, 1 C, 18), 67.8 (-, 1 C, 8), 69.4 (Cquat, 1 C, 6), 76.5 (+, 
1 C, 13), 80.1 (Cquat, 1 C, 3), 84.0 (+, 1 C, 10), 121.8 (Cquat, 1 C, 22), 127.7 (+, 2 C, 20), 
131.2 (+, 2 C, 21), 136.5 (Cquat, 1 C, 19), 154.3 (Cquat, 1 C, 4), 171.0 (Cquat, 1 C, 11). – MS 
(ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 524.3 (29) [MH+], 543.4 (100) [M + 
NH4+], 524.4 (100) [M – H+], 582.4 (81) [M + CH3COO-]. – Elemental analysis calcd. (%) 
for C26H38BrNO5 (524.49): C 59.42, H 7.08, N 2.66; found: C 59.54, H 7.30, N 2.67. – IR 
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(NEAT) [cm-1]: ν~  = 2957, 2930, 2870, 1714, 1591, 1485, 1367, 1269, 1160, 1103, 1069, 
1011, 847, 757. – MF C26H38BrNO5. – MW 524.49. 
144: 
MP 88-90 °C. – 1H-NMR (600 MHz, COSY, CDCl3): δ = 0.35-0.46 (m, 1 H, 14), 0.59 (d, 
3JH,H = 6.6, 3 H, 23), 0.72-0.76 (m, 1 H, 16), 0.79 (d, 3JH,H = 6.9, 3 H, 25), 0.81 (d, 3JH,H = 
6.4, 3 H, 25), 0.88-0.92 (m, 1 H, 17), 1.16-1.23 (m, 2 H, 14 + 18), 1.25-1.32 (m, 1 H, 15), 
1.47 (s, 9 H, 1), 1.50-1.55 (m, 1 H, 24), 1.56-1.58 (m, 1 H, 16), 1.58-1.61 (m, 1 H, 17), 
2.62-2.71 (m, 1 H, 7), 2.80 (dt, 3JH,H = 8.3, 3JH,H = 13.0, 1 H, 7), 4.18 (q, 3JH,H = 8.1, 1 H, 8), 
4.34 (dt, 3JH,H = 4.2, 3JH,H = 8.4, 1 H, 8), 4.40 (dt, 3JH,H = 4.4, 3JH,H = 10.8, 1 H, 13), 4.97 (s, 
1 H, 10), 5.46 (s, 1 H, 5), 7.19 (d, 3JH,H = 8.4, 2 H, 20), 7.41 (d, 3JH,H = 8.4, 2 H, 21). – 13C-
NMR (150 MHz, HSQC, HMBC, CDCl3): 15.6 (+, 1 C, 23), 21.0 (+, 1 C, 25), 22.0 (+, 1 C, 
25), 22.7 (-, 1 C, 17), 25.2 (+, 1 C, 24), 28.3 (+, 3 C, 1), 31.1 (+, 1 C, 15), 33.9 (-, 1 C, 16), 
35.8 (-, 1 C, 7), 39.7 (-, 1 C, 14), 46.6 (+, 1 C, 18), 67.7 (-, 1 C, 8), 69.7 (Cquat, 1 C, 6), 
76.3 (+, 1 C, 13), 80.5 (Cquat, 1 C, 3), 85.2 (+, 1 C, 10), 122.1 (Cquat, 1 C, 22), 128.1 (+, 2 
C, 20), 131.3 (+, 2 C, 21), 136.2 (Cquat, 1 C, 19), 154.3 (Cquat, 1 C, 4), 170.3 (Cquat, 1 C, 
11). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 524.3 (29) [MH+], 543.4 
(100) [M + NH4+], 524.4 (100) [M – H+], 582.4 (81) [M + CH3COO-]. – IR (NEAT) [cm-1]: ν~  
= 2956, 2927, 2869, 1708, 1591, 1487, 1367, 1247, 1160, 1011, 1070, 1011, 847, 757. – 
MF C26H38BrNO5. – MW 524.49. 
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X-Ray structure and crystal data of 144: 
Monoclinic; space group: P 21; cell dimensions: a = 10.8591(2) Å, α = 90°, b = 5.9417(1) 
Å, β = 93.6936(18)°, c = 20.7199(5) Å, γ = 90°; V = 1334.10(5) Å3; Z = 2, Dx = 1.306 
Mg/m3; µ = 2.377 mm-1; F(000) = 552. Data collection: T = 123 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.200 x 0.060 x 0.010 
mm was used to measure 6636 reflections (3517 unique reflections, Rint = 0.0386) from 
3.32° to 62.28° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan 
method. Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit 0f 0.888 for all reflections and 304 parameters. 
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(2S,3R)-2-(4-Bromophenyl)-3-(((1R,2S,5R)-2-isopropyl-5-methylcyclohexyloxy)carbonyl)-
tetrahydrofuran-3-aminium chloride (145): 
Compound 144 (50 mg, 0.10 mmol) was dissolved under ice bath cooling at 0 °C in diethyl 
ether. To this solution 0.7 ml ice cold HCl saturated ether (7 ml/mmol Boc) was added and 
the mixture was stirred over night at room temperature. The solvent was removed under 
reduced pressure to give the HCl salt of the product as white hygroscopic solid in 
quantitative yield (44 mg, 0.10 mmol). No further purification was necessary. 
MP >180 °C. – 13C-NMR (75 MHz, CDCl3): δ = 14.7 (+, 1 C, 19), 19.8 (+, 1 C, 21), 20.8 (+, 
1 C, 21), 21.7 (-, 1 C, 13), 24.7 (+, 1 C, 20), 30.0 (+, 1 C, 11), 32.7 (-, 1 C, 12), 35.4 (-, 1 
C, 3), 38.2 (-, 1 C, 10), 45.1 (+, 1 C, 14), 66.5 (-, 1 C, 4), 67.9 (Cquat, 1 C, 2), 76.9 (+, 1 C, 
9), 85.1 (+, 1 C, 6), 121.7 (Cquat, 1 C, 18), 127.5 (+, 2 C, CH-Ar) , 130.4 (+, 2 C, CH-Ar), 
133.3 (Cquat, 1 C, 15), 166.5 (Cquat, 1 C, 7). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): 
m/z (%) = 424.2 (100) [MH+]. – IR (NEAT) [cm-1]: ν~  = 2954, 2929, 2870, 1707, 1592, 
1489, 1366, 1242, 1161, 1010, 1071, 1009, 847, 758. – MF C21H30BrNO3 · HCl. – MW 
460.84. 
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(2S,3R)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carboxylic 
acid (146): 
Boc-TAA-Omenthol 144 (200 mg, 0.38 mmol) was dissolved in 3.8 ml of methanol (10 
ml/mmol). To the solution a 1 ml water (2.5 ml/mmol) and powdered KOH (171 mg, 3.05 
mmol, 8 eq) were added and the mixture was stirred at 110 °C for 3 hours in a laboratory 
microwave. The mixture was quenched with water (12 ml/mmol) and the methanol was 
removed under reduced pressure. The resulting slurry was extracted with diethyl ether 
(2x5 ml) and the organic phases were discarded. The aqueous phase was acidified with 
1M aqueous KHSO4-solution and extracted with dichloromethane (3x10 ml). The 
combined organic layers were dried over MgSO4 and the solvent was removed under 
reduced pressure to give the product as colorless solid in 55 % yield (80 mg, 0.21 mmol). 
MP 98-100 °C. – 1H-NMR (300 MHz, MeCN-d3): δ = 1.39 (s, 9 H, Boc-CH3), 2.25-2.41 (m, 
1 H, CH2), 2.68-2.82 (m, 1 H, CH2), 3.92-4.03 (m, 1 H, OCH2), 4.25 (dt, 3JH,H = 3.4, 3JH,H = 
8.3, 1 H, OCH2), 4.84 (bs, 1 H, CH), 7.22 (d, 3JH,H = 8.5, 2 H, CH-Ar), 7.44 (d, 3JH,H = 8.5, 2 
H, CH-Ar). – 13C-NMR (75 MHz, MeCN-d3): δ = 27.2 (+, 3 C, Boc-CH3), 35.1 (-, 1 C, CH2), 
67.2 (-, 1 C, OCH2), 70.0 (Cquat, 1 C, CNH), 83.7 (Cquat, 1 C, C(CH3)3), 85.1 (+, 1 C, CH), 
121.2 (Cquat, 1 C, C-Br), 128.3 (+, 2 C, CH-Ar) , 130.6 (+, 2 C, CH-Ar), 136.9 (Cquat, 1 C, C-
Ar), 154.8 (Cquat, 1 C, Boc-CO), 171.1 (Cquat, 1 C, COOH). – MS (CI, NH3): m/z (%) = 
269.1 (29) [MNH4+ - C4H8, Br vs. H], 325.1 (46) [MNH4+, Br vs. H], 348.9 (45) [MNH4+ - 
C4H8], 386.0 (5) [MH+], 403.0 (100) [MNH4+]. – IR (NEAT) [cm-1]: ν~  = 3248, 3131, 2965, 
2926, 2860, 1737, 1693, 1366, 1247, 1224, 1160, 1107, 1066, 1009, 992, 938, 839, 790, 
698. – MF C16H20BrNO5. – MW 386.24. 
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tert-Butyl 3-(tert-butoxycarbonylamino)-2-isopropyl-tetrahydrofuran-3-carboxylate (157): 
The synthesis followed GP 1 using (3-(tert-butoxycarbonylamino)-4-tert-butoxy-4-
oxobutyl)-dimethylsulfonium iodide 133 (1.25 g, 2.79 mmol, 1.5 eq.), cesium hydroxide 
(418 mg, 2.79 mmol, 1.5 eq.) and isobutyraldehyde 150 (169 µl, 1.86 mmol, 1 eq.). The 
product was purified with a 85:15 mixture of PE:diethyl ether (Rf = 0.2) to give 157 as a 
colorless oil in 2 % yield (18 mg, 0.05 mmol). The product was obtained as an inseparable 
mixture of the cis and trans product with a cis:trans ratio of 1:9. 
1H-NMR (300 MHz, CDCl3): δ = 0.90-0.92 (m, 6 H, CH3), 1.41-1.52 (m, 18 H, tBu-CH3), 
1.69-1.80 (m, 1 H, CH), 2.42 (bs, 1 H, CH2), 2.62-2.79 (m, 1 H, CH2), 3.45-3.55 (m, 1 H, 
CH2), 3.88-4.11 (m, 2 H, CH2 + CH), 5.02 (bs, 0.1 H, cisNH), 5.28 (bs, 0.9 H, trans-NH). – 
13C-NMR (75 MHz, CDCl3): δ = 16.7 (+, 0.1 C, cis-CH3), 17.2 (+, 0.9 C, trans-CH3), 18.5 
(+, 0.1 C, cis-CH3), 19.1 (+, 0.9 C, trans-CH3), 20.4 (+, 0.1 C, cis-CH), 20.8 (+, 0.9 C, 
trans-CH), 27.9 (+, 3 C, tBu-CH3), 28.4 (+, 3 C, tBu-CH3), 32.6 (-, 1 C, CH2), 66.5 (-, 0.1 C, 
cis-OCH2), 66.6 (-, 0.9 C, trans-OCH2), 67.6 (Cquat, 1 C, NHC), 82.3 (Cquat, 2 C, tBu-C), 
87.5 (+, 1 C, CH), 154.0 (Cquat, 0.1 C, cis-NHCO), 154.4 (Cquat, 0.9 C, trans-NHCO), 171.2 
(Cquat, 0.1 C, cis-COO), 171.3 (Cquat, 0.9 C, trans-COO). – MS (CI, NH3): m/z (%) = 218.2 
(9) [MH+ - 2 C4H8], 274.2 (51) [MH+ - C4H8], 330.2 (100) [MH+]. – HR-MS (FAB, 
MeOH/glycerol): [MH+·] calcd. for C17H32NO5 330.2280; found 330.2288. – IR (neat) [cm-1]: 
ν~  = 2977, 2877, 2361, 1708, 1492, 1392, 1366, 1250, 1157, 1085, 1052, 940, 848. – MF 
C17H31NO5. – MW 329.43. 
O
NH
O
OO
O
Section B 2. Synthesis of Novel Cα-tetrasubstituted α-Amino Acids 
 147
tert-Butyl 3-(tert-butoxycarbonylamino)-2-isobutyl-tetrahydrofuran-3-carboxylate (158): 
The synthesis followed GP 1 using (3-(tert-butoxycarbonylamino)-4-tert-butoxy-4-
oxobutyl)-dimethylsulfonium iodide 133 (1.25 g, 2.79 mmol, 1.5 eq.), cesium hydroxide 
(418 mg, 2.79 mmol, 1.5 eq.) and 3-methylbutanal 151 (201 µl, 1.86 mmol, 1 eq.). The 
product was purified with a 85:15 mixture of PE:diethyl ether (Rf = 0.16) to give 158 as a 
colorless oil in 17 % yield (106 mg, 0.18 mmol). The product was obtained as an 
inseparable mixture of the cis and trans product with a cis:trans ratio of 1:5. 
1H-NMR (300 MHz, CDCl3): δ = 0.87-0.90 (m, 6 H, CH3), 1.30-1.41 (m, 2 H, CH2), 1.44-
1.47 (m, 18 H, tBu-CH3), 1.71-1.80 (m, 1 H, CH), 2.37 (bs, 1 H, CH2), 2.65-2.85 (m, 1 H, 
CH2), 3.76-4.08 (m, 3 H, CH2 + CH), 4.93 (bs, 0.2 H, cis-NH), 5.12 (bs, 0.8 H, trans-NH). – 
13C-NMR (75 MHz, CDCl3): δ = 21.6 (+, 0.8 C, trans-CH3), 21.9 (+, 0.2 C, cis-CH3), 23.6 
(+, 0.8 C, trans-CH3), 23.7 (+, 0.2 C, cis-CH3), 25.2 (+, 0.8 C, trans-CH), 25.7 (+, 0.2 C, 
cis-CH), 27.9 (+, 3 C, tBu-CH3), 28.3 (+, 3 C, tBu-CH3), 38.0 (-, 0.2 C, cis-CH2), 39.3 (-, 
0.8, trans-CH2), 66.3 (-, 0.2 C, cis-OCH2), 66.9 (-, 0.8 C, trans-OCH2), 67.6 (Cquat, 0.2 C, 
cis-NHC), 68.2 (Cquat, 0.8 C, trans-NHC), 79.8 (Cquat, 1 C, tBu-C), 81.7 (Cquat, 0.2 C, cis-
tBu-C), 82.0 (Cquat, 0.8 C, trans-tBu-C), 82.1 (+, 0.8 C, trans-CH), 82.8 (+, 0.2 C, cis-CH), 
154.7 (Cquat, 0.8 C, trans-NHCO), 155.1 (Cquat, 0.2 C, cis-NHCO), 170.6 (Cquat, 0.2 C, cis-
COO), 170.7 (Cquat, 0.8 C, trans-COO). – MS (CI, NH3): m/z (%) = 244.2 (25) [MH+ - Boc], 
288.2 (44) [MH+ - C4H8], 305.2 (19) [MNH4+ - C4H8], 344.3 (100) [MH+]. – HR-MS (FAB, 
MeOH/glycerol): [M+·] calcd. for C18H33NO5 343.2359; found 343.2358. – IR (neat) [cm-1]: 
ν~  = 3326, 2957, 2359, 1708, 1497, 1366, 1250,1160, 1116, 1098, 1055, 885, 849, 781. – 
MF C18H33NO5. – MW 343.46. 
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tert-Butyl 3-(tert-butoxycarbonylamino)-2-propyl-tetrahydrofuran-3-carboxylate (159): 
The synthesis followed GP 1 using (3-(tert-butoxycarbonylamino)-4-tert-butoxy-4-
oxobutyl)-dimethylsulfonium iodide 133 (480 mg, 0.75 mmol, 1.5 eq.), cesium hydroxide 
(112 mg, 0.75 mmol, 1.5 eq.) and butyraldehyde 147 (44 µl, 0.5 mmol, 1 eq.). The product 
was purified with a 85:15 mixture of PE:diethyl ether (Rf = 0.21) to give 159 as a colorless 
oil in 36 % yield (60 mg, 0.18 mmol). The product was obtained as an inseparable mixture 
of the cis and trans product with a cis:trans ratio of 1:3. 
1H-NMR (300 MHz, CDCl3): δ = 0.86 (q, 3JH,H = 8.2, 3 H, CH3), 1.21-1.55 (m, 22 H, tBu-
CH3 + CH2), 2.29 (bs, 1 H, CH2), 2.61-2.79 (m, 1 H, CH2), 3.62-4.15 (m, 3 H, CH2 + CH), 
4.91 (bs, 0.25 H, cis-NH), 5.01 (bs, 0.75 H, trans-NH). –  13C-NMR (75 MHz, CDCl3): δ = 
14.0 (+, 0.75 C, trans-CH3), 14.1 (+, 0.25 C, cis-CH3), 19.8 (-, 0.75 C, trans-CH2), 20.0 (-, 
0.25 C, cis-CH2), 27.9 (+, 3 C, tBu-CH3), 28.3 (+, 3 C, tBu-CH3), 31.3 (-, 0.25 C, cis-CH2), 
32.7 (-, 0.75 C, trans-CH2), 35.6 (-, 0.25, cis-CH2), 37.2 (-, 0.75 C, trans-CH2), 66.2 (-, 
0.25 C, cis-OCH2), 66.8 (-, 0.75 C, trans-OCH2), 67.3 (Cquat, 0.25 C, cis-NHC), 68.2 (Cquat, 
0.75 C, trans-NHC), 79.8 (Cquat, 1 C, tBu-C), 81.7 (Cquat, 0.25 C, cis-tBu-C), 82.0 (Cquat, 
0.75 C, trans-tBu-C), 84.1 (+, 0.75 C, trans-CH), 84.5 (+, 0.25 C, cis-CH), 154.8 (Cquat, 
0.25 C, cis-NHCO), 155.1 (Cquat, 0.75 C, trans-NHCO), 170.6 (Cquat, 0.75 C, trans-COO), 
170.7 (Cquat, 0.25 C, cis-COO). – MS (CI, NH3): m/z (%) = 230.2 (18) [MH+ - Boc], 274.2 
(30) [MH+ - C4H8], 291.2 (19) [MNH4+ - C4H8], 330.2 (100) [MH+], 676.6 (9) [2 M + NH4+]. – 
HR-MS (FAB, MeOH/glycerol): [M+·] calcd. for C17H31NO5 329.2202; found 329.2210. – IR 
(neat) [cm-1]: ν~  = 3334, 2975, 2357, 1709, 1490, 1366, 1250, 1157, 1077, 949, 848. – MF 
C17H31NO5. – MW 329.43. 
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tert-Butyl 3-(tert-butoxycarbonylamino)-2-methyl-tetrahydrofuran-3-carboxylate (160): 
The synthesis followed GP 1 using (3-(tert-butoxycarbonylamino)-4-tert-butoxy-4-
oxobutyl)-dimethylsulfonium iodide 133 (670 mg, 1.50 mmol, 1.2 eq.), cesium hydroxide 
(225 mg, 1.50 mmol, 1.2 eq.) and acetaldehyde 152 (70 µl, 1.25 mmol, 1 eq.). The 
product was purified with a 80:20 mixture of PE:diethyl ether (Rf = 0.1) to give 160 as a 
colorless oil in 28 % yield (105 mg, 0.93 mmol). The product was obtained as an 
inseparable mixture of the cis and trans product with a cis:trans ratio of 1:2. 
MP 70 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.16 (d, 3JH,H = 6.3, 2 H, trans-CH3), 1.23 (d, 
3JH,H = 6.3, 1 H, cis-CH3), 1.44 (s, 9 H, tBu-CH3), 1.47 (s, 9 H, tBu-CH3), 2.21-2.40 (m, 1 H, 
CH2), 2.67-2.82 (m, 1 H, CH2), 3.78-3.99 (m, 2.33 H, CH2 + cis-CH), 4.06 (dt, 3JH,H = 4.1, 
3JH,H = 8.5, 0.66 H, trans-CH), 4.94 (bs, 0.34 H, cis-NH), 5.13 (bs, 0.66, trans-NH). – 13C-
NMR (75 MHz, CDCl3): δ = 13.3 (+, 0.33 C, cis-CH3), 15.2 (+, 0.66 C, trans-CH3), 26.9 (+, 
2 C, trans- tBu-CH3), 26.9 (+, 1 C, cis-tBu-CH3), 27.3 (+, 2 C, trans-tBu-CH3), 27.3 (+, 1 C, 
cis-tBu-CH3), 34.1 (-, 0.66 C, trans-CH2), 36.1 (-, 0.33 C, cis-CH2), 65.1 (-, 0.33 C, cis-
OCH2), 65.8 (-, 0.66 C, trans-OCH2), 66.2 (Cquat, 0.33 C, cis-NHC), 67.5 (Cquat, 0.66 C, 
trans-NHC), 78.9 (Cquat, 1 C, tBu-C), 79.9 (Cquat, 1 C, tBu-C), 80.7 (+, 0.33 C, cis-CH), 81.0 
(+, 0.66 C, trans-CH), 153.8 (Cquat, 0.66 C, trans-NHCO), 154.1 (Cquat, 0.33 C, cis-NHCO), 
169.4 (Cquat, 0.66 C, COO), 169.6 (Cquat, 0.33 C, COO). – MS (CI, NH3): m/z (%) = 202.1 
(25) [MH+ - Boc], 246.1 (40) [MH+ - C4H8], 263.1 (34) [MNH4+ - C4H8], 302.1 (100) [MH+], 
319.1 (4) [MNH4+]. – HR-MS (FAB, MeOH/DCM/NBA): [MH+] calcd. for C15H28NO5 
302.1967; found 302.1966. – IR (neat) [cm-1]: ν~  = 2973, 2361, 1705, 1489, 1369, 1247, 
1158, 1073, 955, 849. – MF C15H27NO5. – MW 301.38.  
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X-Ray structure and crystal data of trans-160: 
Orthorhombic; space group: P n a 21; cell dimensions: a = 10.1882(3) Å, α = 90°, b = 
10.6160(4) Å, β = 90°, c = 16.3593(5) Å, γ = 90°; V = 1769.39(10) Å3; Z = 4, Dx = 1.128 
Mg/m3; µ = 0.691 mm-1; F(000) = 652. Data collection: T = 123 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.500 x 0.080 x 0.020 
mm was used to measure 4695 reflections (2087 unique reflections, Rint = 0.0251) from 
4.97° to 66.69° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan 
method. Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit 0f 1.070 for all reflections and 194 parameters. 
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tert-Butyl 3-(tert-butoxycarbonylamino)-2-(prop-1-en-2-yl)-tetrahydrofuran-3-carboxylate 
(161): 
The synthesis followed GP 1 using (3-(tert-butoxycarbonylamino)-4-tert-butoxy-4-
oxobutyl)-dimethylsulfonium iodide 133 (2.39 g, 5.35 mmol, 1.5 eq.), cesium hydroxide 
(802 mg, 5.35 mmol, 1.5 eq.) and methacrylaldehyde 153 (294 µl, 3.57 mmol, 1 eq.). The 
product was purified with a 80:20 mixture of PE:diethyl ether (Rf = 0.22) to give 161 as a 
colorless oil in 18 % yield (210 mg, 0.64 mmol). 
1H-NMR (300 MHz, CDCl3): δ = 1.37 (s, 9 H, tBu-CH3), 1.40 (s, 9 H, tBu-CH3), 1.69 (s, 3 
H, CH3), 2.35-2.53 (m, 1 H, CH2), 2.57-2.71 (m, 1 H, CH2), 4.00 (q, 3JH,H = 8.1, 1 H, 
OCH2), 4.12 (dt, 3JH,H = 4.5, 3JH,H = 8.4, 1 H, OCH2), 4.31 (s, 1 H, CH), 4.86 (s, 1 H, =CH2), 
5.04 (s, 1 H, =CH2), 5.32 (bs, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 18.5 (+, 1 C, 
CH3), 26.8 (+, 3 C, tBu-CH3), 27.3 (+, 3 C, tBu-CH3), 34.8 (-, 1 C, CH2), 66.4 (Cquat, 1 C, 
NHC), 67.5 (-, 1 C, OCH2), 81.2 (Cquat, 2 C, tBu-C), 85.5 (+, 1 C, CH), 112.2 (-, 1 C, 
=CH2), 139.7 (Cquat, 1 C, C=), 153.4 (Cquat, 1 C, NHCO), 169.4 (Cquat, 1 C, COO). – MS (CI, 
NH3): m/z (%) = 228.1 (28) [MH+ - Boc], 272.1 (41) [MH+ - C4H8], 289.1 (50) [MNH4+ - 
C4H8], 328.1 (100) [MH+], 345.1 (8) [MNH4+]. – HR-MS (FAB, MeOH/glycerol): [M+·] calcd. 
for C17H29NO5 327.2046; found 327.2043. – IR (neat) [cm-1]: ν~  = 3409, 3059, 2063, 1614, 
1483, 1335, 1242,1133, 1098, 1055, 887, 823, 708. – MF C17H29NO5. – MW 327.42. 
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3. Stable Right- and Left-handed Peptide Helices 
3.1. Introduction 
The de novo design of peptides and peptidomimetics with a defined and predictable 
3-dimensional structure219, 220 has received considerable interest from chemists and 
biologists in recent years. Short peptide sequences consisting only of natural α-amino 
acids typically show flexible structures. In contrast, stable structures in solution can be 
accomplished by replacing natural amino acids by non-proteinogenic analogues which 
may induce a defined secondary structure even in short peptides.221 Such amino acid 
mimetics attracted much attention in the last years because of their potential use as 
peptide models, biological probes, drug candidates or catalysts.222 Their often more rigid 
structure leads to conformational constraints that might lock the peptide in its bioactive or 
catalytically active conformation.223 An additional advantage can be an increase of the 
peptides metabolic stability after incorporation of amino acid mimetics.224 One very 
successful way among others143a to increase peptide backbone rigidity is the use of 
Cα-tetrasubstituted α-amino acids (TAAs).225 α-Aminoisobutyric acid (Aib), which also 
occurs in natural peptide sequences of peptaibiomics or peptaibols,185, 186, 187 is the most 
extensively investigated compound of this kind. The helical tendencies of Aib containing 
peptides are well characterized, showing that short strands form a stable 310-helix while 
longer helices emerge into mixed 310/α-helices or pure α-helices.212a Cycloaliphatic 
Cα-tetrasubstituted α-amino acids Acnc (n = 3-9)226 with varying ring sizes are also well 
studied.227 However, the lack of a Cα-stereocenter and of a side-chain functional group for 
further derivatization is a drawback of these compounds. Therefore the synthesis of cyclic 
Cα-tetrasubstituted α-amino acids which show at least one stereocenter228 and have an 
additional functional group in their side chain was investigated in recent years,216 but only 
very few examples of successful incorporation into peptide chains have been reported.229 
Our group has recently introduced the Cα-tetrasubstituted tetrahydrofuran amino acid rac-
137 which has two stereocenters at the quaternary Cα- and at the Cβ-atom. The 
brominated arene substituent allows further functionalization by standard Pd(0)- or Cu(I)-
catalysis.230 When inserted into small tripeptides, the molecule induces stable secondary 
structures in solution by the formation of β-turns.218 
In the following the extension of this concept by incorporating the unnatural amino acid 
into longer peptide chains to form stable helices as structurally predictable and tunable 
scaffolds for peptidomimetics is reported. 
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3.2. Synthesis of the Peptides 
In a first approach to the synthesis of Cα-tetrasubstituted tetrahydrofuran amino acid 
containing peptides it was decided to try a direct coupling of two TAAs with each other. To 
obtain a stereochemically pure peptide, the previously synthesized building blocks 145 
and 146 were used. As coupling reagents, the very reactive combination of HATU and 
HOAt was used but no product was formed. 
Scheme 21: Peptide coupling reaction of the enantiomerically pure amino acids 145 and 
146. 
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The reason for this seems to be the high sterical demand of the unnatural amino acids 
themselves which, in this special case, is further increased by the large ester functionality. 
Furthermore, the synthesis of peptides with numerous Cα-tetrasubstituted amino acids is a 
rather challenging task due to their relatively low reactivity in amide bond formation.231 To 
overcome these difficulties it was decided to reduce the sterical demand by the use of 
natural amino acids in combination with the unnatural ones, leading to an alternating 
peptide sequence of natural and unnatural amino acids. 
As natural amino acids to be used in combination with the unnatural TAA rac-138, S- and 
R-valine were chosen. Reasons for the use of valine are the absence of a side chain 
functionality which could lead to side reactions and also the absence of a side chain 
stereo center. Another criterion was the sterical demand of the side chain which on the 
one hand should be larger than the one of an alanine to help inducing a stable secondary 
structure but on the other hand should not lower the reactivity too much. 
Therefore, the isomeric di-, tetra- and hexapeptides and one octapeptide shown in Figure 
74 were synthesized and their structure was analyzed in solid state and in solution. 
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Figure 74: TAA-containing isomeric di-, tetra-, hexa- and octapeptides prepared and 
investigated in this study. 
3.2.1. Synthesis of Peptides Containing S-Valine 
The target peptides were prepared by a combination of protecting and deprotecting steps 
together with standard solution phase peptide coupling chemistry. The synthesis is shown 
in Scheme 22 and starts from N-terminally Boc-protected racemic tetrahydrofuran amino 
acid Boc-TAA-OH rac-138.218 The compound was coupled with H-S-Val-OMe*HCl 180 
using EDC/HOBt to give the dipeptides (RS) 167 and (SS) 170. Two diastereomers 
emerged from the coupling reaction, which were separated by column chromatography. 
The isolated dipeptides 167 and 170 were then used separately in the next steps to yield 
enantiomerically pure tetrapeptides. To achieve this, two equimolar amounts of compound 
167 were deprotected either C-terminal with 1M aqueous LiOH to give free acid 181, or N-
terminal with HCl saturated diethyl ether cleaving the Boc protecting group. Carboxylic 
acid 181 and amine 182 were coupled using HATU/HOAt to give tetrapeptide (RS)2 168 in 
67 % yield. The tetrapeptide (SS)2 171 was obtained analogously in comparable yield. 
Compound (RS)2 168 was Boc deprotected and subsequently coupled with dipeptide acid 
181 to give hexapeptide (RS)3 169. The same procedure was used to synthesize the 
hexapeptide 172 (SS)3. 
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Scheme 22: Synthesis pathway leading to the S-valine containing peptides 167 - 172. a) 
DIPEA, EDC, HOBt, dry DMF, 24h, rt; b) LiOH, water/THF, 24h, rt; c) HCl sat. diethyl 
ether, DCM, 24h, rt; d) DIPEA, HATU, HOAt, dry DMF, 24h, rt. 
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3.2.2. Synthesis of Peptides Containing R-Valine 
In analogy to the synthesis of the S-valine containing peptides, the peptides with R-valine 
were also synthesized. By this method it was possible to synthesize peptides which are 
enantiomeric to their S-valine counterparts. This should lead to a enantiomeric secondary 
structure, meaning that a helix formed of R-valine amino acids should have an opposite 
handedness as the one containing S-valine. 
The first step of the synthesis was again the coupling of the racemic Boc-TAA-OH rac-138 
with the methyl ester of R-valine 187. The synthesis gave the two diastereomeric products 
(SR) 173 and (RR) 176 in an excellent yield of 83 %. After separation by column 
chromatography and deprotection using HCl saturated diethyl ether for the Boc-group and 
LiOH for the ester functionality, the resulting building blocks (SR) 188, 189 and (RR) 190, 
191 were used for the synthesis of the tetrapeptides 174 and 177. The tetrapeptide (RR)2 
177, which is all R-configurated in the backbone and the diastereomer (SR)2 174 were 
obtained in good yields of 58 % for the former and 55 % for the latter. After removal of the 
Boc-group with HCl saturated diethyl ether both amines (SR)2 192 and (RR)2 193 were 
used for the synthesis of the hexapeptides (SR)3 175 and (RR)3 178. As the peptide (RR)3 
178 was formed in reasonable yields, it was decided to synthesize an octapeptide using 
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the hexapeptide as starting material. The octapeptide (RR)4 179 was synthesized by the 
use of the Boc-deprotected hexapeptide (RR)3 194 together with the dipeptide free acid 
(RR) 190. The peptide (RR)4 179 was formed in a yield of 28 %. 
Scheme 23: Synthesis pathway leading to the R-valine containing peptides 173 – 176. a) 
DIPEA, EDC, HOBt, dry DMF, 24h, rt; b) LiOH, water/THF, 24h, rt; c) HCl sat. diethyl 
ether, DCM, 24h, rt; d) DIPEA, HATU, HOAt, dry DMF, 24h, rt. 
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Scheme 24: Synthesis pathway leading to the R-valine containing peptides 177 – 179. a) 
DIPEA, EDC, HOBt, dry DMF, 24h, rt; b) LiOH, water/THF, 24h, rt; c) HCl sat. diethyl 
ether, DCM, 24h, rt; d) DIPEA, HATU, HOAt, dry DMF, 24h, rt. 
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3.3. Structure Analysis of the Synthesized Peptides 
The structure of the 13 different peptides 167 – 179 was determined in the solid state by 
X-ray crystallography and in solution by 2D-NMR, temperature dependent 1H-NMR and 
CD measurements.  
3.3.1. Solid State Structure Analysis 
From all four dipeptides crystal structures were obtained (Figure 75) showing that the 
pairs 167, 173 and 170, 176 are enantiomeric in configuration and structure. The 
structures indicate that molecules 170 (SS) and 176 (RR) with either two S-configured 
amino acids or two R-configured amino acids in their amide backbone show a turn-like 
structure, whereas the other two compounds 167 (RS) and 173 (SR) do not have this 
structural feature. 
 
Figure 75: Crystal structures of dipeptides 167 (RS), 173 (SR), 170 (SS) and 176 (RR). 
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This correlation becomes even more pronounced in the structures of tetrapeptides 171 
(SS)2 and 177 (RR)2, which were again determined by X-ray crystal structure analysis 
(Figure 76): The homochiral tetrapeptides form a characteristic 310-helix in the solid 
state.232 The helix is right-handed for the all-S-configured peptide 171 and left-handed for 
the all-R-configured enantiomer 177. 
 
Figure 76: Crystal structures of the right-handed (top) and left-handed (bottom) helices 
171 and 177 (view from the side on the left; view perpendicular to the helical axis on the 
right). Hydrogen atoms except NH-protons were omitted for clarity. 
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Figure 77: Crystal structures of the right-handed hexapeptide 172 (top) and the left-
handed helix forming octapeptide 179 (bottom) are shown. Hydrogen atoms except NH-
protons were omitted for clarity. 
For both peptides 171 (SS)2 and 177 (RR)2 the average backbone torsion angles φ and ψ 
of all four amino acids were determined (Table 4). The φ-angles are between the values 
of an ideal 310- and an α-helix. The ψ-angles are in good agreement with those of an ideal 
310-helix.233 One ψ-angle in compound 171 is slightly smaller than expected, while another 
in compound 177 is larger. This indicates the still high flexibility of the tetrapeptides that 
form just one turn of a 310-helix. The average i?i+3 C=O···N intramolecular hydrogen 
bond angles were found to be 133.9° (molecule 171) and 131.9° (molecule 177): both 
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values are slightly higher than those reported for other 310-helices, but still significantly 
smaller than those of an α-helix. The pitch (axial translation) for the two peptides being 
6.61 Å (171) for the right-handed and 6.42 Å (177) for the left-handed helix, is larger than 
expected for a 310-helix. A slightly smaller number of residues per turn (3.16 and -3.20) 
leads to a higher axial translation per residue for the new tetrapeptides than for an ideal 
310-helix. The extension from tetra- to hexa- and octapeptides results in smaller torsion 
angles φ and ψ of compounds 172 (SS)3 (-60.2°, -26.7°) and 179 (RR)4 (59.8°, 26.3°) and 
less variation in comparison to their smaller homologues 171 and 177 - 178, respectively. 
This indicates a more stable structure which can be ascribed to the increased number of 
intramolecular hydrogen bonds. The average i?i+3 C=O···N intramolecular hydrogen 
bond angles, 133.8° for compound 172 and 132.9° for compound 179, are in the same 
range as those determined for the tetrapeptides.  
Table 4: Structural parameters derived from the crystal structures of compounds 171, 
172, 177 and 179. The literature data for an ideal right-handed 310- and an α-helix 9a, 233 
are reported for comparison. 
parameter 
171 
(SS)2 
177 
(RR)2 
172 
(SS)3 
179 
(RR)4 
310-
helix 
α-helix 
φ -61.6° 61.7° -60.2° 59.8° -57° -63° 
ψ -28.4° 30.9° -26.7° 26.3° -30° -42° 
N···O=C hydrogen bond 
angle 
133.9° 131.9° 133.8° 132.9° 128° 156° 
N···O=C hydrogen bond 
distance 
3.00 Å 2.99 Å 2.99 Å 3.04 Å 2.81 Å 2.86 Å 
Rotation (per residue) 111.5° 111.1° 111.6° 111.6° 111° 99° 
Residues per turn 3.16 -3.20 3.12 3.10 3.24 3.63 
Axial translation (per 
residue) 
2.09 Å 2.01 Å 2.10 Å 2.10 Å 1.94 Å 1.56 Å 
Axial translation (per 
helical turn) 
6.61 Å 6.42 Å 6.55 Å 6.51 Å 6.29 Å 5.67 Å 
 
All i?i+3 C=O···H-N intramolecular H-bonds are of typical length with N···O=C distances 
between 2.81 and 3.04 Å. This corresponds well to values of type 2 (amide–amide) 
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hydrogen bonds, which are of an expected N···O=C distance between 2.8 and 3.0 Å.234 
The determined parameters and their comparison to examples from the literature assign a 
310-helical geometry to all four crystal structures. However, the higher C=O···N 
intramolecular hydrogen bond angles, the reduced number of residues per turn and the 
higher pitch result in helices that are a little more stretched than the ideal 310-helix. 
3.3.2. Solution Structure Analysis using NMR 
One compound of each length (tetra-, hexa- and octamer) was investigated by NMR-
spectroscopy to gain information about its structure in solution. With peptides 171 (SS)2, 
172 (SS)3 and 179 (RR)4, temperature dependent 1H-NMR studies were performed in 
DMSO (d6) solution (temperature range 300–373 K). Tetrapeptide 171 showed a high 
temperature dependency for two NH-proton resonances (N1H and N2H; -5.40 ppb/K and 
-5.72 ppb/K, respectively), indicating that these two protons are not involved in 
intramolecular hydrogen bonds. In contrast, the N3H and N4H protons are part of 
intramolecular hydrogen bonds, as supported by their much smaller temperature 
coefficients (-1.12 ppb/K for N3H and -1.72 ppb/K for N4H). These results correlate to the 
X-ray diffraction structure of 171, in which protons N1H and N2H are not involved in 
intramolecular hydrogen bonds, while the other two (N3H and N4H) form i?i+3 C=O···H-N 
intramolecular hydrogen bonds. 
 
Figure 78: Part of the 1H-NMR spectrum of 171 at different temperatures. 
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Figure 79: Temperature dependent 1H-NMR of compound 171. 
Similar results were found for the variable temperature NMR of peptide 172, where again 
two proton resonances for N1H and N2H were strongly temperature dependent (-4.63 
ppb/K and -8.25 ppb/K), while the other four NH-protons involved in hydrogen bonds 
showed only slight resonance shifts (N3H -2.21 ppb/K, N4H -1.31 ppb/K, N5H -0.97 
ppb/K, N6H -1.36 ppb/K). 
 
Figure 80: Part of the 1H-NMR spectrum of 172 at different temperatures. 
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Figure 81: Temperature dependent 1H-NMR of compound 172. 
Also for octapeptide 179 N1H and N2H exhibit large temperature coefficients (-4.56 and -
7.92 ppb/K, respectively), whereas all other proton resonances have a much smaller 
temperature dependency (N3H -1.68 ppb/K, N4H -0.82 ppb/K, N5H -1.00 ppb/K, N6H -
1.20 ppb/K, N7H -0.77, N8H -1.99). These results clearly show that all peptides adopt a 
stable C-terminal helical structure in solution. 
 
Figure 82: Part of the 1H NMR spectrum of 179 at different temperatures. 
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Figure 83: Temperature dependent 1H-NMR of compound 179. 
It is known that short peptides containing Cα-tetrasubstituted α-amino acids can undergo 
an α/310-helix transition in solution.235 To determine the predominant helix type in DMSO, 
ROESY spectra of 171, 172 and 179 were recorded in DMSO (d6). 
For all three peptides strong sequential dNN NOE cross-peaks were observed. These 
cross-peaks evoke from the interaction of the NH proton of amino acid i with the NH 
proton of amino acid i+1 and are characteristic for helical structures in solution and with 
that provide another proof for the helical structure adopted by the investigated peptides in 
solution.  
 
Figure 84: Part of the ROESY spectra of compound 171 in DMSO-d6. 
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Figure 85: Part of the ROESY spectra of compound 172 in DMSO-d6. 
 
Figure 86: Part of the ROESY spectra of compound 179 in DMSO-d6. 
To discriminate between α- and 310-helix, the ROE spectra were searched for the dαN (i, 
i+2) contacts characteristic for 310-helices and the dαN (i, i+4) contacts normally observed 
for α-helices. These cross signals originate from the interaction between the Cα-proton of 
amino acid i and the NH proton of amino acid i+2 or i+4. In contrast to peptides consisting 
only of Cα-tetrasubstituted α-amino acids, in our case it was possible to observe this kind 
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of interaction due to the presence of valine in the peptide chain. 
For the tetrapeptide 171 only the dαN (i, i+2) (i = 2) was found indicating the presence of a 
C-terminal 310-helix. 
 
Figure 87: dNN (i, i+1) (i = 1 - 3) and dαN (i, i+2) (i = 2) NOE contacts of 171 detected 
spectroscopically in a DMSO-d6 solution. 
For the hexapeptide 172 two dαN (i, i+2) (i = 2 and 4) cross-peaks were found, but no dαN 
(i, i+4) (i = 2) NOE contact was detected. Accordingly, these findings clearly indicate a 
preference for the formation of a 310-helix over an α-helix. 
 
Figure 88: dNN (i, i+1) (i = 1 - 5) and dαN (i, i+2) (i = 2 and 4) NOE contacts of 172 detected 
spectroscopically in a DMSO-d6 solution. 
For compound 179 no structural insights could be obtained by its ROESY spectrum, due 
to strong overlap of the Cα-proton resonances.236 
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Figure 89: dNN (i, i+1) (i = 1 - 7) NOE contacts of 179 detected spectroscopically in a 
DMSO-d6 solution. 
The NMR measurements strongly indicate that the investigated peptides based on 
alternating natural and Cα-tetrasubstituted unnatural α-amino acids form stable helices in 
solution, as they do in solid state. The tetra- and hexamers prefer a 310-helix structure in 
deuterated DMSO. 
3.3.3. Solution Structure Analysis using Circular Dichroism 
The conformation of all synthesized peptides was further investigated in methanol by CD 
spectroscopy.3 
Figure 90 shows the effect of the peptide chain length elongation on the dichroic 
properties of the oligopeptides. Peptides 167 (RS), 168 (RS)2 and 169 (RS)3 which have 
no helix character based on the NMR investigation, show two opposite CD bands near 
210 nm (positive) and 222 nm (negative), with a crossover close to 215 nm. The intensity 
of the CD spectra decreases by increasing the peptide-chain length. Similarly, peptides 
174 (SR)2 and 175 (SR)3 (no helix character based on NMR) are characterized by much 
less intense CD curves than dipeptide 173 (SR): they still show a broad minimum near 
210 nm, whereas the positive shoulder of 173 at 230 nm disappears, until it becomes a 
weak negative shoulder for hexapeptide 175. 
                                                
3 The interpretation of the measured data was accomplished with the help of Prof. Dr. C. Cabrele 
(Ruhr-Universität Bochum). 
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Figure 90: CD-Spectra of compounds 167 - 169 (RS)1-3 (panel A), 170 - 172 (SS)1-3 
(panel B), 173 - 175 (SR)1-3 (panel C) and 176 - 179 (RR)1-4 (panel D), recorded in 
methanol at a peptide concentration of 1mM. 
Upon elongation of dipeptide 170 (SS) to tetrapeptide 171 (SS)2 and hexapeptide 172 
(SS)3 (right-handed 310-helix in the crystal), the minimum near 205 nm is slightly red-
shifted and increases in intensity, whereas the positive CD contribution above 215 nm is 
substituted by a negative maximum near 222 nm, followed by a minimum near 234 nm. 
The CD spectra of peptides 177 - 179 (RR)2-4 (left-handed 310-helix in the crystal) are 
reminiscent of the one of dipeptide 176 (RR), but shifted towards positive ellipticity values, 
which leads to the appearance of a maximum near 210 nm and a positive valley near 222 
nm. Moreover, a new positive band is detected near 233 nm, whose intensity increases 
when going from tetrapeptide 177 up to octapeptide 179. The corresponding enantiomers 
171 (SS)2 and 172 (SS)3 also show this band, obviously opposite in sign, whereas the 
tetra- and hexapeptides from the (RS) and (SR) series do not (Figure 91): as only the 
peptides from the (RR) and (SS) series adopt a 310-helical structure in the crystal and 
show NOEs characteristic of helical structures, this band near 233 nm, together with the 
increased CD intensity in the range of 210-230 nm, should reflect the presence of an 
ordered structure that becomes better defined in the larger oligopeptides (CD intensity 
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over 210-230 nm: 172 > 171, and 179 > 178 > 177).  
 
Figure 91: Comparison of the CD-Spectra of the helical peptides 171, 172 (panel A) and 
177 - 179 (panel B) with the non-helical oligomers 174, 175 and 168, 169, respectively. 
We assume that the dipeptides contain the highest amount of disordered and irregular 
conformations. Therefore, the increase in the ordered peptide fraction of the larger 
peptides can be visualized by subtracting the CD spectrum of the dipeptides from the CD 
spectra of the larger peptides. This eliminates the CD contribution of the disordered 
fraction and possible CD contributions from the aromatic group of the TAA. The difference 
CD spectra for the four peptide series (SS, RR, SR, RS) are shown in Figure 92. The 
difference CD spectra obtained for the peptides (SS)2-3 and (RR)2-4 that adopt a right-
handed and left-handed 310-helix, respectively, in the crystal are characterized by a red-
shifted helix-like band pattern (panel A of Figure 92), with two minima for (171−170) and 
(172−170), or two maxima for (177−176), (178−176) and (179−176) near 210 nm and 230 
nm. 
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Figure 92: Difference CD spectra of oligopeptides (RR)2-4 minus dipeptide (RR) and of 
oligopeptides (SS)2-3 minus dipeptide (SS) are shown in panel A. Difference CD spectra of 
oligopeptides (RS)2-3 minus dipeptide (RS) and of oligopeptides (RS)2-3 minus dipeptide 
(RS) are shown in panel B. 
The remarkable red shift of the longer wavelength band can be due to the highly 
hydrophobic character of the peptides.237 The intensity of the spectra increases with the 
peptide length, suggesting an increase in ordered structure; moreover, for the 
tetrapeptides of both series the ratio between the ellipticity values at 230 nm and 210 nm 
is < 1, whereas for the larger peptides this ratio becomes > 1. This suggests that the 
tetrapeptides are likely to form both a 310- and an α-helical turn in methanol, whereas the 
larger peptides are able to build a stable short α-helix. The tendency of peptide chains 
with eight or more amino acids in length to form an preferred α-helical structure was 
previously discribed.9a The difference CD spectra obtained for the peptides (SR)2-3 and 
(RS)2-3 are completely different from those ones of the peptides (SS)2-3 and (RR)2-4, which 
excludes a helical conformation. 
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3.4. Conclusion 
In summary, 13 new peptides based on an alternated sequence of the S- or R-configured 
α-amino acid valine and the unnatural Cα-tetrasubstituted tetrahydrofuran α-amino acid 
rac-138 were prepared. Homo- and heterochiral stereoisomers with up to eight residues in 
length were systematically synthesized in good yields and high purity by solution phase 
chemistry. X-ray crystallography, NMR- and CD-measurements showed that all 
homochiral peptides, even the tetrapeptides, form helical structures in the solid state and 
in solution. The handedness of the helix is determined by the use of S-amino acids for 
right-handed or R-amino acids for left-handed peptide helices.  
The stable and predictable secondary structure of the new peptides makes them suitable 
for applications as scaffolds and peptidomimetics. Additional moieties e.g. dyes, can be 
introduced by metal catalyzed functionalization of the brominated arene substituent (see 
Chapter 3).218 Comparison of the crystallographic data of octamer 179 (RR)4 with an 
idealized α-helix geometry reveals that the residues i, i+3 and i+6 of the octamer 
correspond to residues i, i+3 and i+7 of the natural α-helix. These positions are of 
importance for numerous protein-protein interactions, as the side chains of these residues 
are located on the same face of an amphipathic α–helical protein or peptide segment.238 
 
Figure 93: Crystal structure of compound 179 (red ribbon, top) and of an α-helix (green 
ribbon, bottom). The i, i+3 and i+6 residues of peptide 179 are in close proximity to the i, 
i+3 and i+7 side chains of the natural α-helix (in this example alanine was used to indicate 
the side chains of the natural peptide). 
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3.5. Experimental Part 
General 
A Jasco Model J-710 spectropolarimeter was used. A 0.5 mm quartz cell was purchased 
from Hellma and Uvasol solvents from Merck. X-ray data collections were performed 
using an Oxford Gemini Ultra diffractometer. IR spectra were recorded on a Bio-Rad FT-
IR FTS 155 and a Bio-Rad FTS 2000 MX FT-IR using a Specac Golden Gate Mk II ATR 
accessory where stated. NMR spectrometers used were: Bruker Avance 600 (1H: 600.1 
MHz, 13C: 150.1 MHz, T = 300 K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T 
= 300 K) and Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K). The 
chemical shifts are reported in δ [ppm] relative to external standards (solvent residual 
peak). The spectra were analyzed by first order, the coupling constants are given in Hertz 
[Hz]. Characterization of the signals: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, bs = broad singlet, psq = pseudo quintet, dd = double doublet, dt = double 
triplet, ddd = double double doublet. Integration is determined as the relative number of 
atoms. Assignment of signals in 13C-spectra was determined with DEPT-technique (pulse 
angle: 135 °) and given as (+) for CH3 or CH, (-) for CH2 and (Cquat) for quaternary C. Error 
of reported values: chemical shift: 0.01 ppm for 1H-NMR, 0.1 ppm for 13C-NMR and 0.1 Hz 
for coupling constants. The solvent used is reported for each spectrum. Mass spectra 
were recorded on Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD) and Finnigan 
MAT TSQ 7000 (ESI). Xenon served as the ionization gas for FAB. Melting Points were 
determined on a Büchi SMP-20 or Stanford Research System OpitMelt melting point 
apparatus and are uncorrected. Elemental analyses were carried out by the Center for 
Chemical Analysis of the Faculty of Natural Sciences of the University Regensburg. 
All reagents and solvents used were of analytical grade purchased from commercial 
sources and were used without further purification. Unless stated otherwise, purification 
and drying of the solvents used was done according to accepted general procedures.239 
All reactions were performed under an inert atmosphere of N2 using standard Schlenk 
techniques if not otherwise stated. TLC analyses were performed on silica gel 60 F-254 
with a 0.2 mm layer thickness. Detection was via UV light at 254 nm / 366 nm or through 
discoloration with ninhydrin in EtOH. For preparative column-chromatography, Merck 
Geduran SI 60 (70-230 mesh) and Macherey-Nagel GmbH & Co. KG 60M (230–400 
mesh) silica gels were used. For chromatography commercially available solvents of 
standard quality were used without further purification. 
The unnatural amino acid Boc-TAA-OH rac-137 was synthesized according to a literature 
known procedure.218 
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(2S)-Methyl 2-(2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanoate (167/170): 
Under an atmosphere of nitrogen compound rac-138 (1.50 g, 3.88 mmol, 1 eq.) was 
dissolved in 3.9 ml DMF (1 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (1.99 ml, 11.7 mmol, 3 eq.), HOBt (793 mg, 5.83 mmol, 1.5 eq.) and EDC (1.03 ml, 
5.83 mmol, 1.5 eq.) were added in this sequence. Then H-Val-OMe*HCl 180 (911 mg, 
5.44 mmol, 1.4 eq.) was slowly added in portions. The mixture was allowed to warm to 
room temperature and stirred for 24 h. The reaction was quenched with 6 ml of water and 
4 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x10 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 80:20) to give the product as 
two diasteriomers as colorless solids with an overall yield of 76 % (1.47 g, 2.94 mmol). 
167: Rf (PE:diethyl ether 70:30) = 0.24 
MP 147 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.48 (d, 3JH,H = 6.9, 3 H, 18), 0.61 (d, 3JH,H = 
6.9, 3 H, 18), 1.47 (s, 9 H, 1), 1.86 (septet, 3JH,H = 4.6, 3JH,H = 6.8, 1 H, 17), 2.52-2.71 (m, 
1 H, 7), 2.73-2.92 (m, 1 H, 7), 3.70 (s, 3 H, 16), 4.21 (dd, 3JH,H = 4.4, 3JH,H = 8.5, 1 H, 13), 
4.27-4.45 (m, 2 H, 8), 5.42 (bs, 1 H, 10), 6.16 (bs, 1 H, NH), 6.48 (d, 3JH,H = 8.0, 1 H, NH), 
7.24 (d, 3JH,H = 8.2, 2 H, 20), 7.41 (d, 3JH,H = 8.5, 2 H, 21). – 13C-NMR (75 MHz, CDCl3): δ 
= 17.3 (+, 1 C, 18), 18.3 (+, 1 C, 18), 28.4 (+, 3 C, 1), 31.0 (+, 1 C, 17), 36.1 (-, 1 C, 7), 
52.2 (+, 1 C, 16), 57.3 (+, 1 C, 13), 66.6 (-, 1 C, 8), 67.5 (Cquat, 1 C, 6), 80.2 (Cquat, 1 C, 2), 
80.4 (+, 1 C, 10), 121.6 (Cquat, 1 C, 22), 127.0 (+, 2 C, 20), 131.3 (+, 2 C, 21), 136.4 (Cquat, 
1 C, 19), 154.2 (Cquat, 1 C, 4), 171.2 (Cquat, 1 C, 11), 172.1 (Cquat, 1 C, 14). – MS (CI, NH3): 
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m/z (%) = 500.9 (100) [MH+], 518.0 (17) [MNH4+]. – Elemental analysis calcd. (%) for 
C22H31BrN2O6 (499.4): C 52.95, H 6.28, N 5.59; found: C 53.02, H 6.33, N 5.50. – IR 
(neat) [cm-1]: ν~  = 3384, 3271, 2959, 2518, 2361, 1725, 1673, 1527, 1491, 1437, 1373, 
1211, 1147, 1072, 1009, 830, 802. – MF C22H31BrN2O6. – MW 499.4. 
X-Ray structure and crystal data of 167: 
Monoclinic; space group: C 2; cell dimensions: a = 19.0217(5) Å, α = 90°, b = 6.13650(10) 
Å, β = 106.897(3)°, c = 20.6038(5) Å, γ = 90°; V = 2301.19(10) Å3; Z = 4, Dx = 1.441 
Mg/m3; µ = 2.776 mm-1; F(000) = 1040. Data collection: T = 123 K; graphite 
monochromator. A colorless crystal with dimensions of 0.490 x 0.070 x 0.050 mm was 
used to measure 7262 reflections (3078 unique reflections, Rint = 0.0455) from 2.24° to 
62.28° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. 
Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit of 1.020 for all reflections and 286 parameters.  
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170: Rf (PE:diethyl ether = 70:30) = 0.20 
MP 135 °C. – 1H-NMR (300 MHz, benzene-d6): δ = 0.68 (d, 3JH,H = 6.9, 6 H, 18), 1.44 (s, 9 
H, 1), 1.70-1.91 (m, 1 H, 17), 2.22-2.42 (m, 1 H, 7), 2.59-2.81 (m, 1 H, 7), 3.15 (s, 3 H, 
16), 3.75-3.94 (m, 1 H, 13), 3.92 (dd, 3JH,H = 7.1, 3JH,H = 16.2, 8), 4.27 (dd, 2JH,H = 4.9, 3JH,H 
= 7.9, 1 H, 8), 5.51 (bs, 1 H, 10), 6.40 (s, 1 H, NH), 6.75 (d, 3JH,H = 5.8, 1 H, NH), 7.20 (d, 
3JH,H = 8.5, 2 H, 20), 7.30 (d, 3JH,H = 8.2, 2 H, 21). – 13C-NMR (75 MHz, CDCl3): δ = 17.9 
(+, 1 C, 18), 18.7 (+, 1 C, 18), 28.4 (+, 3 C, 1), 31.8 (+, 1 C, 17), 36.1 (-, 1 C, 7), 52.1 (+, 1 
C, 16), 57.2 (+, 1 C, 13), 66.5 (-, 1 C, 8), 67.6 (Cquat, 1 C, 6), 80.2 (Cquat, 1 C, 2), 80.7 (+, 1 
C, 10), 121.6 (Cquat, 1 C, 22), 127.3 (+, 2 C, 20), 131.0 (+, 2 C, 21), 135.5 (Cquat, 1 C, 19), 
154.3 (Cquat, 1 C, 4), 171.3 (Cquat, 1 C, 11 + 14). – MS (CI, NH3): m/z (%) = 500.9 (100) 
[MH+], 518.0 (33) [MNH4+]. – Elemental analysis calcd. (%) for C22H31BrN2O6 (499.4): C 
52.91, H 6.26, N 5.61; found: C 53.02, H 6.33, N 5.50. – IR (neat) [cm-1]: ν~  = 3440, 3271, 
2957, 2874, 2357, 1742, 1719, 1652, 1507, 1367, 1244, 1162, 1088, 1014, 987, 798. – 
MF C22H31BrN2O6. – MW 499.4. 
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X-Ray structure and crystal data of 170: 
Orthorhombic; space group: P 21 21 21; cell dimensions: a = 6.1755(3) Å, α = 90°, b = 
12.6779(6) Å, β = 90°, c = 30.4159(11) Å, γ = 90°; V = 2381.33(18) Å3; Z = 4, Dx = 1.393 
Mg/m3; µ = 2.682 mm-1; F(000) = 1040. Data collection: T = 123 K; graphite 
monochromator. A colorless crystal with dimensions of 0.480 x 0.040 x 0.030 mm was 
used to measure 7259 reflections (3553 unique reflections, Rint = 0.0616) from 3.78° to 
62.35° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. 
Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit of 1.005 for all reflections and 286 parameters.  
Section B 3. Stable Right- and Left-handed Peptide Helices 
 179
(S)-2-((2S,3R)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanoic acid (181): 
Compound 167 (440 mg, 0.88 mmol) was dissolved in 22 ml of a MeCN:water mixture 
(4:1, 25 ml/mmol). To the solution 1M aqueous LiOH (970 μl, 0.97 mmol) was added drop 
by drop. The mixture was stirred over night at room temperature. After acidification with 
1M aqueous KHSO4 solution the mixture was extracted with DCM (3x10 ml). The 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure to give the product as colorless solid 93 % yield. (400 mg, 0.82 mmol) 
MP 133-135 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.44 (d, 3JH,H = 5.2, 3 H, 16), 0.62 (d, 
3JH,H = 5.8, 3 H, 16), 1.42 (m, 9 H, 1), 1.78-1.95 (m, 1 H, 15), 2.41-2.65 (m, 1 H, 7), 2.67-
2.86 (m, 1 H, 7), 4.13-4.39 (m, 3 H, 8 + 13), 5.39 (bs, 1 H, 10), 6.17 (bs, 1 H, NH), 6.47 (d, 
3JH,H = 7.7, 1 H, NH), 7.20 (d, 3JH,H = 8.2, 2 H, 18), 7.35 (d, 3JH,H = 8.8, 2 H, 19). – 13C-
NMR (75 MHz, CDCl3): δ = 17.2 (+, 1 C, 16), 18.4 (+, 1 C, 16), 28.4 (+, 3 C, 1), 30.7 (-, 1 
C, 15), 36.0 (-, 1 C, 7), 57.2 (+, 1 C, 13), 66.5 (-, 1 C, 8), 67.5 (Cquat, 1 C, 6), 80.2 (+, 1 C, 
10), 80.3 (Cquat, 1 C, 2), 121.6 (Cquat, 1 C, 20), 127.0 (+, 2 C, 18), 131.4 (+, 2 C, 19), 136.4 
(Cquat, 1 C, 17), 154.3 (Cquat, 1 C, 4), 171.4 (Cquat, 1 C, 11), 176.3 (Cquat, 1 C, 14). – MS 
(ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 485.1 (100) [MH+], 502.2 (57) [MNH4+], 
523.1 (26) [MK+], 1007.3 (22) [2M + K+]; 409.0 (35) [M – tBuOH - H+], 483.1 (100) [M – H+]. 
– IR (neat) [cm-1]: ν~  = 3397, 3334, 2967, 2891, 1734, 1710, 1667, 1492, 1256, 1164, 
1067, 1044, 1010, 827, 793. – MF C21H29BrN2O6. – MW 485.37. 
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(S)-2-((2R,3S)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanoic acid (183): 
Compound 170 (300 mg, 0.60 mmol) was dissolved in 15 ml of a MeCN:water mixture 
(4:1, 25 ml/mmol). To the solution 1M aqueous LiOH (660 μl, 0.66 mmol) was added drop 
by drop. The mixture was stirred over night at room temperature. After acidification with 
1M aqueous KHSO4 solution the mixture was extracted with DCM (3x8 ml). The combined 
organic layers were dried over MgSO4 and concentrated under reduced pressure to give 
the product as colorless solid 96 % yield. (280 mg, 0.58 mmol) 
MP 118-119 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.62 (d, 3JH,H = 8.2, 3 H, 14), 0.64 
(d, 3JH,H = 8.0, 3 H, 14), 1.78 (sextet, 3JH,H = 6.7, 1 H, 13), 2.36 (ddd, 3JH,H = 2.5, 3JH,H = 
7.3, 2JH,H = 14.4, 1 H, 3), 3.00 (dt, 3JH,H = 14.4, 3JH,H = 9.3, 1 H, 1 H, 3), 3.67 (s, 3 H, 12), 
3.84 (d, 3JH,H = 6.6, 1 H, 9), 4.18 (dt, 3JH,H = 7.2, 3JH,H = 9.3, 1 H, 4), 4.54 (dt, 3JH,H = 2.5, 
3JH,H = 9.1, 1 H, 4), 4.99 (s, 1 H, 6), 7.32 (d, 3JH,H = 8.2, 2 H, 16), 7.53 (d, 3JH,H = 8.8, 2 H, 
17). – 13C-NMR (75 MHz, MeOH-d4): δ = 19.1 (+, 1 C, 14), 19.4 (+, 1 C, 14), 31.1 (+, 1 C, 
13), 36.0 (-, 1 C, 3), 52.6 (+, 1 C, 12), 60.6 (+, 1 C, 9), 67.8 (-, 1 C, 4), 70.0 (Cquat, 1 C, 2), 
86.8 (+, 1 C, 10), 123.8 (Cquat, 1 C, 18), 129.2 (+, 2 C, 16), 132.8 (+, 2 C, 17), 136.2 (Cquat, 
1 C, 15), 169.2 (Cquat, 1 C, 7), 173.3 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 399.1 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3394, 2960, 2362, 2341, 
1723, 1672, 1509, 1437, 1213, 1145, 1070, 1010, 830, 703. – MF C21H29BrN2O6. – MW 
485.37. 
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(S)-Methyl 2-((2S,3R)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-3-
methyl-butanoate (182): 
Compound 167 (290 mg, 0.58 mmol) was dissolved under ice bath cooling at 0 °C in 
diethyl ether. To this solution 4.1 ml ice cold HCl saturated ether (7 ml/mmol Boc) was 
added and the mixture was stirred over night at room temperature. The solvent was 
removed under reduced pressure to give the HCl salt of the product as white hygroscopic 
solid in quantitative yield (250 mg, 0.57 mmol). No further purification was necessary. 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.62 (d, 3JH,H = 8.2, 3 H, 14), 0.64 (d, 
3JH,H = 8.0, 3 H, 14), 1.78 (sextet, 3JH,H = 6.7, 1 H, 13), 2.36 (ddd, 3JH,H = 2.5, 3JH,H = 7.3, 
2JH,H = 14.4, 1 H, 3), 3.00 (dt, 3JH,H = 14.4, 3JH,H = 9.3, 1 H, 1 H, 3), 3.67 (s, 3 H, 12), 3.84 
(d, 3JH,H = 6.6, 1 H, 9), 4.18 (dt, 3JH,H = 7.2, 3JH,H = 9.3, 1 H, 4), 4.54 (dt, 3JH,H = 2.5, 3JH,H = 
9.1, 1 H, 4), 4.99 (s, 1 H, 6), 7.32 (d, 3JH,H = 8.2, 2 H, 16), 7.53 (d, 3JH,H = 8.8, 2 H, 17). – 
13C-NMR (75 MHz, MeOH-d4): δ = 19.1 (+, 1 C, 14), 19.4 (+, 1 C, 14), 31.1 (+, 1 C, 13), 
36.0 (-, 1 C, 3), 52.6 (+, 1 C, 12), 60.6 (+, 1 C, 9), 67.8 (-, 1 C, 4), 70.0 (Cquat, 1 C, 2), 86.8 
(+, 1 C, 10), 123.8 (Cquat, 1 C, 18), 129.2 (+, 2 C, 16), 132.8 (+, 2 C, 17), 136.2 (Cquat, 1 C, 
15), 169.2 (Cquat, 1 C, 7), 173.3 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 399.1 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3288, 2965, 2874, 2362, 
2341, 1749, 1684, 1646, 1519, 1488, 1157, 1074, 1010, 841. – MF C17H23BrN2O4*HCl. – 
MW 435.74. 
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(S)-Methyl 2-((2R,3S)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-3-
methyl-butanoate (184): 
Compound 170 (300 mg, 0.60 mmol) was dissolved under ice bath cooling at 0 °C in 
diethyl ether. To this solution 4.2 ml ice cold HCl saturated ether (7 ml/mmol Boc) was 
added and the mixture was stirred over night at room temperature. The solvent was 
removed under reduced pressure to give the HCl salt of the product as white hygroscopic 
solid in quantitative yield (260 mg, 0.60 mmol). No further purification was necessary. 
MP >180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.85 (t, 3JH,H = 6.9, 6 H, 14), 2.02 
(sextet, 3JH,H = 6.8, 1 H, 13), 2.40-2.51 (m, 1 H, 3), 2.93 (dt, 2JH,H = 14.4, 3JH,H = 9.0, 1 H, 
3), 3.67 (s, 3 H, 12), 4.03 (d, 3JH,H = 7.1, 1 H, 9), 4.21 (q, 3JH,H = 8.3, 1 H, 4), 4.53 (t, 3JH,H = 
8.9, 1 H, 4), 5.02 (s, 1 H, 6), 7.29 (d, 3JH,H = 8.2, 2 H, 16), 7.45 (d, 3JH,H = 8.5, 2 H, 17). – 
13C-NMR (75 MHz, MeOH-d4): δ = 18.9 (+, 1 C, 14), 19.4 (+, 1 C, 14), 32.6 (+, 1 C, 13), 
36.2 (-, 1 C, 3), 52.8 (+, 1 C, 12), 59.5 (+, 1 C, 9), 67.8 (-, 1 C, 4), 69.8 (Cquat, 1 C, 2), 87.0 
(+, 1 C, 10), 123.7 (Cquat, 1 C, 18), 129.4 (+, 2 C, 16), 132.5 (+, 2 C, 17), 135.3 (Cquat, 1 C, 
15), 168.8 (Cquat, 1 C, 7), 172.4 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 399.1 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3399, 2957, 2526, 2362, 
2341, 1723, 1672, 1509, 1488, 1437, 1212, 1069, 1009, 829, 803. – MF 
C17H23BrN2O4*HCl. – MW 435.74. 
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(S)-Methyl 2-((2S,3R)-2-(4-bromophenyl)-3-((S)-2-((2S,3R)-2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-tetrahydro-
furan-3-carbox-amido)-3-methylbutanoate (168): 
Under an atmosphere of nitrogen compound 181 (150 mg, 0.31 mmol, 1 eq.) was 
dissolved in 2.5 ml DMF (8 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (159 µl, 0.93 mmol, 3 eq.), HOAt (64 mg, 0.46 mmol, 1.5 eq.) and HATU (176 mg, 
0.46 mmol, 1.5 eq.) were added in this sequence. Then the amine 182 (148 mg, 0.34 
mmol, 1.1 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 2 ml of water and 1 
ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x10 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 60:40, Rf = 0.14) to give the 
product as colorless solids with an overall yield of 67 % (180 mg, 0.21 mmol). 
MP 159-161 °C. – 1H-NMR (600 MHz, COSY, CDCl3): δ = 0.65 (d, 3JH,H = 6.8, 3 H, 38), 
0.67 (d, 3JH,H = 7.2, 3 H, 28), 0.74 (d, 3JH,H = 6.6, 3 H, 38), 0.81 (d, 3JH,H = 6.8, 3 H, 28), 
1.48 (s, 9 H, 1), 1.91-1.99 (m, 1 H, 37), 2.00-2.06 (m, 1 H, 27), 2.46-2.61 (m, 2 H, 19 + 
29), 2.82-2.91 (m, 1 H, 29), 3.15 (bs, 1 H, 19), 3.59-70 (m, 4 H, 9 + 18), 3.98-4.08 (m, 1 H, 
30), 4.16 (dd, 3JH,H = 5.5, 3JH,H = 8.8, 1 H, 15), 4.23 (dd, 3JH,H = 8.7, 3JH,H = 15.7, 1 H, 20), 
4.33 (dt, 3JH,H = 2.8, 3JH,H = 8.5, 1 H, 30), 4.43 (dt, 3JH,H = 5.3, 3JH,H = 8.6, 1 H, 20), 5.00 (s, 
1 H, 22), 5.21 (s, 1 H, 32), 5.84 (s, 1H 5), 6.32 (s, 1H, 8), 6.87 (d, 3JH,H = 7.7, 1 H,14), 7.14 
(d, 3JH,H = 8.4, 2 H, 24), 7.17 (d, 3JH,H = 8.6, 2 H, 34), 7.28 (d, 3JH,H = 7.9, 2 H, 25), 7.35 (d, 
3JH,H = 8.4, 2 H, 35), 7.48 (s, 1 H, 11). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 
17.4 (+, 1 C, 28), 17.7 (+, 1 C, 38), 18.7 (+, 1 C, 38), 19.0 (+, 1 C, 28), 28.4 (+, 3 C, 1), 
30.0 (+, 1 C, 27), 31.2 (+, 1 C, 37), 35.5 (-, 1 C, 29), 35.6 (-, 1 C, 19), 51.8 (+, 1 C, 18), 
57.5 (+, 1 C, 15), 59.7 (+, 1 C, 9), 67.4 (-, 1 C, 30), 67.6 (-, 1 C, 20), 69.0 (Cquat, 1 C, 6), 
69.6 (Cquat, 1 C, 12), 81.7 (Cquat, 1 C, 2), 83.8 (+, 1 C, 32), 84.3 (+, 1 C, 22), 121.7 (Cquat, 1 
C, 36), 122.6 (Cquat, 1 C, 26), 127.7 (+, 2 C, 24), 127.9 (+, 2 C, 34), 131.0 (+, 2 C, 35), 
131.4 (+, 2 C, 25), 135.1 (Cquat, 1 C, 23), 136.6 (Cquat, 1 C, 33), 155.5 (Cquat, 1 C, 4), 189.7 
(Cquat, 1 C, 13), 169.9 (Cquat, 1 C, 10), 171.0 (Cquat, 1 C, 7), 171.8 (Cquat, 1 C, 16). –  
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MS (ES, DCM/MeOH + 10 mM NH4OAc): m/z (%) = 867.3 (100) [MH+], 884.3 (74) 
[MNH4+]; 865.3 (100) [M – H+], 925.3 (55) [M + OAc-]. – HR-MS (PI-LSIMS, 
MeOH/DCM/NBA): [MH+] calcd. for C38H50Br2N4O9 865.2023; found 865.2022. – IR (neat) 
[cm-1]: ν~  = 3252, 3312, 3241, 2964, 2941, 2884, 2361, 2341, 1736, 1668, 1595, 1519, 
1463, 1259, 1118, 1010, 994, 829. – MF C38H50Br2N4O9. – MW 866.63. 
(S)-Methyl 2-((2R,3S)-2-(4-bromophenyl)-3-((S)-2-((2R,3S)-2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-tetrahydro-
furan-3-carbox-amido)-3-methylbutanoate (171): 
Under an atmosphere of nitrogen compound 183 (180 mg, 0.37 mmol, 1 eq.) was 
dissolved in 3.0 ml DMF (8 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (190 µl, 1.11 mmol, 3 eq.), HOAt (76 mg, 0.56 mmol, 1.5 eq.) and HATU (212 mg, 
0.56 mmol, 1.5 eq.) were added in this sequence. Then the amine 184 (178 mg, 0.41 
mmol, 1.1 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 2 ml of water and 1 
ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x10 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 50:50, Rf = 0.13) to give the 
product as colorless solids with an overall yield of 56 % (180 mg, 0.21 mmol). 
MP 148-149 °C. – 1H-NMR (600 MHz, COSY, MeOH-d4): δ = 0.65 (d, 3JH,H = 7.1, 3 H, 28), 
0.66 (d, 3JH,H = 7.0, 3 H, 38), 0.73 (d, 3JH,H = 7.0, 3 H, 38), 0.82 (d, 3JH,H = 7.0, 3 H, 28), 
1.51 (s, 9 H, 1), 1.64 (sextet, 3JH,H = 6.8, 1 H, 37), 1.92-1.99 (m, 1 H, 27), 2.17-2.24 (m, 2 
H, 19 + 29), 3.09 (ddd, 3JH,H = 8.4, 3JH,H = 10.4, 2JH,H = 13.3, 29), 3.25-3.32 (m, 2 H, 9 + 
19), 3.42 (d, 3JH,H = 6.4, 1 H, 15), 3.59 (s, 3 H, 18), 3.70-3.76 (m, 1 H, 30), 4.09 (q, 3JH,H = 
8.1, 1 H, 20), 4.26 (dt, 3JH,H = 2.4, 3JH,H = 8.3, 1 H, 30), 4.34 (dt, 3JH,H = 4.5, 3JH,H = 8.4, 1 
H, 20), 4.89 (s, 1 H, 22), 5.14 (s, 1 H, 32), 7.26 (d, 3JH,H = 8.3, 2 H, 24), 7.37 (d, 3JH,H = 
8.6, 2 H, 34), 7.39 (d, 3JH,H = 8.8, 2 H, 35), 7.47 (d, 3JH,H = 8.6, 2 H, 25). – 13C-NMR (150 
MHz, HSQC, HMBC, MeOH-d4): δ = 17.9 (+, 1 C, 28), 19.0 (+, 1 C, 38), 19.2 (+, 1 C, 28), 
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19.7 (+, 1 C, 38), 28.7 (+, 3 C, 1), 30.5 (+, 1 C, 27), 31.2 (+, 1 C, 37), 37.8 (-, 1 C, 29), 
38.0 (-, 1 C, 19), 52.0 (+, 1 C, 18), 60.9 (+, 1 C, 15), 61.8 (+, 1 C, 9), 68.8 (-, 2 C, 20 + 
30), 72.0 (Cquat, 1 C, 6), 72.4 (Cquat, 1 C, 12), 82.6 (Cquat, 1 C, 2), 86.9 (+, 1 C, 22), 88.2 (+, 
1 C, 32), 123.2 (Cquat, 1 C, 36), 123.7 (Cquat, 1 C, 26), 129.9 (+, 2 C, 24), 130.6 (+, 2 C, 
34), 131.9 (+, 2 C, 35), 132.4 (+, 2 C, 25), 138.0 (Cquat, 1 C, 23), 138.4 (Cquat, 1 C, 33), 
158.9 (Cquat, 1 C, 4), 172.0 (Cquat, 1 C, 13), 172.7 (Cquat, 1 C, 10), 172.8 (Cquat, 1 C, 16), 
173.3 (Cquat, 1 C, 7). – 1H-NMR (600 MHz, COSY, DMSO-d6): δ = 0.58 (d, 3JH,H = 6.8, 6 H, 
28 + 38), 0.66 (d, 3JH,H = 6.9, 3 H, 38), 0.73 (d, 3JH,H = 6.9, 3 H, 28), 1.43 (s, 9 H, 1), 1.55 
(octet, 3JH,H = 6.8, 1 H, 37), 1.86 (bs, 1 H, 27), 2.06-2.16 (m, 2 H, 19 + 29), 2.85 (q, 3JH,H = 
10.6, 1 H, 29), 3.05 (dt, 2JH,H = 12.6, 3JH,H = 8.6, 1 H, 19), 3.17 (s, 1 H, 9), 3.20 (t, 3JH,H = 
6.1, 1 H, 15), 3.46 (s, 3 H, 18), 3.60 (dd, 3JH,H = 7.3, 2JH,H = 17.0, 30), 3.94 (q, 3JH,H = 7.9, 1 
H, 20), 4.19 (t, 3JH,H = 7.7, 1 H, 30), 4.22 (dt, 3JH,H = 3.9, 3JH,H = 8.3, 1 H, 20), 5.02 (s, 1 H, 
22), 5.03 (s, 1 H, 32), 7.14 (d, 3JH,H = 6.2, 2 H, 14), 7.18 (d, 3JH,H = 2.6, 2 H, 8), 7.25 (d, 
3JH,H = 8.1, 2 H, 34), 7.26 (d, 3JH,H = 6.4, 2 H, 24), 7.42 (d, 3JH,H = 8.3, 2 H, 35), 7.47 (d, 
3JH,H = 8.3, 2 H, 25), 7.76 (s, 1 H, 11), 8.15 (s, 1 H, 5). – 13C-NMR (150 MHz, HSQC, 
HMBC, DMSO-d6): δ = 17.9 (+, 1 C, 28), 18.6 (+, 1 C, 38), 18.7 (+, 1 C, 28), 19.3 (+, 1 C, 
38), 28.4 (+, 3 C, 1), 29.2 (+, 1 C, 27), 29.8 (+, 1 C, 37), 35.9 (-, 1 C, 29), 36.6 (-, 1 C, 19), 
51.5 (+, 1 C, 18), 59.2 (+, 1 C, 15), 60.3 (+, 1 C, 9), 67.5 (-, 2 C, 20 + 30), 70.7 (Cquat, 1 C, 
6), 70.8 (Cquat, 1 C, 12), 80.5 (Cquat, 1 C, 2), 84.9 (+, 1 C, 22), 86.5 (+, 1 C, 32), 121.5 
(Cquat, 1 C, 36), 121.7 (Cquat, 1 C, 26), 129.4 (+, 2 C, 24), 129.6 (+, 2 C, 34), 130.7 (+, 2 C, 
35), 131.0 (+, 2 C, 25), 137.5 (Cquat, 1 C, 23), 138.0 (Cquat, 1 C, 33), 156.8 (Cquat, 1 C, 4), 
169.7 (Cquat, 1 C, 13), 170.4 (Cquat, 1 C, 10), 171.2 (Cquat, 1 C, 16), 171.8 (Cquat, 1 C, 7). – 
MS (ES, DCM/MeOH + 10 mM NH4OAc): m/z (%) = 867.2 (100) [MH+], 884.3 (24) 
[MNH4+]. – HR-MS (PI-LSIMS, MeOH/DCM/NBA): [MH+] calcd. for C38H50Br2N4O9 
865.2023; found 865.2026. – IR (neat) [cm-1]: ν~  = 3249, 3312, 3242, 2967, 2941, 2879, 
2360, 2341, 1736, 1672, 1594, 1519, 1465, 1256, 1111, 1010, 997, 831. – MF 
C38H50Br2N4O9. - MW 866.63. 
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X-Ray structure and crystal data of 171: 
Orthorhombic; space group: P 21 21 21; cell dimensions: a = 10.14170(10) Å, α = 90°, b = 
16.2309(2) Å, β = 90°, c = 27.0320(4) Å, γ = 90°; V = 4449.71(10) Å3; Z = 4, Dx = 1.389 
Mg/m3; µ = 2.811 mm-1; F(000) = 1936. Data collection: T = 123 K; graphite 
monochromator. A colorless crystal with dimensions of 0.420 x 0.360 x 0.230 mm was 
used to measure 15559 reflections (6662 unique reflections, Rint = 0.0341) from 3.18° to 
62.13° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. 
Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit 0f 1.024 for all reflections and 550 parameters.  
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(S)-Methyl 2-((2S,3R)-3-((S)-2-((2S,3R)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-
carboxamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-
3-methylbutanoate · HCl (185): 
Compound 167 (260 mg, 0.33 mmol) was dissolved under ice bath cooling at 0 °C in 
dichloromethane. To this solution 2.3 ml ice cold HCl saturated ether (7 ml/mmol Boc) was 
added and the mixture was stirred over night at room temperature. The solvent was 
removed under reduced pressure to give the HCl salt of the product as white hygroscopic 
solid in quantitative yield (240 mg, 0.31 mmol). No further purification was necessary. 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.67 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.72 
(d, 3JH,H = 6.9, 3 H, Val-CH3), 0.93 (d, 3JH,H = 7.1, 3 H, Val-CH3), 0.96 (d, 3JH,H = 6.9, 3 H, 
Val-CH3), 1.82 (septet, 3JH,H = 6.4, 1 H, Val-CH), 2.09 (septet, 3JH,H = 6.4, 1 H, Val-CH), 
2.21 (ddd, 3JH,H = 3.2, 3JH,H = 7.5, 2JH,H = 12.8, 1 H, CH2), 2.44-2.59 (m, 1 H, CH2), 2.97 (dt, 
2JH,H = 13.3, 3JH,H = 8.6, 2 H, CH2), 3.67 (s, 3 H, OCH3), 3.83 (d, 3JH,H = 5.8, 1 H, CHNH), 
4.02 (q, 3JH,H = 8.2, 1 H, CHNH), 4.12 (d, 3JH,H = 5.5, 1 H, OCH2), 4.24 (q, 3JH,H = 8.4, 1 H, 
OCH2), 4.36 (dt, 3JH,H = 3.1, 3JH,H = 8.4, 1 H, OCH2), 4.48 (dt, 3JH,H = 2.4, 3JH,H = 8.2, 1 H, 
OCH2), 5.09 (s, 1 H, OCH), 5.13 (s, 1 H, OCH), 7.24 (d, 3JH,H = 8.2, 2 H, Ar-CH), 7.31 (d, 
3JH,H = 8.5, 2 H, Ar-CH), 7.38 (d, 3JH,H = 8.8, 4 H, Ar-CH). – 13C-NMR (75 MHz, MeOH-d4): 
δ = 18.7 (+, 1 C, Val-CH3), 18.9 (+, 1 C, Val-CH3), 19.2 (+, 1 C, Val-CH3), 20.2 (+, 1 C, 
Val-CH3), 32.9 (+, 1 C, Val-CH), 33.1 (+, 1 C, Val-CH), 37.0 (-, 2 C, CH2), 52.9 (+, 1 C, 
OCH3), 59.3 (+, 1 C, CHNH), 60.3 (+, 1 C, CHNH), 67.6 (-, 1 C, OCH2), 68.7 (-, 1 C, 
OCH2), 69.3 (Cquat, 1 C, CNH), 71.6 (Cquat, 1 C, CNH), 85.9 (+, 1 C, OCH), 86.4 (+, 1 C, 
OCH), 123.1 (Cquat, 1 C, CBr), 123.8 (Cquat, 1 C, CBr), 129.6 (+, 2 C, Ar-CH), 129.7 (+, 2 C, 
Ar-CH), 132.3 (+, 2 C, Ar-CH), 132.6 (+, 2 C, Ar-CH), 135.1 (Cquat, 1 C, Ar-C), 138.1 (Cquat, 
1 C, Ar-C), 168.9 (Cquat, 1 C, CO), 171.3 (Cquat, 1 C, CO), 172.8 (Cquat, 1 C, CO), 173.0 
(Cquat, 1 C, CO). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 765.2 (100) 
[MH+]; 799.1 (100) [M + Cl-]. – IR (neat) [cm-1]: ν~  = 3289, 2965, 2872, 2362, 2342, 1749, 
1681, 1646, 1519, 1483, 1157, 1074, 1007, 841. – MF C33H42Br2N4O7*HCl. – MW 802.98. 
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(S)-Methyl 2-((2R,3S)-3-((S)-2-((2R,3S)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-
carboxamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-
3-methylbutanoate · HCl (186): 
Compound 170 (130 mg, 0.15 mmol) was dissolved under ice bath cooling at 0 °C in 
dichloromethane. To this solution 1.1 ml ice cold HCl saturated ether (7 ml/mmol Boc) was 
added and the mixture was stirred over night at room temperature. The solvent was 
removed under reduced pressure to give the HCl salt of the product as white hygroscopic 
solid in quantitative yield (120 mg, 0.15 mmol). No further purification was necessary. 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.70 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.81 
(d, 3JH,H = 6.9, 3 H, Val-CH3), 0.93 (d, 3JH,H = 6.6, 3 H, Val-CH3), 0.97 (d, 3JH,H = 6.6, 3 H, 
Val-CH3), 1.74 (octet, 3JH,H = 6.5, 1 H, Val-CH), 2.13 (q, 3JH,H = 5.8, 1 H, Val-CH), 2.34 (dd, 
3JH,H = 5.8, 2JH,H = 12.9, 1 H, CH2), 2.45-2.61 (m, 1 H, CH2), 2.75-3.04 (m, 2 H, CH2), 3.61 
(s, 3 H, OCH3), 3.81-3.90 (m, 1 H, CHNH), 4.02 (q, 3JH,H = 7.9, 1 H, CHNH), 4.15 (d, 3JH,H 
= 5.5, 1 H, OCH2), 4.22 (q, 3JH,H = 8.0, 1 H, OCH2), 4.39 (t, 3JH,H = 8.4, 1 H, OCH2), 4.49 (t, 
3JH,H = 6.6, 1 H, OCH2), 5.04 (s, 1 H, OCH), 5.12 (s, 1 H, OCH), 7.21 (d, 3JH,H = 8.2, 2 H, 
Ar-CH), 7.30 (d, 3JH,H = 8.2, 2 H, Ar-CH), 7.39 (d, 3JH,H = 3.8, 2 H, Ar-CH), 7.42 (d, 3JH,H = 
3.6, 2 H, Ar-CH). – 13C-NMR (75 MHz, MeOH-d4): δ = 18.6 (+, 1 C, Val-CH3), 19.1 (+, 1 C, 
Val-CH3), 19.2 (+, 1 C, Val-CH3), 20.1 (+, 1 C, Val-CH3), 32.4 (+, 1 C, Val-CH), 33.3 (+, 1 
C, Val-CH), 36.1 (-, 1 C, CH2), 36.8 (-, 1 C, CH2), 52.7 (+, 1 C, OCH3), 59.5 (+, 1 C, 
CHNH), 60.0 (+, 1 C, CHNH), 67.4 (-, 1 C, OCH2), 68.6 (-, 1 C, OCH2), 69.1 (Cquat, 1 C, 
CNH), 71.8 (Cquat, 1 C, CNH), 86.1 (+, 1 C, OCH), 86.3 (+, 1 C, OCH), 123.1 (Cquat, 1 C, 
CBr), 123.9 (Cquat, 1 C, CBr), 129.6 (+, 2 C, Ar-CH), 129.8 (+, 2 C, Ar-CH), 132.2 (+, 2 C, 
Ar-CH), 132.7 (+, 2 C, Ar-CH), 134.9 (Cquat, 1 C, Ar-C), 138.3 (Cquat, 1 C, Ar-C), 168.8 
(Cquat, 1 C, CO), 171.3 (Cquat, 1 C, CO), 172.6 (Cquat, 1 C, CO), 172.8 (Cquat, 1 C, CO). – 
MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 765.1 (100) [MH+]. – IR (neat) [cm-
1]: ν~  = 3401, 2957, 2526, 2361, 2341, 1727, 1672, 1513, 1488, 1436, 1212, 1069, 1005, 
829, 802. – MF C33H42Br2N4O7*HCl. – MW 802.98. 
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(S)-Methyl 2-((2S,3R)-2-(4-bromophenyl)-3-((S)-2-((2S,3R)-2-(4-bromophenyl)-3-((S)-2-
((2S,3R)-2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)3-methylbutanamido)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-
tetrahydrofuran-3-carboxamido)-3-methylbutanoate (169): 
Under an atmosphere of nitrogen compound 181 (73 mg, 0.15 mmol, 1.5 eq.) was 
dissolved in 1.5 ml DMF (10 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (75 µl, 0.44 mmol, 4.4 eq.), HOAt (30 mg, 0.22 mmol, 2.2 eq.) and HATU (80 mg, 
0.22 mmol, 2.2 eq.) were added in this sequence. Then the amine 185 (80 mg, 0.10 
mmol, 1.0 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 2 ml of water and 
0.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x5 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 50:50, Rf = 0.21) to give the 
product as colorless solids with an overall yield of 66 % (82 mg, 0.066 mmol). 
MP 109-110 °C. – 1H-NMR (600 MHz, COSY, ROESY, CDCl3): δ = 0.58 (d, 3JH,H = 7.0, 3 
H, 34), 0.69 (d, 3JH,H = 7.0, 3 H, 44), 0.76 (d, 3JH,H = 7.0, 3 H, 34), 0.84 (d, 3JH,H = 6.8, 3 H, 
54), 0.86 (d, 3JH,H = 7.2, 3 H, 44), 0.87 (d, 3JH,H = 7.0, 3 H, 54), 1.52 (s, 9 H, 1), 1.98 
(dquintet, 3JH,H = 3.5, 3JH,H = 7.0, 1 H, 33), 2.02-2.11 (m, 3 H, 35 + 43 + 53), 2.20 (ddd, 
3JH,H = 5.2, 3JH,H = 8.3, 2JH,H = 13.0,1 H, 25), 2.37 (ddd, 3JH,H = 3.6, 3JH,H = 6.2, 2JH,H = 13.3, 
1 H, 45), 3.17-3.23 (m, 1 H, 45), 3.25 (t, 3JH,H = 4.5, 1 H, 15), 3.32 (t, 3JH,H = 3.6, 1 H, 9), 
3.34 (dt, 2JH,H = 12.6, 3JH,H = 7.6, 1 H, 25), 3.59 (s, 3 H, 24), 3.62 (dt, 2JH,H = 13.2, 3JH,H = 
8.4, 1 H, 35), 3.87-3.94 (m, 2 H, 36 + 46), 4.09 (dd, 3JH,H = 6.8, 3JH,H = 9.0, 1 H, 21), 4.17 
(dd, 3JH,H = 8.4, 2JH,H = 15.6, 1 H, 26), 4.35 (dt, 3JH,H = 3.4, 3JH,H = 8.1, 1 H, 46), 4.39-4.47 
(m, 2 H, 26 + 36), 4.75 (s, 1 H, 28), 5.07 (s, 1 H, 38), 5.19 (s, 1 H, 48), 5.88 (d, 3JH,H = 3.3, 
1 H, 8), 6.20 (s, 1 H, 5), 6.88 (d, 3JH,H = 4.2, 1 H, 14), 7.16 (d, 3JH,H = 8.4, 2 H, 30), 7.27 (d, 
3JH,H = 7.5, 2 H, 51), 7.30-7.38 (m, 7 H, 20 + 40 + 41 + 50), 7.45 (s, 1 H, 17), 7.49 (d, 3JH,H 
= 8.4, 2 H, 31), 7.99 (s, 1 H, 11). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 16.5 
(+, 1 C, 44), 17.0 (+, 1 C, 34), 18.3 (+, 1 C, 54), 18.6 (+, 1 C, 44), 18.9 (+, 1 C, 34), 19.1 
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(+, 1 C, 54), 28.4 (+, 3 C, 1), 29.0 (+, 1 C, 33 + 43), 31.5 (+, 1 C, 53), 36.5 (-, 1 C, 45), 
36.6 (-, 1 C, 25), 38.0 (-, 1 C, 35), 51.5 (+, 1 C, 24), 57.7 (+, 1 C, 21), 60.3 (+, 1 C, 9), 61.7 
(+, 1 C, 15), 67.9 (-, 1 C, 26), 68.5 (-, 1 C, 46), 68.6 (-, 1 C, 36), 70.5 (Cquat, 1 C, 6), 70.9 
(Cquat, 1 C, 12), 71.1 (Cquat, 1 C, 18), 83.0 (Cquat, 1 C, 2), 86.6 (+, 1 C, 38), 68.7 (+, 1 C, 
28), 87.4 (+, 1 C, 48), 121.5 (Cquat, 1 C, 52), 122.5 (Cquat, 1 C, 42), 123.4 (Cquat, 1 C, 32), 
128.0 (+, 2 C, 30), 128.8 (+, 2 C, 40), 129.1 (+, 2 C, 50), 130.4 (+, 2 C, 51), 131.0 (+, 2 C, 
41), 131.8 (+, 2 C, 31), 135.2 (Cquat, 1 C, 29), 136.4 (Cquat, 1 C, 39), 137.4 (Cquat, 1 C, 49), 
156.8 (Cquat, 1 C, 4), 169.4 (Cquat, 1 C, 19), 170.9 (Cquat, 1 C, 13), 170.9 (Cquat, 1 C, 7), 
171.5 (Cquat, 1 C, 22), 171.7 (Cquat, 1 C, 16), 171.9 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH 
+ 10 mM NH4OAc): m/z (%) = 1231.3 (100) [MH+], 1248.5 (5) [MNH4+]. – IR (neat) [cm-1]: 
ν~  = 3253, 3313, 3240, 2962, 2945, 2887, 2361, 2340, 1733, 1658, 1595, 1523, 1454, 
1259, 1116, 1007, 997, 826. – MF C54H69Br3N6O12. – MW 1233.87. 
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(S)-Methyl 2-((2R,3S)-2-(4-bromophenyl)-3-((S)-2-((2R,3S)-2-(4-bromophenyl)-3-((S)-2-
((2R,3S)-2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanamido)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-
tetrahydrofuran-3-carboxamido)-3-methylbutanoate (172): 
Under an atmosphere of nitrogen compound 183 (77 mg, 0.16 mmol, 1.5 eq.) was 
dissolved in 1.6 ml DMF (10 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (80 µl, 0.47 mmol, 4.4 eq.), HOAt (33 mg, 0.23 mmol, 2.2 eq.) and HATU (89 mg, 
0.23 mmol, 2.2 eq.) were added in this sequence. Then the amine 186 (85 mg, 0.11 
mmol, 1.0 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 2 ml of water and 
0.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x5 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 50:50, Rf = 0.29) to give the 
product as colorless solids with an overall yield of 21 % (28 mg, 0.023 mmol). 
MP 241-242 °C. – 1H-NMR (600 MHz, COSY, CDCl3): δ = 0.63 (d, 3JH,H = 6.8, 6 H, 34 + 
54), 0.68 (d, 3JH,H = 7.0, 3 H, 44), 0.70 (d, 3JH,H = 6.8, 3 H, 54), 0.79 (d, 3JH,H = 6.2, 3 H, 
34), 0.86 (d, 3JH,H = 7.0, 3 H, 44), 1.52 (s, 9 H, 1), 1.68 (sextet, 3JH,H = 6.5, 1 H, 53), 1.98-
2.08 (m, 2 H, 33 + 35), 2.10-2.18 (m, 1 H, 43), 2.19-2.33 (m, 2 H, 25 + 45), 3.22 (dt, 2JH,H 
= 13.2, 3JH,H = 8.3, 1 H, 45), 3.27-3.39 (m, 4 H, 9 + 15 + 25 + 35), 3.49-3.53 (m, 1 H, 21), 
3.61 (s, 3 H, 24), 3.83 (dd, 3JH,H = 8.6, 2JH,H = 16.1, 1 H, 36), 3.93 (dd, 3JH,H = 8.3, 2JH,H = 
15.5, 1 H, 46), 4.17 (q, 3JH,H = 7.6, 1 H, 26), 4.32 (dt, 3JH,H = 3.7, 3JH,H = 8.0, 1 H, 46), 4.37 
(dt, 3JH,H = 3.3, 3JH,H = 8.4, 1 H, 36), 4.41 (dt, 3JH,H = 5.0, 3JH,H = 7.9, 1 H, 26), 4.89 (s, 1 H, 
28), 5.09 (s, 1 H, 38), 5.16 (s, 1 H, 48), 7.22 (bs, 2 H, 30), 7.31 (d, 3JH,H = 8.4, 2 H, 40), 
7.32 (d, 3JH,H = 8.6, 2 H, 51), 7.36 (d, 3JH,H = 8.4, 2 H, 21), 7.41 (d, 3JH,H = 8.6, 2 H, 50), 
7.49 (d, 3JH,H = 7.1, 2 H, 31). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 16.3 (+, 1 
C, 44), 17.1 (+, 1 C, 34), 18.4 (+, 1 C, 54), 18.5 (+, 2 C, 44 + 54), 18.9 (+, 1 C, 34), 28.4 
(+, 3 C, 1), 29.0 (+, 1 C, 33), 29.1 (+, 1 C, 43), 29.8 (+, 1 C, 53), 36.4 (-, 1 C, 25), 37.4 (-, 
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1 C, 45), 37.8 (-, 1 C, 35), 51.7 (+, 1 C, 24), 59.3 (+, 1 C, 21), 60.3 (+, 1 C, 15), 61.2 (+, 1 
C, 9), 67.9 (-, 1 C, 26), 68.0 (-, 1 C, 36), 68.3 (-, 1 C, 46), 70.6 (Cquat, 1 C, 6), 70.8 (Cquat, 1 
C, 12), 71.2 (Cquat, 1 C, 18), 82.8 (Cquat, 1 C, 2), 86.5 (+, 2 C, 28 + 38), 87.1 (+, 1 C, 48), 
121.9 (Cquat, 1 C, 52), 122.5 (Cquat, 1 C, 42), 123.2 (Cquat, 1 C, 32), 128.2 (+, 2 C, 30), 
128.8 (+, 2 C, 40), 129.5 (+, 2 C, 50), 130.7 (+, 2 C, 51), 131.0 (+, 2 C, 41), 131.7 (+, 2 C, 
31), 135.6 (Cquat, 1 C,29), 136.3 (Cquat, 1 C, 39), 137.6 (Cquat, 1 C, 49), 157.0 (Cquat, 1 C, 4), 
170.5 (Cquat, 2 C, CO), 170.6 (Cquat, 1 C, 19), 171.2 (Cquat, 1 C, CO), 171.9 (Cquat, 1 C, 22), 
172.3 (Cquat, 1 C, CO). – 1H-NMR (600 MHz, COSY, ROESY, DMSO-d6): δ = 0.56 (d, 3JH,H 
= 6.7, 3 H, 54), 0.60 (d, 3JH,H = 7.0, 3 H, 44), 0.62 (d, 3JH,H = 6.9, 3 H, 54), 0.73 (d, 3JH,H = 
7.2, 3 H, 44), 0.74 (d, 3JH,H = 7.6, 3 H, 34), 0.80 (d, 3JH,H = 7.0, 3 H, 34), 1.48 (s, 9 H, 1), 
1.49-1.56 (m, 1 H, 53), 1.86 (dquintet, 3JH,H = 4.8, 3JH,H = 6.8, 1 H, 43), 1.95 (dquintet, 3JH,H 
= 3.8, 3JH,H = 6.8, 1 H, 43), 2.03-2.16 (m, 3 H, 25 + 35 + 45), 2.86 (ddd, 3JH,H = 8.4, 3JH,H = 
9.7, 2JH,H = 13.3, 1 H, 45), 3.03-3.15 (m, 4 H, 9 + 15 + 25 + 35), 3.23 (t, 3JH,H = 6.4, 1 H, 
21), 3.47 (s, 3 H, 24), 3.63-3.73 (m, 2 H, 36 + 46), 3.99 (quartet, 3JH,H = 8.1, 1 H, 36), 4.19 
(dt, 3JH,H = 2.8, 3JH,H = 8.1, 1 H, 46), 4.26 (dd, 3JH,H = 2.3, 3JH,H = 8.2, 1 H, 36), 4.29 (dt, 
3JH,H = 3.5, 3JH,H = 8.1, 1 H, 26), 4.95 (s, 1 H, 48), 4.96 (s, 1 H, 28), 5.07 (s, 1 H, 38), 7.11 
(s, 1 H, 20), 7.11 (s, 1 H, 14), 7.22 (d, 3JH,H = 8.5, 2 H, 30), 7.28 (d, 3JH,H = 8.4, 2 H, 40 + 
50), 7.40 (d, 3JH,H = 8.5, 2 H, 51), 7.41 (s, 1 H, 17), 7.42 (d, 3JH,H = 8.7, 2 H, 31), 7.46 (d, 
3JH,H = 8.4, 2 H, 41), 7.88 (d, 3JH,H = 2.3, 1 H, 8), 8.22 (s, 1 H, 11), 8.31 (s, 1 H, 5), 7.55 (s, 
1 H, 20), 7.99 (s, 1 H, 11). – 13C-NMR (150 MHz, HSQC, HMBC, DMSO-d6): δ = 16.8 (+, 1 
C, 44), 18.1 (+, 1 C, 44), 18.1 (+, 1 C, 34), 18.52(+, 1 C, 54), 18.5 (+, 1 C, 34), 18.7 (+, 1 
C, 54), 28.1 (+, 3 C, 1), 28.5 (+, 1 C, 33), 28.8 (+, 1 C, 43), 29.4 (+, 1 C, 53), 35.7 (-, 1 C, 
45), 36.0 (-, 1 C, 35), 37.0 (-, 1 C, 25), 51.1 (+, 1 C, 24), 58.7 (+, 1 C, 21), 60.5 (+, 1 C, 
15), 61.2 (+, 1 C, 9), 67.3 (-, 2 C, 26 + 46), 67.4 (-, 1 C, 36), 70.4 (Cquat, 1 C, 18), 70.4 
(Cquat, 1 C, 6), 70.5 (Cquat, 1 C, 12), 80.3 (Cquat, 1 C, 2), 84.4 (+, 1 C, 28), 85.5 (+, 1 C, 38), 
86.2 (+, 1 C, 48), 121.0 (Cquat, 1 C, 52), 121.3 (Cquat, 1 C, 32), 123.5 (Cquat, 1 C, 42), 128.8 
(+, 2 C, 30), 128.9 (+, 2 C, 40), 129.3 (+, 2 C, 50), 130.2 (+, 2 C, 51), 130.5 (+, 2 C, 31), 
130.6 (+, 2 C, 41), 136.8 (Cquat, 1 C, 39), 137.2 (Cquat, 1 C, 29), 137.7 (Cquat, 1 C, 49), 
156.7 (Cquat, 1 C, 4), 169.4 (Cquat, 1 C, 19), 170.3 (Cquat, 1 C, 13), 170.6 (Cquat, 1 C, 16), 
170.7 (Cquat, 1 C, 22), 172.0 (Cquat, 1 C, 7), 172.2 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 
10 mM NH4OAc): m/z (%) = 1231.5 (15) [MH+], 1248.5 (100) [MNH4+]; 1234.6 (55) [M – 
H+], 1294.7 (100) [M + OAc-], 1366.6 (79) [M + TFA- + H2O]. – IR (neat) [cm-1]: ν~  = 3252, 
3313, 3238, 2965, 2941, 2887, 2358, 2340, 1735, 1669, 1595, 1519, 1461, 1259, 1114, 
1007, 992, 826. – MF C54H69Br3N6O12. – MW 1233.87. 
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X-Ray structure and crystal data of 172: 
Prism; space group: P 21; cell dimensions: a = 14.51660(10) Å, α = 90°, b = 28.6529(2) Å, 
β = 104.3050(10)°, c = 15.38410(10) Å, γ = 90°; V = 6200.50(8) Å3; Z = 4, Dx = 1.322 
Mg/m3; µ = 2.902 mm-1; F(000) = 2544. Data collection: T = 123 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.270 x 0.250 x 0.240 
mm was used to measure 52330 reflections (21037 unique reflections, Rint = 0.0293) from 
2.96° to 66.69° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan 
method. Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit 0f 1.059 for all reflections and 1352 parameters. 
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(2R)-Methyl 2-(2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanoate (173/176): 
Under an atmosphere of nitrogen compound rac-138 (1.40 g, 3.62 mmol, 1 eq.) was 
dissolved in 3.6 ml DMF (1 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (1.86 ml, 11.7 mmol, 3 eq.), HOBt (637 mg, 4.71 mmol, 1.3 eq.) and EDC (834 µl, 
4.71 mmol, 1.3 eq.) were added in this sequence. Then H-D-Val-OMe*HCl 187 (729 mg, 
4.35 mmol, 1.2 eq.) was slowly added in portions. The mixture was allowed to warm to 
room temperature and stirred for 24 hours. The reaction was quenched with 5 ml of water 
and 3.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x10 ml). The 
combined organic layers were washed twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (PE:diethyl ether 80:20) to give the 
product as two diasteriomers as colorless solids with an overall yield of 83 % (1.50 g, 3.00 
mmol). 
173: Rf (PE:diethyl ether 70:30) = 0.24 
MP 146 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.42 (d, 3JH,H = 6.9, 3 H, 18), 0.56 (d, 3JH,H = 
6.9, 3 H, 18), 1.41 (s, 9 H, 1), 1.81 (dseptet, 3JH,H = 4.5, 3JH,H = 6.8, 1 H, 17), 2.42-2.63 (m, 
1 H, 7), 2.65-2.89 (m, 1 H, 7), 3.64 (s, 3 H, 16), 4.16 (dd, 3JH,H = 4.4, 3JH,H = 8.5, 1 H, 13), 
4.21-4.37 (m, 2 H, 8), 5.36 (bs, 1 H, 10), 6.11 (bs, 1 H, NH), 6.61 (d, 3JH,H = 4.7, 1 H, NH), 
7.20 (d, 3JH,H = 8.6, 2 H, 20), 7.35 (d, 3JH,H = 8.5, 2 H, 21). – 13C-NMR (75 MHz, CDCl3): δ 
= 17.3 (+, 1 C, 18), 18.3 (+, 1 C, 18), 28.4 (+, 3 C, 1), 31.0 (+, 1 C, 17), 36.1 (-, 1 C, 7), 
52.2 (+, 1 C, 16), 57.3 (+, 1 C, 13), 66.6 (-, 1 C, 8), 67.6 (Cquat, 1 C, 6), 80.2 (Cquat, 1 C, 2), 
80.5 (+, 1 C, 10), 121.6 (Cquat, 1 C, 22), 127.0 (+, 2 C, 20) , 131.3 (+, 2 C, 21), 136.4 (Cquat, 
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1 C, 19), 154.2 (Cquat, 1 C, 4), 171.1 (Cquat, 1 C, 11), 172.0 (Cquat, 1 C, 14). – MS (ES, 
DCM/MeOH + 10 mM NH4OAc): m/z (%) = 498.8 (33) [MH+ - Boc], 442.8 (65) [MH+ - 
C4H8], 498.8 (100) [MH+]; 422.9 (100) [M – H+ - tBuOH], 497.1 (70) [M - H+]. – Elemental 
analysis calcd. (%) for C22H31BrN2O6 (499.4): C 52.95, H 6.28, N 5.59; found: C 52.82, H 
6.25, N 5.46. – IR (neat) [cm-1]: ν~  = 3382, 3271, 2957, 2520, 2361, 1724, 1673, 1528, 
1491, 1436, 1373, 1210, 1147, 1059, 1009, 830, 801. – MF C22H31BrN2O6. – MW 499.4. 
X-Ray structure and crystal data of 173: 
Monoclinic; space group: C 2; cell dimensions: a = 19.0053(5) Å, α = 90°, b = 6.12864(16) 
Å, β = 106.886(3)°, c = 20.6060(7) Å, γ = 90°; V = 2296.64(12) Å3; Z = 4, Dx = 1.444 
Mg/m3; µ = 2.781 mm-1; F(000) = 1040. Data collection: T = 123 K; graphite 
monochromator. A colorless crystal with dimensions of 0.470 x 0.130 x 0.050 mm was 
used to measure 11706 reflections (3796 unique reflections, Rint = 0.0521) from 4.48° to 
66.81° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. 
Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit of 1.034 for all reflections and 286 parameters.  
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176: Rf (PE:diethyl ether = 70:30) = 0.20 
MP 136 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.60-0.79 (m, 6 H, 18), 1.41 (s, 9 H, 1), 
1.76-2.06 (m, 1 H, 17), 2.35-2.57 (m, 1 H, 7), 2.64-2.90 (m, 1 H, 7), 3.56 (s, 3 H, 16), 4.03 
(t, 3JH,H = 6.3, 1 H, 13), 4.25 (dd, 3JH,H = 4.8, 3JH,H = 8.1, 2 H, 8), 5.31 (bs, 1 H, 10), 6.14 (s, 
1 H, NH), 6.61 (d, 3JH,H = 4.7, 1 H, NH), 7.13 (d, 3JH,H = 8.2, 2 H, 20), 7.31 (d, 3JH,H = 8.5, 2 
H, 21). – 13C-NMR (75 MHz, CDCl3): δ = 17.9 (+, 1 C, 18), 18.7 (+, 1 C, 18), 28.4 (+, 3 C, 
1), 31.7 (+, 1 C, 17), 36.1 (-, 1 C, 7), 52.1 (+, 1 C, 16), 57.3 (+, 1 C, 13), 66.5 (-, 1 C, 8), 
67.7 (Cquat, 1 C, 6), 80.2 (Cquat, 1 C, 2), 80.9 (+, 1 C, 10), 121.6 (Cquat, 1 C, 22), 127.3 (+, 2 
C, 20), 131.0 (+, 2 C, 21), 135.6 (Cquat, 1 C, 19), 154.3 (Cquat, 1 C, 4), 171.3 (Cquat, 2 C, 11 
+ 14). – MS (CI, NH3): m/z (%) = 442.8 (37) [MH+ - C4H8], 498.9 (100) [MH+], 516.0 (20) 
[MNH4+]; 422.7 (55) [M – H+ - C4H10O], 497.0 (100) [M – H+]. – Elemental analysis calcd. 
(%) for C22H31BrN2O6 (499.4): C 52.91, H 6.26, N 5.61; found: C 52.86, H 6.21, N 5.41. – 
IR (neat) [cm-1]: ν~  = 3441, 3270, 2956, 2877, 2357, 1742, 1720, 1654, 1507, 1367, 1245, 
1162, 1088, 1016, 988, 798. – MF C22H31BrN2O6. – MW 499.4. 
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X-Ray structure and crystal data of 176: 
Orthorhombic; space group: P 21 21 21; cell dimensions: a = 6.18536(6) Å, α = 90°, b = 
17.91432(12) Å, β = 90°, c = 21.08060(15) Å, γ = 90°; V = 2335.87(3) Å3; Z = 4, Dx = 
1.420 Mg/m3; µ = 2.734 mm-1; F(000) = 1040. Data collection: T = 123 K; graphite 
monochromator. A colorless crystal with dimensions of 0.500 x 0.120 x 0.040 mm was 
used to measure 19627 reflections (4015 unique reflections, Rint = 0.0361) from 3.24° to 
66.69° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. 
Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit of 1.051 for all reflections and 286 parameters. 
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(R)-2-((2R,3S)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanoic acid (188): 
Compound 173 (480 mg, 0.96 mmol) was dissolved in 24 ml of a MeCN:water mixture 
(4:1, 25 ml/mmol). To the solution 1M aqueous LiOH (1.06 ml, 1.06 mmol) was added 
drop by drop. The mixture was stirred over night at room temperature. After acidification 
with 1M aqueous KHSO4 solution the mixture was extracted with DCM (3x10 ml). The 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure to give the product as colorless solid 94 % yield. (440 mg, 0.91 mmol) 
MP 132-133 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.48 (d, 3JH,H = 5.2, 3 H, 16), 0.67 (d, 
3JH,H = 6.0, 3 H, 16), 1.47 (m, 9 H, 1), 1.95 (dquintet, 3JH,H = 4.4, 3JH,H = 6.7,1 H, 15), 2.49-
2.67 (m, 1 H, 7), 2.73-2.88 (m, 1 H, 7), 4.22-4.36 (m, 3 H, 8 + 13), 5.45 (bs, 1 H, 10), 6.21 
(bs, 1 H, NH), 6.50 (d, 3JH,H = 7.9, 1 H, NH), 7.25 (d, 3JH,H = 8.2, 2 H, 18), 7.40 (d, 3JH,H = 
8.5, 2 H, 19). – 13C-NMR (75 MHz, CDCl3): δ = 17.2 (+, 1 C, 16), 18.4 (+, 1 C, 16), 28.4 (+, 
3 C, 1), 30.7 (- , 1 C, 15), 36.0 (-, 1 C, 7), 57.1 (+, 1 C, 13), 66.5 (-, 1 C, 8), 67.5 (Cquat, 1 
C, 6), 80.1 (+, 1 C, 10), 80.3 (Cquat, 1 C, 2), 121.6 (Cquat, 1 C, 20), 127.0 (+, 2 C, 18), 131.4 
(+, 2 C, 19), 136.4 (Cquat, 1 C, 17), 154.3 (Cquat, 1 C, 4), 171.4 (Cquat, 1 C, 11), 176.4 (Cquat, 
1 C, 14). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 484.9 (100) [MH+], 
502.0 (38) [MNH4+]; 483.0 (100) [M – H+], 543 (18) [M + OAc-], 969.9 (56) [2M – H+]. – IR 
(neat) [cm-1]: ν~  = 3394, 2960, 2362, 2341, 1723, 1672, 1509, 1437, 1213, 1145, 1070, 
1010, 830, 703. – MF C21H29BrN2O6. – MW 485.37. 
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(R)-2-((2S,3R)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanoic acid (190): 
Compound 176 (490 mg, 0.98 mmol) was dissolved in 25 ml of a MeCN:water mixture 
(4:1, 25 ml/mmol). To the solution 1M aqueous LiOH (1.08 ml, 1.08 mmol) was added 
drop by drop. The mixture was stirred over night at room temperature. After acidification 
with 1M aqueous KHSO4 solution the mixture was extracted with DCM (3x10 ml). The 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure to give the product as colorless solid 93 % yield. (440 mg, 0.91 mmol) 
MP 118-120 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.44 (d, 3JH,H = 5.2, 3 H, 16), 0.62 (d, 
3JH,H = 5.8, 3 H, 18), 1.42 (m, 9 H), 1.78-1.95 (m, 1 H, 15), 2.41-2.65 (m, 1 H, 7), 2.67-2.86 
(m, 1 H, 7), 4.13-4.39 (m, 3 H, 8 + 13), 5.39 (bs, 1 H, 10), 6.17 (bs, 1 H, NH), 6.47 (d, 3JH,H 
= 7.7, 1 H, NH), 7.20 (d, 3JH,H = 8.2, 2 H, 18), 7.35 (d, 3JH,H = 8.8, 2 H, 19). – 13C-NMR (75 
MHz, CDCl3): δ = 17.8 (+, 1 C, 16), 18.8 (+, 1 C, 16), 28.4 (+, 3 C, 1), 31.4 (- , 1 C, 15), 
36.2 (-, 1 C, 7), 57.2 (+, 1 C, 13), 66.5 (-, 1 C, 8), 67.8 (Cquat, 1 C, 6), 80.5 (+, 1 C, 10), 
81.2 (Cquat, 1 C, 2), 121.8 (Cquat, 1 C, 20), 127.4 (+, 2 C, 18), 131.2 (+, 2 C, 19), 135.4 
(Cquat, 1 C, 17), 154.5 (Cquat, 1 C, 4), 171.4 (Cquat, 1 C, 11), 175.7 (Cquat, 1 C, 14). – MS 
(ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 483.1 (100) [M - H+]; 967.4 (51) [2M - 
H+]. – IR (neat) [cm-1]: ν~  = 3394, 2960, 2362, 2341, 1723, 1672, 1509, 1437, 1213, 1145, 
1070, 1010, 830, 703. – MF C21H29BrN2O6. – MW 485.37. 
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(R)-Methyl 2-((2R,3S)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-3-
methyl-butanoate (189): 
Compound 173 (400 mg, 0.80 mmol) was dissolved under ice bath cooling at 0 °C in 
ether. To this solution 5.6 ml ice cold HCl saturated ether (7 ml/mmol Boc) was added and 
the mixture was stirred over night at room temperature. The solvent was removed under 
reduced pressure to give the HCl salt of the product as white hygroscopic solid in 
quantitative yield (345 mg, 0.80 mmol). No further purification was necessary. 
MP >180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.62 (d, 3JH,H = 6.9, 3 H, 14), 0.65 (d, 
3JH,H = 6.9, 3 H, 14), 1.78 (sextet, 3JH,H = 6.7, 1 H, 13), 2.39 (ddd, 3JH,H = 2.5, 3JH,H = 7.1, 
2JH,H = 14.3, 1 H, 3), 3.00 (dt, 2JH,H = 14.4, 3JH,H = 9.2, 1 H, 1 H, 3), 3.67 (s, 3 H, 12), 3.84 
(d, 3JH,H = 6.3, 1 H, 9), 4.21 (dt, 3JH,H = 7.1, 3JH,H = 9.3, 1 H, 4), 4.53 (dt, 3JH,H = 2.5, 3JH,H = 
9.1, 1 H, 4), 5.00 (s, 1 H, 6), 7.33 (d, 3JH,H = 8.2, 2 H, 16), 7.52 (d, 3JH,H = 8.5, 2 H, 17). – 
13C-NMR (75 MHz, MeOH-d4): δ = 21.6 (+, 1 C, 14), 21.9 (+, 1 C, 14), 33.6 (+, 1 C, 13), 
38.5 (-, 1 C, 3), 55.1 (+, 1 C, 12), 63.1 (+, 1 C, 9), 70.3 (-, 1 C, 4), 72.4 (Cquat, 1 C, 2), 89.3 
(+, 1 C, 10), 126.3 (Cquat, 1 C, 18), 131.7 (+, 2 C, 16), 135.3 (+, 2 C, 17), 138.7 (Cquat, 1 C, 
15), 171.7 (Cquat, 1 C, 7), 175.7 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 10 mmol/l 
NH4OAc): m/z (%) = 398.9 (100) [MH+], 799.2 (34) [2m + H+]; 397 (100) [M – H+], 456.9 
(24) [M + OAc-]. – IR (neat) [cm-1]: ν~  = 3399, 2957, 2526, 2362, 2341, 1723, 1672, 1509, 
1488, 1437, 1212, 1069, 1009, 829, 803. – MF C17H23BrN2O4*HCl. – MW 435.74. 
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(R)-Methyl 2-((2S,3R)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-3-
methyl-butanoate (191): 
Compound 176 (350 mg, 0.70 mmol) was dissolved under ice bath cooling at 0 °C in 
ether. To this solution 4.9 ml ice cold HCl saturated ether (7 ml/mmol Boc) was added and 
the mixture was stirred over night at room temperature. The solvent was removed under 
reduced pressure to give the HCl salt of the product as white hygroscopic solid in 
quantitative yield (304 mg, 0.76 mmol). No further purification was necessary. 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.85 (t, 3JH,H = 6.6, 6 H, 14), 2.02 
(sextet, 3JH,H = 7.0, 1 H, 13), 2.41 (ddd, 3JH,H = 2.6, 3JH,H = 7.5, 2JH,H = 14.4, 1 H, 3), 2.92 
(dt, 2JH,H = 14.4, 3JH,H = 9.1, 1 H, 3), 3.67 (s, 3 H, 12), 4.04 (d, 3JH,H = 7.1, 1 H, 9), 4.19 (dt, 
3JH,H = 7.6, 3JH,H = 9.2, 1 H, 4), 4.53 (dt, 3JH,H = 2.7, 3JH,H = 9.0, 1 H, 4), 4.99 (s, 1 H, 6), 
7.28 (d, 3JH,H = 8.5, 2 H, 16), 7.46 (d, 3JH,H = 8.5, 2 H, 17). – 13C-NMR (75 MHz, MeOH-d4): 
δ = 18.9 (+, 1 C, 14), 19.3 (+, 1 C, 14), 32.6 (+, 1 C, 13), 36.1 (-, 1 C, 3), 52.7 (+, 1 C, 12), 
59.5 (+, 1 C, 9), 67.8 (-, 1 C, 4), 69.8 (Cquat, 1 C, 2), 87.0 (+, 1 C, 10), 123.7 (Cquat, 1 C, 
18), 129.4 (+, 2 C, 16), 132.5 (+, 2 C, 17), 135.3 (Cquat, 1 C, 15), 168.8 (Cquat, 1 C, 7), 
172.3 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 398.9 
(100) [MH+]; 387.0 (100) [M – H+], 433.0 (17) [M + Cl-], 457 (15) [M + OAc-]. – IR (neat) 
[cm-1]: ν~  = 3288, 2965, 2874, 2362, 2341, 1749, 1684, 1646, 1519, 1488, 1157, 1074, 
1010, 841. – MF C17H23BrN2O4*HCl. – MW 435.74. 
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(R)-Methyl 2-((2r,3S)-2-(4-bromophenyl)-3-((R)-2-((2R,3S)-2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-tetrahydro-
furan-3-carbox-amido)-3-methylbutanoate (174): 
Under an atmosphere of nitrogen compound 188 (220 mg, 0.45 mmol, 1 eq.) was 
dissolved in 3.6 ml DMF (8 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (233 µl, 1.36 mmol, 3 eq.), HOAt (93 mg, 0.68 mmol, 1.5 eq.) and HATU (259 mg, 
0.68 mmol, 1.5 eq.) were added in this sequence. Then the amine 189 (178 mg, 0.41 
mmol, 0.9 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 3 ml of water and 
1.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x10 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 60:40, Rf = 0.14) to give the 
product as colorless solids with an overall yield of 55 % (196 mg, 0.23 mmol). 
MP 163-164 °C. – 1H-NMR (600 MHz, COSY, CDCl3): δ = 0.65 (d, 3JH,H = 6.0, 6 H, 28 + 
38), 0.74 (d, 3JH,H = 6.6, 3 H, 38), 0.80 (d, 3JH,H = 6.8, 3 H, 28), 1.47 (s, 9 H, 1), 1.91-1.99 
(m, 1 H, 37), 2.00 (sextet, 3JH,H = 6.2, 1 H, 27), 2.43-2.60 (m, 2 H, 19 + 29), 2.82-2.91 (m, 
1 H, 29), 3.16 (bs, 1 H, 19), 3.57-70 (m, 4 H, 9 + 18), 3.96-4.05 (m, 1 H, 30), 4.16 (dd, 
3JH,H = 5.6, 3JH,H = 8.9, 1 H, 15), 4.22 (quartet, 3JH,H = 7.6, 1 H, 20), 4.33 (dt, 3JH,H = 2.9, 
3JH,H = 8.5, 1 H, 30), 4.43 (dt, 3JH,H = 5.2, 3JH,H = 8.5, 1 H, 20), 5.00 (s, 1 H, 22), 5.21 (s, 1 
H, 32), 5.87 (s, 1H 5), 6.29 (s, 1H, 8), 6.88 (d, 3JH,H = 7.3, 1 H,14), 7.14 (d, 3JH,H = 8.4, 2 H, 
24), 7.17 (d, 3JH,H = 8.4, 2 H, 34), 7.29 (d, 3JH,H = 7.7, 2 H, 25), 7.35 (d, 3JH,H = 8.4, 2 H, 
35), 7.49 (s, 1 H, 11). – 13C-NMR (150 MHz, CDCl3): δ = 17.3 (+, 1 C, 28), 17.7 (+, 1 C, 
38), 18.7 (+, 1 C, 38), 19.0 (+, 1 C, 28), 28.4 (+, 3 C, 1), 29.9 (+, 1 C, 27), 31.2 (+, 1 C, 
37), 35.4 (-, 1 C, 29), 35.9 (-, 1 C, 19), 51.8 (+, 1 C, 18), 57.5 (+, 1 C, 15), 59.7 (+, 1 C, 9), 
67.4 (-, 1 C, 30), 67.6 (-, 1 C, 20), 69.1 (Cquat, 1 C, 6), 69.7 (Cquat, 1 C, 12), 81.8 (Cquat, 1 C, 
2), 83.9 (+, 1 C, 32), 84.4 (+, 1 C, 22), 121.7 (Cquat, 1 C, 36), 122.6 (Cquat, 1 C, 26), 127.7 
(+, 2 C, 24), 129.0 (+, 2 C, 34), 131.0 (+, 2 C, 35), 131.4 (+, 2 C, 25), 135.1 (Cquat, 1 C, 
23), 136.6 (Cquat, 1 C, 33), 155.5 (Cquat, 1 C, 4), 169.7 (Cquat, 1 C, 13), 169.9 (Cquat, 1 C, 
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10), 171.1 (Cquat, 1 C, 7), 171.9 (Cquat, 1 C, 16). – MS (ES, DCM/MeOH + 10 mM 
NH4OAc): m/z (%) = 867.2 (100) [MH+], 884.3 (74) [MNH4+]; 865.3 (100) [M – H+], 925.3 
(25) [M + OAc-]. – HR-MS (PI-LSIMS, DCM/NBA): [MH+] calcd. for C38H51Br2N4O9 
865.2036; found 865.2022. – IR (neat) [cm-1]: ν~  = 3254, 3313, 3240, 2964, 2941, 2886, 
2359, 2341, 1735, 1668, 1597, 1519, 1462, 1259, 1118, 1008, 995, 828. – MF 
C38H50Br2N4O9. – MW 866.63. 
(R)-Methyl 2-((2S,3R)-2-(4-bromophenyl)-3-((R)-2-((2S,3R)-2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-tetrahydro-
furan-3-carbox-amido)-3-methylbutanoate (177): 
Under an atmosphere of nitrogen compound 190 (230 mg, 0.47 mmol, 1 eq.) was 
dissolved in 3.8 ml DMF (8 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (243 µl, 1.42 mmol, 3 eq.), HOAt (97 mg, 0.71 mmol, 1.5 eq.) and HATU (270 mg, 
0.71 mmol, 1.5 eq.) were added in this sequence. Then the amine 191 (186 mg, 0.43 
mmol, 0.9 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 3 ml of water and 
1.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x10 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 50:50, Rf = 0.13) to give the 
product as colorless solids with an overall yield of 58 % (217 mg, 0.25 mmol). 
MP 147-148 °C. – 1H-NMR (600 MHz, MeOH-d4): δ = 0.64 (d, 3JH,H = 7.0, 3 H, 28), 0.66 
(d, 3JH,H = 7.0, 3 H, 38), 0.73 (d, 3JH,H = 6.8, 3 H, 38), 0.81 (d, 3JH,H = 7.0, 3 H, 28), 1.51 (s, 
9 H, 1), 1.64 (sextet, 3JH,H = 6.8, 1 H, 37), 1.91-1.98 (m, 1 H, 27), 2.16-2.23 (m, 2 H, 19 + 
29), 3.10 (ddd, 3JH,H = 8.5, 3JH,H = 10.3, 2JH,H = 13.4, 29), 3.24-3.34 (m, 2 H, 9 + 19), 3.41 
(t, 3JH,H = 6.7, 1 H, 15), 3.59 (s, 3 H, 18), 3.69-3.78 (m, 1 H, 30), 4.09 (q, 3JH,H = 8.1, 1 H, 
20), 4.26 (dt, 3JH,H = 2.4, 3JH,H = 8.4, 1 H, 30), 4.34 (dt, 3JH,H = 4.6, 3JH,H = 8.4, 1 H, 20), 
4.89 (s, 1 H, 22), 5.14 (s, 1 H, 32), 6.66 (d, 3JH,H = 3.7, 1 H, NH), 7.26 (d, 3JH,H = 8.4, 2 H, 
24), 7.37 (d, 3JH,H = 8.6, 2 H, 34), 7.39 (d, 3JH,H = 8.8, 2 H, 35), 7.47 (d, 3JH,H = 8.4, 2 H, 
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25). – 13C-NMR (150 MHz, MeOH-d4): δ = 17.9 (+, 1 C, 28), 19.0 (+, 1 C, 38), 19.2 (+, 1 C, 
28), 19.7 (+, 1 C, 38), 28.7 (+, 3 C, 1), 30.5 (+, 1 C, 27), 31.2 (+, 1 C, 37), 37.8 (-, 1 C, 
29), 38.0 (-, 1 C, 19), 52.0 (+, 1 C, 18), 61.0 (+, 1 C, 15), 61.9 (+, 1 C, 9), 68.8 (-, 2 C, 20 
+ 30), 72.0 (Cquat, 1 C, 6), 72.5 (Cquat, 1 C, 12), 82.6 (Cquat, 1 C, 2), 86.9 (+, 1 C, 22), 88.3 
(+, 1 C, 32), 123.2 (Cquat, 1 C, 36), 123.7 (Cquat, 1 C, 26), 129.8 (+, 2 C, 24), 130.5 (+, 2 C, 
34), 131.9 (+, 2 C, 35), 132.4 (+, 2 C, 25), 137.9 (Cquat, 1 C, 23), 138.4 (Cquat, 1 C, 33), 
158.8 (Cquat, 1 C, 4), 172.1 (Cquat, 1 C, 13), 172.7 (Cquat, 1 C, 10), 172.8 (Cquat, 1 C, 16), 
173.3 (Cquat, 1 C, 7). – MS (ES, DCM/MeOH + 10 mM NH4OAc): m/z (%) = 867.2 (100) 
[MH+], 884.2 (21) [MNH4+]; 865.3 (100) [M – H+]. – HR-MS (PI-LSIMS, DCM/NBA): [MH+] 
calcd. for C38H51Br2N4O9 865.2036; found 865.2039. – IR (neat) [cm-1]: ν~  = 3252, 3313, 
3240, 2965, 2941, 2887, 2359, 2340, 1735, 1668, 1595, 1519, 1460, 1259, 1114, 1007, 
995, 826. – MF C38H50Br2N4O9. – MW 866.63. 
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X-Ray structure and crystal data of 177: 
Prism; space group: P 21 21 21; cell dimensions: a = 10.19490(10) Å, α = 90°, b = 
16.36340(10) Å, β = 90°, c = 50.9856(4) Å, γ = 90°; V = 8505.58(12) Å3; Z = 4, Dx = 1.389 
Mg/m3; µ = 2.889 mm-1; F(000) = 3684. Data collection: T = 123 K; graphite 
monochromator. A colorless crystal with dimensions of 0.230 x 0.110 x 0.080 mm was 
used to measure 58646 reflections (14747 unique reflections, Rint = 0.0299) from 2.84° to 
66.63° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. 
Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit 0f 1.034 for all reflections and 1006 parameters.  
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(R)-Methyl 2-((2R,3S)-3-((R)-2-((2R,3S)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-
carboxamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-
3-methylbutanoate · HCl (192): 
Compound 174 (190 mg, 0.22 mmol) was dissolved under ice bath cooling at 0 °C in 
dichloromethane. To this solution 1.5 ml ice cold HCl saturated ether (7 ml/mmol Boc) was 
added and the mixture was stirred over night at room temperature. The solvent was 
removed under reduced pressure to give the HCl salt of the product as white hygroscopic 
solid in quantitative yield (176 mg, 0.22 mmol). No further purification was necessary. 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.66 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.71 
(d, 3JH,H = 6.9, 3 H, Val-CH3), 0.94 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.97 (d, 3JH,H = 6.9, 3 H, 
Val-CH3), 1.81 (sextet, 3JH,H = 6.6, 1 H, Val-CH), 2.09 (sextet, 3JH,H = 6.5, 1 H, Val-CH), 
2.22 (ddd, 3JH,H = 3.4, 3JH,H = 7.6, 2JH,H = 12.8, 1 H, CH2), 2.48 (ddd, 3JH,H = 3.5, 3JH,H = 8.2, 
2JH,H = 14.0, 1 H, CH2), 2.86-3.03 (m, 2 H, CH2), 3.67 (s, 3 H, OCH3), 3.79-3.86 (m, 1 H, 
CHNH), 4.04 (q, 3JH,H = 8.3, 1 H, CHNH), 4.18 (d, 3JH,H = 5.8, 1 H, OCH2), 4.21-4.28 (m, 1 
H, OCH2), 4.38 (dt, 3JH,H = 3.2, 3JH,H = 8.6, 1 H, OCH2), 4.50 (dt, 3JH,H = 3.4, 3JH,H = 9.1, 1 
H, OCH2), 5.02 (s, 1 H, OCH), 5.09 (s, 1 H, OCH), 6.61 (d, 3JH,H = 8.0, 1 H, NH), 7.22 (d, 
3JH,H = 8.5, 2 H, Ar-CH), 7.30 (d, 3JH,H = 8.5, 2 H, Ar-CH), 7.38 (d, 3JH,H = 6.0, 2 H, Ar-CH), 
7.40 (d, 3JH,H = 6.0, 2 H, Ar-CH). – 13C-NMR (75 MHz, MeOH-d4): δ = 18.7 (+, 1 C, Val-
CH3), 18.8 (+, 1 C, Val-CH3), 19.1 (+, 1 C, Val-CH3), 20.1 (+, 1 C, Val-CH3), 32.9 (+, 1 C, 
Val-CH), 33.2 (+, 1 C, Val-CH), 36.8 (-, 2 C, CH2), 52.8 (+, 1 C, OCH3), 59.3 (+, 1 C, 
CHNH), 60.0 (+, 1 C, CHNH), 67.4 (-, 1 C, OCH2), 68.7 (-, 1 C, OCH2), 69.1 (Cquat, 1 C, 
CNH), 71.5 (Cquat, 1 C, CNH), 85.8 (+, 1 C, OCH), 86.4 (+, 1 C, OCH), 123.1 (Cquat, 1 C, 
CBr), 123.8 (Cquat, 1 C, CBr), 129.4 (+, 2 C, Ar-CH), 129.6 (+, 2 C, Ar-CH), 132.3 (+, 2 C, 
Ar-CH), 132.5 (+, 2 C, Ar-CH), 134.9 (Cquat, 1 C, Ar-C), 138.0 (Cquat, 1 C, Ar-C), 168.9 
(Cquat, 1 C, CO), 171.2 (Cquat, 1 C, CO), 172.9 (Cquat, 2 C, CO). – MS (ES, DCM/MeOH + 
10 mmol/l NH4OAc): m/z (%) = 765.1 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3290, 2964, 
2872, 2362, 2341, 1749, 1679, 1646, 1519, 1483, 1155, 1077, 1014, 841. – MF 
C33H42Br2N4O7*HCl. – MW 802:98. 
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(R)-Methyl 2-((2S,3R)-3-((R)-2-((2S,3R)-3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-
carboxamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetrahydrofuran-3-carboxamido)-
3-methylbutanoate · HCl (193): 
Compound 177 (140 mg, 0.16 mmol) was dissolved under ice bath cooling at 0 °C in 
dichloromethane. To this solution 1.1 ml ice cold HCl saturated ether (7 ml/mmol Boc) was 
added and the mixture was stirred over night at room temperature. The solvent was 
removed under reduced pressure to give the HCl salt of the product as white hygroscopic 
solid in quantitative yield (129 mg, 0.16 mmol). No further purification was necessary. 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.70 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.81 
(d, 3JH,H = 6.9, 3 H, Val-CH3), 0.94 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.97 (d, 3JH,H = 6.9, 3 H, 
Val-CH3), 1.74 (septet, 3JH,H = 6.7, 1 H, Val-CH), 2.13 (septet, 3JH,H = 6.4, 1 H, Val-CH), 
2.32-2.45 (m, 1 H, CH2), 2.52 (ddd, 3JH,H = 3.7, 3JH,H = 8.4, 2JH,H = 14.1, 1 H, CH2), 2.76-
3.01 (m, 2 H, CH2), 3.62 (s, 3 H, OCH3), 3.80-3.89 (m, 1 H, CHNH), 4.02 (q, 3JH,H = 7.9, 1 
H, CHNH), 4.16 (d, 3JH,H = 5.8, 1 H, OCH2), 4.23 (q, 3JH,H = 8.8, 1 H, OCH2), 4.40 (t, 3JH,H = 
7.8, 1 H, OCH2), 4.49 (dt, 3JH,H = 3.4, 3JH,H = 9.1, 1 H, OCH2), 5.06 (s, 1 H, OCH), 5.14 (s, 
1 H, OCH), 7.22 (d, 3JH,H = 8.2, 2 H, Ar-CH), 7.30 (d, 3JH,H = 8.5, 2 H, Ar-CH), 7.39 (d, 3JH,H 
= 8.5, 2 H, Ar-CH), 7.41 (d, 3JH,H = 8.2, 2 H, Ar-CH). – 13C-NMR (75 MHz, MeOH-d4): δ = 
18.6 (+, 1 C, Val-CH3), 19.1 (+, 1 C, Val-CH3), 19.2 (+, 1 C, Val-CH3), 20.1 (+, 1 C, Val-
CH3), 32.4 (+, 1 C, Val-CH), 33.3 (+, 1 C, Val-CH), 36.1 (-, 1 C, CH2), 36.7 (-, 1 C, CH2), 
52.6 (+, 1 C, OCH3), 59.5 (+, 1 C, CHNH), 60.0 (+, 1 C, CHNH), 67.4 (-, 1 C, OCH2), 68.5 
(-, 1 C, OCH2), 69.2 (Cquat, 1 C, CNH), 71.9 (Cquat, 1 C, CNH), 86.1 (+, 1 C, OCH), 86.3 (+, 
1 C, OCH), 123.1 (Cquat, 1 C, CBr), 123.9 (Cquat, 1 C, CBr), 129.6 (+, 2 C, Ar-CH), 129.9 (+, 
2 C, Ar-CH), 132.2 (+, 2 C, Ar-CH), 132.7 (+, 2 C, Ar-CH), 134.9 (Cquat, 1 C, Ar-C), 138.3 
(Cquat, 1 C, Ar-C), 168.8 (Cquat, 1 C, CO), 171.2 (Cquat, 1 C, CO), 172.7 (Cquat, 1 C, CO), 
172.8 (Cquat, 1 C, CO). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 765.0 
(100) [MH+], 787.0 (21) [MNa+]. – IR (neat) [cm-1]: ν~  = 3398, 2956, 2526, 2361, 2343, 
1728, 1672, 1510, 1489, 1436, 1212, 1072, 1006, 829, 801. – MF C33H42Br2N4O7*HCl. – 
MW 802.98. 
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(R)-Methyl 2-((2R,3S)-2-(4-bromophenyl)-3-((R)-2-((2R,3S)-2-(4-bromophenyl)-3-((R)-2-
((2R,3S)-2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carboxamido) 
-3-methylbutanamido)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-tetrahydro-
furan-3-carboxamido)-3-methylbutanoate (175): 
Under an atmosphere of nitrogen compound 188 (149 mg, 0.31 mmol, 1.4 eq.) was 
dissolved in 3.1 ml DMF (10 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (166 µl, 0.97 mmol, 4.4 eq.), HOAt (66 mg, 0.48 mmol, 2.2 eq.) and HATU (184 
mg, 0.48 mmol, 2.2 eq.) were added in this sequence. Then the amine 192 (177 mg, 0.22 
mmol, 1.0 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 2 ml of water and 
0.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x5 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 50:50, Rf = 0.21) to give the 
product as colorless solids with an overall yield of 35 % (96 mg, 0.078 mmol). 
MP 100-112 °C. – 1H-NMR (600 MHz, COSY, ROESY, CDCl3): δ = 0.58 (d, 3JH,H = 7.0, 3 
H, 34), 0.68 (d, 3JH,H = 7.0, 3 H, 44), 0.76 (d, 3JH,H = 7.0, 3 H, 34), 0.84 (d, 3JH,H = 7.2, 3 H, 
54), 0.85 (d, 3JH,H = 7.7, 3 H, 44), 0.86 (d, 3JH,H = 7.0, 3 H, 54), 1.52 (s, 9 H, 1), 1.98 
(dquintet, 3JH,H = 3.8, 3JH,H = 6.9, 1 H, 33), 2.02-2.11 (m, 3 H, 35 + 43 + 53), 2.20 (ddd, 
3JH,H = 5.3, 3JH,H = 8.4, 2JH,H = 13.0,1 H, 25), 2.36 (ddd, 3JH,H = 3.5, 3JH,H = 6.2, 2JH,H = 13.3, 
1 H, 45), 3.13-3.23 (m, 1 H, 45), 3.25 (t, 3JH,H = 4.5, 1 H, 15), 3.32 (t, 3JH,H = 3.4, 1 H, 9), 
3.34 (dt, 2JH,H = 12.5, 3JH,H = 7.6, 1 H, 25), 3.59 (s, 3 H, 24), 3.62 (dt, 2JH,H = 13.1, 3JH,H = 
8.4, 1 H, 35), 3.87-3.96 (m, 2 H, 36 + 46), 4.06-4.14 (m, 1 H, 21), 4.16 (dd, 3JH,H = 8.4, 
2JH,H = 15.6, 1 H, 26), 4.35 (dt, 3JH,H = 3.4, 3JH,H = 8.0, 1 H, 46), 4.39-4.47 (m, 2 H, 26 + 
36), 4.76 (s, 1 H, 28), 5.07 (s, 1 H, 38), 5.18 (s, 1 H, 48), 5.89 (d, 3JH,H = 3.5, 1 H, 8), 6.22 
(s, 1 H, 5), 6.88 (d, 3JH,H = 4.2, 1 H, 14), 7.16 (d, 3JH,H = 8.4, 2 H, 30), 7.27 (d, 3JH,H = 7.5, 2 
H, 51), 7.30-7.36 (m, 7 H, 20 + 40 + 41 + 50), 7.45 (s, 1 H, 17), 7.49 (d, 3JH,H = 8.6, 2 H, 
31), 7.99 (s, 1 H, 11). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 16.5 (+, 1 C, 44), 
17.0 (+, 1 C, 34), 18.3 (+, 1 C, 54), 18.6 (+, 1 C, 44), 18.9 (+, 1 C, 34), 19.1 (+, 1 C, 54), 
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28.4 (+, 3 C, 1), 29.0 (+, 1 C, 33 + 43), 31.5 (+, 1 C, 53), 36.5 (-, 1 C, 45), 36.5 (-, 1 C, 
25), 38.0 (-, 1 C, 35), 51.5 (+, 1 C, 24), 57.7 (+, 1 C, 21), 60.3 (+, 1 C, 9), 61.7 (+, 1 C, 
15), 67.9 (-, 1 C, 26), 68.5 (-, 1 C, 46), 68.6 (-, 1 C, 36), 70.5 (Cquat, 1 C, 6), 70.9 (Cquat, 1 
C, 12), 71.1 (Cquat, 1 C, 18), 83.0 (Cquat, 1 C, 2), 86.6 (+, 1 C, 38), 68.7 (+, 1 C, 28), 87.4 
(+, 1 C, 48), 121.5 (Cquat, 1 C, 52), 122.5 (Cquat, 1 C, 42), 123.4 (Cquat, 1 C, 32), 128.0 (+, 2 
C, 30), 128.8 (+, 2 C, 40), 129.1 (+, 2 C, 50), 130.4 (+, 2 C, 51), 131.0 (+, 2 C, 41), 131.8 
(+, 2 C, 31), 135.3 (Cquat, 1 C, 29), 136.4 (Cquat, 1 C, 39), 137.4 (Cquat, 1 C, 49), 156.8 
(Cquat, 1 C, 4), 169.4 (Cquat, 1 C, 19), 170.9 (Cquat, 1 C, 13), 170.9 (Cquat, 1 C, 7), 171.5 
(Cquat, 1 C, 22), 171.7 (Cquat, 1 C, 16), 171.9 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 10 
mM NH4OAc): m/z (%) = 1231.7 (100) [MH+], 1248.7 (34) [MNH4+]; 1155.4 (100) [M – H+ - 
tBuOH], 1229.6 (89) [M – H+]. – IR (neat) [cm-1]: ν~  = 3252, 3312, 3240, 2967, 2941, 2887, 
2359, 2332, 1735, 1657, 1595, 1519, 1462, 1259, 1121, 1007, 989, 826. – MF 
C54H69Br3N6O12. – MW 1233.87. 
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(R)-Methyl 2-((2S,3R)-2-(4-bromophenyl)-3-((R)-2-((2S,3R)-2-(4-bromophenyl)-3-((R)-2-
((2S,3R)-2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carboxamido) 
-3-methylbutanamido)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-tetrahydro-
furan-3-carboxamido)-3-methylbutanoate (178): 
Under an atmosphere of nitrogen compound 190 (116 mg, 0.24 mmol, 1.4 eq.) was 
dissolved in 2.4 ml DMF (10 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (128 µl, 0.75 mmol, 4.4 eq.), HOAt (51 mg, 0.37 mmol, 2.2 eq.) and HATU (124 
mg, 0.37 mmol, 2.2 eq.) were added in this sequence. Then the amine 193 (137 mg, 0.17 
mmol, 1.0 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 2 ml of water and 
0.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x5 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:diethyl ether 50:50, Rf = 0.29) to give the 
product as colorless solids with an overall yield of 23 % (49 mg, 0.04 mmol). 
MP 248-249 °C. – 1H-NMR (600 MHz, COSY, ROESY, CDCl3): δ = 0.59 (d, 3JH,H = 7.0, 3 
H, 34), 0.62 (d, 3JH,H = 7.0, 3 H, 54), 0.67 (d, 3JH,H = 7.0, 3 H, 44), 0.70 (d, 3JH,H = 6.8, 3 H, 
54), 0.77 (d, 3JH,H = 7.0, 3 H, 34), 0.87 (d, 3JH,H = 7.0, 3 H, 44), 1.51 (s, 9 H, 1), 1.65 
(sextet, 3JH,H = 6.5, 1 H, 53), 1.97-2.06 (m, 2 H, 33 + 35), 2.09-2.16 (m, 1 H, 43), 2.21 
(ddd, 3JH,H = 5.2, 3JH,H = 8.0, 2JH,H = 12.9, 1 H, 25), 2.32 (ddd, 3JH,H = 3.6, 3JH,H = 6.1, 2JH,H 
= 13.3, 1 H, 45), 3.23 (dt, 2JH,H = 13.5, 3JH,H = 8.6, 1 H, 45), 3.31-3.38 (m, 4 H, 9 + 15 + 25 
+ 35), 3.54 (t, 3JH,H = 6.2, 1 H, 21), 3.61 (s, 3 H, 24), 3.83 (quartett, 3JH,H = 8.1, 1 H, 36), 
3.93 (dt, 3JH,H = 7.0, 3JH,H = 8.6, 1 H, 46), 4.17 (q, 3JH,H = 7.6, 1 H, 26), 4.33 (dt, 3JH,H = 3.4, 
3JH,H = 8.0, 1 H, 46), 4.37 (dt, 3JH,H = 3.5, 3JH,H = 8.4, 1 H, 26), 4.41 (dt, 3JH,H = 5.5, 3JH,H = 
8.4, 1 H, 26), 4.77 (s, 1 H, 28), 5.06 (s, 1 H, 38), 5.16 (s, 1 H, 48), 5.93 (d, 3JH,H = 5.9, 1 H, 
8), 6.15 (s, 1 H, 5), 6.88 (d, 3JH,H = 2.9, 3 H, 14), 7.18 (d, 3JH,H = 8.4, 2 H, 30), 7.30 (d, 3JH,H 
= 8.4, 2 H, 40), 7.32 (d, 3JH,H = 8.4, 2 H, 51), 7.37 (d, 3JH,H = 8.4, 2 H, 41), 7.41 (d, 3JH,H = 
8.4, 2 H, 50), 7.52 (s, 1 H, 17), 7.50 (d, 3JH,H = 7.1, 2 H, 31), 7.55 (s, 1 H, 20), 7.99 (s, 1 H, 
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11). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 16.3 (+, 1 C, 44), 17.0 (+, 1 C, 34), 
18.4 (+, 1 C, 44), 18.5 (+, 1 C, 54), 18.6 (+, 1 C, 54), 18.9 (+, 1 C, 34), 28.4 (+, 3 C, 1), 
29.0 (+, 1 C, 33), 29.2 (+, 1 C, 43), 29.9 (+, 1 C, 53), 36.6 (-, 1 C, 25), 37.4 (-, 1 C, 45), 
37.8 (-, 1 C, 35), 51.5 (+, 1 C, 24), 59.3 (+, 1 C, 21), 60.3 (+, 1 C, 15), 61.3 (+, 1 C, 9), 
67.9 (-, 1 C, 26), 68.1 (-, 1 C, 36), 68.2 (-, 1 C, 46), 70.5 (Cquat, 1 C, 6), 70.8 (Cquat, 1 C, 
12), 71.3 (Cquat, 1 C, 18), 82.9 (Cquat, 1 C, 2), 86.6 (+, 1 C, 38), 86.7 (+, 1 C, 28), 87.3 (+, 1 
C, 48), 121.8 (Cquat, 1 C, 52), 122.6 (Cquat, 1 C, 22), 123.4 (Cquat, 1 C, 32), 128.0 (+, 2 C, 
30), 128.8 (+, 2 C, 40), 129.6 (+, 2 C, 50), 130.7 (+, 2 C, 51), 131.0 (+, 2 C, 41), 131.8 (+, 
2 C, 31), 135.3 (Cquat, 1 C, 29), 136.2 (Cquat, 1 C, 39), 137.8 (Cquat, 1 C, 49), 156.8 (Cquat, 1 
C, 4), 170.4 (Cquat, 1 C, 13), 170.6 (Cquat, 1 C, 19), 171.0 (Cquat, 1 C, 7), 171.7 (Cquat, 1 C, 
22), 171.8 (Cquat, 1 C, 16), 172.2 (Cquat, 1 C, 10). – MS (ES, DCM/MeOH + 10 mM 
NH4OAc): m/z (%) = 1231.5 (100) [MH+]; 1155.2 (48) [M – H+ - tBuOH], 1229.6 (100) [M – 
H+], 1275.5 (95) [M + HCOO-]. – IR (neat) [cm-1]: ν~  = 3402, 2961, 2526, 2361, 2342, 
1727, 1669, 1513, 1488, 1439, 1209, 1071, 1005, 829, 804. – MF C54H69Br3N6O12. – MW 
1233.87. 
(R)-Methyl 2-((2S,3R)-3-((R)-2-((2S,3R)-3-((R)-2-((2S,3R)-3-amino-2-(4-bromophenyl)-
tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetrahydrofuran-
3-carboxamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanoate · HCl (194): 
Compound 178 (200 mg, 0.16 mmol) was dissolved under ice bath cooling at 0 °C in 
dichloromethane. To this solution 1.1 ml ice cold HCl saturated ether (7 ml/mmol Boc) was 
added and the mixture was stirred over night at room temperature. The solvent was 
removed under reduced pressure to give the HCl salt of the product as white hygroscopic 
solid in quantitative yield (190 mg, 0.16 mmol). No further purification was necessary. 
MP > 180 °C. – 1H-NMR (400 MHz, COSY, MeOH-d4): δ = 0.76 (d, 3JH,H = 6.6, 6 H, Val-
CH3), 0.86 (d, 3JH,H = 6.6, 3 H, Val-CH3), 0.88 (d, 3JH,H = 6.8, 3 H, Val-CH3), 0.94 (d, 3JH,H = 
6.7, 3 H, Val-CH3), 1.00 (d, 3JH,H = 6.6, 3 H, Val-CH3), 1.80 (septet, 3JH,H = 6.8, 1 H, Val-
CH), 1,87-1.99 (m, 1 H, Val-CH), 2.10 (ddd, 3JH,H = 3.1, 3JH,H = 7.0, 2JH,H = 13.0, 1 H, CH2), 
2.15-2.26 (m, 1 H, Val-CH), 2.28-2.36 (m, 1 H, CH2), 2.46 (ddd, 3JH,H = 3.1, 3JH,H = 8.0, 
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2JH,H = 14.0, 1 H, CH2), 2.85-3.00 (m, 2 H, CH2), 3.20 (q, 3JH,H = 7.2, 1 H, CH2), 3.38 (d, 
3JH,H = 4.4, 1 H, CHNH), 3.54 (d, 3JH,H = 6.6, 1 H, CHNH), 3.59 (s, 3 H, OCH3), 3.79-3.88 
(m, 1 H, OCH2), 3.93-4.08 (m, 3 H, CHNH + OCH2), 4.28 (dt, 3JH,H = 3.1, 3JH,H = 8.8, 1 H, 
OCH2), 4.33 (dt, 3JH,H = 1.2, 3JH,H = 8.7, 1 H, OCH2), 4.39 (dt, 3JH,H = 3.1, 3JH,H = 8.4, 1 H, 
OCH2), 4.95 (s, 1 H, OCH), 5.31 (s, 1 H, OCH), 5.33 (s, 1 H, OCH), 7.23 (d, 3JH,H = 8.4, 2 
H, Ar-CH), 7.32 (d, 3JH,H = 8.6, 2 H, Ar-CH), 7.34 (d, 3JH,H = 9.2, 2 H, Ar-CH), 7.40 (d, 3JH,H 
= 8.6, 2 H, Ar-CH), 7.42 (d, 3JH,H = 8.5, 2 H, Ar-CH), 7.45 (d, 3JH,H = 8.3, 2 H, Ar-CH). – 
13C-NMR (100 MHz, MeOH-d4): δ = 18.7 (+, 1 C, Val-CH3), 19.0 (+, 1 C, Val-CH3), 19.1 (+, 
1 C, Val-CH3), 19.3 (+, 1 C, Val-CH3), 19.8 (+, 1 C, Val-CH3), 20.3 (+, 1 C, Val-CH3), 31.0 
(+, 1 C, Val-CH), 31.4 (+, 1 C, Val-CH), 33.1 (+, 1 C, Val-CH), 36.0 (-, 1 C, CH2), 36.9 (-, 1 
C, CH2), 37.4 (-, 1 C, CH2), 52.2 (+, 1 C, OCH3), 60.6 (+, 1 C, CHNH), 60.8 (+, 1 C, 
CHNH), 62.3 (+, 1 C, CHNH), 67.3 (-, 1 C, OCH2), 68.6 (-, 1 C, OCH2), 68.8 (-, 1 C, 
OCH2), 69.2 (Cquat, 1 C, CNH), 72.3 (Cquat, 1 C, CNH), 72.4 (Cquat, 1 C, CNH), 86.0 (+, 1 C, 
OCH), 86.3 (+, 1 C, OCH), 87.6 (+, 1 C, OCH), 123.0 (Cquat, 1 C, CBr), 123.5 (Cquat, 1 C, 
CBr), 123.9 (Cquat, 1 C, CBr), 129.4 (+, 2 C, Ar-CH), 130.0 (+, 2 C, Ar-CH), 130.2 (+, 2 C, 
Ar-CH), 131.9 (+, 2 C, Ar-CH), 132.3 (+, 2 C, Ar-CH), 132.6 (+, 2 C, Ar-CH), 135.2 (Cquat, 
1 C, Ar-C), 138.3 (Cquat, 1 C, Ar-C), 138.9 (Cquat, 1 C, Ar-C), 169.2 (Cquat, 1 C, CO), 171.5 
(Cquat, 1 C, CO), 172.2 (Cquat, 1 C, CO), 172.7 (Cquat, 1 C, CO), 172.8 (Cquat, 1 C, CO), 
174.2 (Cquat, 1 C, CO). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 1131.4 
(100) [MH+], 1153.4.0 (89) [MNa+]; 1129,2 (50) [M – H+], 1165.2 (100) [M + Cl-], 1243.4 
(41) [M + TFA-]. – IR (neat) [cm-1]: ν~  = 3401, 2955, 2526, 2365, 2339, 1728, 1672, 1511, 
1488, 1436, 1213, 1072, 1004, 829, 799. – MF C49H61Br3N6O10*HCl. – MW 1170.22. 
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(R)-Methyl 2-((2S,3R)-2-(4-bromophenyl)-3-((R)-2-((2S,3R)-2-(4-bromophenyl)-3-((R)-2-
((2S,3R)-2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-carbox-
amido)-3-methylbutanamido)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)-tetra-
hydrofuran-3-carboxamido)-3-methylbutanoate (179): 
Under an atmosphere of nitrogen compound 190 (95 mg, 0.20 mmol, 1.4 eq.) was 
dissolved in 1.7 ml DMF (12 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (72 µl, 0.42 mmol, 3.0 eq.), HOAt (29 mg, 0.21 mmol, 1.5 eq.) and HATU (80 mg, 
0.21 mmol, 1.5 eq.) were added in this sequence. Then the amine 194 (164 mg, 0.16 
mmol, 1.0 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 3 ml of water and 
0.5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x5 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (PE:EtOAc 50:50, Rf = 0.21) to give the product 
as colorless solids with an overall yield of 28 % (48 mg, 0.04 mmol). 
1H-NMR (600 MHz, COSY, ROESY, DMSO-d6): δ = 0.61 (d, 3JH,H = 6.7, 3 H, 70), 0.66-75 
(m, 12 H, 40 + 60 + 70), 0.78 (d, 3JH,H = 7.1, 3 H, 40), 0.79 (d, 3JH,H = 6.8, 3 H, 50), 0.83 (d, 
3JH,H = 6.9, 3 H, 50), 1.49 (s, 9 H, 1), 1.83 (septet, 3JH,H = 7.1, 1 H, 69), 1.86-1.94 (m, 2 H, 
39 + 59), 1.96-2.03 (m, 1 H, 49), 2.04-2.20 (m, 4 H, 31 + 41 + 51 + 61), 2.82 (ddd, 3JH,H = 
8.2, 3JH,H = 10.7, 2JH,H = 13.2, 1 H, 61), 3.00 (t, 3JH,H = 5.1, 1 H, 27), 3.02-3.11 (m, 5 H, 9 + 
15 + 21 + 31 + 41), 3.23 (dt, 2JH,H = 13.3, 3JH,H = 8.6, 1 H, 51), 3.52 (s, 3 H, 30), 3.64 (ddd, 
3JH,H = 6.1, 3JH,H = 8.3, 3JH,H = 10.8, 1 H, 62), 3.78 (dd, 3JH,H = 7.3, 3JH,H = 9.1, 1 H, 42), 3. 
82 (dd, 3JH,H = 8.7, 2JH,H = 16.5, 1 H, 52), 3.99 (dd, 3JH,H = 8.2, 2JH,H = 16.1, 1 H, 32), 4.16-
4.25 (m, 1 H, 32), 4.26-4.34 (m, 2 H, 42 + 52), 4.97 (s, 1 H, 64), 5.04 (s, 1 H, 54), 5.09 (s, 
1 H, 34), 5.19 (s, 1 H, 44), 6.98 (d, 3JH,H = 5.5, 20), 7.17 (d, 3JH,H = 8.4, 2 H, 66), 7.20 (d, 
3JH,H = 9.2, 2 H, 26), 7.22-27 (m, 4 H, 36 + 46), 7.28-7.34 (m, 4 H, 56 +67), 7.36 (d, 3JH,H = 
8.6, 2 H, 47), 7.40 (s, 1 H, 23), 7.42 (d, 3JH,H = 5.3, 2 H, 57), 7.44 (d, 3JH,H = 5.4, 2 H, 37), 
7.83 (s, 1 H, 17), 8.07 (s, 1 H, 8), 8.29 (s, 1 H, 11), 8.36 (s, 1 H, 5). – 13C-NMR (150 MHz, 
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HSQC, HMBC, DMSO-d6): δ = 17.3 (+, 1 C, 70), 17.7 (+, 1 C, 360), 17.8 (+, 1 C, 40), 18.2 
(+, 2 C, 40 + 50), 18.3 (+, 1 C, 70), 18.7 (+, 1 C, 50), 18.8 (+, 1 C, 60), 28.1 (+, 3 C, 1), 
28.4 (+, 1 C, 49), 28.8 (+, 1 C, 69), 28.9 (+, 1 C, 59), 30.7 (+, 1 C, 39), 33.3 (-, 1 C, 61), 
36.0 (-, 1 C, 31), 36.4 (-, 1 C, 41), 36.6(-, 1C, 51), 51.3 (+, 1 C, 30), 57.3 (+, 1 C, 21), 61.2 
(+, 2 C, 15 + 27), 61.7 (+, 1 C, 9), 67.2 (-, 2 C, 32 + 62), 67.5 (-, 1 C, 42), 67.8 (-, 1 C, 52), 
70.3 (Cquat, 2 C, 18 + 25), 70.5 (Cquat, 1 C, 6), 70.6 (Cquat, 1 C, 12), 80.4 (Cquat, 1 C, 2), 84.4 
(+, 1 C, 34), 85.4 (+, 2 C, 44 + 54), 86.0 (+, 1 C, 64), 120.7 (Cquat, 1 C, 68), 121.3 (Cquat, 1 
C, 58), 121.4 (Cquat, 1 C, 38), 121.5 (Cquat, 1 C, 48), 128.8 (+, 2 C, 46), 128.9 (+, 4 C, 36 + 
56), 129.0 (+, 2 C, 66), 130.0 (+, 2 C, 67), 130.5 (+, 4 C, 37 + 57), 130.6 (+, 2 C, 47), 
136.8 (Cquat, 1 C, 45), 137.0 (Cquat, 1 C, 55), 137.2 (Cquat, 1 C, 35), 137.7 (Cquat, 1 C, 65), 
156.8 (Cquat, 1 C, 4), 168.1 (Cquat, 1 C, 25), 170.2 (Cquat, 1 C, 19), 170.6 (Cquat, 2 C, 22 + 
28), 170.9 (Cquat, 1 C, 13), 172.4 (Cquat, 1 C, 7), 172.5 (Cquat, 2 C, 10 +16). – MS (ES, 
DCM/MeOH + 10 mM NH4OAc): m/z (%) = 799.1 (100) [MH+], 1597.5 (21) [MH+]; 1595.5 
(100) [M – H+]. – IR (neat) [cm-1]: ν~  = 3398, 2961, 2530, 2357, 2342, 1729, 1670, 1511, 
1486, 1439, 1210, 1071, 1015, 829, 805. – MF C70H88Br4N8O15. – MW 1601.01. 
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X-Ray structure and crystal data of 179: 
Monoclinic; space group: P 21; cell dimensions: a = 10.9445(1) Å, α = 90°, b = 19.3924(1) 
Å, β = 104.032(1)°, c = 17.9304(1) Å, γ = 90°; V = 3692.00(5) Å3; Z = 2, Dx = 1.440 Mg/m3; 
µ = 3.223 mm-1; F(000) = 1648. Data collection: T = 123 K; graphite monochromator. A 
colorless crystal with dimensions of 0.212 x 0.160 x 0.131 mm was used to measure 
23708 reflections (12033 unique reflections, Rint = 0.0221) from 2.54° to 67.17° on a 
Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. Structure 
refinement: The F2 value was refined using the full-matrix least squares refinement 
method, with a goodness-of-fit 0f 1.027 for all reflections and 886 parameters. 
Section B  4. Derivatization of TAAs and the Synthesis of Cyclic Peptides 
 216 
4. Derivatization of TAAs and the Synthesis of 
Cyclic Peptides 
4.1. Introduction 
The design and synthesis of small molecules which mimic natural peptide sequences 
have attracted much attention from organic, bioorganic and peptide chemists.222c, 123 This 
is due to numerous advantages of peptidomimetics over short natural sequences, such as 
greater steric constrains leading to a more pronounced secondary structure and the 
higher biological and chemical stability.125a, 212a 
Many different ways are known for the synthesis of peptidomimetics138, 199, 209, 219b among 
which the preparation of cyclic peptides has received considerable attention. Cyclic 
peptides occur in a variety of natural bioactive compounds and they are of great interest 
for synthetic chemists and biologist, because they often show higher in vivo stability and 
reduced conformational mobility than their linear counterparts thus making them potential 
drug candidates.240 A large number of cyclic peptides was designed and synthesized in 
the last years with some being biologically active natural products,193, 194b while others are 
mimics of natural peptide sequences like for example the large group of bio-active 
analogues of the natural RGD-sequence.192, 241 Additionally, different cyclic peptido-
mimetic inhibitors for enzymes like HIV 1 protease were developed and successfully 
tested for their activity.242 
Another strategy to peptidomimetics with enhanced proteolytic stability compared to their 
natural analogues uses unnatural constrained amino acids like Cα-tetrasubstituted 
α-amino acids which are incorporated into the peptide sequence.227b A large number of 
such unnatural cyclic or acyclic amino acids with and without a stereocenter at the 
Cα-carbon has been reported216 and used in the synthesis of peptidomimetics resulting in 
stable helices243 and turn-like structures221b, c of which some show biological 
activity.185, 222b, d, 229c One example of such a cyclic Cα-tetrasubstituted α-amino acid is the 
tetrahydrofuran derivative rac-135 developed in our group, which introduces β-turn 
structures in tripeptides.218 Despite the many known examples of cyclic α-amino acids and 
their applications as structure inducing elements in peptide strands,222a to the best of our 
knowledge cyclic Cα-tetrasubstituted α-amino acids have not been used in the synthesis of 
cyclic peptidomimetics so far. 
Hence, we developed a general methodology for the Cu(I)-catalyzed N-arylation reaction 
of the Cα-tetrasubstituted tetrahydrofuran amino acid rac-135 with a variety of different 
amines and used it to link the N-terminus of a tripeptide with the side chain aryl halide of 
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rac-135 incorporated in the sequence (Scheme 25, 1 ? 2). A cyclic tripeptide mimetic 
containing an aromatic ether244 was obtained by an O-arylation reaction using palladium 
catalysis (Scheme 25, 3 ? 4). 
Scheme 25: Synthesis of cyclic peptide mimics by an N-arylation reaction using Cu(I) 
(top) or by an O-arylation reaction using Pd(0) (bottom). 
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4.2. Synthesis 
4.2.1. Development of the CuI-Catalysis Reaction Conditions 
Initially, we explored the scope for CuI-catalyzed reactions of the unnatural amino acid 
rac-135 with aliphatic benzylamine (Scheme 26). Previous studies served as a starting 
point for the optimization experiments.230a, 245 The ligands L-proline A and N,N-dimethyl-
glycine B were found to be good promoters for the CuI-catalyzed reaction. K3PO4 and 
K2CO3 were found to be suitable bases. In Table 5, entries 1 to 6 summarize the reaction 
conditions for the model reaction of benzylamine with the unnatural amino acid rac-135. 
These results illustrate that when using K3PO4 as base with 10 mol% of catalyst and 
20 mol% ligand A at 100 °C, a yield of about 50 % was obtained. The use of larger 
amounts of CuI in combination with ligand A gave no better results. Decreasing the 
temperature to about 50 °C resulted in no product formation (entry 3). A significant 
increase in yield by about 20 % was obtained when the base was changed from K3PO4 to 
the more basic K2CO3 (entry 4). A substitution of ligand A by ligand B while retaining the 
other conditions, gave the same amount of product (entries 4 and 5). 
Scheme 26: C-N bond formation reactions catalyzed by a combination of CuI and 
L-amino acids. 
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Following the development of appropriate reaction conditions, several different amines 
were coupled under these conditions to elucidate the scope of the CuI catalyzed reaction. 
In entries 6 to 9 three different primary amines with and without functional groups were 
used. Butylamine was coupled in good yields to rac-135. The reaction was conducted at a 
tenfold higher dilution as a test of the cyclisation reactions for which a higher dilution is 
necessary to promote the intramolecular cyclisation reaction and to avoid polymerization. 
The product was obtained, although in poor yield. Entry 8 shows that 2-aminoethanol 
selectively undergoes the N-arylation reaction without an adverse effect of the 
unprotected hydroxyl moiety of the amino alcohol. This reaction and entry 9 show that 
also amines containing different functional groups are compatible with the applied reaction 
conditions. Another example is shown in entry 21 where a mono Cbz-protected alkyl 
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diamine was successfully coupled introducing a second amine functionality with an 
orthogonal protecting group. Secondary amines were also tried as reaction partners for 
the amino acid rac-135 but their increased steric hindrance decreased their reactivity: 
diethylamine (entries 10 to 12) showed no conversion. Neither the change from ligand A 
to B nor from the base K2CO3 to K3PO4 gave any product. Morpholine (entries 13 and 14) 
gave about 30 % product yield. The yield did not increase with larger amounts of catalyst 
and ligand. Pyrrolidine (entry 15) gave over 70 % yield. The reactivity of diethyl amine and 
pyrrolidine differ significantly which is explained by the different geometry of the two 
amines.230a The formation of diarylamines was examined using p-anisidine together with 
10 mol% CuI which gave the diphenylamine in about 50 % yield. The heterocyclic 
imidazole was coupled to rac-135 under CuI catalysis giving the product in 45 % yield 
when using 10 mol% CuI and in a slightly higher yield when using 30 mol% CuI. 
Furthermore, amino acid esters can be coupled in the Ullmann-type reaction in moderate 
yields. The amino acid ester hydrochloride must be neutralized by extraction under basic 
conditions using a sat. aqueous NaHCO3 solution and ethyl acetate prior to use, because 
the salt itself was found to be unreactive under the applied reaction conditions even with 
large excess of an inorganic base (entries 19 and 20). 
Table 5: CuI catalyzed C-N bond formation reaction conditions and yields. 
entry amine CuI (eq.) ligand base product yield (%)
1 0.1 A K3PO4 49* 
2 0.2 A K3PO4 47* 
3 0.1 A K3PO4 - a 
4 0.1 A K2CO3 70 
5 
NH2
 
199 
0.1 B K2CO3
rac-210,  
R = benzyl, R´= H 
70 
6 0.1 A K3PO4 65* 
7 
NH2  
200 0.1 A K3PO4
rac-211,  
R = Bu, R´= H 12*, b 
8 
HO
NH2  
201 
0.1 A K2CO3
rac-212,  
R = C2H4OH, R´= H 
42* 
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entry amine CuI (eq.) ligand base product yield (%)
9 
NH2  
202 
0.1 A K2CO3
rac-213,  
R = allyl, R´= H 
54* 
10 0.1 A K2CO3 -* 
11 0.1 A K3PO4 -* 
12 
NH
 
203 
0.1 B K2CO3
rac-214, 
R, R` = Et 
- 
13 0.1 A K2CO3 31 
14 
NHO
 
204 0.3 A K2CO3
rac-215, 
R-R´ = O(C2H4)2 33* 
15 
NH
 
205 
0.1 A K2CO3
rac-216, 
R-R´= C4H8 
73* 
16 
O NH2
 
206 
0.1 A K2CO3
rac-217, 
R = p-MeO-C6H4, 
R´= H 
49* 
17 0.1 A K2CO3 45* 
18 
NHN  
207 0.3 A K2CO3
rac-218, 
NRR´ = imidazole 49* 
19 
H-Gly-OMe*HCl 
208-HCl 
0.1 A K2CO3 - -*c) 
20 
H-Gly-OMe 
208 
0.1 A K2CO3
rac-219, 
R = Gly-Ome, R´= H 
13 
21 
H
N
NH2Cbz  
209 
0.1 A K2CO3
rac-220, 
R = C2H4NHCbz, 
R´= H 
23 
All reactions except the ones indicated were performed using 1 eq. rac-135, 1.5 eq. amine, 2 eq. base, 10 
mol% CuI (based on the rac-135), 20 mol% ligand (based on the rac-135), dry DMSO, concentration of rac-135 
c = 1M, 100 °C, 48 hours 
a) carried out at 50 °C 
b) the reaction was performed at a concentration 0f rac-135 C = 1M in dry DMSO 
c) the reaction was performed using 4 eq. of base 
* Reactions were carried out in collaboration with A. Späth at the Shanghai Institute For Organic Chemistry 
(SIOC) under the supervision of Prof. D. Ma. 
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All reactions shown in Table 5 where performed under conventional heating in an oil bath 
and required about 2 days to come to completion. Microwave irradiation has been used as 
an alternative energy input, reducing the required reaction time in some cases.246 For CuI 
promoted C-N bond formations, one example of microwave heating was reported.247 
Table 6: CuI catalyzed C-N bond formation reactions using microwave heating.. 
entry amine 
CuI 
(eq.) 
ligand base, eq. product yield (%)
1 0.1 A 
K3PO4, 
2.0 eq. 
- 
2 0.1 A 
K2CO3, 
2.0 eq. 
- 
3 0.1 A 
K2CO3, 
0.2 eq. 
10a 
4 
NH2
199 
0.1 A 
K2CO3, 
0.5 eq. 
rac-210,  
R = benzyl, 
R´= H 
15 
5 0.1 A 
K2CO3, 
2.0 eq. 
- 
6 
NHN  
207 0.1 A 
K2CO3, 
0.2 eq. 
rac-218, 
NRR´ = imidazole 
- 
All reactions except the ones indicated were performed using 1 eq. rac-135, 1 eq. amine, 10 mol% CuI (based 
on rac-135), 20 mol% ligand (Based on rac-135), 1 ml/mmol (rac-135) dry DMSO, 160 °C, 20 minutes 
a reaction was carried out a second time with 60 minutes of microwave irradiation without any effect 
 
In Table 6 the results from the microwave experiments are summarized. The first 
reactions (entries 1, 2 and 5) were carried out using the same equivalents of base as for 
the reactions shown in Table 5. Those reactions gave no product. Accordingly, the 
amount of base was reduced to 0.2 eq., the same amount which was used by Veverková 
et al.247 The coupling with imidazole 207 (entry 6) gave again no product but at least a 
small amount was obtained when using benzyl amine 199 (entry 3). This reaction was 
then repeated with a longer reaction time of 60 minutes instead of 20 minutes as for all 
other experiments but with no measurable improvement of the yield. As a last experiment 
(entry 4) the amount of base was increased to 0.5 eq. which altered the yield to 15 %. 
However, this is still far less than for the ones using conventional heating and the longer 
reaction time.  
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Based on the results shown in Table 5 it was decided to try to use sterically more 
demanding secondary amines which comprise functional groups and can be used for 
example for the complexation of metal ions like Zn(II) or Cu(II) and with that in molecular 
recognition. Therefore some metal catalyzed reactions using mostly the system 
CuI/L-proline A but also CuI/cyclohexane-1,2-diamine C (Table 7) Boc-cyclen 223. As 
none of these experiments showed success one attempt was conducted using Pd(OAc)2 
together with PPh3 D as ligand, but again no product was formed. In contrast to all other 
reactions, for the ones where 3-Boc-cyclen 223 was used as amine, the Cbz-TAA-OtBu 
rac-140 was used to offer orthogonality between the protecting groups of the amino acid 
and the side chain amines of the cyclen. 
Table 7: C-N bond formation reactions using metal ligand precursors. 
 
In summary, it can be noted that it is possible to couple a variety of different mono- or 
dialkylated amines to rac-135 by the use of 10 mol% CuI as catalyst in combination with 
L-amino acids as ligands. In addition to simple alkyl amines, this methodology offers the 
possibility to replace the bromine substituent of rac-135 by different functional groups like 
protected amines and carboxylic acids, but also by unprotected alcohol functionalities, 
aromatic and heteroaromatic compounds or olefin moieties. The reactions gave the 
products in moderate to good yields of up to 70 %. 
entry ArX amine metal salt ligand base 
yield 
(%) 
1 CuI, 0.1 eq. A K3PO4 - 
2 
rac-135 
HN
O
OO
O  
221 
CuI, 0.2 eq. A K3PO4 - 
3 rac-135 
HN
O
OO
O  
222 
CuI, 0.2 eq A K3PO4 - 
4 CuI, 0.1 eq. A K3PO4 - 
5 CuI, 0.1 eq. C K3PO4 - 
6 
rac-140 N N
NN
Boc
HBoc
Boc
 
223 
Pd(OAc)2, 
0.1 eq. 
D NaOtBu - 
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4.2.2. Synthesis of Cyclic Tripeptide Mimics via C-N Arylation 
To demonstrate the use of the developed C-N bond formation conditions in cyclisation 
reactions, the cyclic tripeptide 196 and its diastereomer were synthesized applying the 
developed C-N bond formation reactions. A 15-membered ring system should result from 
the reaction of unnatural amino acid rac-135, L-valine 226 and 4-aminobutanoic acid 224, 
while a 17-membered ring is expected if 6-aminohexanoic acid 225 was used instead of 
4-aminobutanoic acid 224. Both tripeptides were synthesized using standard peptide 
coupling reactions starting from the Boc-protected amino acids 224 or 225 which were 
coupled with L-valine methyl ester 226 to afford the dipeptides 227 and 228. 
Scheme 27: Reaction sequence leading to the cyclic tripeptides 196 and 234: a) DIPEA, 
EDC, HOBt, dry DMF, 24h, rt; b) LiOH, water/THF, 24h, rt; c) HCl sat. diethyl ether, DCM, 
24h, rt; d) 8 % TFA, dry DCM, 3-4h, rt; e) CuI, L-proline, K2CO3, DMSO, 48 h, 100 °C. 
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After ester saponification using LiOH as base, the resulting dipeptide acids 229 and 230 
were coupled to the Boc-deprotected TAA rac-136. Both tripeptides were obtained in good 
yields, but as a 1:1 mixture of diastereomers because the racemic amine rac-136 was 
used. A chromatographic separation of the diastereomers was not possible after this step 
of the synthesis. The following Boc-deprotection of both compounds 231 and 234 was 
accomplished by the use of 8 % TFA solution in dry DCM. Higher concentrations of TFA 
or the use of HCl saturated diethyl ether lead to a partial cleavage of the tert. butyl ester 
moiety. The obtained diastereomeric mixtures of the amines 195 and 233 were used in 
the CuI catalyzed cyclisation reaction (10 mol% CuI, 20 mol% L-proline, K2CO3, DMSO) 
after deprotonation by a strongly basic ion exchange resin. The concentration of the 
starting materials in the reaction mixture was lowered for the cyclisation reactions by a 
factor of ten to prevent the deprotected precursors 195 and 233 from intermolecular 
polymerisation instead of the desired intramolecular cyclisation. The shorter amine 233 
was found to be unreactive under the applied conditions which may be rationalized by the 
small ring size of 15 atoms and the resulting strained cyclic tripeptide. Compound 195 
gave product 196 although only in 7 % yield.4 
Besides the successful attempt to couple the N-terminus of the tripeptide 195 with the aryl 
halide sidechain, it was also tried to develop reactions to couple the C-terminus of a 
tripeptide or the side chain of a second amino acid to the side chain aryl halide of rac-135 
incorporated in the sequence. The reactions were conducted using the previously 
prepared dipeptides 181 and 183. To allow a coupling of the C-terminus with the side 
chain aryl halide of 181 and 183, two different mono-Cbz-protected amines 50 and 235 
were coupled to the dipeptides in good yields. For the cyclisation reaction between two 
side chains, the protected lysine 240 was coupled to the diastereomers 181 and 183 in 
good yields. 
Problems were encountered during the deprotection of the Cbz-group. Under the 
conditions normally used to cleave this protecting group, meaning the use of 10 % Pd on 
activated charcoal248 under an atmosphere of 10 bar hydrogen, no cleavage was 
observed. When using higher pressures and a longer reaction time of up to three days we 
observed a decomposition of the starting material. Further cleavage experiments were 
undertaken in the scope of the research internship at the SIOC, Shanghai. With the Pd on 
activated charcoal and the hydrogenation equipment used at the SIOC to cleave Cbz-
groups, it was possible to quantitatively cleave the protecting group in 4 hours but 
unfortunately the aryl halide was replaced by a hydrogen atom. It is known that aromatic 
                                                
4 Due to the low yield only spectroscopic analysis of the product 198 was possible. An analysis of 
the structural properties could not be performed. 
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systems can be dehalogenated by the use of Pd as catalyst and hydrogen. On the other 
hand, several examples are known in literature where aryl bromides have proven to be 
stable to the use of Pd and hydrogen at least for several hours.249 Astonishingly, under the 
conditions applied the dehalogenation took place in less than 30 minutes while the Cbz-
deprotection needed about 4 hours to come to completion. Hence, it was not possible to 
form the desired precursors, at least not with the combination of Pd and hydrogen. 
Looking for alternatives, it was attempted to cleave the Cbz group by use of HBr in glacial 
acidic acid.248, 250 Obviously these conditions also cleave the Boc-protecting group, but we 
expected the N-terminus of the precursors to be less reactive in the cyclisation reaction 
when compared to the C-terminal amine because of the sterically demanding environment 
of the N-terminus. Unfortunately, HBr in glacial acetic acid gave a mixture containing a 
variety of decomposition products. Due to the high polarity caused by two free amine 
groups a purification was not successful. 
Scheme 28: Preparation of the precursors for the Cu(I) catalyzed cyclisation via the 
C-terminus: a) DIPEA, HATU, HOAt, dry DMF, 24h, rt. 
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Scheme 29: Preparation of the precursors for the Cu(I) catalyzed cyclisation via the 
C-terminus: a) DIPEA, HATU, HOAt, dry DMF, 24h, rt. 
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Because of the low yields obtained for the cyclisation reaction of compound 195 further 
attempts towards the synthesis of C-terminal side chain and side chain-side chain cyclized 
peptide mimetics were not performed. 
4.2.3. Synthesis of Cyclic Tripeptide Mimics via C-O Arylation 
The synthesis of cyclic peptides through a C-O arylation reaction was tested by the 
formation of a 15-membered ring system shown in Scheme 30. The structure was derived 
from a cyclic tripeptide mimic consisting of Phe, Ile and 3-bromopropan-1-amine. Fairlie et 
al. used this macrocycle to substitute the Phe-Ile-Val motif in the peptide Ac-Leu-Val-Phe-
CHOHCH2-{Phe-Ile-Val}-NH2, which is a known inhibitor of HIV-1 protease derived from a 
substrate sequence. The substitution of the natural by the unnatural cyclic group resulted 
in an enhanced inhibitory activity.223, 251 Our goal was to synthesize a similar tripeptide 
macrocycle by the use of the unnatural amino acid rac-138 instead of Phe leading to an 
even higher conformational constraint and to a more rigid secondary structure. 
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Scheme 30: Reaction sequence scheme leading to the macrocycles 198 and 252: a) 
DIPEA, TBTU, HOAt, dry DMF, 24h, rt; b) LiOH, water/THF, 24h, rt; c) CH3COOH, 1M 
TBAF in THF, MeCN, 12h, 0 °C - rt; d) Pd(OAc)2, dicyclohexyl(2',4',6'-triisopropylbiphenyl-
2-yl)phosphine, CsCO3, toluene, 24 h, 80 °C. 
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To form the acyclic precursors for the C-O arylation reaction, Boc-TAA-OH rac-138 was 
coupled to L-isoleucine methyl ester hydrochloride 243 using EDC and HOBt as coupling 
reagents. Due to the racemic amino acid rac-138, two diastereomers 244 and 245 were 
formed, which could be easily separated by column chromatography. Crystals were 
obtained of compound 244 and an X-ray analysis was performed which revealed the 
absolute configuration (see Figure 94). The subsequent reaction steps were carried out 
separately with both diastereomers leading to two stereochemically different macrocycles 
with different secondary structures. After ester saponification the resulting free acids 246 
and 247 were coupled with 3-(tert-butyldimethylsilyloxy)propan-1-amine 248 using TBTU 
and HOAt as coupling reagents. The protected precursors 249 and 250 were formed in 
good yields. After deprotection of the TBS-group they were used in the metal-catalyzed 
cyclisation reaction. As catalytic system, Pd(OAc)2 with dicyclohexyl(2',4',6'-triisopropyl-
biphenyl-2-yl)phosphine as ligand and CsCO3 as base were chosen. The reaction was 
conducted under an atmosphere of nitrogen at 80 °C in dry toluene as solvent. These 
reaction conditions were adopted from literature by changing the ligand to the 
dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine.230b, c The use of a bulky ligand is 
important to prevent a β-hydride elimination in the temporarily formed oxidative addition. 
Another crucial reaction parameter is the concentration of the starting materials: When the 
reaction mixture was diluted the yield dropped drastically, while high concentrations 
resulted in the formation of cyclic dimers instead of the intramolecular ring closing 
reaction. The best results were obtained when 40 ml of toluene per mmol of starting 
material (197 or 251) were used, which corresponds to a concentration of c = 25 mmol/L. 
These reaction conditions yield 40 % for compound 198 and about 19 % of its 
diastereomer 252.5 
                                                
5 Both cyclic compounds 198 and 252 and their acyclic precursors 197 and 251 were tested in the 
Group of Prof. W. Diederich from the Philipps-University Marburg for their activity as HIV 1 
protease inhibitors but were all found to be inactive. 
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Figure 94: X-ray structure of compound 244. 
4.3. Conclusion 
The CuI-catalyzed N-arylation of rac-135 proceeds in moderate to good yields with a 
variety of amines allowing to introduce aliphatic aldehydes and different functional group 
containing amines into the side chain of the protected TAA rac-135. An intramolecular 
Cu(I)-catalyzed N-arylation reaction was used for the synthesis of the 17-membered 
macrocycle 196, but the obtained yield was low. Pd(0)-catalyzed O-arylations gave higher 
yields for the macrocylization of non-natural tripeptides containing TAA rac-135: The 15-
membered macrocycle 198 was obtained in 40% isolated yield using Pd(OAc)2 and a 
sterically demanding ligand. The examples illustrate that copper(I)-catalyzed N-arylations 
and palladium(0)-catalyzed O-arylations give access to side chain modified derivatives of 
the unnatural amino acid rac-135 and macrocyclic peptidomimetics. 
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4.4. Experimental Part 
X-ray data collections were performed using an Oxford Gemini Ultra diffractometer. The 
microwave irradiation experiments were conducted in a CEM Discover S-class laboratory 
microwave apparatus. IR spectra were recorded on a Bio-Rad FT-IR FTS 155 and a Bio-
Rad FTS 2000 MX FT-IR using a Specac Golden Gate Mk II ATR accessory where 
stated. NMR spectrometers used were: Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 
MHz, T = 300 K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K) and 
Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are 
reported in δ [ppm] relative to external standards (solvent residual peak). The spectra 
were analyzed by first order, the coupling constants are given in Hertz [Hz]. 
Characterization of the signals: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, bs = broad singlet, psq = pseudo quintet, dd = double doublet, dt = double 
triplet, ddd = double double doublet. Integration is determined as the relative number of 
atoms. Assignment of signals in 13C-spectra was determined with DEPT-technique (pulse 
angle: 135 °) and given as (+) for CH3 or CH, (-) for CH2 and (Cquat) for quaternary C. Error 
of reported values: chemical shift: 0.01 ppm for 1H-NMR, 0.1 ppm for 13C-NMR and 0.1 Hz 
for coupling constants. The solvent used is reported for each spectrum. Mass spectra 
were recorded on Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD) and Finnigan 
MAT TSQ 7000 (ESI). Xenon served as the ionization gas for FAB. Melting Points were 
determined on a Büchi SMP-20 or Stanford Research System OpitMelt melting point 
apparatus and are uncorrected. Elemental analyses were carried out by the Center for 
Chemical Analysis of the Faculty of Natural Sciences of the University Regensburg. 
All reagents and solvents used were of analytical grade purchased from commercial 
sources and were used without further purification. Unless otherwise stated, purification 
and drying of the solvents used was done according to accepted general procedures.239 
CuI was washed with THF using a Soxhlet extractor before use to ensure a satisfactory 
catalytic activity. All reactions were performed under an inert atmosphere of N2 or Ar using 
standard Schlenk techniques if not otherwise stated. TLC analyses were performed on 
silica gel 60 F-254 with a 0.2 mm layer thickness. Detection was via UV light at 254 nm / 
366 nm or through discoloration with ninhydrin in EtOH. For preparative column-
chromatography, Merck Geduran SI 60 (70-230 mesh) and Macherey-Nagel GmbH & Co. 
KG 60M (230–400 mesh) silica gels were used. For chromatography commercially 
available solvents of standard quality were used without further purification. 
The following compounds were synthesized according to literature known procedures: 
Boc-TAA-OtBu rac-135 and Boc-TAA-OH rac-138,218 4-(tert-butoxycarbonylamino)-
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butanoic acid 224,252 6-(tert-butoxycarbonylamino)hexanoic acid 225,253 3-(tert-butyldi-
methylsilyloxy)propan-1-amine 248254 and benzyl 4-aminobutylcarbamate 235.255 
General Procedure for the CuI-catalyzed reactions (GP 2) 
An oven-dried Schlenk tube equipped with a Teflon septum was charged with a magnetic 
stir bar. The tube was evacuated and backfilled with argon three times. The compound 
rac-135 (1 eq.), the inorganic base K2CO3 or K3PO4 (2 eq.), CuI (10 - 30 mol%), the 
appropriate amino acid A or B (20 – 60 mol%) and the amine (1.5 eq.) if solid were added. 
The tube was again evacuated and backfilled with argon (this procedure was repeated 
three times). Under a counter flow of argon the amine (if liquid, 1.5 eq.) and the solvent 
DMSO (1 ml/mmol of compound rac-135, dry) were added via syringe. The tube was 
sealed and heated under stirring at the indicated temperature (50 – 100 °C) for 48 hours. 
After completion of the reaction the mixture was allowed to cool to room temperature and 
was then quenched with water (2 ml/mmol rac-135). The mixture was extracted three 
times with ethyl acetate (5 ml/mmol rac-135, each), the combined organic layers were 
dried over MgSO4, filtered and the solvent was evaporated under reduced pressure to 
give the crude product. Purification was accomplished by the use of column 
chromatography with the solvent mixture indicated for each reaction. 
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rac-tert-Butyl 2-(4-(benzylamino)phenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-
carboxylate (rac-210): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-butoxy-
carbonylamino)-tetrahydrofuran-3-carboxylate rac-135 (200 mg, 0.45 mmol), benzylamine 
199 (74 µl, 0.68 mmol), K2CO3 (125 mg, 0.90 mmol), CuI (9 mg, 0.05 mmol), L-proline (10 
mg, 0.10 mmol) and 0.45 ml DMSO. The crude product was purified using a 8:2 mixture of 
PE and EtOAc (Rf = 0.08) giving the product as a colorless solid in 70 % yield. (148 mg, 
0.32 mmol) 
MP 148 °C. – 1H-NMR (300 MHz, CDCl3) δ = 1.06 (s, 9 H, 10), 1.33 (s, 9 H, 1), 2.45 (bs, 1 
H, 11), 2.62–2.78 (m, 1 H, 11), 3.96-4.10 (m, 2 H, 12 + 19), 4.16-4.28 (m, 3 H, 12 + 20), 
4.72 (s, 1 H, 14), 5.33 (bs, 1 H, 5), 6.46 (d, 3JH,H = 8.5, 2 H, 17), 7.01 (d, 3JH,H = 8.5, 2 H, 
16), 7.12-7.30 (m, 5 H, 22-24). – 13C-NMR (75 MHz, CDCl3): δ = 27.5 (+, 3 C, 1), 28.4 (+, 
3 C, 10), 35.6 (-, 1 C, 11), 48.1 (-, 1 C, 20), 67.6 (-, 1 C, 12), 69.8 (Cquat, 1 C, 6), 79.8 
(Cquat, 1 C, 2), 81.7 (Cquat, 1 C, 9), 86.6 (+, 1 C, 14), 112.4 (+, 2 C, 17), 126.0 (Cquat, 1 C, 
15), 127.1 (+, 1 C, 24), 127.3 (+, 2 C, 22/23), 127.6 (Cquat, 1 C, 22/23), 128.6 (+, 2 C, 16), 
139.4 (Cquat, 1 C, 21), 148.0 (Cquat, 1 C, 18), 154.7 (Cquat, 1 C, 4), 170.0 (Cquat, 1 C, 7). – 
MS (ESI, MeOH): m/z (%) = 469.2 (12) [MH+], 491.2 (100) [MNa+]. – HR-MS (PI-EIMS, 
MeOH): [M+·] calcd. for C27H36N2O5 468.2624; found 468.2621. – IR (neat) [cm-1]: ν~  = 
3370, 2979, 2931, 2869, 2361, 1708, 1617, 1505, 1367, 1274, 1257, 1166, 1058, 965, 
884, 832. – MF C27H36N2O5. – MW 468.59. 
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X-Ray structure and crystal data of rac-210: 
Monoclinic; space group: P 21/n; cell dimensions: a = 12.8379(5) Å, α = 90°, b = 
5.8585(2) Å, β = 90.048(4)°, c = 33.9533(13) Å, γ = 90°; V = 2553.66(16) Å3; Z = 4, Dx = 
1.219 Mg/m3; µ = 0.676 mm-1; F(000) = 1008. Data collection: T = 123 K; graphite 
monochromator. A colorless crystal with dimensions of 0.490 x 0.060 x 0.030 mm was 
used to measure 6964 reflections (4049 unique reflections, Rint = 0.0388) from 3.68° to 
66.79° on a Oxford Diffraction Gemini Ultra diffractometer with the omega-scan method. 
Structure refinement: The F2 value was refined using the full-matrix least squares 
refinement method, with a goodness-of-fit 0f 1.100 for all reflections and 1006 parameters.  
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rac-tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-(butylamino)phenyl)-tetrahydrofuran-3-
carboxylate (rac-211): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-butoxycarbonyl-
amino)-tetrahydrofuran-3-carboxylate rac-135 (250 mg, 0.57 mmol), butylamine 200 (84 
µl, 0.85 mmol), K3PO4 (240 mg, 1.13 mmol), CuI (11 mg, 0.06 mmol), L-proline (13 mg, 
0.11 mmol) and 0.57 ml DMSO. The crude product was purified using a 9:1 mixture of PE 
and EtOAc (Rf = 0.19) giving the product as a colorless solid in 65 % yield. (161 mg, 0.37 
mmol) 
MP 149 °C. – 1H-NMR (300 MHz, CDCl3) δ = 0.93 (t, 3JH,H = 7.3, 3 H, 23), 1.16 (s, 9 H, 
10), 1.33–1.49 (m, 11 H, 1 + 22), 1.63–1.51 (m, 2 H, 21), 2.53 (bs, 1 H, 11), 2.88–2.71 (m, 
1 H, 11), 3.08 (t, 3JH,H = 8.2, 2 H, 20), 3.60 (s, 1 H, 19), 4.10 (q, 3JH,H = 8.1, 1 H, 12), 4.29 
(td, 3JH,H = 3.7, 3JH,H = 8.3, 1 H, 12), 4.80 (s, 1 H, 5), 5.41 (s, 1 H, 14), 6.52 (d, 3JH,H = 8.5, 2 
H, 17), 7.09 (d, 3JH,H = 8.5, 2 H, 18). – 13C-NMR (75 MHz, CDCl3): δ = 13.9 (+, 1 C, 23), 
20.2 (-, 1 C, 22), 27.5 (+, 3 C, 1), 28.4 (+, 3 C, 10), 31.5 (-, 1 C, 21), 35.6 (-, 1 C, 11), 43.7 
(-, 1 C, 20), 67.5 (-, 1 C, 12), 69.8 (Cquat, 1 C, 6), 79.8 (Cquat, 1 C, 2), 81.7 (Cquat, 1 C, 9), 
86.7 (+, 1 C, 14), 112.2 (+, 2 C, 17), 125.5 (Cquat, 1 C, 15), 127.5 (+, 2 C, 16), 148.5 (Cquat, 
1 C, 18), 154.7 (Cquat, 1 C, 4), 170.1 (Cquat, 1 C, 7). – MS (ESI, MeOH): m/z (%) = 457.2 
(100) [MNa+], 473.1 (34) [MK+]. – HR-MS (FAB, MeOH/glycerol): [M+·] calcd. for 
C24H38N2O5 434.2781; found 434.2775. – IR (neat) [cm-1]: ν~  = 3371, 2976, 2869, 1708, 
1617, 1505, 1367, 1274, 1180, 1059, 965, 833. – MF C24H38N2O5. – MW 434.57. 
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rac-tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-(2-hydroxyethylamino)phenyl)-tetrahydro-
furan-3-carboxylate (rac-212): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxylate rac-135 (250 mg, 0.57 mmol), 
2-aminoethanol 201 (52 µl, 0.85 mmol), K2CO3 (156 mg, 1.13 mmol), CuI (11 mg, 0.06 
mmol), L-proline (13 mg, 0.11 mmol) and 0.57 ml DMSO. The crude product was purified 
using an gradient of DCM and methanol (DCM:MeOH 99.5:0.5 ? 99:1, Rf (99:1) = 0.16) 
giving the product as a colorless solid in 42 % yield. (100 mg, 0.24 mmol) 
MP 166-167 °C. – 1H-NMR (300 MHz, CDCl3) δ = 1.16 (s, 9 H, 10), 1.47 (s, 9 H, 1), 2.53 
(bs, 1 H, 11), 2.70–2.85 (m, 1 H, 11), 3.23 (bs, 2 H, 20), 3.77 (t, 3JH,H = 5.1, 2 H, 21), 4.10 
(q, 3JH,H = 8.0, 1 H, 12), 4.29 (dt, 3JH,H = 3.6, 3JH,H = 8.2, 1 H, 12), 4.80 (bs, 1 H, 14), 5.37 
(bs, 1 H, 5), 6.55 (d, 3JH,H = 8.4, 2 H, 17), 7.10 (d, 3JH,H = 8.4, 2 H, 16). – 13C-NMR (125 
MHz, CDCl3): δ = 27.5 (+, 3 C, 1), 28.3 (+, 3 C, 10), 35.6 (-, 1 C, 11), 46.1 (-, 1 C, 20), 
61.0 (-, 1 C, 21), 67.6 (-, 1 C, 12), 69.8 (Cquat, 1 C, 6), 79.9 (Cquat, 1 C, 2), 81.9 (Cquat, 1 C, 
9), 86.5 (+, 1 C, 14), 112.8 (+, 2 C, 17), 126.3 (Cquat, 1 C, 15), 127.6 (+, 2 C, 16), 148.2 
(Cquat, 1 C, 18), 154.8 (Cquat, 1 C, 4), 170.0 (Cquat, 1 C, 7). – MS (ESI, MeOH): m/z (%) = 
445.1 (100) [MNa+], 461.2 (22) [MK+]. – HR-MS (PI-EIMS, MeOH): [M+·] calcd. for 
C22H34N2O6 422.2417; found 422.2427. – IR (neat) [cm-1]: ν~  = 3363, 2975, 2936, 2868, 
1707, 1615, 1510, 1368, 1274, 1255, 1171, 1039, 826. – MF C22H34N2O6. – MW 422.52. 
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rac-tert-Butyl 2-(4-(allylamino)phenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-
carboxylate (rac-213): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxylate rac-135 (250 mg, 0.57 mmol), 
allylamine 202 (64 µl, 0.85 mmol), K2CO3 (156 mg, 1.13 mmol), CuI (11 mg, 0.06 mmol), 
L-proline (13 mg, 0.11 mmol) and 0.57 ml DMSO. The crude product was purified using a 
9:1 mixture of PE and EtOAc (Rf = 0.13) giving the product as a colorless solid in 54 % 
yield. (129 mg, 0.31 mmol) 
MP 132-134 °C. – 1H-NMR (300 MHz, CDCl3): δ = 1.15 (s, 9 H, 10), 1.47 (s, 9 H, 1), 2.53 
(bs, 1 H, 11), 2.69-2.85 (m, 1 H 11), 3.75-3.94 (m, 3 H, 19 + 20), 4.11 (q, 3JH,H = 8.1, 1 H, 
12), 4.29 (dt, 3JH,H = 8.3, 3JH,H = 3.7, 1 H, 12), 4.80 (s, 1 H, 14), 5.13 (dd, 2JH,H = 1.4, 3JH,H = 
10.3, 1 H, 22a), 5.23 (dd, 2JH,H = 1.5, 3JH,H = 17.2, 1 H, 22b), 5.41 (s, 1 H, 5), 5.83-5.98 (m, 
1 H, 21), 6.54 (d, 3JH,H = 8.6, 2 H, 17), 7.10 (d, 3JH,H = 8.4, 2 H, 16). – 13C-NMR (75 MHz, 
CDCl3): δ = 27.5 (+, 3 C, 1), 28.4 (+, 3 C, 10), 35.6 (-, 1 C, 11), 46.4 (-, 2 C, 20), 67.6 (-, 1 
C, 12), 69.8 (Cquat, 1 C, 6), 79.9 (Cquat, 1 C, 2), 81.8 (Cquat, 1 C, 9), 86.5 (+, 1 C, 14), 112.5 
(+, 2 C, 17), 116.1 (-, 1 C, 22), 126.0 (Cquat, 1 C, 15), 127.5 (+, 2 C, 16), 135.3 (+, 1 C, 21), 
148.0 (Cquat, 1 C, 18), 154.7 (Cquat, 1 C, 4), 170.1 (Cquat, 1 C, 7). – MS (ESI, MeOH): m/z 
(%) = 441.1 (100) [MNa+], 457.0 (23) [MK+]. – HR-MS (PI-EIMS, MeOH): [M+·] calcd. for 
C23H34N2O5 418.2468; found 418.2457. – IR (neat) [cm-1]: ν~  = 3413, 3355, 2983, 2931, 
2884, 2357, 1707, 1614, 1510, 1368, 1270, 1179, 1067, 1044, 909, 824. – MF 
C23H34N2O5. – MW 418.53. 
O
NH
O
O
N
H
O
O
1
42
3
5
6
7
8
9
10
11
12
13
14
15
16 17
18
19
20
21
22aH
H
H
22b
Section B 4. Derivatization of TAAs and the Synthesis of Cyclic Peptides 
 237
rac-tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-morpholinophenyl)-tetrahydrofuran-3-
carboxylate (rac-215): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-butoxycarbony-
lamino)-tetrahydrofuran-3-carboxylate rac-135 (250 mg, 0.57 mmol), morpholine 204 (74 
µl, 0.85 mmol), K2CO3 (156 mg, 1.13 mmol), CuI (11 mg, 0.06 mmol), L-proline (13 mg, 
0.11 mmol) and 0.57 ml DMSO. The crude product was purified using a 9:1 mixture of PE 
and EtOAc (Rf = 0.13) giving the product as a colorless solid in 33 % yield. (90 mg, 0.19 
mmol) 
Literature know compound.218 
rac-tert-Butyl 2-(4-(allylamino)phenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-
carboxylate (rac-216): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-butoxycarbonyl-
amino)-tetrahydrofuran-3-carboxylate rac-135 (250 mg, 0.57 mmol), pyrrolidine 205 (60 
mg, 0.85 mmol), K2CO3 (156 mg, 1.13 mmol), CuI (11 mg, 0.06 mmol), L-proline (13 mg, 
0.11 mmol) and 0.57 ml DMSO. The crude product was purified using a 9:1 mixture of PE 
and EtOAc (Rf = 0.25) giving the product as a colorless solid in 73 % yield. (179 mg, 0.41 
mmol) 
MP 108-110 °C. – 1H-NMR (300 MHz, CDCl3) δ = 1.18 (s, 9 H, 10), 1.47 (s, 9 H, 1), 1.94-
2.01 (m, 2 H, 21), 2.54 (bs, 1 H, 11), 2.73–2.86 (m, 1 H, 11), 3.18-3.37 (m, 2 H, 20), 4.11 
(q, 3JH,H = 8.0, 1 H, 12), 4.30 (dt, 3JH,H = 8.3, 3JH,H = 3.9, 1 H, 12), 4.81 (s, 1 H, 14), 5.40 
(bs, 1 H, 5), 6.48 (d, 3JH,H = 8.5, 2 H, 17), 7.13 (d, 3JH,H = 8.6, 2 H, 16). – 13C-NMR (75 
MHz, CDCl3): δ = 25.3 (-, 2 C, 21), 27.6 (+, 3 C, 1), 28.3 (+, 3 C, 10), 35.4 (-, 1 C, 11), 
47.7 (-, 2 C, 20), 67.4 (-, 1 C, 12), 69.8 (Cquat, 1 C, 6), 79.7 (Cquat, 1 C, 2), 81.7 (Cquat, 1 C, 
9), 86.6 (+, 1 C, 14), 111.3 (+, 2 C, 17), 123.8 (Cquat, 1 C, 15), 127.4 (+, 2 C, 16), 147.9 
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(Cquat, 1 C, 18), 154.7 (Cquat, 1 C, 4), 170.0 (Cquat, 1 C, 7). – MS (ESI, MeOH): m/z (%) = 
377.1 (13) [MH+ - C4H8], 433.1 (100) [MH+], 455.1 (19) [MNa+]. – HR-MS (PI-EIMS, 
MeOH): [M+·] calcd. for C24H36N2O5 432.2624; found 432.2629. – IR (neat) [cm-1]: ν~  = 
3371, 2971, 2853, 2168, 1707, 1613, 1511, 1369, 1278, 1253, 1160, 1045, 817. – MF 
C24H36N2O5. – MW 432.55. 
rac-tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-(4-methoxyphenylamino)phenyl)tetra-
hydrofuran-3-carboxylate (rac-217): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-butoxycarbony-
lamino)-tetrahydrofuran-3-carboxylate rac-135 (250 mg, 0.57 mmol), pyrrolidine 206 (104 
mg, 0.85 mmol), K2CO3 (156 mg, 1.13 mmol), CuI (11 mg, 0.06 mmol), L-proline (13 mg, 
0.11 mmol) and 0.57 ml DMSO. The crude product was purified using a 9:1 mixture of PE 
and EtOAc (Rf = 0.29) giving the product as a colorless solid in 73 % yield. (135 mg, 0.28 
mmol) 
MP 139 °C. – 1H-NMR (300 MHz, CDCl3) δ = 1.18 (s, 9 H, 10), 1.47 (s, 9 H, 1), 2.56 (bs, 1 
H, 11), 2.71–2.83 (m, 1 H, 11), 3.78 (s, 3 H, 25), 4.13 (q, 3JH,H = 8.0, 1 H, 12), 4.30 (dt, 
3JH,H = 3.6, 3JH,H = 8.2, 1 H, 12), 4.85 (bs, 1 H, 14), 5.47 (bs, 1 H, 5), 6.83 (d, 3JH,H = 8.3, 4 
H, 17 + 22), 7.01 (d, 3JH,H = 8.8, 2 H, 16), 7.15 (d, 3JH,H = 8.4, 2 H, 21). – 13C-NMR (75 
MHz, CDCl3): δ = 27.5 (+, 3 C, 1), 28.4 (+, 3 C, 10), 35.6 (-, 1 C, 11), 55.5 (+, 1 C, 25), 
67.6 (-, 1 C, 12), 69.8 (Cquat, 1 C, 6), 79.9 (Cquat, 1 C, 2), 81.9 (Cquat, 1 C, 9), 86.2 (+, 1 C, 
14), 114.6 (+, 2 C, 17/22), 115.3 (+, 2 C, 17/22), 121.8 (+, 2 C, 21), 127.5 (+, 2 C, 16), 
128.3 (Cquat,, 1 C, 15), 135.8 (Cquat, 1 C, 20), 144.9 (Cquat, 1 C, 18), 154.6 (Cquat, 1 C, 4), 
155.2 (Cquat, 1 C, 23), 170.1 (Cquat, 1 C, 7). – MS (ESI, MeOH): m/z (%) = 507.1 (100) 
[MNa+], 523.0 (11) [MK+]. – HR-MS (FAB, MeOH/glycerol): [M+·] calcd. for C27H36N2O6 
484.2573; found 484.2567. – IR (neat) [cm-1]: ν~  = 3364, 2980, 1710, 1616, 1502, 1368, 
1250, 1163, 1037, 926. – MF C27H36N2O6. – MW 484.58. 
O
NH
O
O
N
H
O
O
1
42
3
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20 21
22
23
24
O 25
Section B 4. Derivatization of TAAs and the Synthesis of Cyclic Peptides 
 239
rac-tert-Butyl 2-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-
3-carboxylate (rac-218): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxylate rac-135 (250 mg, 0.57 mmol), 
imidazole 207 (104 mg, 0.85 mmol), K2CO3 (156 mg, 1.13 mmol), CuI (11 mg, 0.06 
mmol), L-proline (13 mg, 0.11 mmol) and 0.57 ml DMSO. The crude product was purified 
using a 8:2 mixture of PE and EtOAc (Rf = 0.18) giving the product as a colorless solid in 
49 % yield. (119 mg, 0.28 mmol) 
MP 110 °C. – 1H-NMR (300 MHz, CDCl3): δ = δ = 1.05 (s, 9 H, 10), 1.42 (s, 9 H, 1), 2.42-
2.77 (m, 2 H, 11), 4.14 (q, 3JH,H = 8.1, 1 H, 12), 4.27 (dt, 3JH,H = 4.0, 3JH,H = 8.1, 1 H, 12), 
5.06 (s, 1 H, 14), 5.96 (s, 1 H, NH), 7.12 (s, 1 H, 22), 7.19 (s, 1 H, 23), 7.27 (d, 3JH,H = 8.8, 
2 H, 17), 7.41 (d, 3JH,H = 8.5, 2 H, 16), 7.77 (s, 1 H, 20). – 13C-NMR (75 MHz, CDCl3): δ = 
27.4 (+, 3 C, 1), 28.4 (+, 3 C, 10), 35.9 (-, 1 C, 11), 67.9 (-, 1 C, 12), 69.9 (Cquat, 1 C, 6), 
80.0 (Cquat, 1 C, 2), 82.3 (Cquat, 1 C, 9), 84.6 (+, 1 C, 14), 118.2 (+, 1 C, 23), 120.8 (+, 2 C, 
17), 127.9 (+, 2 C, 16), 130.3 (+, 1 C, 22), 135.4 (+, 1 C, 20), 136.8 (Cquat, 1 C, 18), 137.4 
(Cquat, 1 C, 15), 154.5 (Cquat, 1 C, 4), 169.9 (Cquat, 1 C, 7). – MS (ESI, MeOH): m/z (%) = 
430.1 (100) [MH+], 452.1 (24) [MNa+]. – HR-MS (FAB, MeOH/glycerol): [MH+] calcd. for 
C23H32N3O6 430.2342; found 430.2334. – IR (neat) [cm-1]: ν~  = 3414, 3357, 2982, 2883, 
1706, 1612, 1510, 1367, 1252, 1154, 1111, 1067, 910, 825. – MF C24H36N2O7. – MW 
464.25. 
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rac-tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-(2-methoxy-2-oxoethylamino)phenyl)-
tetrahydrofuran-3-carboxylate (rac-219): 
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxylate rac-135 (200 mg, 0.45 mmol), H-Gly-
OMe 208 (70 mg, 0.68 mmol), K2CO3 (125 mg, 0.90 mmol), CuI (9 mg, 0.05 mmol), L-
proline (10 mg, 0.09 mmol) and 0.45 ml DMSO. The crude product was purified using an 
7:3 mixture of PE and EtOAc (Rf = 0.21) giving the product as a colorless solid in 13 % 
yield. (27 mg, 0.06 mmol) 
MP 100-102 °C. – 1H-NMR (300 MHz, CDCl3): δ = δ = 1.14 (s, 9 H, 10), 1.46 (s, 9 H, 1), 
2.55 (bs, 1 H, 11), 2.76 (dt, 3JH,H = 8.4, 3JH,H = 12.9, 1 H 11), 2.85 (s, 3 H, 23), 4.11 (q, 
3JH,H = 7.2, 2 H, 20), 4.29 (dt, 3JH,H = 8.2, 3JH,H = 3.8, 2 H, 12), 4.83 (s, 1 H, 14), 5.42 (s, 1 
H, NH), 6.54 (d, 3JH,H = 8.5, 2 H, 17), 7.13 (d, 3JH,H = 8.5, 2 H, 16). – 13C-NMR (75 MHz, 
CDCl3): δ = 27.5 (+, 3 C, 1), 28.4 (+, 3 C, 10), 35.6 (-, 1 C, 11), 45.7 (-, 1 C, 20), 52.3 (+, 1 
C, 23), 67.7 (-, 1 C, 12), 69.8 (Cquat, 1 C, 6), 80.0 (Cquat, 1 C, 2), 81.9 (Cquat, 1 C, 9), 86.3 
(+, 1 C, 14), 112.5 (+, 2 C, 17), 126.9 (Cquat, 1 C, 15), 127.6 (+, 2 C, 16), 146.9 (Cquat, 1 C, 
18), 154.7 (Cquat, 1 C, 4), 170.1 (Cquat, 1 C, 7), 171.6 (Cquat, 1 C, 21). – MS (ESI, 
DCM/MeOH + 10 mM NH4OAc): m/z (%) = 451.0 (50) [MH+], 489.0 (100) [MK+]. – HR-MS 
(PI-LSIMS, DCM/NBA): [M+·] calcd. for C23H34N2O7 450.2366; found 450.2360. – IR (neat) 
[cm-1]: ν~  = 3361, 2983, 2361, 2337, 1722, 1698, 1617, 1511, 1367, 1174, 1067, 1046, 
997, 824. – MF C24H36N2O7. – MW 464.25. 
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tert-Butyl 2-(4-(2-(benzyloxycarbonylamino)ethylamino)phenyl)-3-(tert-butoxycarbonyl-
amino)-tetrahydrofuran-3-carboxylate (rac-220):  
The synthesis followed GP2 using rac-tert-butyl 2-(4-bromophenyl)-3-(tert-
butoxycarbonylamino)-tetrahydrofuran-3-carboxylate rac-135 (200 mg, 0.45 mmol), benzyl 
2-aminoethylcarbamate 209 (132 mg, 0.68 mmol), K2CO3 (125 mg, 0.90 mmol), CuI (9 
mg, 0.05 mmol), L-proline (10 mg, 0.09 mmol) and 0.45 ml DMSO. The crude product was 
purified using an 7:3 mixture of PE and EtOAc (Rf = 0.18) giving the product as a colorless 
solid in 23 % yield. (58 mg, 0.11 mmol) 
MP 133 °C. – 1H-NMR (300 MHz, CDCl3): δ = δ = 1.14 (s, 9 H, 10), 1.46 (s, 9 H, 1), 2.53 
(bs, 1 H, 11), 2.77 (dt, 3JH,H = 8.5, 2JH,H = 12.9, 1 H, 11), 3.14-3.43 (m, 4 H, 20 + 21), 4.01-
4.09 (m, 1 H, 12), 4.28 (dt, 3JH,H = 8.3, 3JH,H = 3.8, 1 H, 12), 5.07 (s, 1 H, 14), 5.09 (s, 2 H, 
25), 5.44 (s, 1 H, NH), 6.49 (s, 1 H, NH), 6.52 (s, 1 H, NH), 7.08 (d, 3JH,H = 8.2, 2 H, 17), 
7.27-7.41 (m, 7 H,18 + 27 - 29). – 13C-NMR (75 MHz, CDCl3): δ = 27.6 (+, 3 C, 1), 28.5 (+, 
3 C, 10), 40.5 (-, 1 C, CH2), 41.3 (-, 1 C, CH2), 44.2 (-, 1 C, CH2), 67.0 (-, 1 C, CH2), 67.7 
(-, 1 C, CH2), 69.9 (Cquat, 1 C, 6), 80.0 (Cquat, 1 C, 2), 81.9 (Cquat, 1 C, 9), 86.5 (+, 1 C, 14), 
112.4 (+, 2 C, 17), 127.7 (+, 2 C, 16), 128.2 (Cquat, 1 C, 27/28), 128.3 (+, 1 C, 29), 128.6 
(+, 2 C, 27/28), 136.4 (Cquat, 1 C, 26), 147.8 (Cquat, 1 C, 18), 154.8 (Cquat, 1 C, 4), 156.9 
(Cquat, 1 C, 23), 170.1 (Cquat, 1 C, 7). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): 556.1 
(100) [MH+], 1111.7 (19) [2M + H+] – HR-MS (PI-EIMS, MeOH): [M+·] calcd. for C30H41N3O7 
555.2945; found 555.2933. – MF C24H36N2O7. – MW 464.25. 
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rac-tert-Butyl 3-amino-2-(4-bromophenyl)-tetrahydrofuran-3-carboxylate · HCl (rac-136): 
Compound rac-135 (1.34 mg, 5.27 mmol) was dissolved in 17 ml of ether (15 ml/mmol) 
and cooled to 0 °C in an ice bath. To the solution 8 ml of HCl saturated ether (7 ml/mmol) 
were added. The mixture was allowed to warm to room temperature and stirred over night. 
The solvent was evaporated under reduced pressure to give the product as colorless 
hygroscopic solid in quantitative yield. No further purification was necessary. (420 mg, 
1.11 mmol) 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 1.16 (s, 9 H, 10), 2.30 (ddd, 3JH,H = 3.6, 
3JH,H = 6.9, 2JH,H = 13.7, 1 H, 3), 2.86 (t, 3JH,H = 6.9, 1 H, 3), 4.15 (dt, 3JH,H = 6.8, 3JH,H = 8.9, 
1 H, 4), 4.46 (dt, 3JH,H = 3.6, 3JH,H = 8.6, 1 H, 4), 4.98 (s, 1 H, 6), 7.35 (d, 3JH,H = 8.2, 2 H, 
12), 7.56 (d, 3JH,H = 8.5, 2 H, 13). – 13C-NMR (75 MHz, MeOH-d4): δ = 27.6 (+, 3 C, 10), 
37.2 (-, 1 C, 3), 68.6 (-, 1 C, 4), 70.1 (Cquat, 1 C, 2), 86.1 (Cquat, 1 C,9), 87.7 (+, 1 C, 6), 
123.8 (Cquat, 1 C, 14), 129.9 (+, 2 C, 12) , 132.6 (+, 2 C, 13), 136.6 (Cquat, 1 C, 11), 168.1 
(Cquat, 1 C, 7). – MS (CI, NH3): m/z (%) = 285.9 (16) [MH+ - C4H8), 303.0 (46) [MNH4+ - 
C4H8], 342.0 (100) [MH+], 359.0 (10) [MNH4+]. – IR (neat) [cm-1]: ν~  = 2978, 2883, 2360, 
2342, 1734, 1653, 1521, 1490, 1369, 1253, 1150, 1135, 1073, 1010, 838, 811, 745. – MF 
C15H21BrClNO3. – MW 378.69. 
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tert-Butyl 2-(4-bromophenyl)-3-((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)-
tetrahydro-furan-3-carboxylate (253): 
Under an atmosphere of nitrogen Boc-Val-OH 254 (236 mg, 1.09 mmol, 1.2 eq.) was 
dissolved in 7.3 ml DMF (8 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (558 µl, 3.26 mmol, 3.6 eq.), HOBt (226 mg, 1.63 mmol, 1.8 eq.) and EDC (289 
µg, 1.63 mmol, 1.8 eq.) were added in this sequence. Then compound rac-136 (350 mg, 
0.91 mmol, 1.0 eq.) was slowly added in portions. The mixture was allowed to warm to 
room temperature and stirred for 24 hours. The reaction was quenched with 14 ml of 
water and 4 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x14 ml). The 
combined organic layers were washed twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (PE:diethyl ether 60:40; Rf = 0.14) 
to give the product as colorless solid in 70 % yield (340 mg, 0.63 mmol). 
MP 139-140 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.93-1.06 (m, 6 H, CH3), 1.08-1.15 (m, 
9 H, tBu-CH3), 1.46-1.49 (m, 9 H, Boc-CH3), 2.10-2.34 (m, 1 H, CH), 2.46-2.72 (m, 2 H, 
CH2), 3.85-4.04 (m, 1 H, CH), 4.25-4.41 (m, 2 H, OCH2), 4.91-5.11 (m, 1 H, CH), 7.18-
7.24 (m, 2 H, CH-Ar), 7.35-7.44 (m, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 17.5 
(+, 1 C, CH3), 19.4/19.6 (+, 1 C, CH3), 27.4 (+, 3 C, tBu-CH3), 28.3 (+, 3 C, Boc-CH3), 
30.4/30.5 (+, 1 C, CH), 35.4/35.7 (-, 1 C, CH2), 60.4/60.7 (+, 1 C, CH), 67.9/68.0 (-, 1 C, 
OCH2), 69.6 (Cquat, 1 C, CNH), 83.1 (Cquat, 2 C, C(CH3)3), 83.2 (+, 1 C, CH), 121.5/121.6 
(Cquat, 1 C, C-Br), 127.7 (+, 2 C, CH-Ar), 130.9/131.0 (+, 2 C, CH-Ar), 136.7 (Cquat, 1 C, C-
Ar), 155.9 (Cquat, 1 C, Boc-CO), 170.0/170.1 (Cquat, 1 C, CO), 170.9/171.1 (Cquat, 1 C, CO). 
– MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 429.0 (84) [MH+ - 2 C4H8], 485.0 
(67) [MH+ - C4H8], 541.0 (100) [MH+], 563.0 (39) [MNa+]. – Elemental analysis calcd. (%) 
for C25H37BrN2O6 (541.48): C 55.45, H 6.89, N 5.17; found: C 55.35, H 6.82, N 4.89. – IR 
(neat) [cm-1]: ν~  = 3390, 3323, 2972, 2934, 2875, 1705, 1664, 1510, 1366, 1254, 1157, 
1071, 1012, 834, 648. – MF C25H37BrN2O6. – MW 541.48. 
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tert-Butyl 3-((S)-2-amino-3-methylbutanamido)-2-(4-bromophenyl)-tetrahydrofuran-3-
carboxylate · TFA (254): 
Compound 253 (500 mg, 0.92 mmol) was dissolved under ice bath cooling in 18.4 ml of a 
8 % TFA containing dry DCM solution (20 ml/mmol), which was prepared in advance. The 
reaction mixture was stirred for 5 hours and reaction progress was monitored by TLC 
(EtOAc). The solvent was evaporated under reduced pressure to give the product as pale 
yellow very hygroscopic solid in quantitative yield (504 mg, 0.91 mmol). 
MP > 180 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.99-1.20 (m, 15 H, CH3), 2.16-2.42 
(m, 2 H, CH + CH2), 2.83-3.01 (m, 1 H, CH2), 3.68-3.85 (m, 1 H, CH2), 3.89-4.08 (m, 1 H, 
CH2), 4.29-4.44 (m, 1 H, CH), 4.95-5.08 (m, 1 H, CH), 7.23-7.31 (m, 2 H, Ar-CH), 7.48 (d, 
3JH,H = 8.5, 2 H, Ar-CH). – 13C-NMR (75 MHz, MeOH-d4): δ = 17.5/18.2 (+, 1 C, CH3), 
19.0/19.2 (+, 1 C, CH3), 27.7/27.8 (+, 3 C, CH3), 28.2 (+, 1 C, CH), 31.6/31.8 (-, 1 C, CH2), 
59.4/59.6 (+, 1 C, CH), 68.9/69.1 (-, 1 C, CH2), 72.0 (Cquat, 1 C, NH-C), 83.8 (Cquat, 1 C, C-
tBu), 87.3/87.4 (+, 1 C, CH), 123.2 (Cquat, 1 C, C-Br), 130.2/130.2 (+, 2 C, Ar-CH), 132.2 
(+, 2 C, Ar-CH), 138.5 (Cquat, 1 C, Ar-C), 169.5 (Cquat, 1 C, CO), 169.9 (Cquat, 1 C, CO). – 
MS (ES, MeOH): m/z (%) = 441.0 (65) [MH+], 462.8 (100) [MNa+]. – IR (neat) [cm-1]: ν~  = 
3354, 2970, 2943, 2361, 2342, 1668, 1519, 1259, 1118, 1011, 831, 721. – MF 
C22H30BrF3N2O6. – MW 554.38. 
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(S)-Methyl 2-(4-(tert-butoxycarbonylamino)butanamido)-3-methylbutanoate (227): 
Under an atmosphere of nitrogen 4-(tert-butoxycarbonylamino)butanoic acid 224 (1.50 
mg, 7.38 mmol, 1 eq.) was dissolved in 14.7 ml DCM (2 ml/mmol) and cooled to 0 °C in an 
ice bath. To the solution DIPEA (3.79 ml, 22.1 mmol, 3 eq.), HOBt (1.51 g, 11.1 mmol, 1.5 
eq.) and EDC (1.96 ml, 11.1 mmol, 1.5 eq.) were added in this sequence. Then H-Val-
OMe · HCl 226 (1.86 g, 11.1 mmol, 1.5 eq.) was slowly added in portions. The mixture 
was allowed to warm to room temperature and stirred for 24 hours. The reaction was 
quenched with 15 ml of water and 15 ml of 1M aqueous KHSO4 and extracted with diethyl 
ether (3x40 ml). The combined organic layers were washed with brine. Afterwards the 
solution was dried over MgSO4 and concentrated under reduced pressure. The crude 
product was then purified by column chromatography on flash silica gel (EE:PE 40:60; 
Rf = 0.16) to give the product as colorless oil in 81 % yield (1.89 mg, 5.97 mmol). 
1H-NMR (300 MHz, CDCl3): δ = 0.94 (t, 3JH,H = 7.3, 6 H, 14), 1.44 (s, 9 H, 1), 1.81 (quintet, 
3JH,H = 6.8, 2 H, 7), 2.11-2.24 (m, 1 H, 15), 2.29 (t, 3JH,H = 7.0, 2 H, 8), 3.09-3.34 (m, 2 H, 
6), 3.73 (s, 3 H, 14), 4.54 (dd, 3JH,H = 4.9, 3JH,H = 8.5, 1 H, 11), 4.73 (bs, 1 H, 5), 6.57 (bs, 
1 H, 10). – 13C-NMR (75 MHz, CDCl3): δ = 17.8 (+, 1 C, 16), 19.0 (+, 1 C, 16), 26.5 (-, 1 C, 
7), 28.4 (+, 3 C, 1), 31.0 (+, 1 C, 8), 39.6 (-, 1 C, 8), 39.6 (-, 1 C, 6), 52.1 (+, 1 C, 14), 57.2 
(+, 1 C, 11), 79.3 (Cquat, 1 C, 2), 156.5 (Cquat, 1 C, 4), 172.7 (Cquat, 1 C, 9/12), 172.7 (Cquat, 
1 C, 9/12). – MS (CI, NH3): m/z (%) = 217.2 (10) [MH+ - Boc], 261.2 (24) [MH+ - C4H8], 
278.2 (7) [MNH4+ - C4H8], 317.3 (100) [MH+], 334.3 (5) [MNH4+]. – IR (neat) [cm-1]: ν~  = 
3356, 2969, 2875, 2360, 2341, 1714, 1514, 1366, 1260, 1159, 1075, 1012, 830. – MF 
C15H28N2O5. – MW 316.39. 
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(S)-Methyl 2-(6-(tert-butoxycarbonylamino)hexanamido)-3-methylbutanoate (228): 
Under an atmosphere of nitrogen 6-(tert-butoxycarbonylamino)hexanoic acid 225 (1.50 
mg, 6.49 mmol, 1 eq.) was dissolved in 13.0 ml DCM (2 ml/mmol) and cooled to 0 °C in an 
ice bath. To the solution DIPEA (3.33 ml, 19.5 mmol, 3 eq.), HOBt (1.32 g, 9.73 mmol, 1.5 
eq.) and EDC (1.72 ml, 9.73 mmol, 1.5 eq.) were added in this sequence. Then H-Val-
OMe · HCl 226 (1.63 g, 9.73 mmol, 1.5 eq.) was slowly added in portions. The mixture 
was allowed to warm to room temperature and stirred for 24 hours. The reaction was 
quenched with 13 ml of water and 13 ml of 1M aqueous KHSO4 and extracted with diethyl 
ether (3x40 ml). The combined organic layers were washed with brine. Afterwards the 
solution was dried over MgSO4 and concentrated under reduced pressure. The crude 
product was then purified by column chromatography on flash silica gel (EtOAc:PE 40:60; 
Rf = 0.18) to give the product as colorless oil in 80 % yield (1.78 mg, 5.17 mmol). 
1H-NMR (300 MHz, CDCl3): δ = 0.89 (d, 3JH,H = 6.9, 3 H, 18), 0.93 (d, 3JH,H = 6.9, 3 H, 18), 
1.32-1.56 (m, 13 H, 1 + 7 + 8), 1.67 (quintet, 3JH,H = 7.5, 2 H, 9), 2.14 (dq, 3JH,H = 4.9, 3JH,H 
= 6.9, 1 H, 15), 2.24 (t, 3JH,H = 7.4, 2 H, 10), 3.10 (dd, 3JH,H = 6.3, 2JH,H = 12.3, 2 H, 6), 3.74 
(s, 3 H, 16), 4.48-4.63 (m, 2 H, 5 + 13), 5.09 (d, 3JH,H = 8.2, 1 H, 12). – 13C-NMR (75 MHz, 
CDCl3): δ = 17.8 (+, 1 C, 18), 18.9 (+, 1 C, 18), 25.2 (-, 1 C, 9), 26.3 (-, 1 C, 8), 28.4 (+, 3 
C, 1), 29.7 (-, 1 C, 7), 31.2 (+, 1 C, 17), 36.4 (-, 1 C, 10), 40.4 (-, 1 C, 6), 52.1 (+, 1 C, 16), 
56.9 (+, 1 C, 13), 79.0 (Cquat, 1 C, 2) 156.0 (Cquat, 1 C, 4), 172.8 (Cquat, 1 C, 11/14), 172.8 
(Cquat, 1 C, 11/14). – MS (CI, NH3): m/z (%) = 245.2 (27) [MH+ - Boc], 289.3 (51) [MH+ - 
C4H8], 306.2 (23) [MNH4+ - C4H8], 345.3 (100) [MH+], 362.3 (17) [MNH4+]. – IR (neat) 
[cm-1]: ν~  = 3364, 3242, 2969, 2930, 2361, 2341, 1668, 1519, 1463, 1259, 1226, 1118, 
994, 829. – MF C17H32N2O5. – MW 344,45. 
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(S)-2-(4-(tert-Butoxycarbonylamino)butanamido)-3-methylbutanoic acid (229): 
The ester 227 (1.00 g, 3.16 mmol) was dissolved in 32 ml of a MeCN:water mixture (4:1, 
10 ml/mmol). To the solution 1M aqueous LiOH (3.48 ml, 3.48 mmol, 1.1 eq.) was slowly 
added. The mixture was stirred over night. After acidification with 1M aqueous KHSO4 
solution the mixture was extracted with DCM (3x30 ml). The combined organic layers 
were dried over MgSO4 and concentrated under reduced pressure to give the product as 
colorless solid in 84 % yield. (800 mg, 2.65 mmol) 
MP 58-59 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.77-0.98 (m, 6 H, 15), 1.24-1.53 (m, 9 H, 
1), 1.61-1.90 (m, 2 H, 7), 2.05-2.41 (m, 3 H, 8 + 14), 2.94-3.37 (m, 2 H, 6), 4.68 (s, 1 H, 
11), 6.66 (bs, 1 H, 5), 7.34 (d, 3JH,H = 8.5, 1 H, 10), 10.99 (bs, 1 H, 13). – 13C-NMR (75 
MHz, CDCl3): δ = 17.9 (+, 1 C, 15), 19.1 (+, 1 C, 15), 26.3 (-, 1 C, 7), 28.3 (+, 3 C, 1), 31.9 
(+, 1 C, 14), 32.9 (-, 1 C, 8), 39.6 (-, 1 C, 6), 56.8 (+, 1 C, 11), 81.7 (Cquat, 1 C, 2), 158.5 
(Cquat, 1 C, 4), 172.7 (Cquat, 1 C, 9), 176.3 (Cquat, 1 C, 12). – MS (CI, NH3): m/z (%) = 203.2 
(9) [MH+ - Boc], 247.1 (30) [MH+ - C4H8], 264.2 (10) [MNH4+ - C4H8], 303.2 (100) [MH+], 
320.2 (5) [MNH4+]. – IR (neat) [cm-1]: ν~  = 3358, 2970, 2873, 2360, 2339, 1712, 1517, 
1365, 1259, 1163, 1075, 1011, 828. – MF C14H26N2O5. – MW 302.37. 
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(S)-2-(4-(tert-Butoxycarbonylamino)butanamido)-3-methylbutanoic acid (230): 
The ester 228 (1.00 g, 2.90 mmol) was dissolved in 29 ml of a MeCN:water mixture (4:1, 
10 ml/mmol). To the solution 1M aqueous LiOH (3.19 ml, 3.19 mmol, 1.1 eq.) was slowly 
added. The mixture was stirred over night. After acidification with 1M aqueous KHSO4 
solution the mixture was extracted with DCM (3x30 ml). The combined organic layers 
were dried over MgSO4 and concentrated under reduced pressure to give the product as 
colorless solid in 91 % yield. (870 mg, 2.63 mmol) 
MP 116 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.92 (d, 3JH,H = 6.9, 3 H, 17), 0.95 (d, 3JH,H = 
6.9, 3 H, 17), 1.24-1.53 (m, 13 H, 1 + 7 + 8), 1.64 (quintet, 3JH,H = 7.1, 2 H, 9), 2.13-2.32 
(m, 3 H, 10 + 16), 3. 07 (bs, 2 H, 6), 4.56 (dd, 3JH,H = 4.9, 3JH,H = 8.8, 1 H, 13), 4.75 (bs, 1 
H, 5), 6.52-6.68 (m, 1 H, 12), 10.56 (bs, 1 H, 15). – 13C-NMR (75 MHz, CDCl3): δ = 17.7 
(+, 1 C, 17), 19.1 (+, 1 C, 17), 25.3 (-, 1 C, 9), 26.2 (-, 1 C, 8), 28.4 (+, 3 C, 1), 29.6 (-, 1 C, 
7), 30.9 (+, 1 C, 16), 36.3 (-, 1 C, 10), 40.4 (-, 1 C, 6), 57.1 (+, 1 C, 13), 79.4 (Cquat, 1 C, 2) 
156.4 (Cquat, 1 C, 4), 174.0 (Cquat, 1 C, 11), 174.8 (Cquat, 1 C, 14). – MS (CI, NH3): m/z (%) 
= 231.2 (18) [MH+ - Boc], 275.2 (36) [MH+ - C4H8], 292.2 (38) [MNH4+ - C4H8], 331.2 (100) 
[MH+], 348.2 (35) [MNH4+]. – IR (neat) [cm-1]: ν~  = 3362, 3245, 2970, 2928, 2362, 2341, 
1667, 1521, 1462, 1255, 1226, 1116, 994, 831. – MF C16H30N2O5. – MW 330.42. 
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tert-Butyl 2-(4-bromophenyl)-3-((S)-2-(4-(tert-butoxycarbonylamino)butanamido)-3-
methylbutan-amido)-tetrahydrofuran-3-carboxylate (231): 
Under an atmosphere of nitrogen compound 229 (500 mg, 1.65 mmol, 1 eq.) was 
dissolved in 6.6 ml DMF (4 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (849 µl, 4.96 mmol, 3 eq.), HOAt (338 mg, 2.48 mmol, 1.5 eq.) and HATU (943 
mg, 2.48 mmol, 1.5 eq.) were added in this sequence. Then compound rac-136 (905 mg, 
1.98 mmol, 1.2 eq.) was slowly added in portions. The mixture was allowed to warm to 
room temperature and stirred for 24 hours. The reaction was quenched with 13 ml of 
water and 3 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x20 ml). The 
combined organic layers were washed twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (DCM:MeOH 98:2; Rf = 0.08) to give 
the product as colorless solid in 58 % yield (602 mg, 0.96 mmol). 
MP 72-73 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.93 (d, 3JH,H = 6.5, 3 H, 24), 0.93 (d, 3JH,H 
= 6.3, 3 H, 24), 1.02 (s, 9 H, 22), 1.36 (s, 9 H, 1), 1.75 (quintet, 3JH,H = 6.3, 2 H, 7), 2.05-
2.18 (m, 1 H, 23), 2.24 (t, 3JH,H = 7.0, 2 H, 8), 2.40-2.51 (m, 1 H, 15), 2.57-2.70 (m, 1 H, 
15), 2.97-3.19 (m, 2 H, 6), 4.11 (q, 3JH,H = 8.1, 1 H, 16), 4.23 (dt, 2JH,H = 3.3, 3JH,H = 8.2, 1 
H, 16), 4.31 (t, 3JH,H = 7.3, 1 H, 11), 4.92 (t, 3JH,H = 4.9, 1 H, NH), 5.07 (s, 1 H, 18), 6.99 (d, 
3JH,H = 7.9, 1 H, NH), 7.16 (d, 3JH,H = 8.2, 2 H, 26), 7.34 (d, 3JH,H = 8.5, 2 H, 27), 7.67 (d, 
3JH,H = 4.9, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 18.1 (+, 1 C, 24), 19.5 (+, 1 C, 24), 
26.7 (- 1 C, 7), 27.3 (+, 3 C, 1), 28.4 (+, 3 C, 22), 30.6 (+, 1 C, 23), 33.4 (-, 1 C, 15), 35.7 
(-, 1 C, 8), 39.6 (-, 1 C, 6), 58.9 (+, 1 C, 11), 67.9 (-, 1 C, 16), 69.9 (Cquat, 1 C, 14), 79.4 
(Cquat, 1 C, 2), 82.7 (Cquat, 1 C, 21), 84.1 (+, 1 C, 18), 121.7 (Cquat, 1 C, 28), 128.1 (+, 2 C, 
26), 131.0 (+, 2 C, 27), 136.8 (Cquat, 1 C, 25), 156.6 (Cquat, 1 C, 4), 169.3 (Cquat, 1 C, 12), 
171.0 (Cquat, 1 C, 19), 173.2 (Cquat, 1 C, 9). – MS (ES, MeOH): m/z (%) = 648.1 (100) 
[MNa+], 664.1 (17) [MK+]. – HR-MS (PI-EIMS): [M+·] calcd. for C29H44BrN3O7 625.2363; 
found 625.2350. – IR (neat) [cm-1]: ν~  = 3281, 2974, 2931, 2877, 1714, 1637, 1528, 1366, 
1251, 1161, 1011, 846, 647. – MF C29H44BrN3O7. – MW 626.58. 
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Alternative synthesis for compound 231: 
Under an atmosphere of nitrogen compound 224 (238 mg, 1.17 mmol, 1.4 eq.) was 
dissolved in 5.0 ml DMF (6 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (602 µl, 3.52 mmol, 4.2 eq.), HOAt (239 mg, 1.76 mmol, 2.1 eq.) and HATU (669 
mg, 1.76 mmol, 2.1 eq.) were added in this sequence. Then compound 254 (400 mg, 0.84 
mmol, 1 eq.) was slowly added in portions. The mixture was allowed to warm to room 
temperature and stirred for 24 hours. The reaction was quenched with 10 ml of water and 
3 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x15 ml). The combined 
organic layers were washed twice with brine. Afterwards the solution was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was then purified by 
column chromatography on flash silica gel (DCM:MeOH 98:2; Rf = 0.08) to give the 
product as colorless solid in 67 % yield (350 mg, 0.56 mmol). 
Section B 4. Derivatization of TAAs and the Synthesis of Cyclic Peptides 
 251
tert-Butyl 2-(4-bromophenyl)-3-((S)-2-(6-(tert-butoxycarbonylamino)hexanamido)-3-
methylbutanamido)-tetrahydrofuran-3-carboxylate (232): 
Under an atmosphere of nitrogen compound 230 (500 mg, 1.51 mmol, 1 eq.) was 
dissolved in 6.0 ml DMF (4 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (777 µl, 4.54 mmol, 3 eq.), HOAt (309 mg, 2.27 mmol, 1.5 eq.) and HATU (863 
mg, 2.27 mmol, 1.5 eq.) were added in this sequence. Then compound rac-136 (828 mg, 
1.82 mmol, 1.2 eq.) was slowly added in portions. The mixture was allowed to warm to 
room temperature and stirred for 24 hours. The reaction was quenched with 12 ml of 
water and 3 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x18 ml). The 
combined organic layers were washed twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (DCM:MeOH 98:2; Rf = 0.11) to give 
the product as colorless solid in 69 % yield (680 mg, 1.04 mmol). 
MP 61-62 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.97 (d, 3JH,H = 6.3, 3 H, 26), 0.99 (d, 3JH,H 
= 6.3, 3 H, 26), 1.08 (s, 9 H, 24), 1.27-1.36 (m, 2 H, 8), 1.39-1.50 (m, 11 H, 1 + 7), 1.59-
1.71 (m, 2 H, 9), 2.11 (q, 3JH,H = 6.5, 2 H, 25), 2.24 (t, 3JH,H = 7.5, 2 H, 10), 2.44-2.55 (m, 1 
H, 17), 2.63-2.74 (m, 1 H, 17), 3.00-3.11 (m, 2 H, 6), 4.19 (q, 3JH,H = 8.4, 1 H, 18), 4.23 (dt, 
2JH,H = 3.5, 3JH,H = 8.3, 1 H, 18), 4.34-4.42 (m, 1 H, 13), 4.61 (bs, 1 H, NH), 5.13 (s, 1 H, 
20), 6.36 (dd, 3JH,H = 5.1, 3JH,H = 8.0, 1 H, NH), 7.22 (d, 3JH,H = 8.5, 2 H, 28), 7.41 (d, 3JH,H 
= 8.5, 2 H, 29), 7.57 (d, 3JH,H = 8.5, 1 H, NH). – 13C-NMR (75 MHz, CDCl3): δ = 18.3 (+, 1 
C, 24), 19.4 (+, 1 C, 24), 25.4 (- 1 C, 9), 26.4 (-, 1 C, 8), 27.4 (+, 3 C, 1), 28.4 (+, 3 C, 24), 
29.7 (- 1 C, 7), 31.1 (+, 1 C, 25), 35.8 (-, 1 C, 17), 36.5 (-, 1 C, 10), 38.7 (-, 1 C, 6), 58.6 
(+, 1 C, 13), 67.9 (-, 1 C, 18), 69.8 (Cquat, 1 C, 16), 79.1 (Cquat, 1 C, 2), 82.9 (Cquat, 1 C, 23), 
84.0 (+, 1 C, 20), 121.7 (Cquat, 1 C, 30), 128.0 (+, 2 C, 28), 131.0 (+, 2 C, 29), 136.6 (Cquat, 
1 C, 27), 156.0 (Cquat, 1 C, 4), 169.4 (Cquat, 1 C, 14), 171.8 (Cquat, 1 C, 21), 173.2 (Cquat, 1 
C, 11). – MS (ES, MeOH): m/z (%) = 676.2 (100) [MNa+], 692.2 (15) [MK+]. – HR-MS (PI-
EIMS): [M+·] calcd. for C31H48BrN3O7 653.2676; found 653.2662. – IR (neat) [cm-1]: ν~  = 
3349, 2941, 2534, 2362, 2341, 1667, 1517, 1453, 1365, 1259, 1226, 1117, 994, 828, 686. 
– MF C31H48BrN3O7. – MW 654.63. 
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tert-Butyl 3-((S)-2-(4-aminobutanamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetra-
hydrofuran-3-carboxylate (233): 
Compound 231 (200 mg, 0.32 mmol) was dissolved under ice bath cooling in 6.4 ml of a 
8 % TFA containing dry DCM solution (20 ml/mmol), which was prepared in advance. The 
reaction mixture was stirred for 5 hours and reaction progress was monitored by TLC 
(EtOAc). The solvent was evaporated and the crude product was dissolved in methanol 
water mixture (1:1) and purified over an ion exchanger column using a strongly basic ion 
exchange resin. The pure product was obtained as colorless solid in quantitative yield. 
(168 mg, 0.32 mmol) 
MP 62 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.93-1.11 (m, 15 H, 18 + 20), 1.78 
(quintet, 3JH,H = 7.3, 2 H, 3), 2.00-2.13 (m, 1 H, 19), 2.25 (dd, 3JH,H = 2.7, 3JH,H = 6.6, 1 H, 
11), 2.32 (t, 3JH,H = 7.6, 2 H, 4), 2.66 (t, 3JH,H = 7.1, 2 H, 2), 2.89 (ddd, 3JH,H = 8.4, 3JH,H = 
9.7, 3JH,H = 13.0, 1 H, 11), 4.01 (ddd, 3JH,H = 6.6, 3JH,H = 8.4, 3JH,H = 9.7, 1 H, 12), 4.17 (d, 
3JH,H = 7.7, 1 H, 7), 4.29 (dt, 3JH,H = 2.8, 3JH,H = 8.3, 1 H, 12), 4.99 (s, 1 H, 14), 7.27 (d, 
3JH,H = 8.2, 2 H, 22), 7.47 (d, 3JH,H = 8.5, 2 H, 23). – 13C-NMR (75 MHz, MeOH-d4): δ = 
19.2 (+, 1 C, 20), 20.1 (+, 1 C, 20), 27.8 (+, 3 C, 18), 29.3 (-, 1 C, 3), 31.6 (+, 1 C, 19), 
34.1 (-, 1 C, 11), 37.0 (-, 1 C, 4), 41.8 (-, 1 C, 2), 60.4 (+, 1 C, 7), 68.9 (-, 1 C, 12), 71.8 
(Cquat, 1 C, 10), 83.1 (Cquat, 1 C, 17), 86.9 (+, 1 C, 14), 123.0 (Cquat, 1 C, 24), 130.3 (+, 2 C, 
22), 132.1 (+, 2 C, 23), 138.7 (Cquat, 1 C, 21), 170.0 (Cquat, 1 C, 8), 173.6 (Cquat, 1 C, 15), 
175.8 (Cquat, 1 C, 5). – MS (ES, MeOH): m/z (%) = 526.1 (33) [MH+], 548.1 (100) [M + 
Na+]. – IR (neat) [cm-1]: ν~  = 3269, 2968, 2936, 2330, 1732, 1636, 1528, 1368, 1253, 
1161, 1072, 1011, 837. – MF C24H36BrN3O5. – MW 526.46. 
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tert-Butyl 3-((S)-2-(6-aminohexanamido)-3-methylbutanamido)-2-(4-bromophenyl)-tetra-
hydrofuran-3-carboxylate (195): 
Compound 232 (300 mg, 0.46 mmol) was dissolved under ice bath cooling in 9.2 ml of a 
8 % TFA containing dry DCM solution (20 ml/mmol), which was prepared in advance. The 
reaction mixture was stirred for 5 hours and reaction progress was monitored by TLC 
(EtOAc). The solvent was evaporated and the crude product was dissolved in methanol 
water mixture (1:1) and purified over an ion exchanger column using a strongly basic ion 
exchange resin. The pure product was obtained as colorless solid in 89 % yield. (228 mg, 
0.41 mmol) 
MP 74 °C. – 1H-NMR (300 MHz, MeOH-d4): δ = 0.95-1.09 (m, 15 H, 20 + 22), 1.30-1.44 
(m, 2 H, 4), 1.51-1.74 (m, 4 H, 3 + 5), 1.99-2.13 (m, 1 H, 21), 2.22 – 2.35 (m, 3 H, 6 + 13), 
2.76 (t, 3JH,H = 7.6, 2 H, 2), 2.89 (ddd, 3JH,H = 8.4, 3JH,H = 9.7, 3JH,H = 13.0, 1 H, 13), 4.01 
(ddd, 3JH,H = 6.8, 3JH,H = 8.3, 3JH,H = 9.7, 1 H, 14), 4.17 (d, 3JH,H = 7.7, 1 H, 9), 4.29 (dt, 3JH,H 
= 2.7, 3JH,H = 8.2, 1 H, 14), 5.01 (s, 1 H, 16), 7.27 (d, 3JH,H = 8.5, 2 H, 24), 7.47 (d, 3JH,H = 
8.5, 2 H, 25). – 13C-NMR (75 MHz, MeOH-d4): δ = 19.3 (+, 1 C, 22), 20.1 (+, 1 C, 22), 26.6 
(-, 1 C, 5), 27.3 (-, 1 C, 4), 27.8 (+, 3 C, 20), 30.7 (-, 1 C, 3), 31.5 (+, 1 C, 21), 36.5 (-, 1 C, 
13), 37.1 (-, 1 C, 6), 41.4 (-, 1 C, 2), 60.5 (+, 1 C, 9), 68.9 (-, 1 C, 14), 71.8 (Cquat, 1 C, 12), 
83.1 (Cquat, 1 C, 19), 86.8 (+, 1 C, 16), 123.1 (Cquat, 1 C, 26), 130.3 (+, 2 C, 24), 132.2 (+, 2 
C, 25), 138.7 (Cquat, 1 C, 23), 170.0 (Cquat, 1 C, 10), 173.7 (Cquat, 1 C, 17), 176.2 (Cquat, 1 
C, 7). – MS (CI, NH3): m/z (%) = 554.1 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3271, 2970, 
2938, 2320, 1730, 1639, 1531, 1370, 1164, 1073, 1011, 835. – MF C26H40BrN3O5. – MW 
554.52. 
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Compound 196: 
The synthesis followed GP2 using compound 195 (40 mg, 0.07 mmol), K2CO3 (20 mg, 
0.14 mmol), CuI (3 mg, 0.01 mmol), L-proline (3 mg, 0.03 mmol) and 0.7 ml DMSO. The 
crude product was purified using a 6:4 mixture of PE and EtOAc (Rf = 0.09) giving the 
product as a colorless solid in 7 % yield. (2.4 mg, 0.004 mmol) 
1H-NMR (600 MHz, COSY, CDCl3) δ = 0.42-0.47 (m, 1 H, 4), 0.74-0.84 (m, 1 H, 4), 0.91 
(d, 3JH,H = 6.6, 3 H, 22), 0.97 (d, 3JH,H = 7.0, 3 H, 22), 1.20-1.25 (m, 1 H, 5), 1.40 (s, 9 H, 
26), 1.44–1.51 (m, 1 H, 5), 1.58-1.65 (m, 1 H, 3), 1.74-1.84 (m, 1 H, 3), 2.00 (ddd, 3JH,H = 
3.1, 3JH,H = 9.7, 2JH,H = 16.8, 1 H, 6), 2.18 (ddd, 3JH,H = 3.3, 3JH,H = 6.8, 2JH,H = 16.6, 1 H, 6), 
2.46 (q, 3JH,H = 10.2, 1 H, 13), 2.57-2.64 (m, 1 H, 21), 2.94 (ddd, 3JH,H = 3.5, 3JH,H = 8.5, 
2JH,H = 12.4, 1 H, 13), 3.01 (dd, 3JH,H = 8.4, 2JH,H = 13.4, 1 H, 2), 3.35 (d, 3JH,H = 8.9, 1 H, 9), 
3.56 (dd, 3JH,H = 8.1, 2JH,H = 13.4, 1 H, 2), 4.22 (ddd, 3JH,H = 3.3, 3JH,H = 7.6, 2JH,H = 10.9, 1 
H, 14), 4.36 (q, 3JH,H = 8.1, 1 H, 14), 5.00 (s, 1 H, 16), 5.70 (d, 3JH,H = 7.7, 2 H, 8), 7.35-
7.52 (m, 4 H, 18 + 19), 7.93 (s, 1 H, NH). – 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ 
= 19.1 (+, 1 C, 22), 19.7 (+, 1 C, 22), 23.2 (-, 1 C, 5), 26.1 (-, 1 C, 3), 27.3 (-, 1 C, 4), 27.3 
(+, 1 C, 21), 28.0 (+, 3 C, 26), 34.1 (-, 1 C, 6), 36.2 (-, 1 C, 13), 50.3 (-, 1 C, 2), 65.9 (-, 1 
C, 9), 67.7 (-, 1 C, 14), 69.1 (Cquat, 1 C, 12), 82.8 (Cquat, 1 C, 25), 84.0 (+, 1 C, 16), 122.3 
(+, 2 C, 19), 129.8 (+, 2 C, 18), 135.5 (Cquat, 1 C, 17), 136.9 (Cquat, 1 C, 20), 169.4 (Cquat, 1 
C, 23), 172.8 (Cquat, 1 C, 10), 173.2 (Cquat, 1 C, 7). – MS (LCMS, MeCN/H2O + 0.1 % TFA): 
m/z (%) = 418.0 (37) [MH+ - C4H8], 474.1 (100) [MH+], 515.1 (44) [MH+ + MeCN]. – MF 
C26H39N3O5. – MW 473.29. 
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tert-Butyl (2S,3R)-3-((S)-1-(2-(benzyloxycarbonooxoylamino)ethylamino)-3-methyl-1-oxo-
butan-2-ylcarbamoyl)-2-(4-bromophenyl)-tetrahydrofuran-3-ylcarbamate (236): 
Under an atmosphere of nitrogen compound 181 (330 mg, 0.68 mmol, 1 eq.) was 
dissolved in 4.1 ml DMF (6 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (349 µl, 2.04 mmol, 3 eq.), HOAt (139 mg, 1.02 mmol, 1.5 eq.) and HATU (388 
mg, 1.02 mmol, 1.5 eq.) were added in this sequence. Then benzyl aminoethylcarbamate 
50 (185 mg, 0.95 mmol, 1.4 eq.) was slowly added in portions. The mixture was allowed to 
warm to room temperature and stirred for 24 hours. The reaction was quenched with 8 ml 
of water and 4 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x12 ml). The 
combined organic layers were washed twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (EE:PE 50:50; Rf = 0.2) to give the 
product as colorless solid in 65 % yield (291 mg, 0.44 mmol). 
MP 153 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.56 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.63 (d, 
3JH,H = 6.9, 3 H, Val-CH3), 1.38 (s, 9 H, Boc-CH3), 1.87-2.01 (m, 1 H, CH), 2.72-2.87 (m, 1 
H, CH2), 2.90-3.02 (m, 1 H, CH2), 3.12-3.24 (m, 3 H, CH2), 3.29-3.40 (m, 1 H, CH2), 3.55 
(t, 3JH,H = 5.8, 1 H, CH2), 3.95 (q, 3JH,H = 4.0, 1 H, CH), 4.10-4.22 (m, 1 H, CH2), 4.90 (s, 1 
H, CH), 5.00 (s, 2 H, Cbz-CH2), 5.64 (bs, 1 H, NH), 6.12-6.26 (m, 2 H, NH), 6.68 (bs, 1 H, 
NH), 7.11 (d, 3JH,H = 8.2, 2 H, CH-Ar), 7.23-7.27 (m, 5 H, Cbz-CH), 7.32 (d, 3JH,H = 8.5, 2 
H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 17.1 (+, 1 C, CH3), 19.1 (+, 1 C, CH3), 28.3 
(+, 3 C, CH3), 29.4 (+, 1 C, CH3), 36.4 (-, 1 C, CH2), 39.5 (-, 1 C, CH2), 40.3 (-, 1 C, CH2), 
59.5 (+, 1 C, CH), 66.6 (-, 1 C, CH2), 67.3 (-, 1 C, CH2), 69.1 (Cquat, 1 C, NH-C), 81.4 
(Cquat, 1 C, CO-tBu), 84.1 (+, 1 C, O-CH), 122.4 (Cquat, 1 C, C-Br), 127.7-128.5 (+, 7 C, 
CH- Ar), 131.4 (+, 2 C, CH-Ar), 135.8 (Cquat, 1 C, C-Ar), 136.6 (Cquat, 1 C, C-Ar), 155.6 
(Cquat, 1 C, O-CO), 156.8 (Cquat, 1 C, O-CO), 171.1 (Cquat, 2 C, CONH). – MS (ES, 
DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 561.2 (61) [MH+ - Boc], 605.2 (40) [MH+ - 
C4H8], 661.2 (100) [MH+], 683.3 (19) [MNa+]. – HR-MS (PI-LSIMS, CH2Cl2/NBA): [MH+] 
calcd. for C31H42BrN4O7 661.2237; found 661.2235. – IR (neat) [cm-1]: ν~  = 3348, 3236, 
2941, 2841, 2535, 2363, 2340, 1668, 1517, 1453, 1259, 1226, 1117, 994, 828, 686. – MF 
C31H41BrN4O7. – MW 661.48. 
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tert-Butyl (2R,3S)-3-((S)-1-(2-(benzyloxycarbonooxoylamino)ethylamino)-3-methyl-1-oxo-
butan-2-ylcarbamoyl)-2-(4-bromophenyl)-tetrahydrofuran-3-ylcarbamate (238): 
Under an atmosphere of nitrogen compound 183 (470 mg, 0.97 mmol, 1 eq.) was 
dissolved in 5.8 ml DMF (6 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (497 µl, 2.91 mmol, 3 eq.), HOAt (198 mg, 1.45 mmol, 1.5 eq.) and HATU (552 
mg, 1.45 mmol, 1.5 eq.) were added in this sequence. Then benzyl aminoethylcarbamate 
50 (263 mg, 1.36 mmol, 1.4 eq.) was slowly added in portions. The mixture was allowed to 
warm to room temperature and stirred for 24 hours. The reaction was quenched with 12 
ml of water and 5 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x18 ml). 
The combined organic layers were washed twice with brine. Afterwards the solution was 
dried over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (PE:diethyl ether 60:40; Rf = 0.26) 
to give the product as colorless solid in 68 % yield (450 mg, 0.66 mmol). 
MP 160 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.66 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.71 (d, 
3JH,H = 6.9, 3 H, Val-CH3), 1.45 (s, 9 H, Boc-CH3), 2.00-2.18 (m, 1 H, CH), 2.29-2.45 (m, 1 
H, CH2), 2.72-2.89 (m, 1 H, CH2), 2.94-3.08 (m, 1 H, CH2), 3.19-3.43 (m, 3 H, CH2), 3.67 
(dd, 3JH,H = 4.8, 3JH,H = 6.2, 1 H, CH2), 4.00-4.13 (m, 1 H, CH), 4.17-4.29 (m, 1 H, CH2), 
5.03 (s, 1 H, CH), 5.07 (s, 2 H, Cbz-CH2), 5.47 (bs, 1 H, NH), 5.94 (m, 2 H, NH), 6.17-6.33 
(bs, 2 H, NH), 7.18 (d, 3JH,H = 8.2, 2 H, CH-Ar), 7.28-7.37 (m, 5 H, Cbz-CH), 7.40 (d, 3JH,H 
= 8.5, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 17.1 (+, 1 C, CH3), 19.3 (+, 1 C, 
CH3), 28.3 (+, 3 C, CH3), 29.4 (+, 1 C, CH3), 36.4 (-, 1 C, CH2), 39.7 (-, 1 C, CH2), 40.4 (-, 
1 C, CH2), 59.6 (+, 1 C, CH), 66.6 (-, 1 C, CH2), 67.2 (-, 1 C, CH2), 68.9 (Cquat, 1 C, NH-C), 
81.4 (Cquat, 1 C, CO-tBu), 83.6 (+, 1 C, O-CH), 122.4 (Cquat, 1 C, C-Br), 127.5-128.4 (+, 7 
C, CH- Ar), 131.5 (+, 2 C, CH-Ar), 135.8 (Cquat, 1 C, C-Ar), 136.6 (Cquat, 1 C, C-Ar), 155.3 
(Cquat, 1 C, O-CO), 156.7 (Cquat, 1 C, O-CO), 170.9 (Cquat, 1 C, CONH), 171.1 (Cquat, 1 C, 
CONH). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 661.2 (100) [MH+], 
678.3 (34) [MNH4+]. – HR-MS (PI-LSIMS, CH2Cl2/NBA): [MH+] calcd. for C31H42BrN4O7 
661.2237; found 661.2245. – IR (neat) [cm-1]: ν~  = 3353, 3236, 2943, 2841, 2531, 2362, 
2340, 1668, 1518, 1453, 1259, 1226, 1117, 994, 828, 686. – MF C31H41BrN4O7. – MW 
661.48. 
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tert-Butyl (2S,3R)-3-((S)-1-(2-(benzyloxycarbonooxoylamino)butylamino)-3-methyl-1-oxo-
butan-2-ylcarbamoyl)-2-(4-bromophenyl)-tetrahydrofuran-3-ylcarbamate (237): 
Under an atmosphere of nitrogen compound 181 (400 mg, 0.82 mmol, 1 eq.) was 
dissolved in 4.9 ml DMF (6 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (423 µl, 2.47 mmol, 3 eq.), HOAt (169 mg, 1.24 mmol, 1.5 eq.) and HATU (470 
mg, 1.24 mmol, 1.5 eq.) were added in this sequence. Then benzyl aminobutylcarbamate 
235 (256 mg, 1.15 mmol, 1.4 eq.) was slowly added in portions. The mixture was allowed 
to warm to room temperature and stirred for 24 hours. The reaction was quenched with 12 
ml of water and 4 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x18 ml). 
The combined organic layers were washed twice with brine. Afterwards the solution was 
dried over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (EE:PE 40:60; Rf = 0.17) to give the 
product as colorless solid in 60 % yield (340 mg, 0.49 mmol). 
MP 104-105 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.52-0.67 (m, 6 H, Val-CH3), 1.31-1.48 
(m, 12 H, Boc-CH3, CH, CH2), 1.58-1.72 (m, 1 H, CH), 1.33-2.52 (m, 1 H, CH2), 2.59-2.78 
(m, 1 H, CH2), 3.06-3.18 (m, 5 H, CH2), 3.55-3.71 (m, 1 H, CH2), 3.99-4.10 (m, 1 H, CH), 
4.27 (dt, 3JH,H = 3.1, 3JH,H = 8.6, 1 H, CH2), 4.97 (s, 1 H, CH), 5.00 (s, 2 H, CH2), 7.08 (d, 
3JH,H = 8.5, 2 H, CH-Ar), 7.11 (d, 3JH,H = 8.5, 2 H, CH-Ar), 7.12-7.36 (m, 5 H, CH-Ar). – 13C-
NMR (75 MHz, CDCl3): δ = 16.4 (+, 1 C, CH3), 16.5 (+, 1 C, CH3), 23.8 (-, 1 C, CH2), 24.7 
(-, 1 , CH2), 25.8 (+, 3 C, CH3), 29.0 (+, 1 C, CH), 33.9 (-, 1 C, CH2), 36.4 (-, 1 C, CH2), 
37.9 (-, 1 C, CH2), 55.8 (+, 1 C, CH), 64.0 (-, 1 C, CH2), 64.8 (-, 1 C, CH2), 66.8 (Cquat, 1 C, 
NH-C), 78.5 (Cquat, 1 C, CO-tBu), 81.0 (+, 1 C, O-CH), 119.6 (Cquat, 1 C, C-Br), 125.2-
126.0 (+, 7 C, CH-Ar), 128.8 (+, 2 C, CH-Ar), 128.8 (Cquat, 1 C, C-Ar), 134.0 (Cquat, 1 C, C-
Ar), 152.1 (Cquat, 1 C, O-CO), 154.3 (Cquat, 1 C, O-CO), 167.9 (Cquat, 1 C, CONH), 168.4 
(Cquat, 1 C, CONH). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 589.2 (66) 
[MH+ - Boc], 632.1 (14) [MH+ - C4H8], 689.3 (100) [MH+]. – HR-MS (PI-LSIMS, 
CH2Cl2/NBA): [MH+] calcd. for C33H46BrN4O7 689.2550; found 689.2547. – IR (neat) [cm-1]: 
ν~  = 3292, 2974, 2931, 2876, 2362, 2332, 1638, 1522, 1366, 1251, 1160, 1071, 1011, 
846. – MF C31H41BrN4O7. – MW 661.48. 
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tert-Butyl (2R,3S)-3-((S)-1-(2-(benzyloxycarbonooxoylamino)butylamino)-3-methyl-1-oxo-
butan-2-ylcarbamoyl)-2-(4-bromophenyl)-tetrahydrofuran-3-ylcarbamate (239): 
Under an atmosphere of nitrogen compound 183 (320 mg, 0.66 mmol, 1 eq.) was 
dissolved in 4.0 ml DMF (6 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (339 µl, 1.98 mmol, 3 eq.), HOAt (136 mg, 0.99 mmol, 1.5 eq.) and HATU (376 
mg, 0.99 mmol, 1.5 eq.) were added in this sequence. Then benzyl aminobutylcarbamate 
235 (205 mg, 0.92 mmol, 1.4 eq.) was slowly added in portions. The mixture was allowed 
to warm to room temperature and stirred for 24 hours. The reaction was quenched with 8 
ml of water and 3 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x12 ml). 
The combined organic layers were washed twice with brine. Afterwards the solution was 
dried over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (EE:PE 40:60; Rf = 0.20) to give the 
product as colorless solid in 56 % yield (253 mg, 0.37 mmol). 
MP 86-87 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.62 (d, 3JH,H = 6.9, 3 H, Val-CH3), 0.66 
(d, 3JH,H = 6.8, 3 H, Val-CH3), 1.32-1.49 (m, 12 H, Boc-CH3, CH2), 1.80-1.94 (m, 1 H, CH), 
2.11-2.31 (m, 1 H, CH2), 2.90-3.01 (m, 2 H, CH2), 3.02-3.11 (m, 2 H, CH2), 3.12-3.24 (m, 1 
H, CH2), 3.48-3.60 (m, 1 H, CH2), 3.92-4.06 (m, 1 H, CH), 4.21-4.31 (m, 2 H, CH2), 4.85 
(s, 1 H, CH), 4.95 (s, 2 H, CH2), 6.29 (s, 1 H, NH), 7.14 (d, 3JH,H = 8.4, 1 H, CH-Ar), 7.23-
7.28 (m, 5 H, CH-Ar), 7.33 (d, 3JH,H = 8.4, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 
20.2 (+, 2 C, CH3), 27.6 (-, 1 C, CH2), 28.1 (-, 1 , CH2), 29.5 (+, 3 C, CH3), 31.1 (+, 1 C, 
CH), 38.1 (-, 1 C, CH2), 40.3 (-, 1 C, CH2), 41.8 (-, 1 C, CH2), 60.6 (+, 1 C, CH), 67.8 (-, 1 
C, CH2), 68.9 (-, 1 C, CH2), 71.2 (Cquat, 1 C, NH-C), 82.5 (Cquat, 1 C, CO-tBu), 86.2 (+, 1 C, 
O-CH), 123.5 (Cquat, 1 C, C-Br), 129.2-130.2 (+, 7 C, CH-Ar), 132.5 (+, 2 C, CH-Ar), 137.3 
(Cquat, 1 C, C-Ar), 138.1 (Cquat, 1 C, C-Ar), 156.5 (Cquat, 1 C, O-CO), 158.6 (Cquat, 1 C, O-
CO), 172.3 (Cquat, 1 C, CONH), 172.6 (Cquat, 1 C, CONH). – MS (ES, DCM/MeOH + 10 
mmol/l NH4OAc): m/z (%) = 589.2 (37) [MH+ - Boc], 632.1 (14) [MH+ - C4H8], 689.3 (100) 
[MH+], 711.3 (21) [MNa+]. – HR-MS (PI-LSIMS, CH2Cl2/NBA): [MH+] calcd. for 
C33H46BrN4O7 689.2550; found 689.2537. – IR (neat) [cm-1]: ν~  = 3349, 2970, 2931, 2361, 
2342, 1668, 1519, 1455, 1260, 1118, 1075, 1011, 995, 830. – MF C31H41BrN4O7. – MW 
661.48. 
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Methyl 6-(benzyloxycarbonylamino)-2-((S)-2-((2S,3R)-2-(4-bromophenyl)-3-(tert-butoxy-
carbonylamino)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)hexanoate (241): 
Under an atmosphere of nitrogen compound 181 (400 mg, 0.82 mmol, 1 eq.) was 
dissolved in 5.7 ml DMF (7 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (423 µl, 2.47 mmol, 3 eq.), HOAt (169 mg, 1.24 mmol, 1.5 eq.) and HATU (470 
mg, 1.24 mmol, 1.5 eq.) were added in this sequence. Then H-Lys(Cbz)-OMe 240 (364 
mg, 1.24 mmol, 1.5 eq.) was slowly added in portions. The mixture was allowed to warm 
to room temperature and stirred for 24 hours. The reaction was quenched with 14 ml of 
water and 4 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x21 ml). The 
combined organic layers were washed twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (EE:PE 40:60; Rf = 0.23) to give the 
product as colorless solid in 59 % yield (370 mg, 0.49 mmol). 
MP 74-75 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.58 (t, 3JH,H = 7.1, 6 H, Val-CH3), 1.27-
1.54 (m, 13 H, Boc-CH3, CH2), 1.62-1.87 (m, 3 H, CH, CH2), 2.47-2.82 (m, 2 H, CH2), 
3.03-3.28 (m, 2 H, CH2), 3.69 (s, 3 H, OCH3), 3.98-4.06 (m, 1 H, CH), 4.16-4.46 (m, 3 H, 
CH, CH2), 5.01-5.15 (m, 3 H, CH, CH2), 5.31 (bs, 1 H, NH), 6.13 (bs, 1 H, NH), 6.54 (d, 
3JH,H = 6.9, 1 H, NH), 6.63 (d, 3JH,H = 8.2, 1 H, NH), 7.20 (d, 3JH,H = 8.2, 2 H, CH-Ar), 7.28-
7.37 (m, 7 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 17.4 (+, 1 C, Val-CH3), 18.7 (+, 1 
C, Val-CH3), 22.1 (-, 1 C, CH2), 28.4 (+, 3 C, Boc-CH3), 29.5 (-, 1 C, CH2), 30.9 (-, 1 C, 
CH2), 31.6 (+, 1 C, CH), 35.7 (-, 1 C, CH2), 39.8 (-, 1 C, CH2), 52.3 (+, 1 C, CH3), 58.2 (+, 
2 C, CH), 66.7 (-, 1 C, CH2), 67.9 (Cquat, 1 C, NH-C), 80.2 (Cquat, 1 C, Boc-C), 81.0 (+, 1 C, 
CH), 121.5 (Cquat, 1 C, C-Br), 127.0-128.5 (+, 7 C, Ar-CH), 131.2 (+, 2 C, Ar-CH), 136.5 
(Cquat, 2 C, C-Ar), 154.2 (Cquat, 1 C, O-CO), 156.9 (Cquat, 1 C, O-CO), 171.0 (Cquat, 1 C, 
CONH), 172.4 (Cquat, 1 C, CONH). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) 
= 761.3 (43) [MH+], 778.4 (100) [MNH4+]. – HR-MS (PI-LSIMS, MeOH/CH2Cl2/NBA): [MH+] 
calcd. for C36H50BrN4O9 761.2761; found 761.2753. – IR (neat) [cm-1]: ν~  = 3352, 3237, 
2941, 2841, 2529, 2362, 2342, 1668, 1517, 1453, 1259, 1226, 1117, 993, 828, 686. – MF 
C36H49BrN4O9. – MW 761.7. 
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Methyl 6-(benzyloxycarbonylamino)-2-((S)-2-((2R,3S)-2-(4-bromophenyl)-3-(tert-butoxy-
carbonylamino)-tetrahydrofuran-3-carboxamido)-3-methylbutanamido)hexanoate (242): 
Under an atmosphere of nitrogen compound 183 (400 mg, 0.82 mmol, 1 eq.) was 
dissolved in 5.7 ml DMF (7 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
DIPEA (423 µl, 2.47 mmol, 3 eq.), HOAt (169 mg, 1.24 mmol, 1.5 eq.) and HATU (470 
mg, 1.24 mmol, 1.5 eq.) were added in this sequence. Then H-Lys(Cbz)-OMe 240 (364 
mg, 1.24 mmol, 1.5 eq.) was slowly added in portions. The mixture was allowed to warm 
to room temperature and stirred for 24 hours. The reaction was quenched with 14 ml of 
water and 4 ml of 1M aqueous KHSO4 and extracted with diethyl ether (3x21 ml). The 
combined organic layers were washed twice with brine. Afterwards the solution was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was then 
purified by column chromatography on flash silica gel (EE:PE 40:60; Rf = 0.20) to give the 
product as colorless solid in 63 % yield (392 mg, 0.51 mmol). 
MP 80-81 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.80 (t, 3JH,H = 6.9, 3 H, Val-CH3), 0.83 (t, 
3JH,H = 6.9, 3 H, Val-CH3), 1.29-1.56 (m, 13 H, Boc-CH3, CH2), 1.45-1.59 (m, 2 H, CH2), 
1.96-2.05 (m, 1 H, CH), 2.55-2.85 (m, 2 H, CH2), 3.05-3.32 (m, 2 H, CH2), 3.70 (s, 3 H, 
OCH3), 3.89 (t, 3JH,H = 6.2, 1 H, CH), 4.20-4.39 (m, 3 H, CH, CH2), 4.94 (d, 3JH,H = 12.3, 1 
H, CH2), 5.00 (t, 3JH,H = 6.2, 1 H, CH), 5.10 (d, 3JH,H = 12.3, 1 H, CH2), 5.24 (bs, 1 H, NH), 
6.11 (bs, 1 H, NH), 6.47 (d, 3JH,H = 6.9, 1 H, NH), 6.74 (d, 3JH,H = 7.4, 1 H, NH), 7.16 (d, 
3JH,H = 8.5, 2 H, CH-Ar), 7.28-7.37 (m, 7 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 17.8 
(+, 1 C, Val-CH3), 18.9 (+, 1 C, Val-CH3), 22.3 (-, 1 C, CH2), 28.4 (+, 3 C, Boc-CH3), 29.6 
(-, 1 C, CH2), 30.7 (-, 1 C, CH2), 31.5 (+, 1 C, CH), 36.1 (-, 1 C, CH2), 39.8 (-, 1 C, CH2), 
52.3 (+, 1 C, CH3), 58.2 (+, 2 C, CH), 66.7 (-, 1 C, CH2), 67.9 (Cquat, 1 C, NH-C), 80.4 
(Cquat, 1 C, Boc-C), 81.8 (+, 1 C, CH), 121.6 (Cquat, 1 C, C-Br), 127.2-128.5 (+, 7 C, Ar-
CH), 131.0 (+, 1 C, Ar-CH), 131.3 (+, 1 C, Ar-CH), 135.6 (Cquat, 1 C, C-Ar), 136.5 (Cquat, 1 
C, C-Ar), 154.4 (Cquat, 1 C, O-CO), 156.9 (Cquat, 1 C, O-CO), 171.1 (Cquat, 1 C, CONH), 
171.1 (Cquat, 1 C, CONH). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 761.2 
(100) [MH+], 778.3 (61) [MNH4+]. – HR-MS (PI-LSIMS, CH2Cl2/NBA): [MH+] calcd. for 
C36H50BrN4O9 761.2761; found 761.2759. – IR (neat) [cm-1]: ν~  = 3352, 3236, 2941, 2841, 
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2536, 2367, 2341, 1667, 1517, 1453, 1259, 1226, 1117, 994, 828, 685. – MF 
C36H49BrN4O9. – MW 761.7. 
(2S,3S)-Methyl 2-(2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-car-
boxamido)-3-methylpentanoate (244 / 245): 
Under an atmosphere of nitrogen compound rac-138 (490 mg, 1.27 mmol, 1 eq.) was 
dissolved in DMF (5 ml) and cooled to 0 °C in an ice bath. To the solution DIPEA (652 µl, 
3.81 mmol, 3 eq.), HOBt (259 mg, 1.90 mmol, 1.5 eq.) and EDC (337 µl, 1.90 mmol, 1.5 
eq.) were added in this sequence. Then H-Ile-OMe*HCl 243 (323 mg, 1.78 mmol, 1.4 eq.) 
was slowly added in portions. The mixture was allowed to warm to room temperature and 
stirred for 24 hours. The reaction was quenched with 4 ml of water and 3 ml of 1M 
aqueous KHSO4 and extracted with diethyl ether (3x5 ml). The combined organic layers 
were washed twice with brine. Afterwards the solution was dried over MgSO4 and 
concentrated under reduced pressure. The crude product was then purified by column 
chromatography on flash silica gel (PE:diethyl ether 70:30) to give the product as two 
diasteriomers as colorless solids with an overall yield of 71 % (460 mg, 0.89 mmol). 
244: 
MP 102-104 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.47 (d, 3JH,H = 6.8, 3 H, 20), 0.69-0.87 
(m, 4 H, 18 + 19), 0.99-1.15 (m, 1 H, 18), 1.39-1.55 (m, 10 H, 1 + 17), 2.50-2.67 (m, 1 H, 
7), 2.73-2.87 (m, 1 H, 7), 3.68 (s, 3 H, 16), 4.18-4.37 (m, 3 H, 8 + 12), 5.41 (bs, 1 H, 10), 
6.19 (bs, 1 H, NH), 6.47 (d, 3JH,H = 8.2, 1 H, NH), 7.23 (d, 3JH,H = 8.3, 2 H, CH-Ar), 7.40 (d, 
3JH,H = 8.5, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 11.4 (+, 1 C, 19), 14.9 (+, 1 C, 
20), 24.6 (-, 1 C, 18), 28.4 (+, 3 C, 1), 36.1 (-, 1 C, 7), 37.7 (+, 1 C, 17), 52.1 (+, 1 C, 16), 
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56.7 (+, 1 C, 13), 66.6 (-, 1 C, 8), 67.5 (Cquat, 1 C, 6), 80.2 (Cquat, 1 C, 2), 80.3 (+, 1 C, 10), 
121.5 (Cquat, 1 C, C-Br), 127.0 (+, 2 C, CH-Ar) , 131.3 (+, 2 C, CH-Ar), 136.4 (Cquat, 1 C, C-
Ar), 154.2 (Cquat, 1 C, 4), 171.1 (Cquat, 1 C, 11), 172.1 (Cquat, 1 C, 14). – MS (CI, NH3): m/z 
(%) = 513.1 (100) [MH+), 530.1 (38) [MNH4+]. – Elemental analysis calcd. (%) for 
C23H33BrN2O6 (513.4): C 53.89, H 6.98, N 5.46; found: C 53.76, H 6.89, N 5.08. – IR 
(neat) [cm-1]: ν~  = 3441, 3289, 2971, 2930, 2864, 2364, 1739, 1712, 1659, 1501, 1362, 
1269, 1230, 1164, 1081, 995, 802. – MF C23H33BrN2O6. – MW 513.42. 
X-Ray structure and crystal data of 244: 
Orthorhombic; space group: P 21 21 21; cell dimensions: a = 6.1856(12) Å, α = 950°, b = 
19.460(2) Å, β = 90°, c = 20.895(2) Å, γ = 940°; V = 2515.2(6) Å3; Z = 4, Dx = 1.356 
Mg/m3; µ = 1.673 mm-1; F(000) = 1072. Data collection: T = 296 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.220 x 0.160 x 0.040 
mm was used to measure 18493 reflections (4700 unique reflections, Rint = 0.1215) from 
1.95° to 25.84° on a STOE-IPDS diffractometer with the rotation method. Structure 
refinement: The F2 value was refined using the full-matrix least squares refinement 
method, with a goodness-of-fit 0f 0.666 for all reflections and 295 parameters. 
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245: 
MP 112-114 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.73 (d, 3JH,H = 5.5, 3 H, 20), 0.85 (t, 
3JH,H = 7.4, 3 H, 19), 1.07-1.13 (m, 1 H, 18), 1.22-1.39 (m, 1 H, 18), 1.47 (s, 9 H, 1), 1.54-
1.69 (m, 1 H, 17), 2.42-2.65 (m, 1 H, 7), 2.73-2.92 (m, 1 H, 7), 3.61 (s, 3 H, 16), 4.14 (dd, 
3JH,H = 4.9, 3JH,H = 7.7, 12), 4.23-4.37 (m, 2 H, 8 + 12), 5.35 (bs, 1 H, 10), 6.13 (s, 1 H, 
NH), 6.71 (bs, 1 H, NH), 7.19 (d, 3JH,H = 8.5, 2 H, CH-Ar), 7.37 (d, 3JH,H = 8.5, 2 H, CH-Ar). 
– 13C-NMR (75 MHz, CDCl3): δ = 11.5 (+, 1 C, 19), 15.2 (+, 1 C, 20), 25.3 (-, 1 C, 18), 28.3 
(+, 3 C, 1), 36.2 (-, 1 C, 7), 38.3 (+, 1 C, 17), 51.9 (+, 1 C, 16), 56.4 (+, 1 C, 13), 66.6 (-, 1 
C, 8), 67.7 (Cquat, 1 C, 6), 80.3 (Cquat, 1 C, 2), 81.1 (+, 1 C, 10), 121.6 (Cquat, 1 C, C-Br), 
127.3 (+, 2 C, CH-Ar) , 131.0 (+, 2 C, CH-Ar), 135.6 (Cquat, 1 C, C-Ar), 154.3 (Cquat, 1 C, 4), 
171.0 (Cquat, 1 C, 11), 171.3 (Cquat, 1 C, 14). – MS (CI, NH3): m/z (%) = 513.1 (100) [MH+), 
530.1 (38) [MNH4+]. – Elemental analysis calcd. (%) for C23H33BrN2O6 (513.4): C 53.89, 
H 6.48, N 5.46; found: C 53.66, H 6.52, N 5.17. – IR (neat) [cm-1]: ν~  = 3439, 3316, 2964, 
2927, 2861, 2369, 2332, 1693, 1641, 1518, 1483, 1364, 1253, 1162, 1091, 1012, 834. – 
MF C23H33BrN2O6. – MW 513.42. 
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(2S,3S)-2-((2S,3R)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-
carboxamido)-3-methylpentanoic acid (246): 
Compound 244 (250 mg, 0.49 mmol) was dissolved in 5 ml of a MeCN:water mixture 
(4:1). To the solution 2M aqueous LiOH (270 μl, 0.54 mmol) was added drop by drop. The 
mixture was stirred over night. After acidification with sat. aqueous NH4Cl solution the 
mixture was extracted with DCM (3x5 ml). The combined organic layers were dried over 
MgSO4 and concentrated under reduced pressure to give the product as colorless solid 
86 % yield. (210 mg, 0.42 mmol) 
MP 95-97 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.51 (d, 3JH,H = 6.6, 3 H, 18), 0.72-0.94 
(m, 4 H, 16 + 17), 1.09-1.22 (m, 1 H, 18), 1.47 (s, 9 H, 1), 1.51-1.62 (m, 1 H, 15), 2.49-
2.66 (m, 1 H, 7), 2.75-2.90 (m, 1 H, 7), 4.22-4.39 (m, 3 H, 8 + 13), 5.46 (bs, 1 H, 10), 6.22 
(bs, 1 H, NH), 6.47 (d, 3JH,H = 7.4, 1 H, NH), 7.21-7.28 (m, 2 H, CH-Ar), 7.41 (d, 3JH,H = 
8.5, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 11.5 (+, 1 C, 17), 14.9 (+, 1 C, 18), 
25.6 (-, 1 C, 16), 28.4 (+, 3 C, 1), 36.1 (-, 1 C, 7), 37.5 (+, 1 C, 15), 56.6 (+, 1 C, 13), 67.4 
(Cquat, 1 C, 6), 67.9 (-, 1 C, 8), 80.1 (Cquat, 1 C, 10), 80.3 (+, 1 C, 2), 121.6 (Cquat, 1 C, C-
Br), 126.9 (+, 2 C, CH-Ar) , 131.4 (+, 2 C, CH-Ar), 136.4 (Cquat, 1 C, C-Ar), 154.2 (Cquat, 1 
C, 4), 171.2 (Cquat, 1 C, 11), 175.9 (Cquat, 1 C, 14). – MS (CI, NH3): m/z (%) = 443.1 (6) 
[MH+ - C4H8], 499.2 (100) [MH+], 516.2 (17) [MNH4+]. – IR (neat) [cm-1]: ν~  = 3428, 3269, 
2965, 2361, 1717, 1652, 1507, 1366, 1255, 1162, 1087, 1011, 795. – MF C22H31BrN2O6. – 
MW 499.40. 
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(2S,3S)-2-((2R,3S)-2-(4-Bromophenyl)-3-(tert-butoxycarbonylamino)-tetrahydrofuran-3-
carboxamido)-3-methylpentanoic acid (247): 
Compound 245 (200 mg, 0.39 mmol) was dissolved in 4 ml of a MeCN:water mixture 
(4:1). To the solution 2M aqueous LiOH (214 μl, 0.43 mmol) was added drop by drop. The 
mixture was stirred over night. After acidification with sat. aqueous NH4Cl solution the 
mixture was extracted with DCM (3x4 ml). The combined organic layers were dried over 
MgSO4 and concentrated under reduced pressure to give the product as colorless solid 
97 % yield. (189 mg, 0.38 mmol) 
MP 177-178 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.70-1.17 (m, 3 H, 18), 0.89 (t, 3JH,H = 
7.3, 3 H, 17), 1.02-1.17 (m, 1 H, 16), 1.31-1.40 (m, 1 H, 16), 1.48 (s, 9 H, 1), 1.61-1.76 (m, 
1 H, 15), 2.48-2.68 (m, 1 H, 7), 2.71-2.90 (m, 1 H, 7), 4.16-4.24 (m, 1H, 8), 4.26-4.41 (m, 
2 H, 8 + 13), 5.35 (bs, 1 H, 10), 6.08 (bs, 1 H, NH), 6.75 (bs, 1 H, NH), 7.22 (d, 3JH,H = 8.2, 
2 H, CH-Ar), 7.39 (d, 3JH,H = 8.5, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 11.6 (+, 1 
C, 17), 15.3 (+, 1 C, 18), 25.6 (-, 1 C, 16), 28.4 (+, 3 C, 1), 36.3 (-, 1 C, 7), 38.1 (+, 1 C, 
15), 56.4 (+, 1 C, 13), 66.6 (Cquat, 1 C, 6), 67.9 (-, 1 C, 8), 80.4 (Cquat, 1 C, 10), 81.4 (+, 1 
C, 2), 127.4 (Cquat, 1 C, C-Br), 131.2 (+, 2 C, CH-Ar) , 135.5 (+, 2 C, CH-Ar), 145.4 (Cquat, 1 
C, C-Ar), 154.5 (Cquat, 1 C, 4), 171.1 (Cquat, 1 C, 11), 175.4 (Cquat, 1 C, 14). – MS (CI, NH3): 
m/z (%) = 443.1 (6) [MH+ - C4H8], 499.2 (100) [MH+], 516.2 (17) [MNH4+]. – IR (neat) [cm-
1]: ν~  = 3428, 3269, 2969, 2359, 1717, 1652, 1506, 1365, 1253, 1162, 1086, 1011, 866. – 
MF C22H31BrN2O6. – MW 499.40. 
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tert-Butyl (2S,3R)-2-(4-bromophenyl)-3-((2S,3S)-1-(3-(tert-butyldimethylsilyloxy)propyl-
amino)-3-methyl-1-oxopentan-2-ylcarbamoyl)-tetrahydrofuran-3-ylcarbamate (249): 
Under an atmosphere of nitrogen compound 246 (1.00 g, 2.00 mmol, 1 eq.) was dissolved 
in DMF (10 ml) and cooled to 0 °C in an ice bath. To the solution DIPEA (1.03 ml, 6.01 
mmol, 3 eq.), HOAt (613 mg, 4.51 mmol, 2.25 eq.) and TBTU (1.45 g, 4.51 mmol, 2.25 
eq.) were added in this sequence. Then 3-(tert-butyldimethylsilyloxy)propan-1-amine 248 
(569 mg, 3.00 mmol, 1.5 eq.) was slowly added in portions. The mixture was allowed to 
warm to room temperature and stirred for 24 hours. The reaction was quenched with 10 
ml of water and extracted with diethyl ether (3x15 ml). The combined organic layers were 
washed twice with brine. Afterwards the solution was dried over MgSO4 and concentrated 
under reduced pressure. The crude product was then purified by column chromatography 
on flash silica gel (PE:diethyl ether 70:30, Rf = 0.25) to give the product as colorless solid 
in 71 % yield (460 mg, 0.89 mmol). 
MP 115-117 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.00 (s, 6 H, 31), 0.52 (d, 3JH,H = 6.6, 3 
H, 30), 0.64 (d, 3JH,H = 4.4, 3 H, 29), 0.75-0.99 (m, 11 H, 22 + 28), 1.30-1.46 (m, 10 H, 1 + 
27), 1.64 (quintet, 3JH,H = 6.0, 2 H, 17), 2.42-2.60 (m, 1 H, 7), 2.62-2.76 (m, 1 H, 7), 3.15-
3.40 (m, 2 H, 16), 3.66 (t, 3JH,H = 5.6, 2 H, 18), 3.80 (dd, 3JH,H = 6.6, 3JH,H = 8.2, 1 H, 13), 
4.19 (q, 3JH,H = 8.3, 1 H, 8), 4.30 (dt, 3JH,H = 3.5, 3JH,H = 8.7, 1 H, 8), 5.26 (bs, 1 H, 10), 
6.08 (bs, 1 H, 15), 6.19 (bs, 1 H, 5), 6.58 (d, 3JH,H = 8.5, 1 H, 12), 7.18 (d, 3JH,H = 8.2, 2 H, 
CH-Ar), 7.33 (d, 3JH,H = 8.5, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = -6.5 (+, 2 C, 
31), 10.2 (+, 1 C, 29), 14.0 (+, 1 C, 29), 17.2 (Cquat, 1 C, 21), 23.4 (-, 1 C, 28), 24.9 (+, 3 C, 
22), 27.4 (+, 3 C, 1), 30.5 (-, 1 C, 17), 34.8 (-, 1 C, 7), 36.9 (+, 1 C, 27), 37.2 (-, 1 C, 16), 
57.1 (+, 1 C, 13), 61.3 (-, 1 C, 18), 65.7 (-, 1 C, 8), 66.9 (Cquat, 1 C, 6), 79.1 (Cquat, 1 C, 2), 
80.3 (+, 1 C, 10), 120.5 (Cquat, 1 C, 16), 126.2 (+, 2 C, CH-Ar) , 130.2 (+, 2 C, CH-Ar), 
135.6 (Cquat, 1 C, 23), 153.2 (Cquat, 1 C, 4), 169.2 (Cquat, 1 C, 14), 169.7 (Cquat, 1 C, 11). – 
MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 572.3 (7) [MH+ - Boc], 616.3 (61) 
[MH+ - C4H8], 672.3 (100) [MH+], 596.3 (70) [M – H+ - tBuOH], 670.3 (98) [M - H+], 706.4 
(17) [M + Cl-], 730.4 (18) [M + CH3COO-]. – Elemental analysis calcd. (%) for 
C23H33BrN2O6·H2O (670.8): C 54.13, H 7.92, N 6.11; found: C 54.36, H 7.98, N 6.11. – IR 
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(neat) [cm-1]: ν~  = 3340, 3319, 2968, 2932, 2883, 2956, 2369, 1693, 1640, 1481, 1363, 
1253, 1162, 1089, 1012, 833. – MF C31H52BrN3O6Si. – MW 670.75. 
tert-Butyl (2R,3S)-2-(4-bromophenyl)-3-((2S,3S)-1-(3-(tert-butyldimethylsilyloxy)propyl-
amino)-3-methyl-1-oxopentan-2-ylcarbamoyl)-tetrahydrofuran-3-ylcarbamate (250): 
Under an atmosphere of nitrogen compound 247 (300 mg, 0.60 mmol, 1 eq.) was 
dissolved in DMF (4 ml) and cooled to 0 °C in an ice bath. To the solution DIPEA (309 µl, 
1.80 mmol, 3 eq.), HOAt (184 mg, 1.35 mmol, 2.25 eq.) and TBTU (434 mg, 1.35 mmol, 
2.25 eq.) were added in this sequence. Then 3-(tert-butyldimethylsilyloxy)propan-1-amine 
248 (171 mg, 0.90 mmol, 1.5 eq.) was slowly added in portions. The mixture was allowed 
to warm to room temperature and stirred for 24 hours. The reaction was quenched with 5 
ml of water and extracted with diethyl ether (3x10 ml). The combined organic layers were 
washed twice with brine. Afterwards the solution was dried over MgSO4 and concentrated 
under reduced pressure. The crude product was then purified by column chromatography 
on flash silica gel (PE:diethyl ether 70:30, Rf = 0.25) to give the product as colorless solid 
in 62 % yield (250 mg, 0.37 mmol). 
MP 154-155 °C. – 1H-NMR (300 MHz, CDCl3): δ = 0.05 (s, 6 H, 31), 0.75 (d, 3JH,H = 6.9, 3 
H, 30), 0.79-1.03 (m, 14 H, 22 + 28 + 29), 1.43-1.51 (m, 10 H, 1 + 27), 1.65-1.83 (m, 2 H, 
17), 2.50-2.64 (m, 1 H, 7), 2.73-2.86 (m, 1 H, 7), 3.06-3.20 (m, 1 H, 16), 3.24-3.36 (m, 1 
H, 16), 3.66 (t, 3JH,H = 5.9, 2 H, 18), 3.70-3.78 (m, 1 H, 13), 4.22-4.40 (m, 2 H, 8), 5.27 (bs, 
1 H, 10), 5.92 (t, 3JH,H = 4.8, 1 H, 15), 6.13 (bs, 1 H, 5), 6.51 (d, 3JH,H = 8.0, 1 H, 12), 7.19 
(d, 3JH,H = 8.2, 2 H, CH-Ar), 7.39 (d, 3JH,H = 8.5, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): 
δ = -6.4 (+, 2 C, 31), 10.4 (+, 1 C, 29), 14.5 (+, 1 C, 30), 17.2 (Cquat, 1 C, 21), 23.8 (-, 1 C, 
28), 24.9 (+, 3 C, 22), 27.4 (+, 3 C, 1), 30.7 (-, 1 C, 17), 35.2 (-, 1 C, 7), 36.3 (+, 1 C, 27), 
36.7 (-, 1 C, 16), 57.1 (+, 1 C, 13), 60.9 (-, 1 C, 18), 65.7 (-, 1 C, 8), 66.7 (Cquat, 1 C, 6), 
79.4 (Cquat, 1 C, 2), 80.4 (+, 1 C, 10), 120.6 (Cquat, 1 C, 26), 127.0 (+, 2 C, CH-Ar) , 131.3 
(+, 2 C, CH-Ar), 134.6 (Cquat, 1 C, 23), 153.4 (Cquat, 1 C, 4), 168.5 (Cquat, 1 C, 14), 170.0 
(Cquat, 1 C, 11). ). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 572.3 (7) [MH+ 
- Boc], 616.3 (61) [MH+ - C4H8], 672.3 (100) [MH+], 596.3 (70) [M – H+ - tBuOH], 670.3 (98) 
[M - H+], 706.4 (17) [M + Cl-], 730.4 (18) [M + CH3COO-]. – Elemental analysis calcd. (%) 
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for C23H33BrN2O6 (670.8): C 55.51, H 7.81, N 6.26; found: C 55.33, H 7.84, N 5.79. – IR 
(neat) [cm-1]: ν~  = 2958, 2933, 2858, 2360, 2330, 1716, 1641, 1513, 1367, 1252, 1163, 
1103, 1072, 1010, 835. – MF C31H52BrN3O6Si. – MW 670.75. 
tert-Butyl (2S,3R)-2-(4-bromophenyl)-3-((3S)-1-(3-hydroxypropylamino)-3-methyl-1-oxo-
pentan-2-ylcarbamoyl)-tetrahydrofuran-3-ylcarbamate (199): 
Under a nitrogen atmosphere compound 249 (650 mg, 0.91 mmol, 1 eq.) was dissolved in 
9 ml of dry acetonitrile (10 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
glacial acetic acid (332 µl, 6.81 mmol, 6 eq.) and 1M TBAF in THF (2.91 ml, 2.91 mmol, 3 
eq.) were added in this sequence. The mixture was allowed to slowly warm to room 
temperature and was stirred for 12 hours. The solvent was evaporated under reduced 
pressure. The crude product was then purified by column chromatography on flash silica 
gel (PE:diethyl ether 75:25, Rf (EE) = 0.57.) to give the product colorless solid with a yield 
of 82 % (440 mg, 0.79 mmol). 
MP 119-121 °C. – 1H-NMR (400 MHz, COSY, CDCl3): 0.61 (d, 3JH,H = 6.8, 3 H, 26), 0.67-
0.75 (m, 4 H, 24 + 25), 1.00-1.12 (m, 1 H, 24), 1.39-1.53 (m, 10 H, 1 + 23), 1.65 (quintet, 
3JH,H = 5.9, 2 H, 17), 2.50-2.71 (m, 2 H, 7), 3.23-3.42 (m, 2 H, 16), 3.59 (t, 3JH,H = 5.7, 2 H, 
18), 3.87 (dd, 3JH,H = 6.9, 3JH,H = 8.2, 1 H, 13), 4.19 (q, 3JH,H = 8.3, 1 H, 8), 4.33 (dt, 3JH,H = 
3.5, 3JH,H = 8.5, 1 H, 8), 5.24 (bs, 1 H, 10), 6.03 (bs, 1 H, 5), 6.50 (t, 3JH,H = 5.6, 1 H, 15), 
6.67 (d, 3JH,H = 8.5, 1 H, 12), 7.19 (d, 3JH,H = 8.4, 2 H, 20), 7.37 (d, 3JH,H = 8.5, 2 H, 21). – 
13C-NMR (100 MHz, HSQC, HMBC, CDCl3): δ = 11.2 (+, 1 C, 25), 15.0 (+, 1 C, 26), 24.4 
(-, 1 C, 24), 28.3 (+, 3 C, 1), 31.9 (-, 1 C, 17), 35.4 (-, 1 C, 7), 36.5 (-, 1 C, 16), 37.3 (+, 1 
C, 23), 58.2 (+, 1 C, 13), 59.6 (-, 1 C, 18), 66.8 (-, 1 C, 8), 68.5 (Cquat, 1 C, 6), 80.5 (Cquat, 1 
C, 2), 82.3 (+, 1 C, 10), 121.8 (Cquat, 1 C, 22), 127.4 (+, 2 C, 20) , 131.2 (+, 2 C, 21), 136.6 
(Cquat, 1 C, 19), 154.4 (Cquat, 1 C, 4), 170.8 (Cquat, 1 C, 11), 171.4 (Cquat, 1 C, 14). – MS 
(ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 500.1 (9) [MH+ - C4H8], 558.2 (100) 
[MH+]. – IR (neat) [cm-1]: ν~  = 3292, 2970, 2931, 2879, 2359, 2340, 1714, 1645, 1488, 
1366, 1253, 1161, 1069, 1010, 849, 583. – MF C25H38BrN3O6. – MW 556.49. 
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tert-Butyl (2R,3S)-2-(4-bromophenyl)-3-((2S,3S)-1-(3-hydroxypropylamino)-3-methyl-1-
oxopentan-2-ylcarbamoyl)-tetrahydrofuran-3-ylcarbamate (251): 
Under a nitrogen atmosphere compound 250 (340 mg, 0.51 mmol, 1 eq.) was dissolved in 
5 ml of dry acetonitrile (10 ml/mmol) and cooled to 0 °C in an ice bath. To the solution 
glacial acetic acid (174 µl, 3.04 mmol, 6 eq.) and 1M TBAF in THF (1.52 ml, 1.52 mmol, 3 
eq.) were added in this sequence. The mixture was allowed to slowly warm to room 
temperature and was stirred for 12 hours. The solvent was evaporated under reduced 
pressure. The product was obtained after column chromatography on flash silica gel 
(EtOAc, Rf = 0.55) as colorless solid in 70 % yield (200 mg, 0.36 mmol). 
MP 119-121 °C. – 1H-NMR (300 MHz, CDCl3): 0.74 (d, 3JH,H = 6.9, 3 H, 26), 0.82-1.01 (m, 
5 H, 24 + 25), 1.44-1.68 (m, 11 H, 1 + 17 + 23), 1.67-1.94 (m, 1 H, 17), 2.69 (t, 3JH,H = 7.3, 
2 H, 7), 2.98-3.12 (m, 1 H, 16), 3.25-3.38 (m, 1 H, 16), 3.52 (t, 3JH,H = 5.6, 2 H, 18), 3.88 
(dd, 3JH,H = 4.9, 3JH,H = 7.5, 1 H, 13), 4.21-4.39 (m, 2 H, 8), 5.23 (bs, 1 H, 10), 5.79 (t, 3JH,H 
= 4.8, 15), 6.05 (bs, 1 H, 5), 6.34 (d, 3JH,H = 7.1, 1 H, 12), 7.24 (d, 3JH,H = 8.2, 2 H, CH-Ar), 
7.46 (d, 3JH,H = 8.5, 2 H, CH-Ar). – 13C-NMR (75 MHz, CDCl3): δ = 10.6 (+, 1 C, 25), 14.8 
(+, 1 C, 26), 23.6 (-, 1 C, 24), 27.3 (+, 3 C, 1), 31.1 (-, 1 C, 17), 34.8 (-, 1 C, 7), 35.3 (+, 1 
C, 23), 35.5 (-, 1 C, 16), 57.6 (+, 1 C, 13), 57.7 (-, 1 C, 18), 65.9 (-, 1 C, 8), 67.2 (Cquat, 1 
C, 6), 79.9 (Cquat, 1 C, 2), 81.1 (+, 1 C, 10), 121.1 (Cquat, 1 C, 22), 126.2 (+, 2 C, CH-Ar) , 
130.5 (+, 2 C, CH-Ar), 134.9 (Cquat, 1 C, 19), 153.8 (Cquat, 1 C, 4), 170.1 (Cquat, 1 C, 11/14), 
170.3 (Cquat, 1 C, 11/14). – MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 458.3 
(7) [MH+ - Boc], 500.3 (55) [MH+ - C4H8], 558.3 (100) [MH+]. – IR (neat) [cm-1]: ν~  = 3251, 
2968, 2932, 2871, 2357, 2341, 1718, 1643, 1487, 1366, 1252, 1165, 1071, 1011, 850, 
581. – MF C25H38BrN3O6. – MW 556.49. 
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Compound 198: 
Compound 197 (100 mg, 0.18 mmol, 1 eq.), CsCO3 (52 mg, 0.27 mmol, 1.5 eq.), 
Pd(OAc)2 (4 mg, 0.02 mmol, 0.1 eq.) and dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-
yl)phosphine (11 mg, 0.02 mmol, 1.25 eq.) were put into an oven dried Schlenk tube. The 
reaction vessel was evacuated and back filled with argon twice. To the mixture 7.2 ml of 
dry toluene (40 ml/mmol) were added and the tube was closed with a glass stopper and 
sealed. The mixture was heated under stirring to 80 °C for 24 h. The mixture was filtered 
and washed with 10 ml of ethyl acetate twice. The organic layers were concentrated under 
reduced pressure. The crude product was then purified by column chromatography on 
flash silica gel using a solvent gradient starting from diethyl ether:ethanol 98:2 and going 
to 95:5 (EtOAc, Rf = 0.20). In a second purification step the compound was submitted to 
HPLC using a phenomenex Luna C18 and a acetonitril/H2O (0.0059 % TFA) gradient (5%-
98% acetonitril) to give the product as colorless solid (34 mg, 0.07 mmol, 40 %). 
MP 146-147 °C. - 1H-NMR (600 MHz, COSY, NOESY, CDCl3): 0.72 (d, 3JH,H = 6.6, 3 H, 
27), 0.81 (t, 3 H, 3JH,H = 6.9, 26), 0.87-0.97 (m, 1 H, 25a), 1.35-1.42 (m, 1 H, 25b), 1.45 (s, 
9 H, 1), 1.53-1.60 (m, 1 H, 24), 1.68 (bs, 1 H, 13a), 2.09 (ddd, 3JH,H = 4.8, 3JH,H = 8.0, 2JH,H 
= 13.1, 1 H, 13b), 2.41-2.55 (m, 1 H, 23b), 2.93 (ddd, 3JH,H = 3.3, 3JH,H = 7.2, 2JH,H = 10.4, 1 
H, 12a), 3.34 (s, 1 H, 23a), 3.41 (s, 1 H, 9), 3.70-3.77 (m, 1 H, 12b), 4.01 (q, 3JH,H = 7.8, 1 
H, 22), 4.22 (dt, 3JH,H = 3.3, 2JH,H = 11.6, 1 H, 14a), 4.41 (dt, 3JH,H = 4.6, 3JH,H = 8.3, 1 H, 
22a/b), 4.47 (dt, 3JH,H = 12.2, 2JH,H = 3.8, 1 H, 14b), 4.55 (s, 1 H,20), 5.03-5.19 (m, 2 H, 5 + 
11), 6.22 (d, 3JH,H = 7.5, 1 H, 8), 6.82 (dd, 3JH,H = 8.3, 4JH,H = 2.5, 1 H, 17a), 6.86 (dd, 3JH,H 
= 8.6, 4JH,H = 2.4, 1 H, 17b), 7.04 (s, 1 H, 18b), 7.37 (dd, 3JH,H = 8.6, 4JH,H = 2.0, 1 H, 17a). 
– 13C-NMR (150 MHz, HSQC, HMBC, CDCl3): δ = 11.5 (+, 1 C, 26), 14.4 (+, 1 C, 27), 25.1 
(-, 1 C, 25), 26.7 (-, 1 C, 13), 28.2 (+, 3 C, 1), 36.8 (-, 1 C, 23), 37.6 (-, 1 C, 12), 38.7 (+, 1 
C, 24), 58.7 (+, 1 C, 9), 67.2 (-, 1 C, 14), 68.6 (-, 1 C, 22), 71.2 (Cquat, 1 C, 6), 81.2 (Cquat, 1 
C, 2), 89.5 (+, 1 C, 20), 114.3 (+, 1 C, 17a), 117.5 (+, 1 C, 17b), 127.0 (+, 1 C, 18b), 127.7 
(+, 1 C, 18a), 129.2 (Cquat, 1 C, 19), 154.6 (Cquat, 1 C, 4), 159.2 (Cquat, 1 C, 16), 169.8 
(Cquat, 1 C, 10), 170.2 (Cquat, 1 C, 7). - MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z 
(%) = 458.3 (7) [MH+ - Boc], 500.3 (55) [MH+ - C4H8], 558.3 (100) [MH+]. - HR-MS (FAB, 
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MeOH/glycerol): [M·] calcd. for C25H37N3O6 475.2684; found 475.2682. – MF C25H37N3O6. 
– MW 475.58. 
Compound 252: 
Compound 251 (80 mg, 0.14 mmol, 1 eq.), CsCO3 (42 mg, 0.22 mmol, 1.5 eq.), Pd(OAc)2 
(3 mg, 0.01 mmol, 0.1 eq.) and dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (9 
mg, 0.02 mmol, 1.25 eq.) were put into an oven dried Schlenk tube. The reaction vessel 
was evacuated and back filled with argon twice. To the mixture 5.6 ml of dry toluene (40 
ml/mmol) were added and the tube was closed with a glass stopper and sealed. The 
mixture was heated under stirring to 80 °C for 24 h. The mixture was filtered and washed 
with 10 ml of ethyl acetate twice. The organic layers were concentrated under reduced 
pressure. The crude product was then purified by column chromatography on flash silica 
gel using a solvent gradient starting from diethyl ether:ethanol 98:2 and going to 95:5 
(EtOAc, Rf = 0.20). In a second purification step the compound was submitted to HPLC 
using a phenomenex Luna C18 and a acetonitril/H2O (0.0059 % TFA) gradient (5%-98% 
acetonitril) to give the product as colorless solid (12.4 mg, 0.03 mmol, 19 %). 
MP 159-160 °C. - 1H-NMR (400 MHz, COSY, NOESY, CDCl3): 0.77 (d, 3JH,H = 6.7, 3 H, 
27), 0.83 (t, 3 H, 3JH,H = 7.3, 26), 0.90-1.03 (m, 1 H, 25a), 1.30-1.39 (m, 1 H, 25b), 1.46 (s, 
9 H, 1), 1.68-1.82 (m, 2 H, 13a + 24), 2.10-2.24 (m, 1 H, 13b), 2.31 (dt, 2JH,H = 12.8, 3JH,H 
= 9.4, 1 H, 23b), 2.67-2.80 (m, 1 H, 23a), 2.90 (ddd, 2JH,H = 10.7, 3JH,H = 7.5, 3JH,H = 3.5, 1 
H, 12a), 3.58 (t, 3JH,H = 7.5, 1 H, 9), 3.64-3.75 (m, 1 H, 12b), 4.22 (ddd, 2JH,H = 12.7, 3JH,H = 
9.1, 3JH,H = 3.6, 1 H, 14a), 4.29-4.37 (m, 2 H, 22a/b), 4.42 (dt, 2JH,H = 12.8, 3JH,H = 4.9, 1 H, 
14b), 4.73 (s, 1 H, 11), 5.29 (s, 1 H, 20), 5.77 (d, 3JH,H = 7.8, 8), 6.02 (s, 1 H, 5), 6.86 (dd, 
3JH,H = 8.4, 4JH,H = 2.6, 1 H, 17a), 6.97 (dd, 3JH,H = 8.6, 4JH,H = 2.6, 1 H, 17a), 7.12 (dd, 3JH,H 
= 8.6, 4JH,H = 2.1, 1 H, 18a), 7.39 (dd, 3JH,H = 8.5, 4JH,H = 1.8, 1 H, 18b). - 13C-NMR (100 
MHz, HSQC, HMBC, CDCl3): δ = 11.3 (+, 1 C, 26), 15.5 (+, 1 C, 27), 24.6 (-, 1 C, 25), 
28.2 (-, 1 C, 13), 28.3 (+, 3 C, 1), 35.1 (-, 1 C, 23), 37.3 (-, 1 C, 12), 37.7 (+, 1 C, 24), 59.2 
(+, 1 C, 9), 67.6 (-, 1 C, 22), 68.6 (-, 1 C, 14), 70.2 (Cquat, 1 C, 6), 80.1 (Cquat, 1 C, 2), 83.2 
(+, 1 C, 20), 117.1 (+, 1 C, 17b), 117.6 (+, 1 C, 17a), 126.0 (+, 1 C, 18a), 126.4 (+, 1 C, 
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18b), 131.7 (Cquat, 1 C, 19), 154.6 (Cquat, 1 C, 4), 158.6 (Cquat, 1 C, 16), 170.2 (Cquat, 1 C, 
10), 171.5 (Cquat, 1 C, 7). - MS (ES, DCM/MeOH + 10 mmol/l NH4OAc): m/z (%) = 420.2 
(42) [MH+ - C4H8], 476.2 (25) [MH+], 493.4 (100) [MNH4+], 951.6 (21) [2M + H+]. - HR-MS 
(FAB, MeOH/glycerol): [MH+] calcd. for C25H38N3O6 476.2761; found 476.2758. – MF 
C25H37N3O6. – MW 475.58. 
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C. Abbreviations 
A anion 
abs. absolute 
aq aqueous 
Bn benzyl 
Boc tert-butoxycarbonyl 
BPA bis(pyridin-2-ylmethyl)amine 
Bzl benzyl 
calc calculated 
Cbz benzoyloxycarbonyl 
CD circular dichroism 
CFP cyan fluorescent protein 
COSY correlated spin spectroscopy 
cyclen 1,4,7,10-tetraazacyclododecane 
d day 
DCC dicyclohexyl carbodiimide 
DCM dichloromethane 
DIPEA ethyl diisopropyl amine 
DMAP 4-(dimethylamino) pyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DPA dipicolylamine 
ED ethylene diamine 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EE ethyl acetate 
EI electron impact 
ESI electron spray ionization 
Et ethyl 
EtOAc ethyl acetate 
EtOH ethanol 
FAB fast atom bombardment 
Fmoc fluorenylmethoxycarbonyl 
FRET fluorescence resonance energy transfer 
GFP green fluorescent protein 
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GP general procedure 
h hour 
HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate methanaminium 
HBTU O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
Hepes 4-(2-hydroxyethyl)-piperazine-1-ethane sulfonic acid 
HMBC heteronuclear multiple-bond correlation 
HOAt 1-hydroxy-7-azabenzotriazole 
HOBt 1-hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HR-MS high resolution mass spectroscopy 
HSQC heteronuclear single quantum coherence 
IC50 half maximal inhibitory concentration 
IDA iminodiacetic acid 
IMAC immobilized metal affinity chromatography 
IR infrared spectroscopy 
J coupling constant 
K cation 
LB Langmuir-Blodgett 
LC liquid chromatography 
M molecule 
M mol/L 
Me methyl 
MeCN acetonitril 
MeOH methanol 
MF molecular formula 
min minutes 
MP melting point 
MS mass spectroscopy 
MW molecular weight 
NEt3 triethyl amine 
NIR near infrared 
NMA N-methyl amino acid 
NMR nuclear magnetic resonance 
NOE nuclear overhauser effect 
NOESY nuclear overhauser effect spectroscopy 
NTA nitrilotriacetic acid 
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OAc acetate 
PE petrol ether 
PET photoinduced electron transfer 
Ph phenyl 
rac racemic 
Rf retention factor 
RNA ribonucleic acid 
ROESY rotating-frame NOE spectroscopy 
rt room temperature 
SAM self-assembled monolayers 
sat saturated 
SDS-PAGE sodium dodecyl sulfate-polyacyrlamide gel electrophoresis 
SN nucleophilic substitution 
SPR surface plasmon resonance 
TAA tetrahydrofuran amino acid 
TBAF tetrabutyl ammonium fluoride 
TBDMS/TBS tert-butyldimethylsily 
TBDMSCl tert-butyldimethylsily chloride 
TBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium tetrafluoro borate 
tBu tert-butyl 
tBuOH tert-butanol 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMS trimethylsilyl 
UV ultraviolet 
Vis visible 
YFP yellow fluorescent protein 
Z benzoyloxycarbonyl 
Amino acids 
Aib aminoisobutyric acid 
Ala alanine 
Arg arginine 
Asn asparagine 
Asp aspartic acid 
Cys cysteine 
Gln glutamine 
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Glu glutamic acid 
Gly glycine 
His histidine 
Ile isoleucine 
Leu leucine 
Lys lysine 
Met methionine 
Phe phenylalanine 
Pro proline 
Ser serine 
Thr threonine 
Trp tryptophan 
Tyr tyrosine 
Val valine 
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